DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
NOTE. Pour les tomes additionels. veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional volumes please contact the Canadian Patent Office.
..
PRODUCTION AND USE OF SPECIALTY CANNABIS WITH BD/BT GENOTYPE
AND A BETA CARYOPHYLLENE-DOMINANT TERPENE PROFILE
FIELD OF THE INVENTION
The invention relates to specialty cannabis plants, compositions and methods
for making
and using said cannabis plants and compositions derived thereof.
BACKGROUND OF THE INVENTION
Cannabis, more commonly known as marijuana, is a genus of flowering plants
that
includes at least three species, Cannabis saliva, Cannabis indica, and
Cannabis ruderalis as
determined by plant phenotypes and secondary metabolite profiles. In practice
however,
cannabis nomenclature is often used incorrectly or interchangeably. Cannabis
literature can be
found referring to all cannabis varieties as "sativas" or all cannabinoid
producing plants as
"indicas". Indeed the promiscuous crosses of indoor cannabis breeding programs
have made it
difficult to distinguish varieties, with most cannabis being sold in the
United States having
features of both sativa and indica species.
The use of cannabis for social and medical purposes has been known for almost
of all
humanity's recorded history. Cannabis is most commonly administered via
inhalation or
consumption of marijuana-infused food and drink However, since 1972 marijuana
has been
classified as a Schedule I drug under the U.S. Controlled Substances Act
because the U.S.
Federal Government considers it to have "no accepted medical use." In stark
contrast to this
position, 23 of the 50 U.S. states and the District of Columbia have
recognized the medical
benefits of cannabis and have decriminalized its medical use. The 23 U.S.
states where medical
1
CA 2911168 2017-07-14
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
marijuana has been decriminalized as of the filing date of the present
application are as follows:
Alaska, Arizona, California, Colorado, Connecticut, Delaware, Hawaii,
Illinois, Maine,
Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire,
New Jersey,
New Mexico, New York, Oregon, Rhode Island, Vermont and Washington. The
residency
requirements, approved list of conditions/diseases, and the other laws/rules
regarding the
possession and cultivation of medical marijuana generally differ by state.
President Obama has publicly commented on the recreational legalization of
cannabis in
Colorado and Washington stating that "it's important for it to go forward
because it's important
for society not to have a situation in which a large portion of people have at
one time or another
broken the law and only a select few get punished." Indeed in the same
interview, President
Obama remarked about cannabis "I don't think it's more dangerous than alcohol.
In fact, it is less
dangerous than alcohol in terms of its impact on the individual consumer."
(Conor Friedersdorf
Jan. 2014, "Mama on Pot Legalization: 'It's Important for it to go Forward"
The Atlantic). In
line with the President's comments the U.S. Attorney General Eric Holder
announced that the
federal government would allow states to create a regime that would regulate
and implement the
legalization of cannabis, including loosening banking restrictions for
cannabis dispensaries and
growers (Jacob Sullum "Eric Holder Promises To Reassure Banks About Taking
Marijuana
Money 'Very Soon' Forbes Jan. 2014).
In addition to these recent developments, the U.S. government has already set
a precedent
for patenting cannabis, and cannabis-related inventions. For example, U.S.
Patent No. 6,630,507
issued on October 7, 2003 and assigned on the patent face to The United States
of America, is
directed to methods of treating diseases caused by oxidative stress by
administering
therapeutically effective amounts of a cannabidiol (CBD), a cannabinoid from
cannabis that has
substantially no binding to the N-methyl-D-aspartate (NMDA) receptor, wherein
the CBD acts
as an antioxidant and neuroprotectant. A search of the U.S.P.T.O. Patent
Application Information
Retrieval (PAIR) system also reveals the existence of thousands of cannabis
related applications
and issued patents including US 8,034,843 (use of cannabinoids for treating
nausea, vomiting,
emesis, motion sickness), US 7,698,594 (cannabinoid compositions for treatment
of pain), and
US 8,632,825 (anti-tumoural effects of cannabinoid combinations) among many
others.
Thus, despite the official position of the U.S. Federal Government, and as
recognized by
the states that have legalized it, cannabis has been shown to provide
substantial benefits for
2
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
medical and recreational uses. Cannabis is regularly used by a wide cross-
section of society to
treat a variety of maladies, conditions and symptoms including, but not
limited to, the following:
nausea, glaucoma, lack of appetite, mucous membrane inflammation, epilepsy,
leprosy, fever,
obesity, asthma, urinary tract infections, coughing, anorexia associated with
weight loss in AIDS
patients, pain, and multiple sclerosis.
Cannabis intoxication (i.e., euphoria, relaxation) can occur and other side
effects may
also accompany its use, particularly with higher doses, specific cannabis
varieties and/or over
prolonged periods of usage. Undesirable side effects of using the available
THC-predominant
cannabis varieties can include, but are not limited to, the following:
decreased short-term
memory, dry mouth, impaired visual perception and motor skills, erectile
dysfunction, lower
fertility, red (i.e., blood shot) eyes, increased anxiety, occasional
infarction, stroke, paranoia,
acute psychosis, lowered mental aptitude, hallucinations, bizarre behavior,
irrational panic
attacks, irrational thoughts and various other cognitive and social problems.
Some of the negative or undesirable side effects from using available cannabis
varieties
for medical and recreational purposes are related to the plant's content of
the chemical A9-
tetrahydrocannabinol (THC). A major hurdle to the more wide-spread acceptance
of cannabis
and its legalization is that the land races and commercially available
cannabis genotypes (of drug
varieties) contain relatively high concentrations of THC. Indeed the average
THC content of
traditional recreational cannabis has risen over the years from an average of
0.74% in 1975, to
3.35% in the 1990's, and average of 6.4% in 2003 (Annual Reports (Nov. 9. 1999
to Nov. 8,
2003) of Mahmoud A. ElSohly, PhD, Director of the National institute on Drug
Abuse (N1DA)
Marijuana Project at the National Center for Natural Products Research, School
of Pharmacy,
University of Mississippi). There is a real need for cannabis varieties for
potential medical use
that produce modulated nic concentrations and varying concentrations of other
pharmacologically active substances that reduce the negative side effects of
THC and increase
the medical benefits realized from its use. There is also a need for healthier
cannabis for
recreational use with reduced negative side effects from THC. The inventions
described herein
meet that long-felt need.
3
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
SUMMARY OF THE INVENTION
According to the methods and compositions of the present invention, plants,
plant parts,
plant tissues and plant cells are produced to contain pentyl, propyl, C-4, C-1
and
monomethylether constituents of cannabinoid families, including but not
limited to acidic and
neutral forms of the cannabigerol, cannabichromene, cannabidiol, delta-9-
tetrahydrocannabinol,
delta-8-tetrahydrocannabinol, cannabielsoin, cannabinol and cannabinodiol
cannabinoid classes;
and, cis and trans terpenoids, including but not limited to myrcene, limonene,
linalool, ocimene,
beta-pinene, alpha-pinene, beta-caryophyllene, alpha-caryophyllene, delta-3-
carene, gamma-
bisabolene, alpha-farnesene, beta-fenchol., guajol, alpha-guaiene,
terpinolene, beta-eudesmol,
alpha-bergamotene, epi-alpha-bisabolol and caryophyllene oxide ranging from
0.1% of dry
weight of inflorescences, plant parts, plant tissues and plant cells to 35% of
inflorescences and/or
95% of plant parts, plant parts, plant tissues and plant cells.
in some embodiments, the present invention provides specialty cannabis plants,
plant
parts, plant tissues and plant cells which provide a way to deliver a
consistent and more tolerable
and effective ratio of cannabinoids by providing plants that comprise non-THC
cannabinoids
("CBs") to patients (e.g., <THC:>CBs than in presently-available cannabis
varieties).
In some embodiments, the present invention provides specialty cannabis plants,
plant
parts, plant cells and plant tissues which have an amount, percentage and/or
ratio of cannabinoids
that is different from currently available THCA/THC varieties.
in some embodiments, the present invention provides Medical Cannabis plants,
plant
parts, plant tissues and plant cells having an. alternative cannabinoid (e.g.,
THCV, CBDV, etc.) to
THCA/THC.
In some embodiments, the present invention provides Specialty Cannabis plants,
plant
parts, tissues and cells having a THC content that is >2.0% but <90.0% based
on the dry weight
of plant inflorescences; and, a non-THC CBs content based on the dry weight of
plant
inflorescences that is >1.5%. Thus, in some embodiments, the specialty
cannabis plants, plant
parts, plant tissues and plant cells of the present invention will have a THC
content selected from
the group consisting of 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%,
14%, 15%,
16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%,
31%,
32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%,
47%,
48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,
63%,
4
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%,
79%,
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89% and 90%; and, a CBs content
selected
from the group consisting of 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%,
2.3%, 2.4%,
2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3.0%, 4.0%, 5.0%, 6.0%, 7.0%, 8.0%, 9.0%, 10.0%,
11.0%,
12.0%, 13.0%, 14.0%, 15.0%, 16.0%, 17.0%, 18.0%, 19.0%, 20.0%, 21.0%, 22.0%,
23.0%,
24.0%, 25.0%, 26.0%, 27.0%, 28.0%, 29.0%, 30.0%, 31.0%, 32.0%, 33.0%, 34.0%,
35.0%,
36.0%, 37.0%, 38.0%, 39.0%, 40.0%, 41.0%, 42.0%, 43.0%, 44.0%, 45.0%, 46.0%,
47.0%,
48.0%, 49.0%, 50.0%, 51.0%, 52.0%, 53.0%, 54.0%, 55.0%, 56.0%, 57.0%, 58.0%,
59.0%,
60.0%, 61.0%, 62.0%, 63.0%, 64.0%, 65.0%, 66.0%, 67.0%, 68.0%, 69.0%, 70.0%,
71.0%,
72.0%, 73.0%, 74.0%, 75.0%, 76.0%, 77.0%, 78.0%, 79.0%, 80.0%, 81.0%, 82.0%,
83.0%,
84.0%, 85.0%, 86.0%, 87.0%, 88.0%, 89.0%, 90.0%, 91.0%, 92%, 93%, 94%, 95%,
96%, 97%,
and 98%.
in some embodiments, the present invention provides specialty cannabis plants,
plant
parts, tissues and cells having a THC:CBs ratio greater than or equal to of
8:1. In other
embodiments, the specialty cannabis of the present invention has THC:CBs
ratios approaching
1:1, or lower. By comparison, the THC:CBs ratio of the currently available
cannabis varieties is
20:1 and approaches 25:1, 30:1, 35:1, 40:1 and higher. Thus, in some
embodiments the specialty
cannabis plants, plant parts, plant tissues and plant cells of the present
invention will have a
THC:CBs ratio of less than 20:1, 15:1, 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1,
3:1, 2:1, 1:1, 1:2, 1:3,
1:4, 1:5, 1:6, 1:7, 1:9, or below.
in some embodiments, the present invention provides Classes of Cannabis
Varieties
developed by selection from landraces of mixed cannabis genotypes and
resulting from further
breeding, wherein these Classes of Cannabis Varieties can provide useful
patient treatment and
also are used as breeding material to develop Specialty Cannabis plants and
varieties according
to the present invention.
In some embodiments, the present invention provides Specialty Cannabis plants
and
varieties with increased organoleptic appeal as a result of having specified,
predetermined
terpene and sesquiterpene profiles and content. in some embodiments of the
present invention,
the increased organoleptic appeal of the Specialty Cannabis is inherited in-
whole or in-part as a
result of using the Classes of Cannabis Varieties in the breeding program to
develop the
Specialty Cannabis plants. For, example, in some embodiments, Classes of
Cannabis Varieties
5
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
with specific terpene and sesquiterpene profiles and content are bred with
certain cannabis
varieties with specific CBs profiles and content to develop Specialty Cannabis
Varieties with the
desired combined attributes of the two types of cannabis plants.
The present invention also provides methods to determine higher THC adequate
to down-
regulate the entire Cannabinoid (CB) system. This method uses the 'down-
regulation' as therapy
for hyper-endocarinabinoid systems and to help increase the therapeutic
margin. Additionally,
the present invention provides for a potential role of dosage and its
influence on biosynthesis and
build-up of cholesterol; a healthy means of supplementing the endocannabinoid
system when
consuming an ultra low-cholesterol diet.
In some embodiments, the present invention also provides methods for
determining the
terpene profiles at which 'dosages' are suitable for outcomes related to mood
elevation and/or
sedation (i.e., high limonene for energy, high myrcene for sleep aid, etc.).
In some embodiments,
the present invention teaches a cannabis plant, plant part, tissue, or cell
comprising: a
cannabidiol (CBD) content that is greater than 10/0 by weight, and a terpene
profile in which
myrcene is not the dominant terpene, wherein the terpene profile consists of
terpinolene, alpha
phelladrene, beta ocimene, careen, limonene, gamma terpinene, alpha pinene,
alpha tetpinene,
beta pincnc, fenchol, camphenc, alpha tcrpineol, alpha humulenc, beta
caryophyllene, linalool,
cary oxide, and myrcene of a plant, and wherein the cannabinoid and terpene
content is measured
by GC-FID and calculated based on dry weight of the inflorescence. In
some embodiments,
the cannabis plant, plant part, tissue or cell is chemotype II with BT/BD
genotype.
in some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a tetrahydrocannabinol (THC) content that is at least 1.0%
by weight as
measured by GC-F1D and calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises at least 2% cannabichromene (CBC) content by weight.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a CBD content that is at least 3% by weight, and the THC
content is at least
3% by weight, as measured by GC-FID and calculated based on dry weight of the
inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene oil content greater than about 1.0% by weight
wherein the terpene
6
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
oil content is determined by the additive content of the terpenes in the
terpene profile as
measured by GC-FID, and calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene oil content greater than about 2% by weight
wherein the terpene
oil content is determined by the additive content of the terpenes in the
terpene profile as
measured by GC-FID, and calculated based on dry weight of the inflorescence.
In other embodiments, the present invention teaches a cannabis plant, plant
part, tissue, or
cell comprising a BT/BD genotype, and terpene profile in which myrcene is not
the dominant
terpene, wherein the terpene profile consists of terpinolene, alpha
phelladrene, beta ocimene,
careen, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha tetpineol, alpha humulene, beta caryophyllene, linalool, cary
oxide, and
myrcene of a plant, and wherein the terpene content is measured by GC-FID and
calculated
based on dry weight of the inflorescence.
In other embodiments, the present invention teaches a cannabis plant, plant
part, tissue, or
cell comprising: a BT/BD genotype, a myrcene relative content of less than 60%
of the terpene
profile, and a terpene oil content greater than 1.5% by weight, wherein the
terpene profile
consists of terpinolene, alpha phelladrene, beta ocimene, careen, limonenc,
gamma tcrpinenc,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophylkne, linalool, cary oxide, and myrcene of a plant, and wherein
the terpene oil
content is determined by the additive content of the terpenes in the terpene
profile, and wherein
the terpene contents are measured by GC-FID and calculated based on dry weight
of the
inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a CBD content that is greater than 3% by weight as
measured by GC-FID
and calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a THC content that is greater than 3% by weight as
measured by GC-FID
and calculated based on dry weight of the inflorescence.
In yet another embodiment, the present invention teaches a cannabis plant,
plant part,
tissue, or cell comprising: at least one propyl locus A allele (Apr), and a
terpene oil content
greater than 1.5% by weight, wherein the terpene profile consists of
terpinolene, alpha
7
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
phelladrene, beta ocimene, careen, limonene, gamma terpinene, alpha pinene,
alpha terpinene,
beta pinene, fenchol, camphene, alpha terpineol, alpha humulene, beta
caryophyllene, linalool,
cary oxide, and myrcene of a plant, and wherein the terpene oil content is
determined by the
additive content of the terpenes in the terpene profile, and wherein the
cannabinoid and terpene
contents are measured by GC-FID and calculated based on dry weight of the
inflorescence.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises at least one B. allele.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a BT/BD genotype.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a BD/BD genotype.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a myrcene relative content of less than 60% of the terpene
profile.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a terpene profile in which myrcene is not the dominant
terpene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a cannabidivarin (CBDV) content that is greater than 1% as
measured by
GC-FID and calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a CBDV content that is greater than 4% as measured by GC-
FID and
calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of of the
present
invention comprises a tetrahydrocannabivarin (THCV ) content that is greater
than 1% as
measured by GC-FID and calculated based on dry weight of the inflorescence.
in some embodiments, the cannabis plant, plant part, tissue or cell of of the
present
invention comprises a THCV content that is greater than 4% as measured by GC-
FiD and
calculated based on dry weight of the inflorescence.
In other embodiments, the present invention teaches a cannabis plant, plant
part, tissue, or
cell comprising: at least one Bo allele, and a terpene oil content greater
than 1.5% by weight,
wherein the terpene profile consists of terpinolene, alpha phelladrene, beta
ocimene, careen,
limonenc, gamma terpinene, alpha pinenc, alpha terpinene, beta pinene,
fenchol, camphenc,
8
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
alpha terpineol, alpha humulene, beta caryophyllene, linalool, cary oxide, and
myrcene of a plant,
and wherein the terpene oil content is determined by the additive content of
the terpenes in the
terpenc profile, and wherein the cannabinoid and terpene contents arc measured
by (IC-F1D and
calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a second Bo allele.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a BD allele.
In some embodiments, the cannabis plant, plant part, tissue, or cell of the
present
invention comprises a BT allele.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a Cannabigerol (CBG) content that is greater than 1% as
measured by GC-
FID and calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a CBG content that is greater than 5% as measured by GC-
FID and
calculated based on dry weight of the inflorescence.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is teipinolene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is alpha phelladrene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is careen.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is limonene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is gamma terpinene.
9
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is alpha pinene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is alpha terpinene.
in some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is beta pinerie.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is gamma fenchol.
in some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is camphene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is terpineol.
in some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is alpha humulene.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is beta caryophyllene.
in some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is linalool.
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is cary oxide.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the cannabis plant, plant part, tissue or cell of the
present
invention comprises a terpene profile in which the first or second most
abundant terpene in the
terpene profile is beta ocimene.
In other embodiments, the present invention teaches a method of breeding
cannabis
plants with non-myrcene dominant terpene profiles and a BD allele, said method
comprising:(i)
making a cross between a first cannabis plant and a second cannabis plant to
produce an Fl plant,
wherein the first plant comprises: a CBD content that is greater than 1.0% by
weight, and a
terpene profile in which myrcene is not the dominant terpene,wherein the
terpene profile consists
of terpinolene, alpha phelladrene, beta ocimene, careen, limonene, gamma
tetpinene, alpha
pinene, alpha telpinene, beta pinene, fenchol, camphene, alpha terpineol,
alpha humulene, beta
caryophyllene, linalool, cary oxide, and myrcene of a plant, and wherein the
cannabinoid and
terpene content is measured by GC-FID and calculated based on dry weight of
the inflorescence;
(ii) harvesting the resulting seed; (iii) growing said seed; and (iv)
selecting for the desired
phenotypes; wherein the resulting selected cannabis plant has a non-myrcene
dominant terpene
profile, and comprises a BD allele.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant is chcmotype 11 with BT/BD genotype.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant, comprises a THC content that is at least 1.0% by weight as measured by
GC-F1D and
calculated based on dry weight of the inflorescence.
in some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises at least 2% CBC content by weight.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a terpene oil content greater than 1.0% by weight wherein the
terpene oil content
is determined by the additive content of the terpenes in the terpene profile
as measured by GC-
FID, and calculated based on dry weight of the inflorescence.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a terpene oil content greater than 2.0% by weight wherein the
terpene oil content
is determined by the additive content of the terpenes in the terpene profile
as measured by GC-
FID, and calculated based on dry weight of the inflorescence.
11
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a CBD content that is at least 5% by weight, and the THC
content is at least 5%
by weight, as measured by GC-FID and calculated based on dry weight of the
inflorescence.
In other embodiments, the the present invention teaches a method of breeding
chemotype
II cannabis plants with a non myrcene dominant terpene profile, said method
comprising: (i)
making a cross between a first cannabis plant and a second cannabis plant to
produce an Fl plant,
wherein the first plant comprises: a BT/BD genotype, and a terpene profile in
which myrcene is
not the dominant terpene, wherein the terpene profile consists of terpinolene,
alpha phelladrene,
beta ocimene, careen, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha temineol, alpha humulene, beta catyophyllene,
linalool, cary oxide,
and myrcene of a plant, and wherein the cannabinoid and terpene content is
measured by GC-
FID and calculated based on dry weight of the inflorescence; (ii) harvesting
the resulting seed;
(iii) growing said seed; and (iv) selecting for the desired phenotypes;
wherein the resulting
selected cannabis plant is a chemotype 11 cannabis plant with a non-myrcene
dominant terpene
profile.
In other embodiments, the present invention teaches a method of breeding
chemotype II
cannabis plants with high oil content and low-myrcene content, said method
comprising: (i)
making a cross between a first cannabis plant and a second cannabis plant to
produce an El plant,
wherein the first plant comprises: a BT/BD genotype, a myrcene relative
content of less than 60%
of the terpene profile; and, a terpene oil content greater than 1.5% by
weight, wherein the terpene
profile consists of terpinolene, alpha phelladrene, beta ocimene, careen,
limonene, gamma
terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene,
alpha terpineol, alpha
humulene, beta caryophyllene, linalool, cary oxide, and myrcene of a plant,
and wherein the
terpene oil content is determined by the additive content of the terpenes in
the terpene profile,
and wherein the terpene contents are measured by GC-FID and calculated based
on dry weight of
the inflorescence; (ii) harvesting the resulting seed; (iii) growing said
seed; and (iv) selecting
for the desired phenotypes; wherein the resulting selected cannabis plant is a
chemotype II
cannabis plant with a terpene oil content greater than 1.5% by weight and a
myrcene relative
content of less than 60%.
12
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a CBD content that is greater than 3% by weight as measured by
GC-HD and
calculated based on dry weight of the inflorescence.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a TUC content that is greater than 3% by weight as measured by
GC-FID and
calculated based on dry weight of the inflorescence.
In other embodiments, the present invention teaches a method of breeding
cannabis
plants with propyl cananbinoids and high oil content, said method comprising:
(i) making a cross
between a first cannabis plant and a second cannabis plant to produce an Fl
plant, wherein the
first plant comprises: at least one propyl locus A allele (Apr), and a terpene
oil content greater
than 1.5% by weight; wherein the terpene profile consists of terpinolene,
alpha phelladrene, beta
ocimene, careen, limonene, gamma terpinene, alpha pinene, alpha terpinene,
beta pinene, fenehol,
camphene, alpha terpineol, alpha Immulerie, beta caryophyllene, linalool, cary
oxide, and
myrcene of a plant, and wherein the terpene oil content is determined by the
additive content of
the terpenes in the terpene profile, and wherein the cannabinoid and terpene
contents are
measured by GC-FID and calculated based on dry weight of the inflorescence;
(ii) harvesting the
resulting seed; (iii) growing said seed; and (iv) selecting for the desired
phenotypes; wherein the
resulting selected cannabis plant has at least one propyl locus A allele
capable of producing at
least one propyl cannabinoid, and also has a terpene oil content greater than
1.5% by weight.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises at least one null locus B
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a BT/BD genotype.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a BD/BD genotype.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant, comprises a myrcene relative content of less than 60% of the terpene
profile.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant, comprises a terpene profile in which myrcene is not the dominant
terpene.
13
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a CBDV content that is greater than 1% as measured by GC-FID
and calculated
based on dry weight of the inflorescence.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a CBDV content that is greater than 4% as measured by GC-FID
and calculated
based on dry weight of the inflorescence.
in some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a THCV content that is greater than 1% as measured by GC-FID
and calculated
based on dry weight of the inflorescence.
In some embodiments of the breeding methods of the present invention, the
first cannabis
plant comprises a THCV content that is greater than 4% as measured by GC-FID
and calculated
based on dry weight of the inflorescence.
in some embodiments, the present invention teaches methods of growing cannabis
plants,
said method comprising: obtaining a cannabis seed, cutting, or plant cell of
any of the specialty
cannabis varieties of the present invention capable of growing, placing said
cannabis seed,
cutting, or plant cell in an environment conducive to plant growth, and
allowing said cannabis
seed, cutting, or plant to produce a cannabis plant, wherein cannabis plant
contains the same
genetic makeup as the cannabis seed, cutting, or plant cell from which it was
grown.
in some embodiments, the present invention teaches a cannabis extract from the
cannabis
plant, plant part, tissue, or cell of the present invention.
in some embodiments, the extract of the present invention is selected from the
group
consisting of kief, hashish, bubble hash, solvent reduced oils, sludges, e-
juice, and tinctures.
in some embodiments, the extract of the present invention retains the terpene
profile of
the cannabis plant, plant part, tissue or cell from which it was made.
in some embodiments, the present invention teaches a cannabis edible product
produced
from the cannabis plant, plant part, tissue, or cell of the present invention.
In some embodiments, the present invention teaches a multiplexed cannabis
mixture
(MCM), said MCM comprising: (i) at least one cannabis plant base; (ii) one or
more stock
fortifiers; wherein the mixture is tailored for a specific recreational or
medicinal purpose based
on the pharmacological properties of the cannabinoid and terpene profiles of
the mixture, and
wherein the MCM comprises at least 1.5% tape= oil content, wherein the terpene
profile
14
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
consists of terpinolene, alpha phelladrene, beta ocimene, careen, limonene,
gamma terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha humulene,
beta caryophyllenc, linalool, cary oxide, and myrcene of the mixtures, wherein
the tcrpcnc oil
content is determined by the additive content of the terpenes in the terpene
profile, and wherein
the terpene contents are measured by GC-FID and calculated based on dry weight
of the mixture.
In some embodiments, the multiplexed cannabis mixture of the present invention
comprises at least 0.05% content by weight of at least two terpenes of said
terpene profile.
In some embodiments, the multiplexed cannabis mixture of the present invention
comprises at least 0.05% content by weight of at least three, four, five, six,
seven, eight, or nine
terpenes of said terpene profile.
In some embodiments, the multiplexed cannabis mixture of the present invention
comprises at least 2% content by weight of at least two cannabinoid.s selected
from the group
consisting of: THC, CBD, CBG, CRC, THCV, CBDV, and cannabigevarin (CBGV).
In some embodiments, the multiplexed cannabis mixture of the present invention
comprises at least 2% content by weight of at least three, four, or five
cannabinoids selected from
the group consisting of: THC, CBD, CBG, CBC, THCV, CBDV, CBGV.
In some embodiments, the multiplexed cannabis mixture of the present invention
has at
least one of the stock fortifier that is a cannabinoid fortifier (CB).
In some embodiments, the multiplexed cannabis mixture of the present invention
has at
least one stock fortifier that is a terpene fortifier (EO).
in some embodiments, the present invention teaches a compressed cannabis
pellet for
smoking or vaporization, wherein the pellet comprises the cannabis plant parts
of the present
invention.
In some embodiments, the compressed cannabis pellet of the present invention
comprises
a multiplexed mixture of the present invention.
In some embodiments, the compressed cannabis pellet of the present invention
comprises
cannabis extracts of the present invention.
In some embodiments, the compressed cannabis pellet of the present invention
is in the
shape of a truncated cone.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the compressed cannabis pellet of the present invention
is a
truncated cone, with a height of 2.0 millimeters, a smaller base diameter of
4.0 millimeters, and a
larger base diameter of 6.0 millimeters.
In some embodiments, the compressed cannabis pellet of the present invention
is in the
shape of a donut.
In some embodiments, the compressed cannabis pellet of the present invention
is a
dounut shape with a height of 2.0 millimeters, an inner donut diameter of 1.5
millimeters, and an
outer donut diameter of 6 millimeters.
In some embodiments, the present invention teaches a method of treating
Brachial Plexus
Avulsion, said method comprising: (i) identifying a patient with Brachial
Plexus Avulsion; and
(ii) administering a prescribed amount of the cannabis of the present
invention to a patient;
wherein said patient experiences symptom relief due to said cannabis
administration, with
reduced THC side effects, and a pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of treating
seizures, said
method comprising: (i) identifying a patient with Seizures; and (ii)
administering a prescribed
amount of the cannabis of the present invention to a patient; wherein said
patient experiences
reduced number of seizures due to said cannabis administration, with reduced
THC side effects,
and a pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of treating
Arthritis, said
method comprising: (i) identifying a patient with Arthritis; and (ii)
administering a prescribed
amount of the cannabis of the present invention to a patient; wherein said
patient experiences
joint pain relief due to said cannabis administration, with reduced THC side
effects and a
pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of treating Motion
Sickness, said method comprising: (i) identifying a patient with Motion
Sickness; and (ii)
administering a prescribed amount of the cannabis of the present invention to
a patient; wherein
said patient experiences reduced motion sickness symptoms due to said cannabis
administration,
with reduced THC side effects, and a pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of treating
Neuropathic
Pain, said method comprising: (i) identifying a patient with Neuropathic Pain;
and (ii)
administering a prescribed amount of the cannabis of the present invention to
a patient; wherein
16
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
said patient experiences reduced pain symptoms due to said cannabis
administration, with
reduced THC side effects, and a pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of losing weight,
said
method comprising: administering a prescribed amount of the cannabis of the
present invention
to a person wishing to lose weight, wherein said patient experiences
accelerated weight loss due
to said cannabis administration, with reduced THC side effects, and a pleasing
organoleptic
experience.
In some embodiments, the present invention teaches a method of treating
depression, said
method comprising: (i) identifying a patient with depression; and (ii)
administering a prescribed
amount of the cannabis of the present invention to a patient; wherein said
patient experiences
reduced symptoms due to said cannabis administration, with reduced THC side
effects, and a
pleasing organoleptic experience.
in some embodiments, the present invention teaches a method of treating
Irritable Bowel
Syndrome, said method comprising: (i) identifying a patient with irritable
Bowel Syndrome; and
(ii) administering a prescribed amount of the cannabis of the present
invention to a patient;
wherein said patient experiences reduced symptoms due to said cannabis
administration, with
reduced THC side effects, and a pleasing organoleptic experience.
In some embodiments, the present invention teaches a method of treating pain
from
cancer, said method comprising: (i) identifying a cancer patient experiencing
pain; and (ii)
administering a prescribed amount of the cannabis of the present invention to
a patient; wherein
said patient experiences reduced pain symptoms due to said cannabis
administration, with
reduced THC side effects, and a pleasing organoleptic experience.
in some embodiments, the present invention teaches a method of improving
cholesterol,
said method comprising: (i) identifying a patient with high total cholesterol,
or low HDL
cholesterol; and (ii) administering a prescribed amount of the cannabis of the
present invention to
a patient; wherein said patient experiences a lowering of cholesterol and/or
increase in HDL
cholesterol due to said cannabis administration, with reduced THC side
effects, and a pleasing
organoleptic experience.
In some embodiments, the present invention teaches a method of treating
psychosis
related diseases, said method comprising: (i) identifying a patient with a
psychosis related
disease; and (ii) administering a prescribed amount of the cannabis of the
present invention a
17
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
patient; wherein said patient experiences reduced psychosis symptoms due to
said cannabis
administration, with reduced THC side effects, and a pleasing organoleptic
experience.
In some embodiments, the methods of treating diseases of the present invention
utilize
administer cannabis extracts or edibles of the present invention.
in som.e embodiments, the methods of treating diseases of the present
invention
administer multiplexed cannabis mixtures of the present invention.
in some embodiments, the present invention teaches a bubble packaging for
storing and
shipping cannabis comprising: (i) a sealable storage space to place a cannabis
plant part, extract,
or MCM of the present invention; (ii) a modified atmosphere within said
sealable space, wherein
said bubble packaging increases the shelf life of said cannabis plant part,
extract, or MCM
beyond that of a control of cannabis plant part, extract, or MCM, placed left
out, or placed in a
traditional jar or bag without the modified atmosphere.
in some embodiments, modified atmosphere of the bubble packaging for storing
and
shipping cannabis comprises a vacuum.
in some embodiments, the present invention teaches a method of vaporizing
cannabis and
MCIVIs, said method comprising: placing the cannabis or MCMs of the present
invention in a
zero-point delivery device, turning the zero-point delivery device on, and
vaporizing said
cannabis or MCM.
In some embodiments, the cannabinoid contents of the cannabis plants, plant
parts, plant
cells , or plant cultures of the present invention is measured using HPLC.
in some embodiments of the present invention, the cannabinoids are measured
via HPLC,
and the content of cannabinoids includes the acidic and neutral forms of said
cannabinoid. Thus
in some embodiments reference to total cannabinoids as measured via HPLC can
refer to both
the neutral and the acidic form of said camiabinoid.
in some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with Br/BD, and/or Api. genotypes and the terpene
profiles of one of the
color classes of the present invention. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture produce less than 60% relative myrcene. in
some embodiments,
said cannabis plants, plant parts, plant cells, or plant cell culture are not
myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Gold Class.
18
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture arc not myrccnc dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD. and/or Apr genotypes and the terpene
profile of the Green
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Azure
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Black
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BTIBD, and/or Apr genotypes and the terpene
profile of the Blue Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Bronze
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Brown
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
19
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Fuscia
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. in some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In som.e embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with. BT/BD, and/or Apr genotypes and the terpene
profile of the Grey Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture are not myrcene dominant.
in some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Jade Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture arc not myrcene dominant.
In som.e embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Lemon
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Magenta
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In sonic embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BTIBD, and/or Apr genotypes and the terpene
profile of the Navy Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
CA 02911168 2015-10-90
WO 2015/065544 PCT/US2014/046694
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Olive
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. in some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In som.e embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with I3T/13D, and/or Ap, genotypes and the terpene
profile of the Orange
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not m.yrcene dominant.
in some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Pink Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture arc not myrcenc dominant.
In som.e embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Purple
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Red Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. In some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Apr genotypes and the terpene
profile of the Sea Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
21
less than 60% relative myrcene. in some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture arc not myrecne dominant.
In some embodiments, the present invention teaches cannabis plants, plant
pans, plant
cells, or plant cultures with BT/BD, andlor Arr genotypes and the terpene
profile of the Silver
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with By/BD, and/or Apr genotypes and the ierpene
profile of the Tan Class.
In some embodiments, said cannabis plants, plant parts, plant cells, or plant
cell culture produce
less than 60% relative myrcene. in some embodiments, said cannabis plants,
plant parts, plant
cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Ap, genotypes and the temene
profile of the Violet
Class In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant parts,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with BT/BD, and/or Ar. genotypes and the terpene
profile of the White
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative myrcene. In some embodiments, said cannabis
plants, plant pans,
plant cells, or plant cell culture are not myrcene dominant.
In some embodiments, the present invention teaches cannabis plants, plant
parts, plant
cells, or plant cultures with B[/B1), and/or Apr genotypes and the terpene
profile of the Yellow
Class. In some embodiments, said cannabis plants, plant parts, plant cells, or
plant cell culture
produce less than 60% relative nwrcene. In some embodiments, said cannabis
plants, plant pans,
plant cells, or plant cell culture arc not .myrcene dominant.
22
CA 2911168 2018-06-15
This invention relates to:
<1> A
terpene producing, diploid cannabis plant cell from a female inflorescence of
(i) a
cannabis plant, (ii) an asexual clone of the plant, or (iii) a part of the
plant, wherein said
cannabis plant, asexual clone of the plant or part of the plant produces the
female
inflorescence, said inflorescence comprising:
a) a tetrahydrocannabinol (THC) content that is at least 3% and a cannabidiol
(CBD) content that is at least 3%;
b) a BT allele and a BD allele;
c) a terpene profile in which beta caryophyllene is the dominant terpene; and
d) a terpene oil content greater than 1%;
wherein the terpene profile is defined as terpinolene, alpha phellandrene,
beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene
oxide, and myrcene, and wherein the terpene oil content is the additive
content of the
terpenes in the terpene profile; wherein the THC, CBD, and terpene oil content
are
measured by gas chromatography-flame ionization detection (GC-FID) and
calculated
based on dry weight of the inflorescence, and wherein samples of seed that
produce plants
comprising a), b), c) and d) have been deposited under NCIMB NOs. 42248 and
42249.
<2> The cannabis plant cell of <1>, wherein the terpene oil content is greater
than 1.5%.
<3> The cannabis plant cell of any one of <l>-<2>, wherein the female
inflorescence
comprises a maximum terpene oil content of 2.17%.
<4> The cannabis plant cell of any one of <1>-<3>, wherein the THC content is
at least 4%.
<5> The cannabis plant cell of any one of <1>-<4>, wherein the THC content is
at least 6%.
<6> The cannabis plant cell of any one of <1>-<5>, wherein the CBD content is
at least 5%.
<7> Use of a first cannabis plant, wherein the first cannabis plant comprises
the plant cell of
any one of <I>-<6>, for crossing with a second cannabis plant to produce an Fl
seed,
wherein the Fl seed produces an Fl plant comprising a female Fl inflorescence,
wherein
said Fl inflorescence comprises: a B-r allele and a BD allele, at least 3% THC
content, at
22a
CA 2911168 2018-06-15
least 3% CBD content, a beta caryophyllene dominant terpene profile, and a
terpene oil
content greater than 1%, wherein the terpene profile is defined as
terpinolene, alpha
phellandrene, beta ocimene, carene, limonene, gamma terpinene, alpha pinene,
alpha
terpinene, beta pinene, fenchol, camphene, alpha terpineol, alpha humulene,
beta
caryophyllene, linalool, caryophyllene oxide, and myrcene, and wherein the
terpene oil
content is the additive content of the terpenes in the terpene profile;
wherein the THC,
CBD, and terpene oil content are measured by gas chromatography-flame
ionization
detection (GC-FID) and calculated based on dry weight of the Fl inflorescence.
<8> The use of <7>, wherein said Fl inflorescence comprises a maximum terpene
oil content
of 2.17%.
<9> Use of a cannabis seed, cutting or plant cell from a first cannabis plant
or an asexual clone
thereof, said first cannabis plant comprising the plant cell according to any
one of <1>-
<6>, to produce a second cannabis plant, wherein the second cannabis plant
produces a
new female inflorescence, said new inflorescence comprising: a BT allele and a
BD allele,
at least 3% THC content, at least 3% CBD content, a beta caryophyllene
dominant terpene
profile, and a terpene oil content greater than 1%, wherein the terpene
profile is defined
as terpinolene, alpha phellandrene, beta ocimene, carene, limonene, gamma
terpinene,
alpha pinene, alpha terpinene, beta pinene, fenchol, camphene, alpha
terpineol, alpha
humulene, beta caryophyllene, linalool, caryophyllene oxide, and myrcene, and
wherein
the terpene oil content is the additive content of the terpenes in the terpene
profile; and
wherein the THC, CBD, and terpene oil content are measured by gas
chromatography-
flame ionization detection (GC-FID) and calculated based on dry weight of the
new
inflorescence.
<10> The use
of <9>, wherein said new inflorescence comprises a maximum terpene oil
content of 2.17%.
<11> A cannabis extract produced from the inflorescence of the cannabis
plant of any one
of <1>-<6>, wherein the extract comprises the plant cell of any one of <1>-
<6>.
<12> The cannabis extract of <11>, wherein said extract is kief,
hashish, or bubble hash.
22b
CA 2911168 2018-06-15
<13> A non-viable edible product comprising the cannabis plant or part
thereof of any one
of <1>-<6>, wherein the plant or part thereof comprises the plant cell of any
one of <1>-
<6>.
<14> A non-viable edible product comprising the cannabis extract of any one
of <11>-
<12>.
<15> The cannabis plant cell of any one of <1>-<6>, wherein the cannabis
plant was
generated from a seed deposited under NCIMB No. 42248.
<16> The cannabis plant cell of any one of <1>-<6>, wherein the cannabis
plant was
generated from a seed deposited under NCIMB No. 42249.
<17> The cannabis plant cell of any one of <1>-<6>, wherein the cannabis
plant was
generated from a seed deposited under any one of NCIMB NOs. 42248 and 42249.
<18> A non-viable compressed cannabis pellet for smoking or
vaporization, wherein the
pellet comprises the cannabis plant cell of any one of <1>-<6> or <15>-<17>.
<19> A non-viable compressed cannabis pellet for smoking or vaporization,
wherein the
pellet comprises cannabis extract from any one of <11>-<12>.
<20> The non-viable compressed cannabis pellet of any one of <18>-<19>,
wherein the
pellet is in the shape of a truncated cone.
<21> The non-viable compressed cannabis pellet of <20>, wherein said
truncated cone has
a height of 2.0 millimeters, a smaller base diameter of 4.0 millimeters, and a
larger base
diameter of 6.0 millimeters.
<22> The non-viable compressed cannabis pellet of any one of <18>-<19>,
wherein the
pellet is in the shape of a donut.
22c
CA 2911168 2018-06-15
<23> The non-
viable compressed cannabis pellet of <22> , wherein said donut has a height
of 2.0 millimeters, an inner donut diameter of 1.5 millimeters, and an outer
donut diameter
of 6 millimeters.
<24> Use of a prescribed amount of the cannabis plant cell defined in any
one of <1>-<6>
or <15>-<17> for treating Brachial Plexus Avulsion in a patient, wherein said
patient
experiences symptom relief due to said cannabis with reduced
tetrahydrocannabinol
(THC) side effects compared to use of a cannabis plant cell comprising a BT/BT
genotype.
<25> The use of <24>, wherein the cannabis plant cell is in a form of a
cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<26> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating seizures in a patient, wherein said patient
experiences a reduced
number of seizures due to said cannabis, with reduced tetrahydrocannabinol
(THC) side
effects compared to use of a cannabis plant cell comprising a BT/BT genotype.
<27> The use
of <26>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<28> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating arthritis in a patient, wherein said patient
experiences joint
pain relief due to said cannabis, with reduced tetrahydrocannabinol (THC) side
effects
compared to use of a cannabis plant cell comprising a BT/BT genotype.
<29> The use
of <28>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprise
the plant cell
of any one of <1>-<6> or <15>-<17>.
<30> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <I 5>-<17> for treating motion sickness in a patient, wherein said patient
experiences
reduced motion sickness symptoms due to said cannabis, with reduced
22d
CA 2911168 2018-06-15
tetrahydrocannabinol (THC) side effects compared to use of a cannabis plant
cell
comprising a BT/BT genotype.
<31> The use
of <30>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<32> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating neuropathic pain in a patient, wherein said patient
experiences
reduced pain symptoms due to said cannabis, with reduced tetrahydrocannabinol
(THC)
side effects compared to use of a cannabis plant cell comprising a BT/BT
genotype.
<33> The use
of <32>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<34> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for weight loss in a patient wishing to lose weight, wherein said
patient
experiences accelerated weight loss due to said cannabis, with reduced
tetrahydrocannabinol (THC) side effects compared to use of a cannabis plant
cell
comprising a BT/BT genotype.
<35> The use
of <34>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<36> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating depression in a patient, wherein said patient
experiences
reduced symptoms due to said cannabis, with reduced tetrahydrocannabinol (THC)
side
effects compared to use of a cannabis plant cell comprising a BT/BT genotype.
<37> The use
of <36>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
22e
CA 2911168 2018-06-15
<38> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating irritable bowel syndrome in a patient, wherein said
patient
experiences reduced symptoms due to said cannabis, with reduced
tetrahydrocannabinol
(THC) side effects compared to use of a cannabis plant cell comprising a BT/BT
genotype.
<39> The
use of <38>, wherein the cannabis plant cell is in a form of a cannabis
extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<40> Use of
a prescribed amount of the cannabis plant cell defined in any one of <1>-<6>
or <15>-<17> for treating pain from cancer in a patient, wherein said patient
experiences
reduced pain symptoms due to said cannabis, with reduced tetrahydrocannabinol
(THC)
side effects compared to use of a cannabis plant cell comprising a BT/BT
genotype.
<41> The
use of <40>, wherein the cannabis plant cell is in a form of a cannabis
extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<42> Use of a prescribed amount of the cannabis plant cell defined in any
one of <1>-<6>
or <15>-<17> for improving cholesterol in a patient, wherein said patient
experiences a
lowering of cholesterol and/or increase in HDL cholesterol due to said
cannabis, with
reduced tetrahydrocannabinol (THC) side effects compared to use of a cannabis
plant cell
comprising a BT/BT genotype.
<43> The
use of <42>, wherein the cannabis plant cell is in a form of a cannabis
extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<44> Use of a prescribed amount of the cannabis plant cell defined in any
one of <1>-<6>
or <15>-<17> for treating psychosis related diseases in a patient, wherein
said patient
experiences reduced psychosis symptoms due to said cannabis, with reduced THC
side
effects compared to use of a cannabis plant cell comprising a BT/BT genotype.
22f
CA 2911168 2018-06-15
<45> The use
of <44>, wherein the cannabis plant cell is in a form of a cannabis extract
or an edible product and the cannabis extract or the edible product comprises
the plant cell
of any one of <1>-<6> or <15>-<17>.
<46> A bubble packaging for storing and shipping cannabis comprising:
(i) a sealable storage space comprising (a) a non-viable plant part,
wherein the non-viable plant part comprises the plant cell of any one of <1>-
<6> or
<15>-<17> or (b) the extract as defined in any one of <11>-<12>; and
(ii) a modified atmosphere within said sealable space;
wherein said bubble packaging increases the shelf life of said non-viable
plant part or
extract, beyond that of a control cannabis plant part or extract, which is
unpackaged or
placed in a traditional jar or bag without the modified atmosphere.
<47> The
bubble packaging for storing and shipping cannabis of <46>, wherein said
modified atmosphere comprises a vacuum.
<48> A
method of vaporizing cannabis, said method comprising: placing the cannabis
plant cell as defined in any one of <1>-<6> or <15>-<17>, in a zero-point
delivery device,
turning the zero-point delivery device on, and vaporizing said cannabis.
<49> A dry,
non-viable (i) cannabis plant or (ii) part thereof, wherein said cannabis
plant
or part thereof, comprises a female inflorescence, said inflorescence
comprising:
a) a tetrahydrocannabinol (THC) content that is at least 3% and a cannabidiol
(CBD) content that is at least 3%;
b) a BT allele and a BD allele;
C) a terpene profile in which beta caryophyllene is the dominant terpene; and
d) a terpene oil content greater than 1%;
wherein the terpene profile is defined as terpinolene, alpha phellandrene,
beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene
oxide, and myrcene, and wherein the terpene oil content is the additive
content of the
terpenes in the terpene profile; wherein the THC, CBD, and terpene oil content
are
measured by gas chromatography-flame ionization detection (GC-FID) and
calculated
22g
CA 2911168 2018-06-15
based on dry weight of the inflorescence, and wherein samples of seed that
produce plants
comprising a), b), c) and d) have been deposited under NCIMB NOs. 42248 and
42249.
<50> The
dry, non-viable (i) cannabis plant or (ii) part thereof of <49>, wherein the
terpene oil content is greater than 1.5%.
<51> The
dry, non-viable (i) cannabis plant or (ii) part thereof of any one of <49>-
<50>,
wherein the inflorescence comprises a maximum terpene oil content of 2.17%.
<52> The dry, non-viable (i) cannabis plant or (ii) part thereof of any one
of <49>-<51>,
wherein the THC content is at least 4%.
<53> The
dry, non-viable (i) cannabis plant or (ii) part thereof of any one of <49>-
<52>,
wherein the THC content is at least 6%.
<54> The
dry, non-viable (i) cannabis plant or (ii) part thereof of <49>-<53>, wherein
the
CBD content is at least 5%.
<55> An
assemblage of dry, non-viable female inflorescences from (i) cannabis plants
or
(ii) parts of the plants, wherein said inflorescences comprise:
a) a tetrahydrocannabinol (THC) content that is at least 3% and a cannabidiol
(CBD) content that is at least 3%;
b) a BT allele and a BD allele;
c) a terpene profile in which beta caryophyllene is the dominant terpene; and
d) a terpene oil content greater than 1%;
wherein the terpene profile is defined as terpinolene, alpha phellandrene,
beta ocimene,
carene, limonene, gamma terpinene, alpha pinene, alpha terpinene, beta pinene,
fenchol,
camphene, alpha terpineol, alpha humulene, beta caryophyllene, linalool,
caryophyllene
oxide, and myrcene, and wherein the terpene oil content is the additive
content of the
terpenes in the terpene profile; wherein the THC, CBD, and terpene oil content
are
measured by gas chromatography-flame ionization detection (GC-FID) and
calculated
based on dry weight of the inflorescences, and wherein samples of seed that
produce plants
comprising a), b), c) and d) have been deposited under NCIMB NOs. 42248 and
42249.
22h
CA 2911168 2018-06-15
<56> The assemblage of dry, non-viable female inflorescences of <55>,
wherein the
terpene oil content is greater than 1.5%.
<57> The assemblage of dry, non-viable female inflorescences of any one
of <55>-<56>,
wherein the inflorescences comprise a maximum terpene oil content of 2.17%.
<58> The assemblage of dry, non-viable female inflorescences of any one
of <55>-<57>,
wherein the THC content is at least 4%.
<59> The assemblage of dry, non-viable female inflorescences of any one of
<55>-<58>,
wherein the THC content is at least 6%.
<60> The assemblage of dry, non-viable female inflorescences of any one
of <55>-<59>,
wherein the CBD content is at least 5%.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure Bar graph of the relative terpene contents (y-axis) of
cannabis blends fx-axis)
used for Week I volunteer trials. Each sample comparison pair was blended to
produce similar
terpene profiles so as to compare the effects of added CBD.
22i
CA 2911168 2018-06-15
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Figure 2- Sample questionnaire used for volunteer trials. Questionnaire was
provided to
volunteers with each cannabis blend sample to measure the effects of the
sample when smoked.
Figure 3- Bar graph of Weeks 1 and 2 trials feedback results combined. Values
are
presented as ratings for test sample minus control sample. Higher values
indicated increased
ratings for a category, while lower values indicated decreased ratings for a
category. CBD
containing samples showed decrease in mind and body high as well as increased
ability to
function.
Figure 4- Bar graph of the relative terpene contents (y-axis) of cannabis
blends (x-axis)
used for Week 5 volunteer trials. Each sample comparison pair was blended to
produce similar
terpene profiles so as to compare the effects of increased terpene oil
contents.
Figure 5- Bar graph of Week 5 trial feedback results. Values are presented as
ratings for
test sample minus control sample. Higher values indicate increased ratings for
a category, while
lower values indicate decreased ratings for a category. Samples containing
higher oil showed
increase in aroma and flavor and overall positive ratings.
Figure 6- Bar graph of the relative terpene contents (y-axis) of cannabis
blends (x-axis)
used for Week 7 volunteer trials. Each sample was blended to produce similar
cannabinoid
profiles so as to compare the effects of different terpene profiles. Control
Sample g
representative of traditional myrcene dominant terpene profiles.
Figure 7- Bar graph of Week 7 trial feedback results. Values are presented as
ratings for
each test sample minus control sample. Higher values indicated increased
ratings for a category,
while lower values indicated decreased ratings for a category. Samples labeled
A-F correspond
to the chemical analysis cannabis blends a-f of Figure 6. Samples containing
lower relative
myrcene contents showed increased positive ratings. Diverse and desirable
terpene profiles
demonstrated improved scores for recreational and medical uses. Terpinolene
dominant terpene
profiles showed increased scores for alertness and reduced anxiety. Ocimene
terpene profiles
showed increased mood scores.
Figure 8- Bar graph of the relative terpene contents (y-axis) of cannabis
blends (x-axis)
used for Week 3 volunteer trials. Each sample comparison pair was blended to
produce similar
terpene profiles so as to compare the effects of added THCV.
Figure 9- Bar graph of Weeks 3 and 4 trials feedback results combined. Values
are
presented as ratings for test sample minus control sample. Higher values
indicated increased
23
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
ratings for a category, while lower values indicate decreased ratings for a
category. THCV
containing samples showed decrease in mind and body high as well as increased
ability to
function.
Figure 10- Diagram outlining major sections of feedback cultivation system. A
computing apparatus integrates data from patient management system and plant
growth
environment management system to produce specialty cannabis tailored for
various medicinal or
recreational purposes.
Figure 11- Diagram. outlining environmental management system describing data
collection and environmental control.
Figure 12- Diagram outlining wireless data system integrating environmental
data cues
from sensors at multiple growth sites. Actuators allow for computer responses
to adjust
environmental conditions.
Figure 13- Example diagram of multiplexed cannabis mixtures in which base
cannabis
flower material is enhanced with cannabinoid and/or topene fortifiers to
create custom cannabis
blends for medicinal or recreational uses.
Figure 14- Example diagram of bubble pack dosing. Specialty cannabis,
multiplexed
cannabis medicines, cannabis extracts, or cannabis pellets can be packaged
into individual doses
for consumers in a modified air or vaccum environment to extend shelf
life/quality of product.
Figure 15- Example diagrams of "truncated cone" pressed pellet shapes.
Figure 16- Example diagrams of "donut shape" pressed pellet shapes.
Figure 17- Example diagram of a die for the production of cannabis pellets.
Figure 18- Example diagram of one embodiment of the vaporizer device of the
present
invention. Vaporizer may include dosage selection switches allowing the user
to switch between,
or combine various vaporizable substrates. R1-R4 on the diagram indicate the
activation sites for
the corresponding dosage strips. A on the diagram is the dose selector. B on
the diagram is the
dose activator. 1 on the diagram is the speaker. 2 on the diagram is the LED
light. 3 on the
diagram is the DC dock.
Figure 19- Example diagram of one embodiment of the dosage strips of the
present
invention. Each sample is placed with its own heating element so as to be able
to switch between,
or combine various vaporizing substrates.
24
CA 02911168 2016-07-20
DETAILED DESCRIPTION OF THE INVENTION
The following description includes information that may be useful in
understanding the
present invention. It is not an admission that any of the information provided
herein is prior art
or relevant to the presently claimed inventions, or that any publication
specifically or implicitly
referenced is prior art.
Definitions
As used herein, the verb "comprise" as is used in this description and in the
claims and its
conjugations are used in its non-limiting sense to mean that items following
the word are
included, but items not specifically mentioned are not excluded.
113 The invention provides cannabis plants. As used herein, the term
"plant" refers to plants in
the genus of Cannabis and plants derived thereof. Such as cannabis plants
produced via asexual
reproduction and via seed production.
The invention provides plant parts. As used herein, the term "plant part"
refers to any part
of a plant including but not limited to the embryo, shoot, root, stem, seed,
stipule, leaf, petal,
flower bud, flower, ovule, bract, trichome, branch, petiole, internode, bark,
pubescence, tiller,
rhizome, frond, blade, ovule, pollen, stamen, and the like. The two main parts
of plants grown in
some sort of media, such as soil or vermiculite, are often referred to as the
"above-ground" part,
also often referred to as the "shoots," and the "below-ground" part, also
often referred to as the
"roots". Plant part may also include certain extracts such as kief or hash
which includes cannabis
trichomes or glands.
As used herein, the term dominant refers to a terpene that is the most
abundant in the
terpene profile either in absolute content as a % by dry weight, or in
relative content as a % of
the terpene profile.
The term "a" or "an" refers to one or more of that entity; for example, "a
gene" refers to
one or more genes or at least one gene. As such, the terms "a" (or "an"), "one
or more" and "at
least one" are used interchangeably herein. In addition, reference to "an
element" by the
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
indefinite article "a" or "an" does not exclude the possibility that more than
one of the elements
is present, unless the context clearly requires that there is one and only one
of the elements.
As used herein, a "landrace" refers to a local variety of a domesticated plant
species
which has developed largely by natural processes, by adaptation to the natural
and cultural
environment in which it lives. The development of a landrace may also involve
some selection
by humans but it differs from a formal breed which has been selectively bred
deliberately to
conform to a particular formal, purebred standard of traits.
The International Code of Zoological Nomenclature defines rank, in the
nomenclatural
sense, as the level, for nomenclatural purposes, of a taxon in a taxonomic
hierarchy (e.g., all
families are for nomenclatural purposes at the same rank, which lies between
superfamily and
subfamily). While somewhat arbitrary, there are seven main ranks defined by
the international
nomenclature codes: kingdom, phylum/division, class, order, family, genus, and
species.
The invention provides plant cultivars. As used herein, the term "cultivar"
means a group
of similar plants that by structural features and performance (i.e.,
morphological and
physiological characteristics) can be identified from other varieties within
the same species.
Furthermore, the term "cultivar" variously refers to a variety, strain or race
of plant that has been
produced by horticultural or agronomic techniques and is not normally found in
wild populations.
The terms cultivar, variety, strain and race are often used interchangeably by
plant breeders,
agronomists and farmers.
The term "variety" as used herein has identical meaning to the corresponding
definition
in the International Convention for the Protection of New Varieties of Plants
(UPOV treaty), of
Dec. 2, 1961, as Revised at Geneva on Nov. 10, 1972, on Oct. 23, 1978, and on
Mar. 19, 1991.
Thus, "variety" means a plant grouping within a single botanical taxon of the
lowest known rank,
which grouping, irrespective of whether the conditions for the grant of a
breeder's right are fully
met, can be i) defined by the expression of the characteristics resulting from
a given genotype or
combination of genotypes, ii) distinguished from any other plant grouping by
the expression of at
least one of the said characteristics and iii) considered as a unit with
regard to its suitability for
being propagated unchanged.
As used herein, the term "inbreeding" refers to the production of offspring
via the mating
between relatives. The plants resulting from the inbreeding process are
referred to herein as
"inbred plants" or "inbreds."
26
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The term LOQ as used herein refers to the limit of quantitation for Gas
Chromatography
(GC) and High Performance Liquid Chromatography measurements.
The term secondary metabolites as used herein refers to organic compounds that
are not
directly involved in the normal growth, development, or reproduction of an
organism. In other
words, loss of secondary metabolites does not result in immediate death of
said organism.
The term single allele converted plant as used herein refers to those plants
which are
developed by a plant breeding technique called backcrossing wherein
essentially all of the
desired morphological and physiological characteristics of an inbred are
recovered in addition to
the single allele transferred into the inbred via the backcrossing technique.
The invention provides samples. As used herein, the term. "sample" includes a
sample
from a plant, a plant part, a plant cell, or from a transmission vector, or a
soil, water or air sample.
The invention provides offspring. As used herein, the term "offspring" refers
to any plant
resulting as progeny from a vegetative or sexual reproduction from one or more
parent plants or
descendants thereof. For instance an offspring plant may be obtained by
cloning or selling of a
parent plant or by crossing two parent plants and include selfings as well as
the Fl or F2 or still
further generations. An F 1 is a first-generation offspring produced from
parents at least one of
which is used for the first time as donor of a trait, while offspring of
second generation (F2) or
subsequent generations (F3, F4, etc.) are specimens produced from selfings of
Fl 's, F2's etc. An
F I may thus be (and usually is) a hybrid resulting from a cross between two
true breeding
parents (true-breeding is homozygous for a trait), while an F2 may be (and
usually is) an
offspring resulting from self-pollination of said Fl hybrids.
The invention provides methods for crossing a first plant with a second plant.
As used
herein, the term "cross", "crossing", "cross pollination" or "cross-breeding"
refer to the process
by which the pollen of one flower on one plant is applied (artificially or
naturally) to the ovule
(stigma) of a flower on another plant. Backcrossing is a process in which a
breeder repeatedly
crosses hybrid progeny, for example a first generation hybrid (F1), back to
one of the parents of
the hybrid progeny. Ba.ckcrossing can be used to introduce one or more single
locus conversions
from one genetic background into another.
The invention provides donor plants and recipient plants. As used herein,
"donor plants"
refer to the parents of a variety which contains the gene or trait of interest
which is desired to be
introduced into a second variety (e.g., "recipient plants").
27
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the present invention provides methods for obtaining
plant
genotypes comprising recombinant genes. As used herein, the term "genotype"
refers to the
genetic makeup of an individual cell, cell culture, tissue, organism (e.g., a
plant), or group of
organisms.
In some embodiments, the present invention provides homoz:ygotes. As used
herein, the
term "homozygote" refers to an individual cell or plant having the same
alleles at one or more
loci.
In some embodiments, the present invention provides homozygous plants. As used
herein,
the term "homozygous" refers to the presence of identical alleles at one or
more loci in
homologous chromosomal segments.
In some embodiments, the present invention provides hemizygotes. As used
herein, the
term "hemizygotes" or "hemizygous" refers to a cell, tissue, organism or plant
in which a gene is
present only once in a genotype, as a gene in a haploid cell or organism, a
sex-linked gene in the
heterogametic sex, or a gene in a segment of chromosome in a diploid cell or
organism where its
partner segment has been deleted.
In some embodiments, the present invention provides heterozygotes. As used
herein, the
terms "beterozygote" and "heterozygous" refer to a diploid or polyploid
individual cell or plant
having different alleles (forms of a given gene) present at least at one
locus. In some
embodiments, the cell or organism is heterozygous for the gene of interest
which is under control
of the synthetic regulatory element.
The invention provides methods for obtaining plant lines comprising
recombinant genes.
As used herein, the term "line" is used broadly to include, but is not limited
to, a group of plants
vegetatively propagated from a single parent plant, via tissue culture
techniques or a group of
inbred plants which are genetically very similar due to descent from a common
parent(s). A
plant is said to "belong" to a particular line if it (a) is a primary
transformant (1'0) plant
regenerated from material of that line; (b) has a pedigree comprised of a TO
plant of that line; or
(c) is genetically very similar due to common ancestry (e.g., via inbreeding
or selling). In this
context, the term "pedigree" denotes the lineage of a plant, e.g. in terms of
the sexual crosses
affected such that a gene or a combination of genes, in heterozygous
(hemizygous) or
homozygous condition, imparts a desired trait to the plant.
28
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The invention provides open-pollinated populations. As used herein, the terms
"open-
pollinated population" or "open-pollinated variety" refer to plants normally
capable of at least
some cross-fertilization, selected to a standard, that may show variation but
that also have one or
more genotypic or phenotypic characteristics by which the population or the
variety can be
differentiated from others. A hybrid, which has no barriers to cross-
pollination, is an open-
pollinated population or an open-pollinated variety.
The invention provides self-pollination populations. As used herein, the term
"self-
crossing", "self pollinated" or "self-pollination" means the pollen of one
flower on one plant is
applied (artificially or naturally) to the ovule (stigma) of the same or a
different flower on the
sam.e plant.
The invention provides ovules and pollens of plants. As used herein when
discussing
plants, the term "ovule" refers to the female gametophyte, whereas the term
"pollen" means the
male gametophyte.
The invention provides plant tissue. As used herein, the term "plant tissue"
refers to any
part of a plant. Examples of plant organs include, but are not limited to the
leaf, stem, root, tuber,
seed, branch, pubescence, nodule, leaf axil, flower, pollen, stamen, pistil,
petal, peduncle, stalk,
stigma, style, bract, fruit, trunk, carpel, sepal, anther, ovule, pedicel,
needle, cone, rhizome,
stolen, shoot, pericarp, endosperm, placenta, berry, stamen, and leaf sheath.
The invention provides methods for obtaining plants comprising recombinant
genes
through transformation. As used herein, the term "transformation" refers to
the transfer of
nucleic acid (i.e., a nucleotide polymer) into a cell. As used herein, the
term "genetic
transformation" refers to the transfer and incorporation of DNA, especially
recombinant DNA,
into a cell.
The invention provides transformants comprising recombinant genes. As used
herein, the
term "transformant" refers to a cell, tissue or organism that has undergone
transformation. The
original transformant is designated as "TO" or "To." Selfing the TO produces a
first transformed
generation designated as "Ti" or "T1."
In some embodiments, the present invention provides plant varieties comprising
the
recombinant genes. As used herein, the term "variety" refers to a subdivision
of a species,
consisting of a group of individuals within the species that are distinct in
form or function from
other similar arrays of individuals.
29
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the present invention provides organisms with recombinant
genes.
As used herein, an "organism" refers any life form that has genetic material
comprising nucleic
acids including, but not limited to, prokaryotes, eukaryotes, and viruses.
Organisms of the
present invention include, for example, plants, animals, fungi, bacteria, and
viruses, and cells and
parts thereof.
In some embodiments, the specialty cannabis varieties of the present invention
reduce the
myrcene "couch lock" effects. As used herein, the term couch lock is defined
as a heavy body
high which reduces the ability of users to function, and is associated with
lethargy and lack of
motivation.
In some embodiments, the present invention teaches the use of cannabis
sludges. As used
herein, cannabis sludges are solvent-free cannabis extracts made via multigas
extraction
including the refrigerant 134A., butane, iso-butane and propane in a ratio
that delivers a very
complete and balanced extraction of cannabinoids and essential oils.
Cannabis
Cannabis has long been used for drug and industrial purposes including for
fiber (hemp),
for seed and seed oils, for medicinal purposes, and as a recreational drug.
Industrial hemp
products are made from Cannabis plants selected to produce an abundance of
fiber. Some
Cannabis strains have been bred to produce minimal levels of THC, the
principal psychoactive
constituent responsible for the psychoactivity associated with marijuana.
Marijuana has
historically consisted of the dried flowers of Cannabis plants selectively
bred to produce high
levels of THC and other psychoactive cannabinoids. Various extracts including
hashish and hash
oil are also produced from the plant.
Cannabis is diploid, having a chromosome complement of 2n=20, although
polyploid
individuals have been artificially produced. The first genome sequence of
Cannabis, which is
estimated to be 820 Mb in size, was published in 2011 by a team of Canadian
scientists (Bakel et
al, "The draft genome and transcriptome of Cannabis sativa" Genome Biology
12:R102).
All known strains of Cannabis are wind-pollinated and the fruit is an achene.
Most strains
of Cannabis are short day plants, with the possible exception of C. sativa
subsp. sativa var.
spontanea (= C. ruderalis), which is commonly described as "auto-flowering"
and may be day-
neutral.
CA 02911168 2016-07-20
The genus Cannabis was formerly placed in the Nettle (Urticaceae) or Mulberry
(Moraceae) family, and later, along with the Hurnulus genus (hops), in a
separate family, the
IIemp family (Cannabaceae sensu stricto). Recent phylogenetic studies based on
cpDNA
restriction site analysis and gene sequencing strongly suggest that the
Cannabaceae sensu stricto
arose from within the former Celtidaceae family, and that the two families
should be merged to
form a single monophyletic family, the Cannabaceae sensu lato.
Cannabis plants produce a unique family of terpeno-phenolic compounds called
cannabinoids. Cannabinoids, terpenoids, and other compounds are secreted by
glandular
trichomes that occur most abundantly on the floral calyxes and bracts of
female plants. As a drug
it usually comes in the form of dried flower buds (marijuana), resin
(hashish), or various extracts
collectively known as hashish oil. There are at least 483 identifiable
chemical constituents
known to exist in the cannabis plant (Rudolf Brenneisen, 2007, Chemistry and
Analysis of
Phytocannabinoids (cannabinoids produced produced by cannabis) and other
Cannabis
Constituents, In Marijuana and the Cannabinoids, ElSohly, ed.; and at least 85
different
cannabinoids have been isolated from the plant (El-Alfy, Abir T, et al., 2010,
"Antidepressant-
like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated
from Cannabis sativa
L", Pharmacology Biochemistry and Behavior 95 (4): 434-42. The two
cannabinoids usually
produced in greatest abundance are cannabidiol (CBD) and/or A9-
tetrahydrocannabinol (THC).
THC is psychoactive while CBD is not. See, ElSohly, ed. (Marijuana and the
Cannabinoids,
Humana Press Inc., 321 papers, 2007), for a detailed description and
literature review on the
cannabinoids found in marijuana.
Cannabinoids are the most studied group of secondary metabolites in cannabis.
Most exist
in two forms, as acids and in neutral (decarboxylated) forms. The acid form is
designated by an
"A" at the end of its acronym (i.e. THCA). The phytocannabinoids are
synthesized in the plant
as acid forms, and while some decarboxylation does occur in the plant, it
increases significantly
post-harvest and the kinetics increase at high temperatures. (Sanchez and
Verpoorte 2008). The
biologically active forms for human consumption are the neutral forms.
Decarboxylation is
usually achieved by thorough drying of the plant material followed by heating
it, often by either
combustion, vaporization, or heating or baking in an oven. Unless
31
CA 02911168 2016-07-20
otherwise noted, references to cannabinoids in a plant include both the acidic
and
decarboxylated versions (e.g., CBD and CBDA).
The cannabinoids in cannabis plants include, but are not limited to, 49-
Tetrahydrocannabinol (49-THC), 48-Tetrahydrocannabinol (A8-THC),
Cannabichromene
(CBC), Cannabicyclol (CBL), Cannabidiol (CBD), Cannabielsoin (CBE),
Cannabigerol (CBG),
Cannabinidiol (CBND), Cannabinol (CBN), Cannabitriol (CBT), and their propyl
homologs,
including, but are not limited to cannabidivarin (CBDV), A9-
Tetrahydrocannabiyarin (THCV),
cannabichromevarin (CBCV), and cannabigerovarin (CBGV). See Holley et al.
(Constituents of
Cannabis sativa L. XI Cannabidiol and cannabichromene in samples of known
geographical
origin, J. Pharm. Sci. 64:892-894, 1975) and De Zeeuw et al. (Cannabinoids
with a propyl side
chain in Cannabis, Occurrence and chromatographic behavior, Science 175:778-
779). Non-
THC cannabinoids can be collectively referred to as "CBs", wherein CBs can be
one of THCV,
CBDV, CBGV, CBCV, CBD, CBC, CBE, CBG, CBN, CBND, and CBT cannabinoids.
In one embodiment, the present invention provides specialty cannabis plants,
which are
distinct from the traditional recreational marijuana plants.
As used herein, 'specialty cannabis refers to cannabis plants, lines,
varieties and cultivars
having a THC content based on the dry weight of plant inflorescences less than
or equal to 90%
(i.e., THC <90%) and having a CBs content based on the dry weight of plant
inflorescences
equal to or greater than 1.0% (e.g., CBD, CBDV, THCV, or CBG of >1.0%); or,
alternatively,
having a THC:CBs ratio of 1:20 or greater and approaching 1:1 or greater based
on the dry
weight of plant inflorescences.
As a result of the present invention, select cannabis varieties can be used as
a physician-
recommended form of medicine or herbal therapy without causing any side
effects, or with
reduced general or specific side effects when compared to traditional
recreational marijuana
plants. Methods for administration of medical cannabis include, but are not
limited, to vapor
inhalation, smoking (e.g., dried buds), drinking, eating extracts or food
products infused with
extracts, and taking capsules.
Cannabis Chemistry
32
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Cannabinoids are a class of diverse chemical compounds that activate
cannabinoid
receptors. Cannabinoids produced by plants are called phytocannabinoids,
a.k.a., natural
cannabinoids, herbal cannabinoids, and classical cannabinoids. At least 85
different cannabinoids
have been isolated from the cannabis plants (El-Alf y et al., 2010,
"Antidepressant-like effect of
delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis
saliva L",
Pharmacology Biochemistry and Behavior 95 (4): 434-42; Brenneisen, supra).
Typical
cannabinoids isolated from cannabis plants include, but are not limited to,
Tetrahydrocannabinol
(THC), Cannabidiol (CBD), CBG (Carmabigerol), CBC (Cannabichromene), CBL
(Cannabicyclol), CBV (Carmabivarin), THCV (Tetrahydrocannabivarin), CBDV
(Cannabidivarin), CBCV (Cannabichromevarin), CBGV (Cannabigerovarin), and CBGM
(Cannabigerol Monomethyl Ether). In the Cannabis plant, cannabinoids are
synthesized and
accumulated as cannabinoid acids (e.g., cannabidiolic acid (CBDA)). When the
herbal product
is dried, stored, or heated, the acids decarboxylize gradually or completely
into neutral forms
(e.g., CBDA CBD).
Y:''
Tetrahydrocannabinol (THC)
Known as delta-9-tetrahydrocarmabinol (A9-THC), THC is the principal
psychoactive
constituent (or cannabinoid) of the cannabis plant. The initially synthesized
and accumulated
form in plant is THC acid (THCA).
THC has mild to moderate analgesic effects, and cannabis can be used to treat
pain by
altering transmitter release on dorsal root ganglion of the spinal cord and in
the periaqueductal
gray. Other effects include relaxation, alteration of visual, auditory, and
olfactory senses, fatigue,
and appetite stimulation. TUC has marked antiemetic properties, and may also
reduce aggression
in certain subjects (Hoaken (2003). "Drugs of abuse and the elicitation of
human aggressive
behavior". Addictive Behaviors 28: 1533-1554).
The pharmacological actions of THC result from its partial agonist activity at
the
cannabinoid receptor CBI, located mainly in the central nervous system, and
the CB2 receptor,
mainly expressed in cells of the immune system (Pet/wee, 2006, "The
pharmacology of
33
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
cannabinoid receptors and their ligands: An overview." International Journal
of Obesity 30:
S13-S18.) The psychoactive effects of THC are primarily mediated by its
activation of CB1G-
protein coupled receptors, which result in a decrease in the concentration of
the second
messenger molecule cAMP through inhibition of adenylate cyclase (Elphick et
al., 2001, "The
neurobiology and evolution of cannabinoid signaling." Philosophical
Transactions of the Royal
Society B: Biological Sciences 356 (1407): 381-408.) It is also suggested that
THC has an
anticholinesterase action which may implicate it as a potential treatment for
Alzheimer's and
Myasthenia (Eubanks et al., 2006, "A. Molecular Link Between the Active
Component of
Marijuana and Alzheimer's Disease Pathology." Molecular Pharmaceutics 3 (6):
773-7).
In the cannabis plant, THC occurs mainly as tetrahydrocannabinolic acid
(THCA., 2-
COOH-THC). Geranyl pyrophosphate and olivetolic acid react, catalyzed by an
enzyme to
produce cannabigerolic acid, which is cyclized by the enzyme THC acid synthase
to give THCA.
Over time, or when heated, THCA is decarboxylated producing THC. The pathway
for THCA
biosynthesis is similar to that which produces the bitter acid humulone in
hops. See Fellermeier
et al., (1998, "Prenylation of olivetol.ate by a hemp transferase yields
cannabigerolic acid, the
precursor of tetrahydrocannabinor. FEBS Letters 427 (2): 283-5); de Meijer et
al. I, II, III, and
IV (.1: 2003, Genetics, 163:335-346; 11: 2005, Euphytica, 145:189-198; III:
2009, Euphytica,
165:293-311; and IV: 2009, Euphytica, 168:95-112.)
Non-limiting examples of THC variants include:
:
3, A:- ott
f
9 -m = 1.,..)...i, : :,õ,:
. , *..
WI ) l
--1,õ ....0, ,"õ 0 ; cr - - = , õ, - =
A9- 9
A9-
retahydrocannabinol- Tetrahydrocannabivari Tetrahydrocannabiorc
Tetrahydroc = abinol .
A9-THC-05C4 n ol
A9-THC-C4 A5-THCV-C3 A9-THCO-C1
I ,==
,
. A
L 'M
5 "I013
)
1
¨ = r.. \.,,,^=,...-^=
e)=
, i, õpi j jj,,i, a..x4sy 4 2,=`.
k.'N: 9ii : . . . , ,
...i.,..õ..,e.f....,-õ,.......õ: ."7õ...õ,õ:::.......õ-....õ el ii i
L . õ ,,,,
;
i tc =-=== .
8
itx".1)
A9-Tetrahydro- A9-Tetrahydro-
A9-Tetrahydro- A9-Tetrahydro-
e-Tetrahydro- cannabinolic acid-C4 cannabiorcolic
acid
cannabinolic acid A cannahivariaic acid A
A9-THCA-05 A cannabinolic acid B A and/or B A9-THCNIA-Cs A
A and/or B
A9-THCA-05B A9-THEA-c, A e-
THCOA-C1 A
34
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
and/or B and/or B
,==
==== c:41
0)4 ) .=
k ,k
)4µ.=kr r 9te
-/L)N = ,==== 7\7- No' =-"\-'"N
i
-trans-
(¨)-Ag-trans-
)- R)
(6aR10a-
(6aR,10aR)- (¨)-(6aS,1 OaR)-A8-
As T , etrahydrocannabinol
-i
Tetrahydrocaonabinol
Tetrahydrocannabinol (¨)-cis-A8-THC-05
1J
acid A
A-THC-05
A8-THCA-05 A
Cannabidiol (CBD)
CBD is a cannabinoid found in cannabis. Cannabidiol has displayed sedative
effects in
animal tests (Pickens, 1981, "Sedative activity of cannabis in relation to its
delta'-trans-
tetrahydrocannabinol and cannabidiol content". Br. J. Phannacol. 72 (4): 649-
56). Some
research, however, indicates that CBD can increase alertness, and attenuate
the memory-
impairing effect of THC. (Nicholson et al., June 2004, "Effect of Delta-9-
tetrahydrocannabinol
and cannabidiol on nocturnal sleep and early-morning behavior in young adults"
J (lin
Psychopharmacol 24 (3): 305-13; Morgan et al., 2010, "Impact of cannabidiol on
the acute
memory and psychotomimetic effects of smoked cannabis: naturalistic study, The
British Journal
of. Psychiatry, 197:258-290). It may decrease the rate of TI-IC clearance from
the body, perhaps
by interfering with the metabolism of THC in the liver. Medically, it has been
shown to relieve
convulsion, inflammation, anxiety, and nausea, as well as inhibit cancer cell
growth (Mechoulam,
et al., 2007, "Cannabidiol - recent advances". Chemistry & Biodiversity 4 (8):
1678-1692.)
Recent studies have shown cannabidiol to be as effective as atypical
antipsychotics in treating
schizophrenia (Zuardi et al., 2006, "Cannabidiol, a Cannabis sativa
constituent, as an
antipsychotic drug" Braz. J. Med. Biol. Res. 39 (4): 421-429.). Studies have
also shown that it
may relieve symptoms of dystonia (Consroe, 1986, "Open label evaluation of
cannabidiol in
dystonic movement disorders". The International journal of neuroscience 30
(4): 277-282).
CBD reduces growth of aggressive human breast cancer cells in vitro and
reduces their
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
invasiveness (McAllister et al., 2007, "Cannabidiol as a novel inhibitor of Id-
1 gene expression
in aggressive breast cancer cells". Mod. Cancer Ther. 6 (11): 2921-7.)
Cannabidiol has shown to decrease activity of the limbic system (de Souza
Crippa et al.,
"Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow".
Neuropsychopharmacology
29 (2): 417-426.) and to decrease social isolation induced by THC (Malon et
al., "Cannabidiol
reverses the reduction in social interaction produced by low dose A9-
tetrahydrocannabinol in
rats". Pharmacology Biochemistry and Behavior 93 (2): 91-96.) It's also shown
that Cannabidiol
reduces anxiety in social anxiety disorder (Bergamaschi et al., 2003,
"Cannabidiol Reduces the
A.nxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia
Patients".
Neuropsychopharmacology 36 (6): 1219-1226). Cannabidiol has also been shown as
being
effective in treating an often drug-induced set of neurological movement
disorders known as
dystonia (Snider et al., 1985, "Beneficial and Adverse Effects of Cannabidiol
in a Parkinson
Patient with Sinemet-Induced Dystonic Dyskinesia". Neurology, (Suppl 1): 201.)
Morgan et al.
reported that strains of cannabis which contained higher concentrations of
Cannabidiol did not
produce short-term memory impairment vs. strains which contained similar
concentrations of
THC (2010, "Impact of cannabidiol on the acute memory and psychotomimetic
effects of
smoked cannabis: naturalistic study: naturalistic study [corrected."]. British
Journal of
Psychiatry 197 (4): 285-90.)
Cannabidiol acts as an indirect antagonist of cannabinoid agonists. CBD is an
antagonist
at the putative new cannabinoid receptor, 0PR55. Cannabidiol has also been
shown to act as a 5-
HT1A receptor agonist, an action which is involved in its antidepressant,
anxiolytic, and
neuroprotective effects. Cannabidiol is also an allosteric modulator at the Mu
and Delta opioid
receptor sites.
Cannabis produces CBD-carboxylic acid through the same metabolic pathway as
nic,
until the last step, where CBDA synthase performs catalysis instead of THCA
synthase. See
Marks et al. (2009, "Identification of candidate genes affecting A9-
tetrahydrocannabino1
biosynthesis in Cannabis sativa". Journal of Experimental Botany 60 (13): 3715-
3726.) and
Meijer et al. I, II, III, and IV. Non-limiting examples of CBD variants
include:
f
c41 A e s:)
_______________________________________ 4:'4 144õõ.1.43,L
36
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
(-)-Cannabidiol Cannabidiol Cannabidiol-C4 (-)-
Cannabidivarin Cannabidiorcol
CBD-05 momomethyl ether CBD-C4 CBDV-C3 CBD-
C1
CBDM-05
e
....... : 1
==,'"Z5 Ow 0 ( µ). 9N 9
.;!,,..,... )
. ,it, 344......,.(.4i., 3;
=====< !! '! µ14'' 1===: =-=,:-- 'on
.-"=,.. i: :
=-= g= .:- .. \- 0,,x,..4)-,,,,-.,
:1
Cannahidiolic acid Cannabidivarinic acid
CBDA-05 CBDVA-C3
= H
".... '=,.
80 Cannabigerol (CBG)
CBG is a non-psychoactive cannabinoid found in the Cannabis genus of plants.
Cannabigerol is found in higher concentrations in hemp rather than in
varieties of Cannabis
cultivated for high THC content and their corresponding psychoactive
properties. Cannabigerol
has been found to act as a high affinity a2-adrenergic receptor agonist,
moderate affinity 5-
HT1A receptor antagonist, and low affinity CBI receptor antagonist. It also
binds to the CB2
receptor. Cannabigerol has been shown to relieve intraocular pressure, which
may be of benefit
in the treatment of glaucoma (Craig et al. 1984, "Intraocular pressure, ocular
toxicity and
neurotoxicity after administration of cannabinol or cannabigerol" Experimental
eye research 39
(3):251-259). Cannabigerol has also been shown to reduce depression in animal
models (US
Patent Application 11/760,364). Non-limiting examples of CBG variants include:
-
= Eri HO Qm
, A,
j rol.e...,...N.,..lt:::....,r,"Nom
..,..."......rj,' '.........,,,,,,'N, L '' ji õi
c...0;,........,.....,4. ...I
'.., . ,-,..----,......--....---==... :: Y '= cy-
"...,-4-- ''',...,"µNe''`.... 1`,:, c,A,::::::'=,,,'=.,
1 r),. ,ik, z
)3µ,. . eL, H
e"
Cannabigerol
Cannabigeml Cannabigerovarin
monomethyl ether Cannabinerolic acid A
(E)-CBG-05 (E)-3
(E)-CBGNI-05 A (Z)-CBGA-05 A CBGV-C
! r ii ! `1311 It cm 9
".......,... ....k. ......"....
L ,. ,.... .....
'V. e...., L. ...Ls 4. ',.. ,µ,...
.......,õ = :A. '
Cannabigerolic acid A Cannabigerolic acid A CannabigAzovarinic acid A
37
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
(E)-CBGA-05 A monomethyl ether (L)-CBGVA-C3 A
(E)-C13GAM-05 A
*H
Si
Cannabinol (CBN)
CBN is a psychoactive substance cannabinoid found in Cannabis sativa and
Cannabis
indicalafghanica. It is also a metabolite of tetrahydrocannabinol (rtic). CBN
acts as a weak
agonist of the CB l and CB2 receptors, with lower affinity in comparison to
THC.
examples of CBN variants include:
oii e =-=,1
3 = :
.0=As
sN't
Vs,p,
Cannabinol Cannabinol-C4 Cannabivarin Cannabino1-C2 Cannabionx)1
CB1-05 CBN-C4 CBN-C3 CBN-C2 CBN-C1
9E1
,1 =r
r
Cannabinolie acid A Cannabinol methyl ether
CBNA-05 A CBNM-05
0
1
HO Cannabichromene (CBC)
CBC bears structural similarity to the other natural cannabinoids, including
tetrahydrocannabinol, tetrahydrocannabivarin, carmabidiol, and cannabinol,
among others.
Evidence has suggested that it may play a role in the anti-inflammatory and
anti-viral effects of
cannabis, and may contribute to the overall analgesic effects of cannabis. Non-
limiting examples
of CBC variants include:
38
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
>es
Sek= ===== X
(
µ,..t.OZ'
t
: 2
=-=
VO
vti
( )-Cannabivarichromene,
( )-Cannabichromene = - (
)-Cannabichromevarinic
CBC-Cs ( )-Canriabichroineaic acid A W-Cannabichromevann
acid A
CBCA-Cs A CBCV-C3
CBCVA-C3 A
io = H
0*
Cannabivarin (CBV)
Cannabivarin, also known as cannabivarol or CBV, is a non-psychoactive
cannabinoid
found in minor amounts in the hemp plant Cannabis sativa. It is an analog of
cannabinol (CBN)
with the side chain shortened by two methylene bridges (-CH2-). CBV is an
oxidation product of
tetrahydrocannabivarin (THCV,
=H OH
HO Cannabidivarin (CBDV)
CBDV is a non-psychoactive cannabinoid found in Cannabis. It is a homolog of
carinabidiol (CBD), with the side-chain shortened by two methylene bridges
(CH2 units).
10
Cannabidivarin has been found reduce the number and severity of seizures in
animal models (US
Pat Application 13/075,873). Plants with relatively high levels of CBDV have
been reported in
feral populations of C. indica (= C. saliva ssp. indica var. kafiristanica)
from northwest India,
and in hashish from Nepal.
1.1 OH
N? Ni
¨TNO
Tetrahydrocannablvarin (THCV, 7'HV)
15 THCV,
or THY is a homologue of tetrahydrocannabinol (THC) having a propyl (3-
carbon) side chain. This terpeno-phenolic compound is found naturally in
Cannabis, sometimes
in significant amounts. Plants with elevated levels of propyl cannabinoids
(including THCV)
39
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
have been found in populations of Cannabis sativa L. ssp. indica (= Cannabis
indica Lam.) from
China, India, Nepal, Thailand, Afghanistan, and Pakistan, as well as southern
and western Africa.
THCV has been shown to be a CB1 receptor antagonist, i.e. it blocks the
effects of TI-IC.
Tetrahydrocannabinol has been shown to increase metabolism, help weight loss
and lower
cholesterol in animal models (US Pat Application 11/667,860)
H3c P144 ofi
I
.=".. .--- ,....e"-',...."--NscH3
H3 Cannabicyclol (CBL)
Cannabicyclol (CBI) is a non-psychotomimetic cannabinoid found in the Cannabis
species. CBI. is a degradative product like cannabinol. Light converts
cannabichromene to CBL.
Non-limiting examples of CBL variants include:
00
(71:.
gcs.
Ny:o=- .3,..=
i P ,
. ..,..
-4.-... .1i ,., ... 0---ke-s.----,---, r t
Ney, ...... .......... .......... 31 ! .., ''',-, ..,
e's.
NO ..... ...... ...
es.<314
( )-( I aS,3aR,811R,8cR)- ( )-( I aS,3aR,8bR,8cR)-
Cannabicyc101 (0( I aS,3aR,8bR,8cR)- Cannabicyclovarin
CBL-05 Cannabicyclolic acid A CBLV-C3
CBLA-05 A
OH
,e, OH
vs/(R) OH
0
6
=
Cannabitriol (CBT)
Non-limiting examples of CBT variants include:
r4A.k = iO4.4
k,,...3.k.
',.....4,=,,,,A., =-=.,..#.. , .s.,
r 0 1 js i ',I I- Il 1,-,--,-,- 2:r "rti,
,.....,..., .0 i
-7,;',,, =-k..,-,k, ...,,
-7,0,-= ...,:o. ......,e's,,,,,,, / so,',...:1:0,,,,,,,,,,,..... .,
4:::. .. .
/ .= Ks , ==== ,s3e; õ....,',.....,,,,., , $.1.7; '
'
2.144:k,
(¨)-(9R, 1 OR)-trans- (+)49S, 1 OS)- ( )- (¨)-(9R,10R)-trans- ( )-
Caunabitriol Cartuabitriol (9R, 10S/9S,10R)- 10-
0-Ethyl- (9R, 10R/9S, 1 OS)-
(¨)-trans-CBT-05 (+)-trans-CBT-05 Cannabitriol canuabitricl
Cannabitri 01-C3
CA 02911168 2015-10-30
WO 2015/065544 PCT/U
S2014/046694
( )-c/s-CBT-05 (-)-trans-CBT-OEt- ( )4rans-CBT-C3
C6
t= Po . --.... ..,';`,:t . r `--=== cm.
xa. -N., '4's -,:,,.t-3)"
l':!*1: 1
==: =
z:
I' I ........ ....
: : , .= ====`= = == ===
....4, .X. .=:/. " = ` :' '
1 ) ! / '0... N'V '''' ''
¨>ks , ',....4,',.....,=== - ..; : f I:
õ. =sty ....- ¨ ....-
-/-0.-=,,,,,....--, (-)-
(6aR,9S,10S,10aR)- (-)-6a,7,10a-
10-0xo-A6PA.H03)-
8,9-Dihydroxy-,163(10as,- Cannabidiolic acid A 9,10-Dihydroxy-
Trihydroxy-
tetrahydrocaanabino
tetrahydrocannabinol bexahydrocannabino A9-
caratabitriol ester 1
8,9-Di-OH-CBT-05 CBDA-059-0H-CBT- 1, tetrahydrocannabinol
OTHC
cs ester Cannabiripsol (-)-Cannabitetrol
Cannabiripsol-05
QH
/ H''. 0
H..,. - 1
.--'
0
H (annabielsoin-type (CBE)
Non-limiting examples of CBE variants include:
04 cliq S44 fõ,:"S
..,....:.." ..'..." eiTE , "' ====?.)
¨ .
= t C A.."' . ==.'f) i>
,,...- ,.- = i %. ii s *4.. i"s(:
...)Ci..i:.'. ( s's' = .'4'' \-
--k... isc ; 11
.v. ....k,
...... ......
--µ. ' 1 ¨µ=\")::'..P1 P.,:\vo:'..-.,---
4..so.i - 11õ....,
---. = 1 !: , r` s= + .........-4.
a ....i ....,... ss.
" .;..'
a
. ......¨
0- .01
cirs.0o
(5aS,6S,9R,9aR)- (5aS',6S,9R,9aR)- (5aS,6S,9R,9aR)-
(5aS,6S,9R,9aR)- (5aS,6S,9R,9aR)-
Cantiabielsoin CI-C'annabielsoin
Cannabie1soic acid A CI-Cannabielsoic
'aCannabielsoi cid B = '
CBE-05 CBE-C3 CBEA-05 A CBEA-05 B acid B
CBEA-C3B
i 1 ie
:;õ
I
--1, : ii '''-i= ii ......4 = ::
= ' ' = :;.. ,...
W.) - or'''' = ::õ.= =,... ...., s`s sy`).k"...."*".s..."'",......e"*N.
\ 0=Ake)1========'`,..,'",
i'i 8 8
Cannabig1endo1-C:3 Dehydmcannabifuran Cannabiftwan
OH-iso-HHCV-C3 DCBF-05 CBF-05
41
CA 02911168 2016-07-20
1 OH
(i'...-----'''''.!-L
ii
Cr"' '''''',.--'`=
11 H
....--`-, Cannabigerovarin (CBG V)
s 9 Oil
1
.6 7 2 0". i
0
= CBCV (Cannabichrontevarin)
9H
=t,-------.....---ik
f,
1 1 '
,..õ
CBGM (Cannabigerol Monomethyl Ether)
Biosynthetic pathway of cannabinoids has been studied. See Meijer et at. I,
II, III, and IV
(I: 2003, Genetics, 163:335-346; 11: 2005, Euphytica, 145:189-198; III: 2009,
Euphytico,
165:293-311; and IV: 2009, Euphytica, 168:95-112). According to the current
model, phenolic
5 precursors such as geranyl pyrophosphate (GPP) and polyketide, olivetolic
acid (OA) are
condensed by gera.nyl pyrophosphate olivetolate geranyltransferase (GOT) to
form
Cannabigerol acid (CBGA). Alternatively, GPP and divarine acid are condensed
by GOT to
form Cannabigerovarinic acid (CBGVA). CBGA or CBGAV is transformed to (1) CBC
by
CBC synthase or CBCV by CBC synthase; (2) THC by THC synthase or THCV by THC
to synthase; or (3) CBD by CBD synthase or CBDV by CBD synthase. The genes
coding for THC
synthase and CBD synthase are found on the same B locus. Thus cannabis plants
can be
categorized into THC-CBD chemotypes based on the state of the B locus B1/13T
(THC
producing, chemotype I), B0/130 (CBD producing, chemotype III), and BT/BD
(producing both
THC and CBD, chcmotype II). Additional information on the genetic regulation
of
cannabinoids can be found in Meijer et at. I, II, III, and IV (I: 2003,
Genetics, 163:335-346; II
2005, Ettphyticti, 145:189-198; III: 2009, Ettphytica, 165:293-311; and IV:
2009, Euphyfica,
168:95-112).
42
CA 02911168 2016-07-20
More details of cannabinoids synthesis and the properties and uses of these
cannabinoids
are described in Russo (2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364),
Russo et al.
(2006, A tale of two cannabinoids: the therapeutic rationale for combining
tetrahydrocannabinol and cannabidiol, Medical Hypothesis, 2006, 66:234-246),
Celia et al.
(Impact of cannabidiol on the acute memory and psychotomimetic effects of
smoked cannabis:
naturalistic study, The British Journal of Psychiatry, 201, 197:285-290), de
Mello Schier et al.,
(Cannabidiol, a cannabis sativa constituent, as an anxiolytic drug, Rev. Bras.
Psiquiatr, 2012,
34(S1):5104- 5117), and Zhomitsky et al. (Cannabidiol in Humans - the Quest
for Therapeutic
Targets, Pharmaceuticals, 2012, 5:529-552). Please see Table 1 for a non-
limiting list of
medical uses for cannabinoids.
20
43
Table 1- Non-limiting list of medical uses for cannabinoids.
MEDICAL USES CANNABINOID REFERENCES
c
1 Distonia, Akathisia (a) Consroe, 1986, The
International journal of neuroscience 30 (4): 277-282 ),J
CBD
7.
(Anti convulsant) (b) Snider et al., 1985,
Neurology, (Suppl 1): 201. ,
(a) Colasanti et al, Exp. Eye
Res. 30:251-259, 1984 s
Glaucoma (lowers
'll
v.
2 CBD (b) Gen. Pharmac. 15:479-484,
1984 4.
intraocular
4.
CBG (c) Craig et al. 1984,
Experimental eye research 39 (3):251-259
pressure)
Ischemic disease (a) U.S. PAT 6,630,507
3 (Alzheimer's, (b) Snider et al., 1985,
"Beneficial and Adverse Effects of Cannabidiol in a
Parkinson's, Down CBD Parkinson Patient with Sinemet-
Induced Dystonic Dyskinesia". Neurology, (Suppl 1)
Syndrome, HIV, 201.
Dementia)
Good for patients
treated with
2
.
."
4a oxidant-inducing
4a (a) U.S. PAT 6,630,507
0
4 agents for CBD
'.i.'
chemotherapy,
6-
ia
radiation.
t
Motion Sickness (a) US PAT 8,034,843 GW Pharma
experiments on Shrews
(Anti- emetic) CBD (b) Mechoulam, et al., 2007,
Chemistry & Biodiversity 4 (8): 1678-1692.
Pain- Brachial
TI-IC
6 plexus avulsion (a) US 200601355996W Pharma
THC:CBD
No
(-5
Pain and
1-3
8
7 inflammation- CBD: TI-IC US20080139667C
ct)
(b) Mechoulam, et al., 2007,
Chemistry & Biodiversity 4 (8): 1678-1692. b.)
Arthritis
0
.
(a) US20080262099
4a
p
Anti Cancer- cell CBD: THC
4a
8 (bj Mechoulam, et al., 2007,
Chemistry & Biodiversity 4 (8): 1678-1692. 0,
movement CBD
cr,
(c) McAllister et al., 2007, MoL
Cancer Ther. 6 (11): 2921-7. 4a
MEDICAL USES CANNASINOID REFERENCES
(a) US20120004251
(b) US20120165402
c
,...,
Anti Co n vulsant CBDV (d) Mechoulam, et al., 2007,
Chemistry & Biodiversity 4 (8): 1678-1692.
9
7.
(against seizures) CBD (a) Carlini et al., J. Clin.
Pharmacol. 21:417S-427S, 1981 ,
(b) Karler et al., J.
Clin.Pharmacol. 21:437S-448S, 1981
'll
4.
(c) Consroe et al., J. Clin
Pharmacol. 21:428S-436S, 1981 4..
Neurological Pain
THC: CBD (a) US20100035978
(MS related)
(b) US20090306221
11 Weight loss THCV
(c) US20080119544
12
Anti-Depressant CBG (a) US20080031977
(D) US 60/813,814
Irritable Bowel (c) EP 1361864
13 Syndrome THC:CBD (d) EP 1542657
(Crohns) (e) US20100286098
..'-
CA
14 Type TI diabetes THCV:CBD (a) US20110082195
0
6-
Anti-Psychotic THCV:CBD (c) US20110038958
'a
(d) Zuardi et al., 2006, Braz. I.
Med. Rio!. Res. 39 (4): 421-429. ow
16
Cancer Pain THC:CBD CO U520110230549
Anxiety Reduction (a) Mechoulam, et al., 2007,
Chemistry & Biodiversity 4 (8): 1678-1692.
17 CBD (b) Bergamaschi eta]., 2003,
Neuropsychopharmacology 36 (6): 1219-1226
.1 0
c - 5
1
it.
o
4:.
CA
VDC7'
4:.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Terpenes and Terpenoids in Cannabis Plants
Terpenes are a large and diverse class of organic compounds, produced by a
variety of
plants. They are often strong smelling and thus may have had a protective
function. Terpcnes arc
derived biosynthetically from units of isoprene, which has the molecular
formula C5F18. The
basic molecular formulae of terpenes are multiples of that, (C51-18),, where n
is the number of
linked isoprene units. The isoprene units may be linked together "head to
tail" to form linear
chains or they may be arranged to form rings. Non-limiting examples of
terpenes include
Hemiterpenes, Monoterpenes, Sesquiterpenes, Diterpenes, Sesterterpenes,
Triterpenes,
Sesquarterpenes, Tetraterpenes, Polyterpenes, and Norisoprenoids.
Terpenoids, a.k.a. isoprenoids, are a large and diverse class of naturally
occurring organic
chemicals similar to terpenes, derived from five-carbon isoprene units
assembled and modified
in thousands of ways. Most are multicyclic structures that differ from one
another not only in
functional groups but also in their basic carbon skeletons. Plant terpenoids
are used extensively
for their aromatic qualities. They play a role in traditional herbal remedies
and are under
investigation for antibacterial, antineoplastic, and other pharmaceutical
functions. The terpene
Linalool for example, has been found to have anti-convulsant properties
(Elisabetsky et al.,
Phytomedicine, May 6(2):107-13 1999). Well-known terpenoids include citral,
menthol,
camphor, salvinorin A in the plant Salvia divinorum, and the cannabinoids
found in Cannabis.
Non-limiting examples of terpenoids include, Hemiterpenoids, I isoprene unit
(5 carbons);
Monoterpenoids, 2 isoprene units (10C); Sesquiterpenoids, 3 isoprene units
(15C); Diterpenoids,
4 isoprene units (20C) (e.g. ginkgolides); Sesterterpenoids, 5 isoprene units
(25C); Tritetpenoids,
6 isoprene units (30C) (e.g. sterols); Tetraterpenoids, 8 isoprene units (40C)
(e.g. carotenoids);
and Polyterpenoid with a larger number of isoprene units.
Terpenoids are mainly synthesized in two metabolic pathways: mevalonic acid
pathway
(a.k.a. HMG-CoA reductase pathway, which takes place in the cytosol) and
MEP/DOXP
pathway (a.k.a. The 2-C-methyl-D-erythritol 4-phosphatell -deoxy-D-xylulose 5-
phosphate
pathway, non-mevalonate pathway, or mevalonic acid-independent pathway, which
takes place
in plastids). Geranyl pyrophosphate (GPP), which is used by cannabis plants to
produce
cannabinoids, is formed by condensation of dimethylallyl pyrophosphate
(D.N1APP) and
isopentenyl pyrophosphate (1PP) via the catalysis of GPP synthase.
Alternatively, DMAPP and
IPP are ligated by FPP synthasc to produce famcsyl pyrophosphate (FPP), which
can be used to
46
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
produce sesquiterpenoids. Geranyl pyrophosphate (GPP) can also be converted
into
monoterpenoids by limonene synthase.
In addition to cannabinoids, cannabis also produces over 120 different
terpenes (Russo
2011, Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid
entourage
effects, British Journal of Pharmacology, 163:1344-1364). Within the context
and verbiage of
this document the terms `terpertoid' and `terpene are used interchangeably.
Carinabinoids are
odorless, so terpenoids are responsible for the unique odor of cannabis, and
each variety has a
slightly different profile that can potentially be used as a tool for
identification of different
varieties or geographical origins of samples (Hillig 2004. "A chemotaxonomic
analysis of
terpenoid variation in Cannabis" Biochem System and Ecology 875-891). It also
provides a
unique and complex organoleptic profile for each variety that is appreciated
by both novice users
and connoisseurs. in addition to many circulatory and muscular effects, some
terpenes interact
with neurological receptors. A few terpenes produced by cannabis plants also
bind weakly to
Cannabinoid receptors. Some terpenes can alter the permeability of cell
membranes and allow in
either more or less THC, while other terpenes can affect serotonin and
dopamine chemistry as
neurotransmitters. Terpenoids are lipophilic, and can interact with lipid
membranes, ion channels,
a variety of different receptors (including both 0-protein coupled odorant and
neurotransmitter
receptors), and enzymes. Some are capable of absorption through human skin and
passing the
blood brain barrier.
Generally speaking, terpenes are considered to be pharmacologically relevant
when
present in concentrations of at least 0.05% in plant material (Hazekamp and
Fischedick 2010.
"Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids
for
chemotaxonomic and drug standardization purposes" Phytochemistry 2058-73;
Russo 2011,
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid
entourage effects,
British Journal of Pharmacology, 163:1344-1364). Thus, although there are an
estimated 120
different terpenes, only a few are produced at high enough levels to be
detectable, and fewer still
which are able to reach pharmacologically relevant levels.
For the purposes of this application, cannabis terpene profile will be defined
as the
absolute and relative values of 17 of the most expressed terpenes:
terpinolene, alpha phelladrene,
beta ocimene, carene, limonene, gamma terpinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphcnc, alpha terpincol, alpha humulene, beta caryophyllene,
linalool, cary oxide,
47
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
and myrcene. A survey of the terpene profiles of several cannabis varieties
has found that these
terpenes express at high enough levels so as to have their own pharmacological
effects and also
to act in synergy with cannabinoids. Both experts and consumers believe that
there are
biochemical and phenomenological differences between different varieties of
cannabis, which
are attributed to their unique relative cannabinoid and terpenoid ratios. This
is known as the
entourage effect and is generally considered to result in plants providing
advantages over only
using the natural products that are isolated from them (Russo 2011, Taming
THC: potential
cannabis synergy and phytocannabinoid-terpenoid entourage effects, British
Journal of
Pharmacology, 163:1344-1364).
These advantages include synergy with THC, the primary active ingredient, and
also
mitigation of side effects from. THC (McPartland and Russo 2001 "Cannabis and
Cannabis
Extracts: Greater Than the Sum of Their Parts?" Hayworth Press). Teipenoids
can be extracted
from the plant material by steam distillation (giving you essential oil) or
vaporization, however
the yield varies greatly by plant tissue, type of extraction, age of material,
and other variables
(McPartland and Russo 2001 "Cannabis and Cannabis Extracts: Greater Than the
Sum of Their
Parts?" Hayworth Press). Typically the yield of terpenoids in cannabis is less
than 1% by weight
on analysis; however it is thought that they may comprise up to 10% of the
trichome content.
Monoterpenoids are especially volatile, thus decreasing their yield relative
to sesquiterpenoids
(Russo 2011, Taming THC: potential cannabis synergy and phytocannabinoid-
terpenoid
entourage effects, British Journal of Pharmacology, 163:1344-1364).
D-Limonene is a monoterpenoid that is widely distributed in nature and often
associated
with citrus. It has strong anxiolytic properties in both mice and humans,
apparently increasing
serotonin and dopamine in mouse brain. D-limonene has potent anti-depressant
activity when
inhaled. It is also under investigation for a variety of different cancer
treatments, with some
focus on its hepatic metabolite, perillic acid. There is evidence for activity
in the treatment of
dermatophytes and gastro-oesophageal reflux, as well as having general radical
scavenging
properties (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
fl-Myreene is a monoterpenoid also found in cannabis, and has a variety of
pharmacological effects. It is often associated with a sweet fruit like taste.
It reduces
inflammation, aids sleep, and blocks hepatic carcinogenesis, as well as acting
as an analgesic and
48
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
muscle relaxant in mice. When 13-myrcene is combined with 6,9-THC it could
intensify the
sedative effects of .6,9-THC, causing the well-known "couch-lock" effect that
some cannabis
users experience (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
D-Linalool is a m.onoterpenoid with very well-known anxiolytic effects. It is
often
associated with lavender, and frequented used in aromatherapy for its sedative
impact. It acts as a
local anaesthetic and helps to prevent scaring from bums, is anti-nociceptive
in mice, and shows
antiglutamatergic and anticonvulsant activity. Its effects on glutamate and
GABA
neurotransmitter systems are credited with giving it its sedative, anxiolytic,
and anticonvulsant
activities (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-
terpenoid entourage effects, British Journal of Pharmacology, 163:1344-1364).
a-Pinene is a monotelpene common in nature, also with a plethora of effects on
mammals and humans. It acts as an acetylcholinesterase inhibitor which aids
memory and
counteracts the short-term memory loss associated with 6,9-THC intoxication,
is an effective
antibiotic agent, and shows some activity against MRSA. In addition, a-pinene
is a
bronchodilator in humans and has anti-inflammatory properties via the
prostaglandin E-1.
pathway (Russo 2011, Taming THC: potential cannabis synergy and
phytocannabinoid-terpenoid
entourage effects, British Journal of Pharmacology, 163:1344-1364).
ii-Caryophyllene is often the most predominant sesquiterpenoid in cannabis. It
is less
volatile than the monoterpenoids, thus it is found in higher concentrations in
material that has
been processed by heat to aid in decarboxylation. It is very interesting in
that it is a selective full
agonist at the CB2 receptor, which makes it the only phytocannabinoid found
outside the
cannabis genus. In addition, it has anti-inflammatory and gastric
cytoprotective properties, and
may even have anti-malarial activity.
Caryophyllene oxide is another sesquiterpenoid found in cannabis, which has
antifungal
and anti-platelet aggregation properties. As an aside, it is also the molecule
that drug-sniffing
dogs are trained to find (Russo 2011, Taming THC: potential cannabis synergy
and.
phytocannabinoid-terpenoid entourage effects, British Journal of Pharmacology,
163:1344-
1364).
Nerolidol is a sesquitapene that is often found in citrus peels that exhibits
a range of
interesting properties. It acts as a sedative, inhibits fungal growth, and has
potent anti-malarial
49
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
and antileishtnanial activity. It also alleviated colon adenomas in rats
(Russo 2011, Taming
THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage
effects, British
Journal of Pharmacology, 163:1394-1364). Phytol is a diterpene often found in
cannabis extracts.
It is a degradation product of chlorophyll and tocopherol. It increases GABA
expression and
therefore could be responsible the relaxing effects of green tea and wild
lettuce. It also prevents
vitamin-A induced teratogenesis by blocking the conversion of retinol to its
dangerous
metabolite, all-trans-retinoic acid (Russo 2011, Taming TI-IC: potential
cannabis synergy and
phytocannabinoid-terpenoid entourage effects, British Journal of Pharmacology,
163:1344-
1369).
Some of the most commonly found terpenoids in cannabis are summarized in Table
2,
with their individual organoleptic properties as well as their basic
pharmacology.
Table 2- A non-limiting list of the medical effects of some of the most common
terpenes found
in cannabis
Terpenoid Odor Description Flavor Description
Suggested Pharmacology
I
Woody, piney, Anti-inflammatory,
a -pinene , Herbal, piney
camphoraceous bronchodilator, stimulant
Reduces plasma cholesterol and
Camphoraceous,
catnphene Woody, piney triglycerides,
Antioxidant and free
cooling, minty
radical scavenger
b-pinerte Herbal, cooling, piney Fresh, piney, woody
Strong antimicrobial
Woody, vegetative, Anti-
inflammatory, sedative,
myrcene Spicy, herbaceous
citrus antibiotic,
analgesic
a -pheiiandrene i Terpenic, citrus Terpenic, citrus, lime
Antinociceptive
carene Citrus, sweet None given CNS
depressant, anti-infl amatory
. d -terpinene Woody, citrus, medicinal Terpenic, woody, piney
Antioxidant
i ..............
1--
I
Anxiolytic, antidepressant,
1 timonene Citrus, fresh Sweet, orange, citrus
immunostimulant
,
b-ociiie Floral, green Green, tropical, woody Possible
anti-bacterial
rerpenic, citrus, lime--- Terpenic, woody Antioxidant
like
Sweet, fresh, piney, Comforting, calming, anti-oxidant,
terpinoiene Herbal, woody
citrus antifungai
Citrus, orange, lemon, Sedative,
anxiolytic,
Iinalool Floral, citrus
1 floral immunostimulant
1 fencholCamphor, piney Fresh, piney Possible stimulant
i
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Sedative, AChE inhibitor,
a -terpineol Floral, piney None given
antioxidant
Selective agonist of C82 receptor,
b-caryophyllene Spicy, woody Spicy, dove, rosemary
anti-inflammatory, antimalarial
a-hurnulene ' Woody None given Anti-inflammatory
caryophydene
Woody, sweet None given Antitunga I,
stimulant
oxide
Cannabis Plants
Cannabis is an annual, dioecious, flowering herb. The leaves are palmately
compound or
digitate, with serrate leaflets. Cannabis normally has imperfect flowers, with
staminate "male"
and pistillate "female" flowers occurring on separate plants. It is not
unusual, however, for
individual plants to separately bear both male and female flowers (i.e., have
monoecious plants).
Although monoecious plants are often referred to as "hermaphrodites," true
hermaphrodites
(which are less common in cannabis) bear staminate and pistillate structures
on individual
flowers, whereas monoecious plants bear male and female flowers at different
locations on the
same plant.
The life cycle of cannabis varies with each variety but can be generally
summarized into
germination, vegetative growth, and reproductive stages. Because of heavy
breeding and
selection by humans, most cannabis seeds have lost dormancy mechanisms and do
not require
any pre-treatments or winterization to induce germination (See Clarke, RC et
al. "Cannabis:
Evolution and Ethnobotany" University of California Press 2013). Seeds placed
in viable growth
conditions are expected to germinate in about 3 to 7 days. The first true
leaves of a cannabis
plant contain a single leaflet, with subsequent leaves developing in opposite
formation. In some
embodiments, subsequent leaves develop with increasing number of Icafletts.
Leaflets can be
narrow or broad depending on the morphology of the plant grown. Cannabis
plants are normally
allowed to grow vegetatively for the first 4 to 8 weeks. During this period,
the plant responds to
increasing light with faster and faster growth. Under ideal conditions,
cannabis plants can grow
up to 2.5 inches a day, and are capable of reaching heights of up to 20 feet.
Indoor growth
pruning techniques tend to limit cannabis size through careful pruning of
apical or side shoots.
Although, some cannabis varieties will flower without the need for external
stimuli, most
varieties have an absolute requirement for inductive photoperiods in the form
of short days or
long nights to induce fertile flowering. The first sign of flowering in
cannabis is the appearance
51
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
of undifferentiated flower primordial along the main stem of the nodes. At
this stage, the sex of
the plants are still not distinguishable. As the flower primordia continue to
develop, female
(pistillate), and male (staminate) flowers can be distinguished.
For most cannabinoid producing purposes, only female plants are desired. The
presence
of male flowers is considered undesirable as pollination is known to reduce
the cannabinoid yield,
and potentially ruin a crop. For this reason, most cannabis is grown
"sinsemilla" through
vegetative (i.e., asexual) propagation. In this way, only female plants are
produced and no space
is wasted on male plants.
In breeding new varieties of cannabis, there are many phenotypic and
morphological
characteristics one must consider. For example, plants should produce high
amounts of
cannabinoids. Cannabinoid levels can be measured via chemical analysis of
mature plants, but
can also be estimated in the field by the number and size of the trichomes
produced by a plant's
flower clusters. Plants with dense trichome patterns are said to be "frosty",
and selected for
further breeding. The types of cannabinoids can also be determined in the
field via thin layer
chromatography (TLC) analysis (see "Cannabis Inflorescence & Leaf QC" from The
American
Herbal Pharmacopeia 2013). The absolute cannabinoid and terpene contents are
calculated based
on weight of cannabinoid or terpene present in a sample divided by the dried
weight of the dried
trimmed inflorescence. Dried inflorescences are harvested inflorescence tissue
dried to -- 10%
moisture level. The term trimmed inflorescence as used herein refers to
inflorescences with sun
leaves cut off such that only the calyx and reproductive buds remain. Frosty
leaves are left on the
inflorescence. Trimming can be performed manually, through careful manicuring
of harvested
tissue, or via automated mechanical methods.
Another important aspect of cannabis breeding is the terpene profile of a
plant. In some
embodiments, the present invention teaches the preference for cannabis plant
material with
diverse terpene profiles which are not dominated by myrcene. In other
embodiments, the present
invention teaches cannabis plants with high terpene essential oil contents.
For the purposes of
this application, a cannabis plant's terpene profile is defined in absolute or
relative contents of 17
key terpenes including: terpinolene, alpha phelladrene, beta ocimene, carene,
limonene, gamma
terpinene, alpha pinene, alpha terpinene, beta pinene, fenchol, camphene,
alpha terpineol, alpha
humulene, beta caryophyllene, linalool, cary oxide, and myrcene. A myrcene
dominant terpene is
used to refer to terpene profiles in which myrcene is the most abundant
terpene in the terpene
52
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
profile (i.e., myrcene relative or absolute content is greater than the
content of any single one of
the 16 other terpenes in the terpene profile). While the terpene profile is
meant to indicate that all
17 of the terpenes are assayed, one or more of the terpenes may not be present
at detectable
levels. Terpene essential oil contents are measured by adding the absolute
contents by weight of
the 17 terpenes from the terpene profile as defined above. The absolute
terpene content is
measured as w/w % value based on dry inflorescences. In some embodiments the
terpene
contents are measured via Gas Chromatography Flame Ionization Detection (GC-
FID). The
present invention is based in part on the discovery that consumers prefer
specialty cannabis
varieties with diverse terpene profiles not dominated by m3rrcene and with
high terpene essential
oil contents.
In some embodiments, the specialty cannabis of the present invention has
greater than
about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.4%,
1.6%, 1.8%,
2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, 3.2%, 3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%,
4.6%, 4.8%,
5%, 5.2%, 5.4%, 5.6%, 5.8%, 6%, 6.2%, 6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%,
7.8%, or 8%
terpene essential oil content by dry weight. Thus in some embodiments the
essential oil content
of the specialty cannabis varieties of the present invention is between about
0.5% and about 8%
by dry weight. In other embodiments the essential oil contents of the
specialty cannabis varieties
of the present invention is between about 1.5% and about 5% by dry weight.
In some embodiments, the specialty cannabis of the present invention has an
absolute
content of any one of the 17 terpenes in the terpene profile that is about 0%,
0.01%, 0.02%,
0.04 X,, 0.06%, 0.08%, 0.1%, 0.12%, 0.14%, 0.16%, 0.18%, 0.2%, 0.22%, 0.24%,
0.26%, 0.28%,
0.3%, 0.32%, 0.34%, 0.36%, 0.38%, 0.4%, 0.42%, 0.44%, 0.46%, 0.48%, 0.5%,
0.52%, 0.54%,
0.56%, 0.58%, 0.6%, 0.62%, 0.64%, 0.66%, 0.68%, 0.7%, 0.72%, 0.74%, 0.76%,
0.78%, 0.8%,
0.82%, 0.84%, 0.86%, 0.88%, 0.9%, 0.92%, 0.94%, 0.96%, 0.98%, 1%, 1.02%,
1.04%, 1.06%,
1.08%, 1.10%, 1.12%, 1.14%, 1.16%, 1.18%3.2%, 1.22%, 1.24%, 1.26%, 1.28%,
1.3%, 1.32%,
1.34%, 1.36%, 1.38%, 1.4%, 1.42%, 1.44%, 1.46%, 1.48%, 1.5%, 1.6%, 1.7% 1.8%,
1.9%, 2%,
2.2%, 2.4%, 2.6%, 2.8%, 3%, 3.2%, 3.4%, 3.6%, 3.8%, 4%, 4.2%, 4.3%, 4.4%,
4.6%, 4.8%, 5%,
5.2%, 5.4%, 5.6%, 5.8%, 6%, 6.2%, 6.4%, 6.6%, 6.8%, 7%, 7.2%, 7.4%, 7.6%,
7.8%, 8%, or
greater based on dry weight of inflorescence. Thus in some embodiments the
absolute content of
any one of the terpenes is between about .05% and about .85%.
53
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the specialty cannabis of the present invention has a
myrcene
absolute content of less than about 0.02%, 0.04%, 0.06%, 0.08%, 0.1%, 0.12%,
0.14%, 0.16%,
0.18%, 0.2%, 0.22%, 0.24%, 0.26%, 0.28%, 0.3%, 0.32%, 0.34%, 0.36%, 0.38%,
0.4%, 0.42%,
0.44%, 0.46%, 0.48%, 0.5%, 0.52%, 0.54%, 0.56%, 0.58%, 0.6%, 0.62%, 0.64%,
0.66%, 0.68%,
0.7%, 0.72%, 0.74%, 0.76%, 0.78%, 0.8%, 0.82%, 0.84%, 0.86%, 0.88%, 0.9%,
0.92%, 0.94%,
0.96%, 0.98%, 1%, 1.02%, 1.04%, 1.06%, 1.08%, 1.10%, 1.12%, 1.14%, 1.16%,
1.18%,1.2%,
1.22%, 1.24%, 1.26%, 1.28%, 1.3%, 1.32%, 1.34%, 1.36%, 1.38%, 1.4%, 1.42%,
1.44%, 1.46%,
1.48%, 1.5%, 1.6%, 1.7% 1.8%, 1.9%, 2%, 2.2%, 2.4%, 2.6%, 2.8%, 3%, 3.2%,
3.4%, 3.6%,
3.8%, 4%, 4.2%, 4.3%, 4.4%, 4.6%, 4.8%, 5%, 5.2%, 5.4%, 5.6%, 5.8%, 6%, 6.2%,
6.4%, 6.6%,
6.8%, 7%, 7.2%, 7.4%, 7.6%, 7.8%, or 8% based on dry weight of inflorescence.
Thus in some
embodiments the absolute content of any one of myrcene is between about .05%
and about .85%.
In some embodiments the terpene content of the specialty cannabis of the
present
invention is described in relative terms as a % composition of the total
terpene profile. Thus for
example a specialty cannabis with 1.2% absolute terpinolene content and 1.2%
myrcene content
and no other terpenes would be said to have 50% terpinolene and 50% myrcene
relative content.
In some embodiments, the specialty cannabis of the present invention has a
relative content of
any one of the 17 terpenes in the terpenc profile that is less than about 1%,
2%, 3%, 4%, 5%, 6%,
7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%,
23%,
24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%,
39%,
40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%,
55%,
56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%,
71%,
72%, 73%, 74%, 75%, 76%, 77%, 79%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%,
87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. Thus in
some
embodiments the relative content of any one of the terpenes is between 0% and
100 %.
in some embodiments, the specialty cannabis of the present invention has a
relative
content of any one of the 17 terpenes in the terpene profile that is greater
than about 1%, 2%, 3%,
4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%,
21%,
22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%,
37%,
38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%,
53%,
54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%,
69%,
70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 79%, 79%, 80%, 81%, 82%, 83%, 84%,
85%,
54
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.
Thus
in some embodiments the relative content of any one of the terpenes is between
0% and 100 %.
In some embodiments, the specialty cannabis of the present invention has a
relative
myrcene content of less than about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%,
11%, 12%,
13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%,
28%,
29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%,
44%,
45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%,
60%,
61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%,
76%,
77%, 79%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%,
93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. Thus in som.e embodiments the
specialty
cannabis of the present invention has less than about 60% relative m.yrcene
content. In some
embodiments the specialty cannabis of the present invention has less than
about 50% relative
tnyrcene content.
Another important breeding phenotype is flower color. The accumulation of
anthocyanins,
carotenoids, or other color-producing compounds in leaves and flowers of
cannabis can have an
effect on consumer visual appeal and flavor. Iconic examples of the appeal of
color are the
popular "Purple Kush", "Purple Haze", and "Purple Trainmeck" varieties that
express
anthocyanins in their late maturation stages to produce dark purple leaves.
Color selections can
also be based on (but not limited to) unique coloration of stem, leaf,
inflorescence, calyx, stamen,
trichome bodies and finished products including extracts and hash.
Yield is another important factor in breeding. Cannabis yield is measured by
pounds (lbs),
grams (g) or kilograms (Kg) of dried (10% moisture), and trimmed flowers.
Yield can be
expressed in terms of yield per plant, yield per watt of light, and yield per
squared meter of
growing area among others. Cannabis yield is also dependent on the growing
environment. For
example yields for a particular cannabis strain will vary between outdoor
growth long season,
outdoor growth short season, or indoor growth. Yield may also be affected by
growing
conditions such as type of lighting, soil, fertilizer use, size of growing
pot, etc.
In some embodiments, the specialty cannabis of the present invention
produces , .1g, .2g, .3g, .4g, .5g, .6g, .7g, .8g, .9g, 1.0g, 1.1g, 1.2g,
1.3g, 1.4g, 1.5g, 1.6g, 1.7g,
1.8g, 1.9g, 2.0g, 2.1g, 2.2g, 23g, 2.4g, 2.5g, 2.6g, 2.7g, 2.8g, 2.9g, 3.0g,
3.1g, 3.2g, 3.3g, 3.4g,
3.5g. 3.6g, 3.7g, 3.8g, 3.9g, 4.0g, 4.1g, 4.2g, 4.3g, 4.4g, 4.5g, 4.6g, 4.7g,
4.8g, 4.9g, or 5.0g of
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
dried flowers per watt of light. In some embodiments, the specialty cannabis
of the present
invention produces 10g, 15g, 20g, 25g, 30g, 35g, 40g, 45g, 50g, 55g, 60g, 65g,
70g, 75g, 80g,
85g, 90g, 95g, 100g, 105g, 110g, 115g, 120g, 125g, 130g, 135g, 140g, 145g,
150g, 155g, 160g,
165g, 170g, 175g, 180g, 185g, 190g, 195g, 200g, 210g, 220g, 230g. 240g, 250g,
260g, 270g,
280g, 290g, 300g, 310g, 320g, 330g, 340g, 350g, 360g, 370g, 380g, 390g, 400g,
410g, 420g,
430g, 440g, 450g, 460g, 470g, 480g, 490g, 500g, 550g, 600g, 650g. 700g, 750g,
800g, 850g,
900g, 950g, 1000g, 2000g, 3000g, or 5000g of dried flowers per plant.
Desirable yield phenotypes include:
High Yield Natural Light Production Lona Season - Selection based on yield
performance for early ripening varieties during long seasons.
High Yield Natural Light Production Short Season - Selection based on yield
performance of late ripening varieties during long season and/or yield of
plants that ripen in
winter months and at low light levels.
High Yield Indoor Production - Selection based solely on plant yield
performance in
artificial lighting (e.g., HID).
Another important phenotype that is important for cannabis production is
structural
features for easy harvesting.
Other important breeding phenotypes include:
Structure for Manual Trim/Market - Selections are based on the relative ratio
by weight
of finished flower. This usually is directly related to dense triehome
morphology with very few
sun leaves.
Structure for Automated Trimmina - Selection based on flower morphology that
is more
kola (continuous long bud) with many sun leaves protrucfmg from large
inflorescences. Overall
flower size is typically large, but trichomes are less densely packed and
overall inflorescence is
less dense than what is traditionally selected for manual trim.
Root Structure - Positive root selection is marked by overall root vigor and
adventitious
root growth, ease of transplant, rate of root development on clonal
propagations, and root
shooting from tissue culture samples. Root selections can also be based on
resistance to soil and
hydroponic pathogens including pythium.
56
CA 02911168 2016-07-20
Vigor - Selection for plant vigor are marked by tremendous growth rates and
robust
stem/stalk infrastructure. Often times, selection display morphologies that
are very much
enlarged compared to sibling progeny.
Fungal Resistance - Selections based on plant that exhibit immunity or partial
immunity
to fungal diseases and pathogens including but not limited to powdery mildew,
botrytis, downy
mildew among others.
For a non-limiting list of cannabinoid phenotypes, please see Marijuana
Botany, An
Advanced study: The Propagation and Breeding of Distinctive Cannabis by Robert
Connell
Clarke.
The present invention also relates to variants, mutants and modifications of
the seeds,
plant parts and/or whole plants of the cannabis plants of the present
invention. Variants,
mutants and trivial modifications of the seeds, plants, plant parts, plant
cells of the present
invention can be generated by methods well known and available to one skilled
in the art,
including but not limited to, mutagenesis (e.g., chemical mutagenesis,
radiation mutagenesis,
transposon mutagenesis, insertional mutagenesis, signature tagged mutagenesis,
site-directed
mutagenesis, and natural mutagenesis), knock-outs/knock-ins, antisense and RNA
interference.
For more information of mutagenesis in plants, such as agents, protocols, see
Acquaah et al.
(Principles of plant genetics and breeding, Wiley-Blackwell, 2007, ISBN
1405136464,
9781405136464.
The present invention also relates to a mutagenized population of the cannabis
plants of
the present invention, and methods of using such populations. In some
embodiments, the
mutagenized population can be used in screening for new cannabis lines which
comprises one
or more or all of the morphological, physiological, biological, and/or
chemical characteristics
of cannabis plants of the present invention, in some embodiments, the new
cannabis plants
obtained from the screening process comprise one or more or all of the
morphological,
physiological, biological, and/or chemical characteristics of cannabis plants
of the present
invention, and one or more additional or different new morphological,
physiological,
biological, and/or chemical characteristic.
The mutagenized population of the present invention can be used in Targeting
Induced
Local Lesions in Genomes (TILLING) screening method, which combines a standard
and
efficient technique of mutagenesis with a chemical mutagen (e.g., Ethyl
methanesulfonate
57
CA 02911168 2016-07-20
(EMS)) with a sensitive DNA screening-technique that identifies single base
mutations (also
called point mutations) in a target gene. Detailed description on methods and
compositions on
TILLING can be found in Till et al. (Discovery of induced point mutations in
maize genes by
TILLING, BMC Plant Biology 2004, 4:12), Weil et al., (TILLING in Grass
Species, Plant
Physiology January 2009 vol. 149 no. 1 158-164), Comai, L. and S. Henikoff
("TILLING:
practical single-nucleotide mutation discovery." Plant J 45(4): 684-94),
McCallum et al.,
(Nature Biotechnology, 18: 455-457, 2000), McCallum et al., (Plant Physiology,
123: 439-442,
2000), Colbert et al., (Plant Physiol. 126(2): 480-484, 2001), U.S. Patent.
No. 5,994,075, U.S.
Patent Application Publication No. 2004/0053236A1, and International Patent
Application
Publication Nos. WO 2005/055704 and WO 2005/048692.
The present invention also provides any compositions or any products made from
or
isolated from the plants of the present invention. In some embodiments, the
compositions/products comprises extract of the plants, wherein the extract
contains more than
2% CBD and less than 98% THC. In some embodiments, the extract contains higher
percentage
of terpenes/terpenoids compared to extract isolated from a control cannabis
plant variety (e.g.,
an existing variety, such as a recreational cannabis plant variety).
Methods of Using Cannabis Plants
The present invention provides methods of using the cannabis plants or any
parts, any
compositions, or any chemicals derived from said plants of the present
invention.
In some embodiments, the plants can be used for medical purpose. In other
embodiments, the specialty cannabis plants of the present invention can be
used for recreational
purposes. In some embodiments, the plants can be used by patients having a
disease. In some
embodiments, the diseases includes, but are not limited to, Acquired
Hypothyroidism, Acute
Gastritis, Agoraphobia, AIDS Related Illness, Alcohol Abuse, Alcoholism,
Alopecia Arcata,
Alzheimer's Disease, Amphetamine Dependency, Amyloidosis, Amyotrophic Lateral
Sclerosis
(ALS), Angina Pectoris, Ankylosis, Anorexia, Anorexia Nervosa, Anxiety
Disorders, any
chronic medical symptom that limits major life activities, any Chronic Medical
Symptom that
Limits Major Life Activities, Arteriosclerotic Heart Disease, Arthritis,
Arthritis (Rheumatoid),
Arthropathy, gout, Asthma, Attention Deficit Hyperactivity Disorder
(ADD/ADHD),
58
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Autism/Asperger's, Autoimmune Disease, Back Pain, Back Sprain, Bell's Palsy,
Bipolar
Disorder, Brain Tumor, Malignant, Bruxism, Bulimia, Cachexia, Cancer, Carpal
Tunnel
Syndrome, Cerebral Palsy, Cervical Disk Disease, Cervicobrachial Syndrome,
Chemotherapy
Chronic Fatigue Syndrome, Chronic Pain, Chronic renal failure, Cocaine
Dependence, Colitis,
Conjunctivitis, Constipation, Crohn's Disease, Cystic Fibrosis, Damage to
Spinal Cord Nervous
Tissue, Darier's Disease, Degenerative Arthritis, Degenerative Arthropathy,
Delirium Tremens,
Dermatomyositis, Diabetes, Diabetic Neuropathy, Diabetic Peripheral Vascular
Disease,
Diarrhea, Diverticulitis, Dysthymic Disorder, Eczema, Emphysema, Emphysema,
Endometriosis,
Epidermolysis Bullosa, Epididym.itis, Epilepsy, Felty's Syndrome,
Fibrom.yalgia, Friedreich's
Atax.ia, Gastritis, Genital Herpes, Glaucoma, Glioblastoma Multiforme, Graves
Disease, Cluster
Headaches, Migraine Headaches, Tension Headaches, Hemophilia A, Henoch-
Schonlein
Putpura, Hepatitis C, Hereditary Spinal Ataxia, HIV/AIDS, Hospice Patients,
Huntington's
Disease, Hypertension, Hypertension, Hyperventilation, Hypoglycemia,
Impotence,
Inflammatory autoinatnune-mediated arthritis, Inflammatory Bowel Disease
(IBD), Insomnia,
Intermittent Explosive Disorder (IED), intractable Pain, intractable
'Vomiting, Lipomatosis, Lou
Gehrig's Disease, Lyme Disease, Lymphoma, Major Depression, Malignant
Melanoma, Mania,
M.elorhcostosis, Menicre's Disease, Motion Sickness, Mucopolysaccharidosis (M
PS), Multiple
Sclerosis (MS), Muscle Spasms, Muscular Dystrophy, Myeloid Leukemia, Nail-
Patella
Syndrome, Nightmares, Obesity, Obsessive Compulsive Disorder, Opiate
Dependence,
OsteoartIvitis, Panic Disorder, Parkinson's Disease, Peripheral Neuropathy,
Peritoneal Pain,
Persistent insomnia, Porphyria, Post Polio Syndrome (PPS), Post-traumatic
arthritis, Post-
Traumatic Stress Disorder (PTSD), Premenstrual Syndrome (PMS), Prostatitis,
Psoriasis,
Pulmonary Fibrosis, Quadriplegia, Radiation Therapy, Raynaud's Disease,
Reiter's Syndrome,
Restless Legs Syndrome (RLS), Rheumatoid Arthritis, Rheumatoid Arthritis,
Rheumatoid
Arthritis, Rosacea, Schizoaffective Disorder, Schizophrenia, Scoliosis,
Sedative Dependence,
Seizures, Senile Dementia, Severe Nausea, Shingles (Herpes Zoster), Sinusitis,
Skeletal
Muscular Spasticity, Sleep Apnea, Sleep Disorders, Spasticity, Spinal
Stenosis, Sturge-Weber
Syndrome (SWS), Stuttering, Tardive Dyskinesia (TD), Temporomandibular joint
disorder
Tenosynovitis, Terminal Illness, Thyroiditis, Tic Douloureux, Tietze's
Syndrome,
Tinnitus, Tobacco Dependence, Tourette's Syndrome, Trichotillomania, Viral
Hepatitis, Wasting
Syndrome, Whiplash, Wittmaack-Ekbom's Syndrome, Writers' Cramp, nausea,
vomiting,
59
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
premenstrual syndrome, unintentional weight loss, insomnia, and lack of
appetite, spasticity,
painful conditions, especially neurogenic pain, movement disorders, asthma,
glaucoma, adrenal
disease, inflammatory bowel disease, migraines, fibromyalgia, and related
conditions, multiple
sclerosis, spinal cord injuries. In some embodiments, the specialty cannabis
varieties of the
present invention exhibit antispasmodic and muscle-relaxant properties
andstimulate appetite.
Other studies state that cannabis or cannabinoids may be useful in treating
alcohol abuse,
amyotrophic lateral sclerosis, collagen-induced arthritis, asthma,
atherosclerosis, bipolar disorder,
colorectal cancer, HIV-Associated Sensory Neuropathy, depression, dystonia,
epilepsy, digestive
diseases, gliomas, hepatitis C, Huntington's disease, leukemia, skin tumors,
methicillin-resistant
Staphylococcus aureus (MRSA), Parkinson's disease, pruritus, posttraumatic
stress disorder
(PTSD), psoriasis, sickle-cell disease, sleep apnea, and anorexia nervosa.
In some embodiments, the plants of the present invention provide one or more
medical
benefits to a person in need without any side effects, Of with reduced side
effects compared to a
traditional recreational marijuana plant variety. In some embodiments, the
specialty cannabis of
the present invention can reduce the effect of cannabis use on fetal brain
development by
providing CBs and terpenes which attenuate the activation of CB1 receptor by
THC (Tortoriello
et al., 2013 "Miswiring the brain: delta 9 tetrahydrocananbinol disrupts
cortical development by
inducing an SCG101stathmin-2 degradation pathway" EMBO 10 December 2013). In
some
embodiments, the traditional recreational marijuana plant variety is the
variety 'White Widow.'
In some embodiments, the traditional recreational marijuana plant variety
contains at least 98%,
at least 98.5%, at least 99%, at least 99.5%, at least 99.6%, at least 99.7%,
at least 99.8%, at least
99.9%, or 100% THC in the cannabinoid accumulation in the plant.
In some embodiments, the plants can be used for non-medical purposes. In some
embodiments the specialty cannabis plants of the present invention can be used
for recreational
purposes. In some embodiments, the specialty cannabis plants of the present
invention can be
used for industrial purposes. In some embodiments, the plants are used for
producing food, oil,
wax, resin, rope, cloth, pulp, fiber, feed for livestock, construction
material, plastic and
composite materials, paper, jewelry, water and soil purification materials,
weed control materials,
cultivation materials, textiles, clothing, biodegradable plastics, body
products, health food and
biofuel.
CA 02911168 2016-07-20
Cannabis breeding methods
In some embodiments, the plants of the present invention can be used to
produce new
plant varieties. In some embodiments, the plants are used to develop new,
unique and superior
varieties or hybrids with desired phenotypes.
In some embodiments, selection methods, e.g., molecular marker assisted
selection, can
be combined with breeding methods to accelerate the process. Additional
breeding methods
have been known to one of ordinary skill in the art, e.g., methods discussed
in Chahal and
Gosal (Principles and procedures of plant breeding: biotechnological and
conventional
approaches, CRC Press, 2002, ISBN 084931321X, 9780849313219), Taji et al. (In
vitro plant
breeding, Routledge, 2002, ISBN 156022908X, 9781560229087), Richards (Plant
breeding
systems, Taylor & Francis US, 1997, ISBN 0412574500, 9780412574504), Hayes
(Methods of
Plant Breeding, Publisher: READ BOOKS, 2007, ISBN1406737062, 9781406737066).
Cannabis genome has been sequenced recently (Bakel et al., The draft genome
and
transcriptome of Cannabis sativa, Genome Biology, 12(10):R102, 2011).
Molecular makers for
cannabis plants are described in Datwyler et al. (Genetic variation in hemp
and marijuana
(Cannabis sativa L.) according to amplified fragment length polymorphisms, J
Forensic Sci.
2006 Mar;51(2):371-5.), Pinarkara et al., (RAPD analysis of seized marijuana
(Cannabis sativa
L.) in Turkey, Electronic Journal of Biotechnology', 12(1), 2009), Hakki et
al., (Inter simple
sequence repeats separate efficiently hemp from marijuana (Cannabis sativa
L.), Electronic
Journal of Biotechnology, 10(4), 2007), Datwyler et al., (Genetic Variation in
Hemp and
Marijuana (Cannabis saliva L.) According to Amplified Fragment Length
Polymorphisms, J
Forensic Sci, March 2006, 51(2):371-375), Gilmore et al. (Isolation of
microsatellite markers in
Cannabis sativa L. (marijuana), Molecular Ecology Notes, 3(1):105-107, March
2003), Pacifico
et al., (Genetics and marker-assisted selection of chemotype in Cannabis
sativa L.), Molecular
Breeding (2006) 17:257-268), and Mendoza et al., (Genetic individualization of
Cannabis
sativa by a short tandem repeat multiplex system, Anal Bioanal Chem (2009)
393:719-726).
In some embodiments, molecular markers are designed and made, based on the
genome
of the plants of the present application. In some embodiments, the molecular
markers are
selected from Isozyme Electrophoresis, Restriction Fragment Length
Polymorphisms (RFLPs),
61
CA 02911168 2016-07-20
Randomly Amplified Polymorphic DNAs (RAPDs), Arbitrarily Primed Polymerase
Chain
Reaction (AP-PCR), DNA Amplification Fingerprinting (DAF), Sequence
Characterized
Amplified Regions (SCARs). Amplified Fragment Length Polymorphisms (AFLPs),
and
Simple Sequence Repeats (SSRs) which are also referred to as Microsatellites,
etc. Methods of
developing molecular markers and their applications are described by Avise
(Molecular
markers, natural history, and evolution, Publisher: Sinauer Associates, 2004,
ISBN
0878930418, 9780878930418), Srivastava et al. (Plant biotechnology and
molecular markers,
Publisher: Springer, 2004, ISBN1402019114, 9781402019111), and Vienne
(Molecular
markers in plant genetics and biotechnology, Publisher: Science Publishers,
2003).
The molecular markers can be used in molecular marker assisted breeding. For
example,
the molecular markers can be utilized to monitor the transfer of the genetic
material. In some
embodiments, the transferred genetic material is a gene of interest, such as
genes that contribute
to one or more favorable agronomic phenotypes when expressed in a plant cell,
a plant part, or
a plant.
Details of existing cannabis plants varieties and breeding methods are
described in Potter
et al. (2011, World Wide Weed: Global Trends in Cannabis Cultivation and Its
Control),
Holland (2010, The Pot Book: A Complete Guide to Cannabis, inner Traditions /
Bear & Co,
ISBN1594778981, 9781594778988), Green 1(2009, The Cannabis Grow Bible: The
Definitive
Guide to Growing Marijuana for Recreational and Medical Use, Green Candy
Press, 2009,
ISBN 1931160589, 9781931160582), Green 11 (2005, The Cannabis Breeder's Bible:
The
Definitive Guide to Marijuana Genetics, Cannabis Botany and Creating Strains
for the Seed
Market, Green Candy Press, 1931160279, 9781931160278), Starks (1990, Marijuana
Chemistry: Genetics, Processing & Potency, ISBN 0914171399, 9780914171393),
Clarke
(1981, Marijuana Botany, an Advanced Study: The Propagation and Breeding of
Distinctive
Cannabis, Ronin Publishing, ISBN 091417178X, 9780914171782), Short (2004,
Cultivating
Exceptional Cannabis: An Expert Breeder Shares His Secrets, ISBN 1936807122,
9781936807123), Cervantes (2004, Marijuana Horticulture: The Indoor/Outdoor
Medical
Grower's Bible, Van Patten Publishing, ISBN 187882323X, 9781878823236), Franck
et al.
(1990, Marijuana Grower's Guide, Red Eye Press, ISBN 0929349016,
9780929349015),
Grotenhermen and Russo (2002, Cannabis and Cannabinoids: Pharmacology,
Toxicology, and
Therapeutic Potential, Psychology Press, ISBN
62
CA 02911168 2016-07-20
0789015080, 9780789015082), Rosenthal (2007, The Big Book of Buds: More
Marijuana
Varieties from the World's Great Seed Breeders, ISBN 1936807068,
9781936807062), Clarke,
RC (Cannabis: Evolution and Ethnobotany 2013 (In press)), King, J (Cannabible
Vols 1-3,
2001-2006), and four volumes of Rosenthal's Big Book of Buds series (2001,
2004, 2007, and
2011).
Plant Transformation
Plants of the present invention can be further modified by introducing into
the plants one
or more transgenes which when expressed lead to desired phenotypes. The most
common
method for the introduction of new genetic material into a plant genome
involves the use of
living cells of the bacterial pathogen Agrobacterium tumefaciens to literally
inject a piece of
DNA, called transfer or T-DNA, into individual plant cells (usually following
wounding of the
tissue) where it is targeted to the plant nucleus for chromosomal integration.
There are
numerous patents governing Agrobacterium mediated transformation and
particular DNA
delivery plasmids designed specifically for use with Agrobacterium---for
example, US4536475,
EP0265556, EP0270822, W08504899, W08603516, US5591616, EP0604662, EP0672752,
W08603776, W09209696, W09419930, W09967357, US4399216, W08303259, US5731179,
EP068730, W09516031, US5693512, US6051757 and EP904362A1. Agrobacterium-
mediated
plant transformation involves as a first step the placement of DNA fragments
cloned on
plasmids into living Agrobacterium cells, which are then subsequently used for
transformation
into individual plant cells. Agrobacterium-mediated plant transformation is
thus an indirect
plant transformation method. Methods of Agrobacterium-mediated plant
transformation that
involve using vectors with no T-DNA are also well known to those skilled in
the art and can
have applicability in the present invention. See, for example, U.S. Patent No.
7,250,554, which
utilizes P-DNA instead of T-DNA in the transformation vector.
Direct plant transformation methods using DNA have also been reported. The
first of
these to be reported historically is electroporation, which utilizes an
electrical current applied to
a solution containing plant cells (M. E. Fromm et al., Nature, 319, 791
(1986); H. Jones et al.,
Plant Mol. Biol., 13, 501 (1989) and H. Yang et al., Plant Cell Reports, 7,
421 (1988). Another
direct method, called "biolistic bombardment", uses ultrafine particles,
usually tungsten or gold,
that are coated with DNA and then sprayed onto the surface of a plant tissue
with sufficient
force
63
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
to cause the particles to penetrate plant cells, including the thick cell
wall, membrane and nuclear
envelope, but without killing at least some of them (US 5,204,253, US
5,015,580). A third direct
method uses fibrous forms of metal or ceramic consisting of sharp, porous or
hollow needle-like
projections that literally impale the cells, and also the nuclear envelope of
cells. Both silicon
carbide and aluminum borate whiskers have been used for plant transformation
(Mizuno et al.,
2004; Petolino et al., 2000; US5302523 US Application 20040197909) and also
for bacterial and
animal transformation (Kaepler et al., 1992; Raloff, 1990; Wang, 1995). There
are other methods
reported, and undoubtedly, additional methods will be developed. However, the
efficiencies of
each of these indirect or direct methods in introducing foreign DNA into plant
cells are
invariably extremely low, making it necessary to use some method for selection
of only those
cells that have been transformed, and further, allowing growth and
regeneration into plants of
only those cells that have been transformed.
For efficient plant transformation, a selection method must be employed such
that whole
plants are regenerated from a single transformed cell and every cell of the
transformed plant
carries the DNA of interest. These methods can employ positive selection,
whereby a foreign
gene is supplied to a plant cell that allows it to utilize a substrate present
in the medium that it
otherwise could not use, such as mannose or xylosc (for example, refer US
5,767,378; US
5994629). More typically, however, negative selection is used because it is
more efficient,
utilizing selective agents such as herbicides or antibiotics that either kill
or inhibit the growth of
nontransformed plant cells and reducing the possibility of chimeras.
Resistance genes that are
effective against negative selective agents are provided on the introduced
foreign DNA used for
the plant transformation. For example, one of the most popular selective
agents used is the
antibiotic kanamycin, together with the resistance gene neomycin
phosphotransfera.se (nptI1),
which confers resistance to kanamycin and related antibiotics (see, for
example, Messing &
Vierra, Gene 19: 259-268 (1982); Bevan et al., Nature 304:184-187 (1983)).
However, many
different antibiotics and antibiotic resistance genes can be used for
transformation purposes
(refer US 5034322, US 6174724 and US 6255560). In addition, several herbicides
and herbicide
resistance genes have been used for transformation purposes, including the bar
gene, which
confers resistance to the herbicide phosphinothricin (White et al., .Nucl
Acids Res 18: 1062
(1990), Spencer et al.. Theor Appl Genet 79: 625-631(1990), US 4795855, US
5378824 and US
64
CA 02911168 2016-07-20
6107549). In addition, the dhfr gene, which confers resistance to the
anticancer agent
methotrexate, has been used for selection (Bourouis et al., EMBO J. 2(7): 1099-
1104 (1983).
Genes can be introduced in a site directed fashion using homologous
recombination.
Homologous recombination permits site specific modifications in endogenous
genes and thus
inherited or acquired mutations may be corrected, and/or novel alterations may
be engineered
into the genome. Homologous recombination and site-directed integration in
plants are
discussed in, for example, U.S. Patent Nos. 5,451,513; 5,501,967 and
5,527,695.
Methods of producing transgenic plants are well known to those of ordinary
skill in the
art. Transgenic plants can now be produced by a variety of different
transformation methods
including, but not limited to, electroporation; microinjection;
microprojectile bombardment,
also known as particle acceleration or biolistic bombardment; viral-mediated
transformation;
and Agrobacterium-mediated transformation. See, for example, U.S. Patent Nos.
5,405,765;
5,472,869; 5,538,877; 5,538,880; 5,550,318; 5,641,664; 5,736,369 and
5,736,369; and
International Patent Application Publication Nos. WO/2002/038779 and
WO/2009/117555; Lu
et al., (Plant Cell Reports, 2008, 27:273-278); Watson et al., Recombinant
DNA, Scientific
American Books (1992); Hinchee et al., Bio/Tech. 6:915-922 (1988); McCabe et
al., Bio/Tech.
6:923-926 (1988); Toriyama et al., Bio/Tech. 6:1072-1074 (1988); Fromm et al.,
Bio/Tech.
8:833-839 (1990); Mullins et al., Bio/Tech. 8:833-839 (1990); Hiei et al.,
Plant Molecular
Biology 35:205-218 (1997); Ishida et al., Nature Biotechnology 14:745-750
(1996); Zhang et
al., Molecular Biotechnology 8:223-231 (1997); Ku et al., Nature Biotechnology
17:76-80
(1999); and, Raineri et al., Biot/Tech. 8:33-38 (1990)). Other references
teaching the
transformation of cannabis plants and the production of callus tissue include
Raharjo et al 2006,
"Callus Induction and Phytochemical Characterization of Cannabis sativa Cell
Suspension
Cultures", Indo. J. Chem 6 (1) 70-74; and "The biotechnology of Cannabis
sativa" by Sam R.
Zwenger, electronically published April, 2009.
Microprojectile bombardment is also known as particle acceleration, biolistic
bombardment, and the gene gun (Biolistic Gene Gun). The gene gun is used to
shoot pellets
that are coated with genes (e.g., for desired traits) into plant seeds or
plant tissues in order to get
the plant cells to then express the new genes. The gene gun uses an actual
explosive (.22 caliber
blank) to propel the material. Compressed air or steam may also be used as the
propellant. The
CA 02911168 2016-07-20
Biolistic Gene Gun was invented in 1983-1984 at Cornell University by John
Sanford,
Edward Wolf, and Nelson Allen. It and its registered trademark are now owned
by E. I. du Pont
de Nemours and Company. Most species of plants have been transformed using
this method.
Agrobacterium tumefaciens is a naturally occurring bacterium that is capable
of
inserting its DNA (genetic information) into plants, resulting in a type of
injury to the plant
known as crown gall. Most species of plants can now be transformed using this
method,
including cucurbitaceous species. A transgenic plant formed using
Agrobacterium
transformation methods typically contains a single gene on one chromosome,
although multiple
copies are possible. Such transgenic plants can be referred to as being
hemizygous for the
added gene. A more accurate name for such a plant is an independent segregant,
because each
transformed plant represents a unique T-DNA integration event (U.S. Patent No.
6,156,953). A
transgene locus is generally characterized by the presence and/or absence of
the transgene. A
heterozygous genotype in which one allele corresponds to the absence of the
transgene is also
designated hemizygous (U.S. Patent No. 6,008,437).
General transformation methods, and specific methods for transforming certain
plant
species (e.g., maize) are described in U.S. Patent Nos. 4940838, 5464763,
5149645, 5501967,
6265638, 4693976, 5635381, 5731179, 5693512, 6162965, 5693512, 5981840,
6420630,
6919494, 6329571, 6215051, 6369298, 5169770, 5376543, 5416011, 5569834,
5824877,
5959179, 5563055, and 5968830.
Non-limiting examples of methods for transforming cannabis plants and cannabis
tissue
culture methods are described in Zweger (The Biotechnology of Cannabis saliva,
April 2009);
MacKinnon (Genetic transformation of Cannabis sativa Linn: a multi purpose
fiber crop,
doctoral thesis, University of Dundee, Scotland, 2003), MacKinnon et
al..(Progress towards
transformation of fiber hemp, Scottish Crop Research, 2000), and US
20120311744. The
transformation can be physical, chemical and/or biological.
Breeding Methods
Classical breeding methods can be included in the present invention to
introduce one or
more recombinant expression cassettes of the present invention into other
plant varieties, or
other
66
CA 02911168 2016-07-20
close-related species that are compatible to be crossed with the transgenic
plant of the present
invention.
In some embodiments, said method comprises (i) crossing any one of the plants
of the
present invention comprising the expression cassette as a donor to a recipient
plant line to
create a Fl population; (ii) selecting offspring that have expression
cassette. Optionally, the
offspring can be further selected by testing the expression of the gene of
interest.
In some embodiments, complete chromosomes of the donor plant are transferred.
For
example, the transgenic plant with the expression cassette can serve as a male
or female parent
in a cross pollination to produce offspring plants, wherein by receiving the
transgene from the
donor plant, the offspring plants have the expression cassette.
In a method for producing plants having the expression cassette, protoplast
fusion can
also be used for the transfer of the transgene from a donor plant to a
recipient plant. Protoplast
fusion is an induced or spontaneous union, such as a somatic hybridization,
between two or
more protoplasts (cells in which the cell walls are removed by enzymatic
treatment) to produce
a single bi- or multi-nucleate cell. The fused cell that may even be obtained
with plant species
that cannot be interbred in nature is tissue cultured into a hybrid plant
exhibiting the desirable
combination of traits. More specifically, a first protoplast can be obtained
from a plant having
the expression cassette. A second protoplast can be obtained from a second
plant line,
optionally from another plant species or variety, preferably from the same
plant species or
variety, that comprises commercially desirable characteristics, such as, but
not limited to
disease resistance, insect resistance, valuable grain characteristics (e.g.,
increased seed weight
and/or seed size) etc. The protoplasts are then fused using traditional
protoplast fusion
procedures, which are known in the art to produce the cross.
Alternatively, embryo rescue may be employed in the transfer of the expression
cassette
from a donor plant to a recipient plant. Embryo rescue can be used as a
procedure to isolate
embryo's from crosses wherein plants fail to produce viable seed. In this
process, the fertilized
ovary or immature seed of a plant is tissue cultured to create new plants (see
Pierik, 1999, In
vitro culture of higher plants, Springer. ISBN 079235267x, 9780792352679.
In some embodiments, the recipient plant is an elite line having one or more
certain
desired traits. Examples of desired traits include but are not limited to
those that result in
67
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
increased biomass production, production of specific chemicals, increased seed
production,
improved plant material quality, increased seed oil content, etc. Additional
examples of desired
traits includes pest resistance, vigor, development time (time to harvest),
enhanced nutrient
content, novel growth patterns, flavors or colors, salt, heat, drought and
cold tolerance, and the
like. Desired traits also include selectable marker genes (e.g., genes
encoding herbicide or
antibiotic resistance used only to facilitate detection or selection of
transformed cells), hormone
biosynthesis genes leading to the production of a plant hormone (e.g., auxins,
gibberellins,
cytokinins, abscisic acid and ethylene that are used only for selection), or
reporter genes (e.g.
luciferase, P-glucuronidase, chloramphenicol acetyl transferase (CAT, etc.).
The recipient plant
can also be a plant with preferred chemical compositions, e.g., compositions
preferred for
medical use or industrial applications.
Classical breeding methods can be used to produce new varieties of cannabis
according
to the present invention. Newly developed Fl hybrids can be reproduced via
asexual
reproduction.
Open-Pollinated Populations. The improvement of open-pollinated populations of
such
crops as rye, many maizcs and sugar beets, herbage grasses, legumes such as
alfalfa and clover,
and tropical tree crops such as cacao, coconuts, oil palm and some rubber,
depends essentially
upon changing gene-frequencies towards fixation of favorable alleles while
maintaining a high
(but far from maximal) degree of heterozygosity. Uniformity in such
populations is impossible
and trueness-to-type in an open-pollinated variety is a statistical feature of
the population as a
whole, not a characteristic of individual plants. Thus, the heterogeneity of
open-pollinated
populations contrasts with the homogeneity (or virtually so) of inbred lines,
clones and hybrids.
Population improvement methods fall naturally into two groups, those based on
purely
phenotypic selection, normally called mass selection, and those based on
selection with progeny
testing. Interpopulation improvement utilizes the concept of open breeding
populations; allowing
genes to flow from one population to another. Plants in one population
(cultivar, strain, ecotype,
or any germplasm source) are crossed either naturally (e.g., by wind) or by
hand or by bees
(commonly Apis mellifera L. or Megachile rotundata F.) with plants from other
populations.
Selection is applied to improve one (or sometimes both) population(s) by
isolating plants with
desirable traits from both sources.
68
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
There are basically two primary methods of open-pollinated population
improvement.
First, there is the situation in which a population is changed en masse by a
chosen selection
procedure. The outcome is an improved population that is indefinitely
propagatable by random-
mating within itself in isolation. Second, the synthetic variety attains the
same end result as
population improvement but is not itself propagatable as such; it has to be
reconstructed from
parental lines or clones. These plant breeding procedures for improving open-
pollinated
populations are well known to those skilled in the art and comprehensive
reviews of breeding
procedures routinely used for improving cross-pollinated plants are provided
in numerous texts
and articles, including: Allard, Principles of Plant Breeding, John Wiley &
Sons, Inc. (1960);
Simxrionds, Principles of Crop Improvement, Longman Group Limited (1979);
Hanauer and
Miranda, Quantitative Genetics in Maize Breeding, Iowa State University Press
(1981); and,
Jensen, Plant Breeding Methodology, John Wiley & Sons, Inc. (1988).
Mass Selection. In mass selection, desirable individual plants are chosen,
harvested, and
the seed composited without progeny testing to produce the following
generation. Since
selection is based on the maternal parent only, and there is no control over
pollination, mass
selection amounts to a form of random mating with selection. As stated herein,
the purpose of
mass selection is to increase the proportion of superior genotypes in the
population.
Synthetics. A synthetic variety is produced by crossing inter se a number of
genotypes
selected for good combining ability in all possible hybrid combinations, with
subsequent
maintenance of the variety by open pollination. Whether parents are (more or
less inbred) seed-
propagated lines, as in some sugar beet and beans (Vicia) or clones, as in
herbage grasses,
clovers and alfalfa, makes no difference in principle. Parents are selected on
general combining
ability, sometimes by test crosses or toperosses, more generally by
polycrosses. Parental seed
lines may be deliberately inbred (e.g. by selfing or sib crossing). However,
even if the parents
are not deliberately inbred, selection within lines during line maintenance
will ensure that some
inbreeding occurs. Clonal parents will, of course, remain unchanged and highly
heterozygous.
Whether a synthetic can go straight from the parental seed production plot to
the farmer
or must first undergo one or two cycles of multiplication depends on seed
production and the
scale of demand for seed. In practice, grasses and clovers are generally
multiplied once or twice
and are thus considerably removed from the original synthetic.
69
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
While mass selection is sometimes used, progeny testing is generally preferred
for
polycrosses, because of their operational simplicity and obvious relevance to
the objective,
namely exploitation of general combining ability in a synthetic.
The numbers of parental lines or clones that enter a synthetic vary widely. In
practice,
numbers of parental lines range from 10 to several hundred, with 100-200 being
the average.
Broad based synthetics formed from 100 or more clones would be expected to be
more stable
during seed multiplication than narrow based synthetics.
Pedigreed varieties. A pedigreed variety is a superior genotype developed
from. selection
of individual plants out of a segregating population followed by propagation
and seed increase of
self pollinated offspring and careful testing of the genotype over several
generations. This is an
open pollinated method that works well with naturally self pollinating
species. This method can
be used in combination with mass selection, in variety development. Variations
in pedigree and
mass selection in combination are the most common methods for generating
varieties in self
pollinated crops.
Hybrids. A hybrid is an individual plant resulting from a cross between
parents of
differing genotypes. Commercial hybrids are now used extensively in many
crops, including
corn (maize), sorghum, sugarbect, sunflower and broccoli. Hybrids can be
formed in a number
of different ways, including by crossing two parents directly (single cross
hybrids), by crossing a
single cross hybrid with another parent (three-way or triple cross hybrids.),
or by crossing two
different hybrids (four-way or double cross hybrids).
Strictly speaking, most individuals in an out breeding (i.e., open-pollinated)
population
are hybrids, but the term is usually reserved for cases in which the parents
are individuals whose
genomes are sufficiently distinct for them to be recognized as different
species or subspecies.
Hybrids may be fertile or sterile depending on qualitative and/or quantitative
differences in the
genomes of the two parents. Heterosis, or hybrid vigor, is usually associated
with increased
heterozygosity that results in increased vigor of growth, survival, and
fertility of hybrids as
compared with the parental lines that were used to form the hybrid. Maximum
heterosis is
usually achieved by crossing two genetically different, highly inbred lines.
This invention is further illustrated by the following examples which should
not be
construed as limiting. The contents of all references, patents and published
patent applications
CA 02911168 2016-07-20
cited throughout this application, as well as the Figures and the Sequence
Listing.
Specialty Cannabis
The present invention is based in part on the discovery new specialty cannabis
varieties
with unique terpene and cannabinoid profiles can be bred to produce cannabis
with reduced
THC side effects and increased medicinal uses.
Contemporary "recreational" marijuana cultivars that are currently available
have been
bred and selected primarily for their THC content, without much regard for
their terpenoid
aroma and flavor chemistry, or for their for their production of the other
cannabinoids (CBs),
such as CBD, THCV, CBC, CBG, etc. Indeed, almost 99% of cannabis sold by
dispensaries in
California for medical purposes contains less than 1% non-THC CBs. (personal
communication
with SC Laboratories and Halent Laboratory, 2013).
While THC has considerable medicinal value, it can be responsible for a range
of
poorly tolerated side effects including anxiety, dizziness, tachycardia,
asthenia, etc. It has
recently been discovered that administration of CBD reduces or ameliorates
some undesirable
effects of THC including intoxication, sedation and tachycardia, while
contributing analgesic,
anti-emetic, and anti-carcinogenic properties (Russo and Guy, 2006, Medical
Hypotheses
(2006) 66, 234-246). Evidence has also emerged that CBD may contribute anti-
anxiety effects
to cannabis varieties with THC. See "Cannabidiol, a Cannabis sativa
constituent, as an
anxiolytic drug." (Rev Bras Psiquiatr. 2012;34(Sup11):S104-S117). Also
evidence has emerged
that CBD can ameliorate the memory impairment caused by THC. See Morgan, Celia
JA, et al.
"Impact of cannabidiol on the acute memory and psychotomimetic effects of
smoked cannabis:
naturalistic study." The British Journal of Psychiatry 197.4 (2010): 285-290.
Other non-THC
cannabinoids (CBs) have also been demonstrated to have extensive medicinal
uses (Table 1).
THC is produced primarily by narrow and broad-leafleted drug cannabis
varieties.
CBD is produced primarily by narrow and broad leafleted fiber cannabis
varieties, commonly
known as hemp. Other non-THC CBs such as THCv and CBDv can also be found in
natural
varieties (Meijer and Hammond 2005, Euphytica 145:189-198). CBC production is
associated
with juvenile cannabis and some natural varieties found in India (Meijer and
Hammond 2009,
Euphytica 165:293-311).
71
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Interbreeding drug and other natural varieties of cannabis can produce
cultivars that
produce both THC and other CBs, in amounts that far exceed landrace cannabis
drug or fiber
varieties (See Clarke, RC et al. "Cannabis: Evolution and Ethnobotany"
University of California
Press 2013). Unfortunately, such crosses have been rare, and have only
produced cannabis
varieties lacking the terpenoid constituents responsible for the appealing
aroma and flavor.
Moreover, such varieties, also lack the synergistic entourage effects of
diverse terpene-
cannabinoid combinations (2011, Taming THC: potential cannabis synergy and
phytocannabinoid-tapenoid entourage effects, British Journal of Pharmacology,
163:1344-1364,
Table 2).
Similar problems have been identified with oral administrations of cannabis
extracts such
as Marinol (dronabinol), and Sativex It), which have higher side effects,
and lower consumer
acceptance, partially due to the lack of terpene entourage effects and lack of
positive
aroma/flavors (see Hazenkamp et al 2013, "The Medicinal Use of Cannabis and
Cannabinoids-
An international Cross-Sectional Survey on Administration forms" Journal of
Psychoactive
drugs 45 (3) 199-210; McPartland and Russo 2001 "Cannabis and Cannabis
Extracts: Greater
Than the Sum of Their Parts?" Hayworth Press).
For example, all known varieties of chemotypc II cannabis (BT/BD genotype)
exhibit
terpene profiles dominated by myrcene. That is, these cannabis varieties
produce myrcene at
higher levels than any other terpene. As such, these varieties do not exhibit
diverse terpene
profiles and lack the varied aroma, organoleptic feel of the specialty
cannabis of the present
invention. The aroma and flavors for myrcene dominant varieties tend to be
"single tone", with
the high myrcene levels dominating the flavor and aroma profile. Moreover, as
myrcene is
associated with the cannabis "couch lock" effect, these varieties have produce
less functional
highs, with higher sedation.
The present invention provides specialty cannabis plants with THC and CBs, and
desirable terpene profiles. In some embodiments, the CBs (e.g. CBD, or CBDv)
level in dried
cannabis plants of the present invention is higher compared to that of a dried
recreational
cannabis plants, such as the strain 'White Widow.' In some embodiments, the
THC level in the
dried cannabis plants of the present invention is lower compared to that of a
dried recreational
cannabis plants, such as the strain 'White Widow.' In some embodiments the
specialty cannabis
of the present invention is a chemotype 11 plant. In some embodiments, the
specialty cannabis of
72
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
the present invention produces more than 1.5% of any one CBs. In some
embodiments, the
specialty cannabis plants of the present invention also have terpene profiles
that are not
dominated by myrcene. In some embodiments, the specialty cannabis of the
present invention
have higher terpene oil contents which overcome high myrcene profiles.
In some embodiments, the specialty cannabis varieties of the present invention
have been
bred to produce high terpene oil contents. In currently available cannabis
cultivars, increased
terpene oil content is largely driven by increased myrcene content, which can
increase the
"couch-lock" effect and overshadow the effects of the other terpenes. In
contrast to current
practice, the breeding programs of the present invention were designed to
produce specialty
cannabis varieties with higher terpene oil content with terpene profiles in
which myrcene has a
relative terpene content of less than two-thirds of the terpene profile. In
other embodiments, the
breeding programs of the present invention were designed to produce high
terpene oil cultivars in
which myrcene was not the dominant terpene.
EXAMPLES
Example 1. Chemical Analysis of Cannabinoids and Terpenes.
Chemical analyses of the parental and progeny specialty cannabis varieties of
the present
invention was carried out using standard chemical separation techniques well
known to those
skilled in the arts. Qualitative identification of cannabinoids and terpenes
was carried out by
GCMS, while quantitative analysis was done by GC-F1D and/or HPLC-PDA (Photo
Diode
Array). Initial field analyses of cannabinoids was performed using thin layer
chromatography as
described in ("Cannabis Inflorescence & Leaf QC" from The American Herbal
Pharmacopeia
2013). The in-house assays for cannabinoids included orthogonal methods of GC-
FID and HPLC
for the highest level of accuracy.
Samples were prepared by grinding ¨5 g of dried cannabis flower material in a
coffee
grinder. From this homogenized material, 500 20 mg was placed in a bead
beater vial with ¨1 g
of 2mm beads and 5 mf, of working solution. Each sample was placed in the bead
beater
(BioSpec Products Inc.) and homogenized on high for 3 minutes. The vials were
centrifuged at
1350 xg, decanted into 50 rnL falcon tubes, and the process was repeated with
fresh working
solution. After the second extraction the caps were removed, the vials were
decanted into the
73
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
appropriate falcon tubes, and the vials were rinsed into the falcon tubes with
an additional 5 mL
of working solution. For samples suspected of having lower concentrations of
analytes (i.e.
<10% ...HC or total tc-ipcne content ¨ 0.5%), 3 mL portions of working
solution could be
employed. Approximately 2 mL of the extracts were placed in 2 mL centrifuge
tubes, and the
vials were centrifuged at 9500 xg for 5 minutes. The supernatant was placed in
a GC vial for
terpene analysis without dilution. The supernatant was also diluted with
working solution for GC
and IIPLC analysis. A 1:40 dilution provided the appropriate concentration for
analysis of
cannabinoids present at concentrations above 1.5%, while a 1:3 dilution
allowed for analysis of
cannabinoids below this level.
1. Tetpenoids by gas chromatography-flame ionization detector (GC-FID)
Terpenes were quantified by a method developed on a GC-FID instrument from
Perkin
Elmer TM (Waltham, MA). This method separates and quantifies 17 different
terpenoids
commonly found in cannabis plant tissue. The terpenoids are each quantified by
their own
individual calibration curves generated with analytical reference standards
(Sigma Aldrich) and
all use n-nonane as the internal standard.
The instrumentation includes a Clams 680 gas chromatograph (GC) equipped with
an
autosampler, an Elite-5 column (Perkin Elmer TM (Waltham, MA), 30 m length,
0.25 mm internal
diameter, 0.25 1.tm thickness film diameter) and a flame ionization detector
(FED). Instrument
control and data acquisition and analyses was accomplished by TotalChrom
software version
1.2.3.4 (Perkin Elmer TM, Waltham, MA).
Calibration curves were generated by injecting each standard in triplicate and
the RSDs
provided the measure of precision while the absolute accuracy was determined
by comparing the
concentrations of the standards predicted by the calibration curve to their
"known" values
determined by dilution ratios. AOAC International standards for accuracy and
precision. were
used as quality guidelines for every calibration. Check standards were run at
the start, middle,
and end of every analysis, and recalibration was performed when they varied
more than +/- 5%
of their initial average response. Levels that failed the acceptance criteria
and analytes were not
quantified at those levels until recalibration of the instrument corrected the
deficiency. Most of
the curves were linear to nearly two orders of magnitude and based on the
sample mass extracted
(500 mg) and the two possible extraction volumes (3x3 mL or 3x5mL), this
provided
74
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
quantitation of terpene levels from 0.01-0.9% or 0.02-1.5% (typical) in the
plant matrix. In some
embodiments, GC-FID measurements for terpenes were conducted in triplicate so
as to provide
95% confidence intervals for each terpene measurement. In some embodiments,
only a single
measurement was made, and the confidence intervals were designated as N/A.
Cannabinoids by GC-FID
Cannabinoids were quantified by an analytical method developed and run on a
Perkin
Elmer IM (Waltham, MA) GC-F1D instrument also. This method was developed to
separate six
neutral cannabinoids, CBD, CBG, CBN, THC, A8-THC, and CRC. The cannabinoids
are each
quantified by their own individual calibration curves generated with
analytical reference
standards (Restek) and all use tricosane as the internal standard. The
retention time of THCV
was determined by analyzing THVO1 (vide infra) by GCMS, however since
analytical standards
were not available it was "quantified" by referencing the calibration curve
for THC.
There was no need to consider chromatographic separation of acidic forms of
the
cannabinoids due to their immediate conversion to neutral form in the heated
injector of the
instrument, although a thorough study of the conversion efficiency of THCA was
performed and
is discussed in section iv. (orthogonal analyses of all samples).
The instrumentation includes a Clarus 680 gas chromatograph (GC) equipped with
an
autosampler, an Elite-lcolumn (Perkin Elmer I'm (Waltham, MA), 30 m length,
0.25 mm internal
diameter, 0.25 gm thickness film diameter) and a flame ionization detector
(FM). Instrument
control and data acquisition and analyses was accomplished by TotalChrom
software version
1.2.3.4 (Perkin Elmer TM, Waltham, MA).
Calibration curves were generated by injecting each standard in triplicate and
the RSDs
provided the measure of precision while the absolute accuracy was determined
by comparing the
concentrations of the standards predicted by the calibration curve to their
"known" values
determined by dilution ratios. AOAC International standards for accuracy and
precision were
used as quality guidelines for every calibration. Check standards were run at
the start, middle,
and end of every analysis, and recalibration was performed when they varied
more than +/- 5%
of their initial average response. Levels that failed the acceptance criteria
and analytes were not
quantified at those levels until recalibration of the instrument corrected the
deficiency. Due to
the very linear nature of the FID detector, the GC-FID cannabinoid assay
generally provided
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
satisfactory results over nearly two orders of magnitude (up to 1.0 mg/mL),
however in order to
use the same calibration solutions and "validation" procedures for both GC and
HPLC the range
was reduced to that of the HPLC method. Based on the sample mass extracted
(500 mg) and a
3x3mL extraction (low oil samples), a 1:3 dilution provided quantitation of
cannabinoid levels
from 0.09-1.35% and the 1:40 dilution from 1.15-18% in the plant matrix. A.
3x5mL extraction
(high oil samples, typical), a 1:3 dilution provided quantitation of
cannabinoid levels from 0.14-
2.25% and the 1:40 dilution from 1.9-30% in the plant matrix.
In som.e embodiments, GC-FID measurements for cannabinoids were conducted in
triplicate so as to provide 95% confidence intervals for each cannabinoid
measurement. In some
embodiments, only a single measurement was made, and the confidence intervals
were
designated as N/A.
Cannabinoids by high performance liquid chromatography photo diode array
detector
(HPLC-PDA)
An HPLC-PDA (also known as HPLC-DAD, or simply HPLC) assay was developed as
an orthogonal method to GC-FID for cannabinoid analyses. This method
quantifies six neutral
cannabinoids (CBD, CBG, CBN, THC, A8-THC, and CBC) as well as THCA. based on
calibration curves generated with analytical standards and an internal
reference standard
(ibuprofen). The only acidic cannabinoid that is readily available as an
analytical standard in the
United States is THC.A, so levels of CBDA, CBGA, and THCVA are estimated by
reference to
THCA calibration.
HPLC analyses were performed using a Perkin Elmer TM (Waltham, MA) HPLC system
comprised of a Flexar FX-1.5 binary pump, a Flexar 5-CH solvent manager, an EX
UHPLC
autosampler, and a Peltier LC column oven. IN data was collected at 228nm and
280nm with a
Flexar FX-PDA. UHPLC detector. Chromatography was performed on a Brownlee SPP
C18
column (PIO N9308411, 2.7 m, 3.0x150mm), protected by a Brownlee SPP C18 guard
column
2.1x5mm). HPLC system control, data acquisition and analyses were performed
with
Chromera software version 3.4.1.5904.
76
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Calibration was achieved by performing a five-point calibration curve (0.016
¨0.25mg/mL for each analyte) followed by linear regression analysis. This
analysis was
performed with Microsoft Excel (Redmond, WA) software. The calibration curves
were
generated by injecting each standard in triplicate and the RSDs provided the
measure of
precision while the absolute accuracy was determined by comparing the
concentrations of the
standards predicted by the calibration curve to their "known" values
determined by dilution
ratios. A0A.0 International standards for accuracy and precision were used as
quality guidelines
for every calibration. Check standards were run at the start, middle, and end
of every analysis,
and recalibration was performed when they varied more than +1- 5% of their
initial average
response.
In some embodiments, HPLC measurements for cannabinoids were conducted in
triplicate so as to provide 95% confidence intervals for each cannabinoid
measurement. In some
embodiments, only a single measurement was made, and the confidence intervals
were
designated as N/A. In these cases, an Agilent TM 1290 IIPLC was used with a
0.5mUmin flow
rate on a Poroshell 120 EC-C18, 2.1.x1.50mm, 2.7uM column.
iv. Orthogonal analyses of all samples
The cannabinoid content was quantified by both GC-FID and HPLC. The main
difference
between GC and HPLC is that GC involves thermal stress and mainly resolves
analytes by
boiling points while HPLC does not involve heat and mainly resolves analytes
by polarity. There
are several reasons that this orthogonal approach to analyses is desirable for
highly accurate and
reproducible results in determining chemotype. The first reason is related to
the difference
between the cannabinoids produced naturally by the plant (the acidic
cannabinoids) and those
that are bioactive (the neutral cannabinoids). Cannabis biosynthesizes all the
cannabinoids in
their relatively unstable acidic forms, and these forms are generally not
bioactive in the
traditional sense. The application of heat (flame, vaporizer, oven, etc)
causes a loss of the
carboxylic acid group and generates the neutral forms of the cannabinoids,
which are generally
the bioactive forms that are sought after, however this process is highly
variable and not
quantitative. If one wants to know the native phytochemical profile of the
plant then HPLC
should be used since this assay does not involve heat. If one wants to know
the possible
77
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
available amount of bioactive cannabinoids, then GC should be used since
conversion to these
forms in the injector of the GC is an inherent part of the analytical method.
The second reason is also related to the difference between the acidic and
neutral
cannabinoids, but has to do with the availability of analytical standards to
calibrate the
instruments. While all of the neutral cannabinoids (THC. CBG, CBC, CBD, and
CBN) are
available as analytical standards, THCA is the only acidic cannabinoid
available as an analytical
standard and the instruments were only calibrated for quantification using
actual. analytical
standards. Technically the IIPLC assay could characterize the naturally
occurring chemotypes,
but the acidic analytes are not available as standards, so this quantification
is approximate and
considered for information only. The acidic analytes are all quantified by
reference to the
calibration curve for THCA, and this is not an unreasonable assumption as many
of them have
approximately the same spectral properties. The GC assay is calibrated with
analytical standards,
but these are the neutral cannabinoids and their formation from the naturally
occurring acidic
cannabinoids in the GC injector is not quantitative, which complicates exact
characterization of
the naturally occurring chemotype.
The final reason is simply to have an internal crosscheck of our results by
using
orthogonal testing methods. Each type of assay (GC and H.PLC) has its
strengths and weaknesses,
and by using both methods one can compare results and ensure that both the
identification and
quantitation of the components are accurate. A caveat to this, as mentioned
above, is that the
conversion of the acidic forms to the neutral forms is not quantitative due to
thermal degradation.
Under the highly optimized conditions of a GC injector we have found
conversion can vary
between 75-85% (for analytical THCA standards), while cannabis samples
generally have a
conversion of 70-80%. Similar conversion rates are also described in
literature for highly
optimized analytical instruments (Dussy el al. 2004). Because of this
incomplete conversion our
GC results are consistently 20-30% lower than the HPLC results for cannabis
samples. This
same conversion efficiency can be applied to estimate the maximum availability
of THC based
on THCA content when smoking or vaporizing cannabis.
v. Method "validation"
In order to demonstrate the performance of a method of analysis, a systematic
process
known and method validation can be carried out. This process demonstrates the
method is fit for
78
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
its intended purpose and is necessary for the confident use of that method,
providing assurance
that the results that are reported are precise, accurate, and reflective of
the sample. Very few labs
in the cannabis industry attempt to validate their assays and this fact,
combined with
inappropriate sampling have resulted in erroneous data for several varieties.
In order to validate
the analytical methods employed for this project, an abbreviated protocol
similar to Single
Laboratory Validation (SLY) was carried out. Assay "validation" was carried
out by spiking
blank matrix with the analytes at low, med, and high concentrations and
carrying out the assay
procedure in replicate (n=5). While some analytes provided better results than
others the analyte
RSDs, recoveries, and precisions at these concentrations satisfied AOAC
guidance (based on
mgimL). In general the RSDs for the terpenes at the low, medium, and high
concentrations
(varied by terpene but generally 0.016, 0.125, and 1.0 mg/mL) were less than
5%, 4%, and 3%
respectively. The absolute bias for these analytes was generally less than
10%, 4%, and 2%. In
general the RSDs for the cannabinoids by both GC and HPLC at the low, medium,
and high
concentrations (0.016, 0.61, and 0.250 mg/mL) were less than 2%, 2%, and 1%
respectively. The absolute bias for these analytes was generally less than
10%, 2%, and
2%. The assays all provided satisfactory SiN ratios at the lowest level and
this was initially
taken as the LOQ. After subsequent re-calibrations (n=3 at each level), the
LOQ was taken as
the lowest level of the calibration curve that provided acceptable accuracy
(<10% error)
determined by comparing the known concentration levels (determined by dilution
ratios) to the
predicted levels (obtained from the signal and calibration curve).
The error between the known and measured values establishes the accuracy of
the method and
verifies that real samples do not present any matrix effects that influence
the resulting
measurements. The precision, or closeness of individual measurements, of the
method is also
determined by carrying out all analyses in replicate (n=5). Guidance for
acceptable values was
taken from publications provided by the AOAC.
The in-house validation revealed that the above-described chemical analysis
methods
were accurate and reliable, and the use of orthogonal methods of analyses
provided an internal
check on the assays as well as an understanding of the use of GC to analyze
thermally unstable
molecules. Using multiple dilution ratios kept samples in the linear ranges of
the assays, and
method validation verified that precise and accurate results were obtained.
79
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
vi. Categorization into color classes
Initial assignments to color classes were based on phenotypical traits and
organoleptic
properties observed in the field. Once in-house resources became available for
more rigorous
analyses, cultivars were reassigned based on agglomerative hierarchal
clustering (AHC) using
the relative terpene profiles. Unique parental cultivars were identified when
field observations
suggested unique properties and principal component analysis (PCA) of the
relative terpene
profiles of these cultivars alongside existing cultivars suggested a novel
composition. In some
cases the first two eigerivalues accounted for a relatively small portion of
the variance, which
suggested information might be hidden in the next factors. When this was the
case, correlation
circles and PC plots were generated for combinations of the first two and
three factors (F1, F2,
and F3) to ensure the maps were a good quality projection of the initial multi-
dimensional
terpene tables.
When analyzing the cultivars, relative terpene content was used for both AHC
and PCA.
This allowed for direct comparison to published relative profiles (Hazekamp
2010, Ilillig 2004,
Grassi 2011), which were viewed as superior characterizations to those given
by local
laboratories that gave little thought to method validation. This also allowed
for direct comparison
and color class assignment to of cultivars with differing absolute terpene oil
contents Final
analysis of parental CBD and THC:CBD cultivars was also done using absolute
terpene levels,
as the enhanced total content is also a novel feature of these cultivars.
Example 2. Proprietary Parental Variety Phenotypes
More detailed descriptions of the development and characteristics of
representative
Parental Classes of Cannabis Varieties of the present invention are provided
below. In some
embodiments, the THC parental varieties of the present invention were selected
for their
morphologies and desirable phenotypes.
GOD13
Description of Breeding Stock. Inflorescences were obtained for a land race of
Gold
class varieties and seeds from these inflorescences were isolated and put into
conditions proper
for their germination. The seeds which germinated grew identically. However,
upon flower
onset, the seedlings were selected for the strongest limonene/Pine-Sol
fragrance and narrowed to
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
two phenotypes. Of these, the individual phenotype with the best user
experience based on
testing was selected to create GOD13, a variety classified into the Gold
Class.
Hypothesized Genetics. Cannabis indica ssp. afghanica WLD "Purple Afghan" x C.
indica ssp. indica var. indochinensis NLD "Lemon Thai" x C. indica ssp.
kafiristanica NLDA.
Propagation and Vegetative Growth. Cuttings from GOD13 are marked by 3-finger
leaflet sets with internode buds asymmetrically located on alternate sides on
main shoot. In
particular, the intemode space of this variety tends to be greater than that
of other gold class
varieties and stems harden quicker. Roots nodes appear with 7-10 days and
roots within 10-14
days. The GOD13 grows extremely tall and thin with extreme stretching and
asymmetrical bud
and leaf sets. When root system is not limited or pruned, this variety of gold
class varieties
exhibits unparalleled vigor and stretch. Vegetative growth is marked by a deep
blue-green
(Munsell ID) hue with lime green thin stalks. Petioles are marked by purple
pointillism
increasing on sides exposed to light and the end closest to palm of the
leaflet set. Root bodies are
typically full and bright white. Stalks radiate a pungent smell of body odor
or urine. Canopy
extremely sparse and apical dominance can be disrupted easily with removal of
apical meristem.
Main stems also exhibit purpling, but inflorescences are not purple.
Onset of Flowering and Inflorescences. Leaves are 3 and 5 leaflet patterns
with 3 being
predominant and overall decreasing to 1 and to none in the presence of female
flowers.
Female flowers are spread out due to the large intemode spacing. Upon flower
set, buds
and supporting structures (stems, leaves, etc.) are quickly covered with an
extremely dense field
of trichome bodies. Again, this variety tends to be more densely covered with
trichome bodies
than its parent and other gold class varieties. In fact, the inflorescences
are very dense and have
large calyxes covered in highly resinous glands that exhibit this variety's
distinct lemon Pine-Sol
scent after only 7-10 days. As inflorescences mature, the density compact sets
give way to
foxtailing and 'reaching' by individual calyxes, resulting in an overall
increase in surface area
dedicated to trichome production. In particular, the oily character of these
flowers set this gold
class apart from its parent and other gold class varieties. Textures are
extremely sticky and
fibrous. Sterns do not 'break' they tear, but remain attached via intense
fiber strands.
Description of Finished Flower. GOD13 consistently produces among the highest
THCA
levels of cannabis known in California and is often noted for an intense and
crushing physical
effect combined with a sublime and inspiring mental flight. Aromas of lemon
peel, fuel and
81
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Pine-Sol combine to produce a pure menthol exhalation when smoked. Noted for
excellent
appetite and sexual stimulation often accompanied by uninterrupted sleep.
Description of Planting. Harvesting and Processing of the Plants, This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-800 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days). Upon root onset,
the plantlets were
transplanted into rigid 1 gallon containers filled with a proprietary soil mix
A and remain in 18
hours of daylight for another 14-21 days. Once root bound, plants are
transplanted into rigid 3
gallon containers filled with proprietary soil mix B. Immediately, the light
cycle is altered to
12/12 and flower initiating begins. The plants remain in 12/12 lighting until
harvesting. They
undergo a propriety nutrient regimen and grow as undisturbed as possible for
60-70 days
depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichome heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying.
Yield Data. Yield determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor Controlled Environment
Agriculture (CEA)
technique following the protocol described elsewhere herein. Flower onset was
initiated with
12/12 day/night at approximately 12" in vegetative height. Total biomass
¨150g, finished
flowers ¨50g, and/or ¨50g of seed per plant.
Potential Uses of this Line. Potential uses of GOD13 include but are not
limited to
medical applications, as a source for extractions of plant constituents and
chemicals, for
commercial raw materials, fiber and pulp.
Patient Testimonials/Comments and Visual Observations. Patients rave about the
flavor
and 'oily' composition by comparison to other Gold class varieties. In fact,
besides the extremely
high potency from its combined cannabinoid/terpenoid 'entourage effects", this
line of gold class
has been noted by patients for being particularly effective for sexual and
appetite stimulation.
Palatable CBDA varieties with ideal CBDA:THCA ratio can be developed from
GOD13
to reduce side-effects associated with extant recreational cannabis varieties
related to GOD! 3.
82
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Additionally reduced THCA varieties can be developed that are intended to
reduce side-effects
from extant recreational cannabis varieties related to GOD13.
Flavor when smoked includes distinct citrus and mentholated notes. Significant
analgesia
accompanies its deep range of effects, but with little sedation, but the
"rising/falling" physical
sensations associated with gold class. Some patients have compared its flavor
to bergamot
orange. Patients also remark on the "clarity" of this variety's
psychoactivity, with less sedation
and disorientation, and with considerable euphoria.
Its aroma has been characterized as a tangy, sharp, naphthalene aroma with
orange notes
and a sweet undertone. Also the range of pharmacologically active terpenoids
that this variety
produces provide a significant "entourage effect" that accompanies the effects
of its THC content.
While it stimulates appetite, it does not appear to encourage overeating.
812005
Description of Breeding Stock. Inflorescences were obtained for a landrace of
Haze and
seeds from these inflorescences were isolated and put into conditions proper
for their
germination.
The seeds which germinated grew identically, being short and squatty with
purple leaves
and 'sweet' scent, with one exception which was tall and stretchy with a
savory and musty scent.
There was absolutely no sweetness in the smell of BROO5. Testing proved that
its effects were
the most enjoyable and virtually myrcene free. The lack of myrcene and
presence of pinene and
limonene is quite rare and sets this variety apart from most cannabis
varieties.
Upon flower onset, the seedlings were selected for being short and squatty
with purple
leaves and 'berry' scent to create BROO5, a variety classified into the Gold
Class.
Hypothesized Genetics. "NL#5 x Haze x inbred Thai"
Propagation and Vegetative Growth. Cuttings from BROO5 are marked by 9-finger
very
thin leaflet sets with internode buds asymmetrically located on alternate
sides on main shoot. In
particular, the intemode space of this variety tends to be extremely large.
Stems are tall, frail and
stretchy. Cuttings roots appear within 10-14 days. The BROO5 grows tall and
stretchy with
flimsy stems. It possesses the classic narrow-leafleted morphology associated
with 1970's Haze
cultivars that were inherited from Haze's tropical drug cannabis parents,
including Colombian
and Thai varieties.
83
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
BROO5 grows with asymmetrical bud and leaf sets. Vegetative growth is marked
by a
lightened green (Munsell ID) hue with lime green thin stalks. Leaflets are
longer and narrower
than most of drug cannabis varieties.
BROO5 displays vigorous hybrid character.
There is little or no purple on this plant until the final weeks of flowering.
Leaves turn
deep purple with flowers silvering up as time goes on. Stalks radiate a 'hazy'
or musty urine
scent. Canopy extremely sparse and topping near flowering is encouraged for
even growth.
Onset of Flowering and Inflorescences. Leaves are 9 and 7 leaflet patterns
with 7 being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. In
particular, flower onset is very slow with this variety. 'Hairy' flowers are
not very dense.
Female flowers are spread apart due to the large internode spacing.
Upon flower set, buds and supporting structures (stems, leaves, etc.) take
longer than
most to become covered with trichome bodies. Everything about this plant takes
longer. As
inflorescences mature, they become more hardened and dense. In particular, the
oily character of
these flowers was the driving force for selection.
Description of Finished Flower. BRO05 defines heady, hazy medicine with highly
functional mental effects. This variety has the structure and scent of the
BROO5 lines famous
around the world. With aromas of spice and anise, the hashish flavor when
smoked is
enlightening.
BROO5 is noted for mood elevation, inspiration and creativity and is also
likely to
improve home hygiene.
Chemotvne Descrintion for Patient. Relative potency: strong. Headspace
Terpenes:
pinenes, limonene. Caryophyllene content: high.
Description of Planting. Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
84
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves arc removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichom.e heads but not 'buds', Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying. Slow
drying followed by a one to two month curing process.
Yield Data. Yield determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CE.A technique following
the protocol
described elsewhere herein. Flower onset was initiated with 12/12 day/night at
approximately 16"
in vegetative height. Organic mix of soil in fabric pots, a regimen of
nutrients following standard.
NPK feeding schedules and addition of proprietary mixture. Flower onset was
initiated with
12/12 day/night when plant reached approximately 16" in vegetative height..
Potential Uses of this Line. Potential uses of BRO05 include but are not
limited to
medical applications, extractions, commercial raw material (chemical), fiber
and pulp.
Patient Testimonials/Comments and Visual Observations. Patients rave about the
great
experience of using BRO05. The effects are mind stimulating with some visual
'crispness'. The
patients often comment that this variety is good for the 'new' user because of
its lower THC
concentration and the 'clarity' of the experience.
SIL04
Description of Breeding Stock. Inflorescences were obtained for a proprietary
breeding
program and seas from these inflorescences were isolated and put into
conditions proper for
their germination. The seeds which germinated grew identically. The resulting
plants were then
crossed with GOD13 plants and seeds were planted and germinated for selection
based on oil
content of the plants. Plants with higher oil content were selected to create
SIL04.
Hypothesized Genetics. "Cannabis indica ssp. afghanica WLD "SB Purple" x C
indica
ssp. indica NW x C. indica ssp. kafiristanicaNIDA"
Propagation and Vegetative Growth. Cuttings from SIL04 are marked by 5-finger
leaflet
sets with intemode buds asymmetrically located on alternate sides on main
shoot. In particular,
the intemode space of this variety tends to be longer and stalks thinner (-4-
8" vcg, decreasing
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
flower onset). Plants are tall, stretchy and productive. Roots of the cuttings
appear within 10-14
days.
The SIL04 grows tall and stretchy and exhibits little or no apical dominance.
SIL04
grows with asymmetrical bud and leaf sets. Vegetative growth is marked by a
lavish green
(Munsell ID) hue with green undersides and hard wood like stalks. When
healthy, fan leaves are
extremely jagged and serrations are very pronounced.
The stems are strong and fibrous, but extremely thin. The standout quality of
SIL04 is the
amount of trichomes and their density. The flower sets look 'frosty' before
most other varieties.
Stalks are vanilla spice scent.
Canopy is extremely sparse with clustered bud formation. Topping extremely
encouraged.
Onset of Flowering and Inflorescences. Leaves are 5 leaflet patterns with 5
being
predominant and overall decreasing to I and to none in the presence of female
flowers. In
particular, flower onset is fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are spear-
shaped,
dense and thick although relatively large internode lengths. Again, this
variety tends to be more
densely covered with trichome bodies than most other varieties.
The flowers arc compact and well-formed in the shape of small pinccones. As
inflorescences mature, the density compact sets compound to form bright orange
and silver
flowers that give way to yellow and purple sun leaves.
Plants are marked by unusually high oil mass content and extremely dense small
resinous
buds.
Apical inflorescences are often smaller than lowers. Inflorescences
particularly are
resistant to fungal infestation due to compact oil flowers.
Description of Finished Flower. SIL04 (a.k.a., internally known as 'Heiress'
or "Oily
Heiress') was bred from a dream team of cannabis genetics: Northern Lights x
Haze, Santa
Barbara Purps, a Midwest G-13 and the aforementioned GOD13. The chemotype of
this variety
is indicative of this diverse genetic heritage. The aroma consists of vanilla,
grapefruit, and even
has petroleum notes, but a rich creamy vanilla flavor emerges when smoked.
Noted for its rare
combination of clarity and profound potency, it delivers functional and long
lasting inspiration
and positivity.
86
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Description of Planting. Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that one is actually
harvesting trichome heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying. Slow
drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CEA technique following
the protocol
described elsewhere herein. Flower onset was initiated with 12/12 day/night at
approximately 16"
in vegetative height. Total biomass ¨120g, finished flowers ¨40g, and/or ¨30g
of seed per plant.
Potential Uses of this Line. Potential uses of SIL04 include but are not
limited to medical
applications, extractions, commercial raw material (e.g., chemical), fiber and
pulp.
Patient Testimonials/Comments and Visual Observations. Very interesting from
an
organoleptic standpoint (sweet Amsterdam flavor) and a caryophyllene content
standpoint.
SIL04 produces a happy laughing high, with the classic combusted aroma of
1990's landrace
varieties of the same cannabis class.
W11104
Description of Breeding Stock. Inflorescences were obtained for a landrace of
WI-1104
and seeds from these inflorescences were isolated and put into conditions
proper for their
germination. The seeds which germinated grew fairly similarly. However, upon
flower onset,
the seedlings were selected for trichome density, leaflet width and root vigor
to create WHI04.
87
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Hypothesized Genetics. "Cannabis indica ssp. alkhanica WLD"
Propagation and Vegetative Growth. Cuttings from WHIO4 are marked by 7-finger
leaflet sets with intemode buds asymmetrically located on alternate sides on
main shoot. In
particular, the internode space of this variety tends to be greater than that
of other Silver varieties
and stems harden more slowly. In particular, the cutting roots more rapidly
than other Silver
varieties. In fact, the root bodies of the plant are the most robust and
vigorous of all cannabis
plants tested in our laboratory. Root time varies with nodes appearing within
7-10 days and roots
within 10-14 days.
The WHIO4 grows medium in stature with stocky branches and stalks. Even growth
throughout with asymmetrical bud and leaf sets. Vegetative growth is marked by
a deep blue-
green (Munsell ID) hue with lime green thin stalks. Leaflets are fat and
exhibit classic
recreational 'indica' look. These broad leaflets are indicative of this
variety. Petioles are
marked by purple pointillism increasing on sides exposed to light and the end
closest to palm of
the leaflet set. Root bodies are typically full and bright white. Stalks
radiate a pungent smell of
bubble gum coffee and green class. Canopy extremely sparse and apical
dominance can be
clearly observed and removal of apical meristem often results in stunted
growth. Main stems
may also exhibit purpling, and inflorescences sets are large, but spread out.
Onset of Flowering and Inflorescences. Leaves are 7 and 5 leaflet patterns
with 3 being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. Female
flowers are spread out due to the large intemode spacing.
Upon flower set, buds and supporting structures (stems, leaves, etc.) are
quickly covered
with an extremely dense field of trichome bodies. Again, this variety tends to
be more densely
covered with trichome bodies than its parent and other Silver varieties. In
fact, the
inflorescences are very dense and have large calyxes covered in highly
resinous glands that
exhibit this variety's distinct lemon Pine-Sol scent after only 7-10 days.
As inflorescences mature, the dense and compact calyx clusters or flower sets
give way
to foxtailing and 'reaching' by individual calyxes, resulting in an overall
increase in surface area
dedicated to trichome production. In particular, the oily character of these
flowers set WHIO4
apart from its parent and other Silver varieties. Textures are extremely
sticky and fibrous. Stems
do not 'break' they tear, but remain attached via intense fiber strands.
88
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Description of Finished Flower. WI-1104 has descended from the great Afghan
hashish
cannabis cultivars and is a nearly perfect choice for vaporization. The resin
content delivers a
range of tastes and effects with each draw.
The aroma consists of coffee, spice and exotic incense. This variety is noted
for its
ability to mellow without sedation or fatigue, excellent analgesic effects and
deep introspection.
Chemotvpe Description for Patient. Relative potency: mild. Headspace Terpenes:
pinenes, myrcene, limonene, linalool. Caryophyllene content: medium
Description of Planting. Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichome heads but not the `buds'. Thus, great care is taken not to
disturb the
trichome heads and as much of the plant remains intact as possible to promote
even and slow
drying. Slow drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CEA technique following
the protocol
described elsewhere herein.
Flower onset was initiated with 12/12 day/night at approximately 12" in
vegetative height.
Total biomass -120g, finished flowers -30g, and/or -15g of seed per plant.
Potential Uses of this Line. Potential uses of WHIO4 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
89
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Patient Testimonials/Comments and Visual Observations. Patients rave about the
coffee
flavor and 'oily' and 'silver' composition of Va1104. In fact, besides the
mellow effects, WHIO4
is particularly noted for treating pain and inspiration.
RED08
Description of Breeding Stock. Inflorescences were obtained from a DJ Short's
Flo
(a.k.a. DJ's Flo) pollinated by a hermaphroditic Hawaiian plant and seeds from
these
inflorescences were isolated and put into conditions proper for their
germination.
The seeds which germinated grew very uniformly in appearance. However, the
seedlings
were selected for vigorous phenotype with highest trichome density and 'oily'
feel of resin
glands to create RED08.
Hypothesized Genetics. "1995 Hawaiian Bag Seed x Thai".
Propagation and Vegetative Growth. Cuttings from RED08 are marked by 7-finger
leaflet sets with internode buds asymmetrically located on alternate sides on
main shoot. In
particular, the internode space of this variety tends to be medium-stretchy (--
4" veg, decreasing
flower onset). Plants are tall, robust and lanky. Cuttings root within 10-14
days.
The R.ED08 grows tall and stout with mixed apical dominance.
RED08 grows with asymmetrical bud and leaf sets. Vegetative growth is marked
by a
deeper off green (Mtmsell ID) hue with deep purple strong hollow stalks.
When healthy, sun leaves are gigantic with magenta and purple under side
coloring.
Plants have super vigor and hybrid character. RED08's stand-out quality
feature is the high
amount of trichomes and the high amount of oil. Stalks have a pungent
'medical' scent. Plant
canopy is dense with large cola formation. Topping encouraged.
Onset of Flowering and Inflorescences. Leaves are 7 leaflet patterns with 7
being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. In
particular, flower onset is medium-fast by comparison to most varieties.
Trichome density and
smell are almost immediate. Female flowers are clustered to do decreased
internode spacing.
Again, this variety tends to be more densely covered with trichome bodies than
its parents and
other varieties. In fact, the inflorescences are very dense and have large
calyxes covered in
highly resinous glands that exhibit this variety's distinct blueberry pine
medicine/medicinal scent
after only 7-10 days.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
As inflorescences mature, the density compact sets compound to form bright
green and
extremely oily buds. In particular, the oily character of these flowers set
this its parent and
phenotypes.
Description of Planting. Harvesting and Processine of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in 12/12 lighting until harvesting. They undergo a propriety
nutrient
regimen and grow as undisturbed as possible for 60-70 days depending on
chem.otype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichome heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying. Slow
drying followed by a one to two month curing process.
'Potential Uses of this Line. Potential uses of RED08 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
Patient Testimonials/Comments and Visual Observations. RED08 is very
interesting
from an organoleptic standpoint and it is unique in almost all visual
categories.
SILO
Description of Breeding Stock. Inflorescences were obtained from a, and selfed
seeds
from these plants were germinated. The seeds which germinated grew very
similarly. The
resulting seedlings were selected for vigor.
Hypothesized Genetics. "Cannabis indica ssp. afghanica WLD "Cherry Afghan" x
C.
indica ssp. indica NLD hybrid
Propagation and Vegetative Growth. Cuttings from SIL03 are marked by 7-finger
leaflet
sets with intemodc buds asymmetrically located on alternate sides on main
shoot. In particular,
91
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
the intemode space of this variety tends to be medium-stretchy (-4" veg,
decreasing flower
onset). The plants are tall, robust and lanky. Cuttings root within 10-14
days.
The SIL03 grows tall and strong with little apical dominance. SIL03 grows with
asymmetrical bud and leaf sets.
Vegetative growth is marked by a lighter shade of green (Munsell ID) hue with
deep
purple strong hollow stalks. When healthy, sun leaves are point upward toward
light source.
The stems are strong and fibrous. The plants are super vigorous and hybrid in
character.
The stand-out quality is the high amount of trichomes and the high amount of
oil. Stalks have a
sweet scent Canopy is dense with large cola formation. Topping encouraged.
Onset of Flowering and Inflorescences. Leaves are 7 leaflet patterns with 7
being
predominant and overall decreasing to I and to none in the presence of female
flowers. In
particular, flower onset is medium-fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are clustered
to do
decreased internode spacing. Again, this variety tends to be more densely
covered with trichome
bodies than its parents and other varieties. In fact, the inflorescences are
very dense and have
large calyxes covered in highly resinous glands that exhibit this variety's
distinct blueberry pine
medicine/medicinal scent after only 7-10 days.
As inflorescences mature, the dense and compact calyx clusters or flower sets
form bright
green and extremely oily buds. In particular, the oily character of these
flowers set this variety
apart from its parent and phenotypes.
Description of Finished Flower. SIL03 combines a beautifully sweet cherry WLD
Afghan with a NLD to deliver a strong, cheerful, dreamy psychoactivity. This
variety produces a
pleasant silliness and a 'where'd I put my keys!'?' memory effect and
obliterates most patient
troubles.
Aroma consists of cherry cough drops, fresh strawberries and just a hint of
spice. 51L03
is often noted for long-lasting effects and positive mood impact.
Description of Planting, Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
92
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants arc transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichom.e heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying.
Slow drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CEA technique following
the protocol
described elsewhere herein. Flower onset was initiated with 12/12 day/night at
approximately 16"
in vegetative height. Total biomass ¨180g, finished flowers ¨60g, and/or ¨50g
of seed per plant.
Potential Uses of this Line. Potential uses of SIL03 include but are not
limited to medical
applications, extractions, commercial raw material (e.g., chemical), fiber and
pulp.
Patient Testimonials/Comments and Visual Observations. Noted as being very
interesting from an organoleptic standpoint. SIL03 is unique in almost all
visual categories.
GRE01
Description of Breeding Stock. Inflorescences were obtained and isolated and
put into
conditions proper for their germination.
The seeds which geminated grew identically. However, the seedlings were
selected for
the phenotype that is more densely covered in trichomes, where the oil content
of the gland
heads was higher than other phenotypes of this variety.
Hypothesized Genetics. "Cannabis indica ssp. qfghanica WLD "Afghan #1" x C.
indica
ssp. indica NM hybrid
Propagation and Vegetative Growth. Cuttings from GRE01 are marked by 9-finger
very
thin leaflet sets with internode buds asymmetrically located on alternate
sides on main shoot. In
93
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
particular, the intemode space of this variety tends to be extremely large.
Plants are tall, frail and
stretchy. Cuttings root appears within 10-14 days.
GRE01 grows tall and stretchy with flimsy stems and embodies what it means to
be a true
hybrid.
GRE01 grows with asymmetrical bud and leaf sets. Vegetative growth is marked
by a
lush green (Munsell ID) hue with lim.e green thin stalks.
Leaflets are longer and thinner than varieties. Plants have a vigorous hybrid
character.
GRE01 has little or no purple color on the plant. The stand-out quality is the
high amount of
trichomes and the high amount of oil. Plant stalks have a sweet citrus
`creamsicle' scent.
Plant canopy is dense and even topping near flowering is encouraged for even
growth..
Onset of Flowering and Inflorescences. Leaves are 9 and 7 leaflet patterns
with 7 being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. In
particular, flower onset is fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are clustered
to do
decreased internode spacing. Again, this variety tends to be more densely
covered with trichome
bodies than its parent and other green class varieties. In fact, the
inflorescences are very dense
and have large calyxes covered in highly resinous glands that exhibit this
variety's distinct green
class creamsiele scent after only 7-10 days. As inflorescences mature, the
density compact sets
compound to form orange and bright green extremely oily buds. In particular,
the oily character
of these flowers set this green class apart from its parent and other green
class varieties.
Description of Finished Flower. GRE01 defines sweet, delicious
medicine/medicinal
with functional mental effects. This variety has resin production akin to
Afghan and
psychoactivity reminiscent of original Green class.
GRE01 has aromas of citrus, brown sugar, and banana nut bread combine to
produce a
fantastic fruity hashish flavor when smoked. It is noted for mood elevation
and daytime bursts
of energy that provide for short-term pain relief.
Description of Planting, Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (--80 C). Full
trays were covered,
left under 18 hours of light and allowed to root (7-14 days).
94
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants arc transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichom.e heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying.
Slow drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CEA technique following
the protocol
described elsewhere herein.
Flower onset was initiated with 12/12 day/night at approximately 16" in
vegetative height.
Total biom.ass ¨160g, finished flowers ¨50g, and/or ¨50g of seed per plant.
Potential Uses of this Line. Potential uses of GR.E01 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
Patient Testimonials/Comments and Visual Observations. Patients rave about the
great
experience of using this plant. The flowers of GRE01 consistently produce
approximately 2.0%
CBGA in finished flowers. Its wonderful smell/taste is patient's major reason
for appeal.
NIRO
Description of Breeding Stock. Inflorescences were obtained for a landrace of
purple
class pollinated with a hermaphroditic purple class variety and seeds from
these inflorescences
were isolated and put into conditions proper for their germination.
The seeds which germinated grew very uniformly in appearance. However, upon
flower
onset, the seedlings were selected for the two phenotypes that most smelled
like 'grape and dank',
and producing flowers with the highest trichome density and robust examples of
these two
phenotypes were subsequently crossed to create PUR03.
Hypothesized Genetics. "2007 SB PUP1 x 2009 PPS7".
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Propagation and Vegetative Growth. Cuttings from PUR03 are marked by 7-finger
leaflet sets with internode buds asymmetrically located on alternate sides on
main shoot. In
particular, the internode space of this variety tends to be decreased. Short,
squatty and bushy.
Cuttings root within 10-14 days.
The PUR03 grows stout in the traditional 'Christmas live' shape. PUR.03 grows
with
asymmetrical bud and leaf sets. Vegetative growth is marked by a deeper off
green (Munsell ID)
hue with lime green thin stalks. Leaflets are longer and thinner than
varieties. When healthy, sun
leaves are gigantic. It has vigorous hybrid character. The stand-out quality
is the high amount of
trichomes and the high amount of oil. There is an extremely high cannabinoid
content in PUR03.
Stalks have a sweet 'dank' scent. Canopy dense and do not need to top.
Onset of Flowering and Inflorescences. Leaves are 7 leaflet patterns with 7
being
predominant and overall decreasing to I and to none in the presence of female
flowers. In
particular, flower onset is fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are clustered
to do
decreased internode spacing. Again, this variety tends to be more densely
covered with trichome
bodies than its parents and other purple varieties. In fact, the
inflorescences are very dense and
have large calyxes covered in highly resinous glands that exhibit this
variety's distinct grape
lollipop scent after only 7-10 days. As inflorescences mature, the density
compact sets
compound to form deep purple and dark green extremely oily buds. In
particular, the oily
character of these flowers set this purple apart from its parent and other
green class varieties.
Description of Finished Flower. PUR03 defines sweet, delicious grape flavored
medicine
with functional mental effects and pain relief. This variety has resin
production akin to Afghan
and psychoactivity reminiscent of the PUR03. PUR03 has aromas of grape, sweet
sugar, and
dank which all combine to produce a fantastic grape flavor when smoked. It is
noted for mood
elevation, short-term pain relief and hunger stimulation.
Description of Planting. Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid 1 gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
96
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichom.e heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying. Slow
drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CE.A technique following
the protocol
described elsewhere herein.
Flower onset was initiated with 12/12 day/night at approximately 16" in
vegetative height.
Total biomass ¨160g, finished flowers ¨50g, and/or ¨50g of seed per plant.
Potential Uses of this Line. Potential. uses of PUR03 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
Patient Testimonials/Comments and Visual Observations. Patients rave about the
great
experience. This flower consistently produces approximately 2.0% CBGA in
finished flowers.
Its wonderful smell/taste is patient's major reason for appeal.
YELO3
Description of Breeding Stock. Inflorescences were obtained from an unknown
landrace.,
Seeds from these inflorescences were isolated and put into conditions proper
for their
germination. The seeds which germinated grew uniformly in appearance. However,
the
seedlings were selected for their narrow-leafleted tropical cannabis
morphology and pinene
production to create YEL03.
Hypothesized Genetics. "Cannabis indica ssp. indica NLD "Thai" x C indica ssp.
indica
NLD "Highland Mexican."
Propagation and Vegetative Growth. Cuttings from YEL03 are marked by 9-finger
leaflet sets with intemode buds asymmetrically located on alternate sides on
main shoot. In
97
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
particular, the intemode space of this variety tends to be lengthy and
stretchy (-4" veg,
decreasing flower onset). The plants are tall, robust and lanky. Cuttings root
within 10-14 days.
The YEL03 grows tall and strong with pronounced apical dominance. YEL03 grows
with
asymmetrical bud and leaf sets. Vegetative growth is marked by a lighter dark
green (Munsell
ID) hue with purple undersides and strong hollow stalks. When healthy, sun
leaves are point
upward toward light source at twisted angles. The stems are strong and
fibrous. The stand-out
quality is the high amount of trichomes and the high amount of oil. YEL03 has
stalks with a
sweet scent. Plant canopy is sparse with scattered bud formation. Topping
encouraged.
Onset of Flowering and Inflorescences. Leaves are 9 leaflet patterns with 9
being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. In
particular, flower onset is fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are sparse due
to large
internode spacing. Again, this variety tends to be more densely covered with
trichome bodies
than its parents and other varieties. The flowers are not compact or well-
formed. Inflorescences
are spirals of individual foxtails that form a 'coral' looking structure.
Although buds are made of
individual spirals, the inflorescences are dense and tightly packed. As
inflorescences mature, the
density compact sets compound to form bright green and extremely oily buds.
Description of Finished Flower. YEL03 has descended from the great Oaxacan and
Thai
cannabis landrace plants of the 1970's. This variety delivers an intense "up"
stimulating effect
that can be great for countering the debilitating aspects of many medical
conditions. A complex
aroma of spicy spruce and lemon peel release a cornucopia of sweet and spicy
piney flavors
when smoked. It is often characterized by a clear head, accompanied by mood
elevation.
Description of Planting, Harvesting and Processing of the Plants. This variety
is
asexually propagated via taking cuttings of shoots and putting them in rock
wool cubes. These
cubes were presoaked with pH adjusted water and kept warm (-80 C). Full trays
were covered,
left under 18 hours of light and allowed to root (7-14 days). Upon root onset,
the plantlets were
transplanted into rigid 1 gallon containers filled with a proprietary soil mix
A and remain in 18
hours of daylight for another 14-21 days. Once root bound, plants are
transplanted into rigid 3
gallon containers filled with proprietary soil mix B. Immediately, the light
cycle is altered to
12/12 and flower initiating begins. The plants remain in 12/12 lighting until
harvesting. They
98
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
undergo a propriety nutrient regimen and grow as undisturbed as possible for
60-70 days
depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
harvesting trichom.e heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying.
Slow drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis using the specified
cultivation
techniques employed. In this case, indoor CEA technique following the protocol
described
elsewhere herein. Flower onset was initiated with 12/12 day/night at
approximately 16" in
vegetative height. Total biomass -120g, finished flowers -40e, and/or -30g of
seed per plant.
Potential Uses of this Line. Potential uses of YEL03 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
Patient Testimonials/Comments and Visual Observations. Plants have a very
interesting
from an organoleptic standpoint and are unique in almost all visual
categories.
PUR12
Description of Breeding Stock. inflorescences were obtained for an unknown
landracc.
Seeds from these infl.orescences were isolated and put into conditions proper
for their
germination. The seeds which germinated grew uniformly in appearance. However,
the
seedlings were selected for trichome density and hybrid leaf morphology to
create PUR12.
Hypothesized Genetics. "Cannabis indica ssp. afghanica WLD "Afghan #1" x
Cannabis
indica ssp. indica NLD "Brazilian" x C'. indica ssp. indica NLD "Indian."
Propagation and Vegetative Growth. Cuttings from PUR12 are marked by 5-finger
leaflet sets with intemode buds asymmetrically located on alternate sides on
main shoot. In
particular, the internode space of this variety tends to be shorter and stout
(-2-4" veg, decreasing
flower onset). The plants are short, robust and bushy. Cuttings root within 10-
14 days.
The PURI 2 grows short and bushy with classic 'Christmas tree' apical
dominance.
PUR12 grows with asymmetrical bud and leaf sets. Vegetative growth is marked
by a dark
green (Munsell ID) hue with green undersides and hard wood like stalks. When
healthy, sun
leaves are point upward toward light source and 'reach'. The stems are strong
and fibrous. The
stand out quality is the high amount of trichomes and the high amount of oil.
The flower sets
99
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
look 'white' before most other varieties. Stalks are sweet scent. Plant canopy
is dense with
clustered bud formation. Topping discouraged.
Onset of Flowering and Inflorescences. Leaves are 5 leaflet patterns with 5
being
predominant and overall decreasing to 1 and to none in the presence of female
flowers. In
particular, flower onset is fast by comparison to most varieties.
Trichome density and smell are almost immediate. Female flowers are dense and
thick
due to relatively small internode lengths. Again, this variety tends to be
more densely covered
with trichome bodies than other varieties in the white class. The flowers are
compact and well-
formed in the shape of pinecones. Pistils are fat and of high density. As
inflorescences mature,
the density compact sets compound to form bright neon-green flowers that give
way to red-
orange hair. It is marked by unusually high sesquitetpene content and
extremely resinous buds.
Inflorescences are subject to fungal infestation due to large size and extreme
density.
Description of Finished Flower. PLTRI2 produces prodigious amounts of
psychoactive
resin. This variety was derived from Brazilian, Indian, and Afghan gene pools.
Its aroma of
green classy, balsamic, pineapple gazpacho delivers a sweet, ha.shy flavor
when smoked. It is
noted for fast-onset psychoactivity reminiscent of traditional cannabis
experiences that will leave
you right where it found you. Happiness induced pain relief and considerable
relaxation.
Chemoqpe Description for Patient. Relative potency: very strong. Headspace
Terpenes:
pinenes, myrcene, limonene, humulene, and naphthalene. Caryophyllene content:
very high
Description of Planting.. Harvesting and Processing of the Plants. This
variety is asexually
propagated via taking cuttings of shoots and putting them in rock wool cubes.
These cubes were
presoaked with pH adjusted water and kept warm (-80 C). Full trays were
covered, left under
18 hours of light and allowed to root (7-14 days).
Upon root onset, the plantlets were transplanted into rigid I gallon
containers filled with
a proprietary soil mix A and remain in 18 hours of daylight for another 14-21
days. Once root
bound, plants are transplanted into rigid 3 gallon containers filled with
proprietary soil mix B.
Immediately, the light cycle is altered to 12/12 and flower initiating begins.
The plants remain in
12/12 lighting until harvesting. They undergo a propriety nutrient regimen and
grow as
undisturbed as possible for 60-70 days depending on chemotype analysis.
All sun leaves are removed and plant dismantled to result in approximately 12"
branches
covered in inflorescences and trichomes. The goal in harvesting is to realize
that we are actually
100
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
harvesting trichome heads but not 'buds'. Thus, great care is taken not to
disturb the trichome
heads and as much of the plant remains intact as possible to promote even and
slow drying. Slow
drying followed by a one to two month curing process.
Yield Data. Yield was determined on a 'per plant' basis and determined by
specified
cultivation techniques employed. In this case, indoor CEA technique following
the protocol
described elsewhere herein. Flower onset was initiated with 12/12 day/night at
approximately 16"
in vegetative height. Total biomass ¨140g, finished flowers ¨50g, and/or ¨50g
of seed per plant.
Potential Uses of this Line. Potential uses of PUR12 include but are not
limited to
medical applications, extractions, commercial raw material (e.g., chemical),
fiber and pulp.
Patient Testimonials/Comments and Visual Observations. Very interesting from
an
organolepfic standpoint (sweet Amsterdam flavor) and a caryophyllene content
standpoint.
Happy laughing high. PLTR12 has the burnt scent of 1990's landraces.
Parental Plant Phenotypes-
In order to better describe the morphologies of parental cannabis lines,
plants were grown
indoor to maturity at 120 days post transfer under standard production and
pruning methods.
These plants were assayed for several phenotypes important for cannabis
production. These
phenotypes and their descriptions are listed below, and their measurements for
parental varieties
summarized in Table 3.
Plant Sex- In order to properly assess the progeny morphology of the female
inflorescence important for cannabis production, only pistillate plants were
allowed to fully
develop. Breeding of pistillate flowers was carried out by reversing the sex
of a branch of female
flowers through the application silver thiosulfate. Sex determination was made
during vegetative
growth through the identification of the earliest pre-flowers (see Cervantes
2006 "Marijuana
Horticulture The indoor/outdoor medical grower's bible" editors Linda Meyer
and Estella
Cervantes). Male plants were not allowed to develop in order to avoid
accidental pollination of
female plants.
Plant height- measured in centimeters from the base of the plant to the top of
the apical
meristem. Plants were measured 120 days post transfer.
Plant diameter- measured in centimeters as width of the plant at its widest
diameter.
Plants were measured 120 days post transfer.
101
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Number of Leaflefts- Leafletts on leaves were counted. The leaf with the most
leaflets
was recorded at 120 days post transfer.
Leaf Type- Leaves were visually inspected for broad or narrow leaf
morphologies.
Narrow leaf morphologies produce leaflets less than lcm wide (N). This type of
leaf morphology
is most closely associated with Cannabis saliva varieties. Broad leaf
morphologies produce
leaflets wider than 2 cm (B). This type of leaf morphology is most closely
associated with
Cannabis id/ca. Leaves were designated as medium (M) morphologies if they fell
in between
broad and narrow leaf values, indicating the progeny included genetics from
both C. sativa and
C inc//ca.
Average Internodes - Intemodes were counted at plant maturity at 120 days.
Number of
internodes is highly correlated to plant branching and number of
inflorescences. Intemodes are
defined as the sections of stem between nodes.
Node Branching- Node branching was visually determined by inspecting nodes and
determining the amount of branching at plant maturity at 120 days post
transfer. Higher
branching can increase total flower yield, but can also produce plants that
cannot be grown
closely for indoor production.
Leaf Color- Representative leaves from each plant were harvested and pictures
were
taken. Colors will be analyzed and will be provided using Royal Horticultural
Society color chart
values.
Average Number of Inflorescences at Maturity - inflorescences were visually
inspected
and counted at plant maturity at 120 days post transfer. Plants were
designated as having "low"
number of inflorescences if they produced less than 10 inflorescences per
plant. Plants were
designated as having "medium" number of inflorescences if they produced
between 10 and 15
inflorescences per plant. Plants were designated as having "high" number of
inflorescences if
they produced more than 15 infloresences per plant. In general, higher number
of inflorescences
are associated with higher cannabis flower yield.
Average Non-Apical Inflorescence Size - Inflorescence size was measured by
volume by
measuring the height and radius of each non-apical inflorescence at plant
maturity at 120 days
post transfer. These measurements were used to determine volume of the
inflorescence using a
cylinder shape approximation (formula Pi X radius2 X height). Values for all
non-apical
inflorescences were averaged. Inflorescences with average volumes of less than
100cm3 were
102
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
designated "small". Inflorescences with average volumes between 100cm3 and
300cm3 were
designated "medium". Inflorescences with volumes greater than 300cm3 were
designated "large".
Average Apical Inflorescence Size - Inflorescence size was measured by volume
by
measuring the height and radius of apical inflorescences at plant maturity at
120 days post
transfer. These measurements were used to determine volume of the
inflorescence using a
cylinder shape approximation (formula Pi X radius2 X height). Values for
apical inflorescences
of multiple plants were averaged. Apical inflorescences with average volumes
of less than
400cm3 were designated "small". Apical inflorescences with average volumes
between 400 em3
and 600cm3 were designated "medium". Inflorescences with volumes greater than
600cm.3 were
designated "large".
Floral Cluster Density - Floral cluster density is a measure of how tightly
packed floral
buds are in a plant inflorescence. This measure is correlated with total yield
and is also
associated with the amount of labor necessary for trimming the inflorescence
post harvest. For
parental varieties of this example, floral cluster density was approximated by
measuring the time
it took for the inflorescences to dry (reach ¨10% relative humidity). Faster
drying time were
associated with "low" floral cluster density. Slower drying times were
associated with "high"
floral cluster densities. Low density floral clusters dry in 4-5 days, medium
density floral clusters
take 6-7 days, and dense floral clusters take 8-9 days.
Trichome Density- Trichomes on the inflorescences of mature plants at 120 days
post
transfer were visually inspected for trichome density and assigned a score of
1-10 based on past
experiences of the grower. Lower scores indicated lower trichome densities,
whereas higher
scores indicated higher trichome densities. Trichome density is also commonly
referred to as
"frostiness". Inflorescences with scores higher than 7 appear to be completely
covered in white
trichomes giving a "frost" like appearance. Density scores of 8-10 were
equivalent to what could
be expected of an OG Kush strain.
103
Table 3- Phenotype table of parental varieties.
C
Ls.z
.-c
../i
--...
Avg Number Avg non-apical
Avg apical rim, ci r I Irichome Number of
Variety new Plant height at Meet diameter
Mg * 2--;
Leaf type Branching at each node
Inflorescences at inflorescence inflorescence density (1-10
name maturity f(r) at maturity (cm)
internodes density Leafietrs
maturity size
size (cm) scale)
.1.-
rle
PUR13 154 63.5 B 23 every node: leaf, 1 branch
Low Large High High 9 5
5:104
145 65.2 B 27.5 every node: 1 leaf, 1 branch
High Large High Low 5 5
. .
GRE01 45.7 PA 293 every node: 1 leaf. 1 branch
Medium Mediumium High Medium 7 5
S1103 133 49.8 8 26.5 every node: 1 leaf, 1 branch
Medium Large High Medium 7 7
UR03 71 47.4 B 23 every node: 1 leaf, 1 branch
Low Medium Medium High 5 7
P
S1L01 78 46.5 13 15.7 every node: leaf, 1 branch
LOIN Medium Low High 7 5
g.
.
83 22.9 B 21 every node: 1 leaf, 1 branch
Low Medium Low Low 9 7 0
S:106
ro
co
104 67.6 B 20.8 every node: 1 leaf, 1 branch
Medium Large High Low 7 9
YE103
1-,
=c .
= 1-.
C
e
co
clac WH107 112. 50.2 B 295 every node: 1 leaf, 1 branch
Medium Medium High Medium 9 7
ro
.
o
G0013
121 45.7 8 22 every node: 1 leaf, 1 branch
Medium Small Medium Low 7 ! 5 1.
co
I
e=
ORA02
135 43.2 8 32.3 every node: 1 leaf, 1 branch
High Small High Low 9 5 o
Lo
o
103
WHi04 36.2 B 19.8 every node: I leaf, 1 branch
Low Medium Medium Medium 7 7
125
PUR01 39.4 M 28.8 every node: 1 leaf, 1 branch
Medium Medium High Medium 9 7
C131103 89 41.5 M 26.5 every node: Leaf, 1 branch
High Small Low High 9 7
Se02
94 43.8 M 28.5 every node: 1 leaf, 1 branch
High Medium Medium Low 7 5
. .
BROO1 118 43.2 M 27 every node: 1 leaf, 1 branch
Medium Medium High Low 9 7
PUR'12 103 45.1 M 31.7 every node: 1 leaf. 1 branch
High Medium Medium High 5 5
00
125 44.9 M 38.3 every node: 1 leaf, 1 branch
High Small Low Low 2 e e.)
C8001
94
POR06 44.5 B 27.3 every node: 1 leaf, 1 branch
Medium Medium Low Medium 7 7 C
cn
na
CBD5
132 48.7. 13 37 every node: 1.1eaf,1 branch
High Low Medium Medium 7 1 5
0
ri
cloc
0
cloc.
0.
0.
0
cloc
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 3. Analysis of Proprietary THC Parental Varieties.
One objective of the present invention was to develop cannabis varieties with
high
terpene oil contents and different terpene profiles to satisfy unmet needs for
various aroma/flavor
and medicinal combinations. The parental varieties developed in the present
invention,
underwent chemical analyses as described in Example 1. The resulting
cannabinoid and terpene
profiles were further subjected to agglomerative hierarchal clustering (AHC)
using XI.,Stat to
classify varieties into "classes". Varieties in a given class of cannabis
share certain common
physiological, chemical and/or morphological characteristics. Thus, according
to the present
invention, cannabis plants are grouped into named classes according to their
primary/dominant
flavor(s) in order to establish standard cannabis classes of plants herein
referred to collectively as
'Classes of Cannabis Varieties.'
As explained in greater detail below, individual cannabis plants of the
proprietary
cannabis varieties were identified, tested and grouped to form class
categories of similar varieties.
According to the present invention, more than one variety of cannabis may have
been established
within a single cannabis class. Selected candidate cannabis plants for a
specific variety may have
been subjected to further breeding and selection before being chosen as a
cannabis variety for a
particular class. The final selected varieties were designated as Classes of
Cannabis Varieties.
Therefore, as used herein, 'Classes of Cannabis Varieties' or 'variety
classes' or the like each
refer to certain cannabis varieties originating from proprietary varieties,
wherein they were
selected based on certain desirable phenotypical characteristics and
morphological characteristics
for a particular class of cannabis. Color class parental cannabis tended to be
chemotype I plants.
Table 4 summarizes the classes of the cannabis varieties provided by the
present
invention and the Class color, Class name, Class abbreviations ("ABRV"),
flavor associated with
each class, and the major terpenes measured in each class.
Table 4- Color class characteristics of THC parental varieties.
mgoitog MMAJAMTRAViikr3t:ElaitctOtittids Haven
Azure AR rnyrcene lirnoriene>caryophyllene Woody, fruity
Black !ILK caryoptiyilene:.limonerie>rnyrcene Camphoreovs, baked
sweets
Blue BUJ pinenes>myrcene>cdryuDi,4ti., Ber. y, terpy, solv,nt
Bronze eriz limonerie:nnyrcene>caryophyllene Sweet, lemons
105
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Color Abbrev Class Terpene Characteristics Flavor
Brown BRO myrcene ocimenevinene Musky, sweet, apple cider
Ferscia Fsc myrcene, caryophyllene Fuel, grass, baked lemon
Gold GOD limonene =caryophyliene =myrcene Lemon, pine-sol, fuel
Green GRE myrcene>limonene=ocimene Sweet, cream, citrus, skunk
Grey (Mmyrcene, pinene, limortene Woody, green, sweet, bubblegum,
pine
Jade .1AD terpinolene, myrcene Sweet, pepper, spice
Lemon LMN limonene>myreenerrocimene=caryophyllene Citrus, sweet,
spice
lviagenta mAG myrcene ocimene>limonene,caryophyllene Sweet, orange
peel, spice
Navy Nvy myrcene>pinene>limonener,ocirnerre Sweet, pine, citrus
Olive ow rnyrcene ocimene-Aimonene Sweet, orange, lemon
Orange ORA rnyrcene, terpinolene, ocimene, pinene Intense orange
peel, sweet
Pink pNK -riyfc:=?.iie=ocimener-rpinene Sweet, orange, pine
__Purple poRmyrcene. pinene, caryophyllene Grapes, pine, sweet,
pineapple, berry, floral, acrid, menthol
Red RED ocirnene=limonene=pinene Floral, vanilla, skunk
Sea SEA lirnonenez:caryophylierirrzmyrcene>ocimene Lemons,
pepper, sweet
Silver Sit lirrionene,>caryophyllene, myrcene Lime, pomegranate,
creamy, blueberry, spice, menthol
Tan TAN myrcene>ocirriencriimonene>pinene Sweet, dtrus, pine
Violet VLT mYrr5mezocirvene Sweet, oranges
White WHi limonene=caryophyllene, >myrcene Berry, lime, skunk,
fuel, incense, citrus. pine
Yellow yn terpinolene, ocimene, myrcene Lemon, pine, skunk
The analysis of cannabis class varieties led to the slightly different
abbreviations for color
classes and also to the renaming of varieties disclosed in the original
filing. Name changes in this
application from priority documents (US 61/801,528 and US 61/897,074) arc
summarized in
Table 5. New class categories violet (VLT) and pink (PNK) are included in the
following table.
Table 5- Changes in variety color classification and naming.
New
Old Name , Name
BLU4 HUN
BLU8 RED08
BLU9 GRE09
GRE1 GRE01
VIT
G013 GOD13
GOD3 GODO3
106
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
New
Old Name Name
G002 GODO2
GOD11 G0011
G0010 GOD10
BLU5 SIL06
GOD12 5IL12
GOD8 SIL08
RED2 SIL03
RED1 SIL02
SIL01
WHI2 SIL04
GODS WHIO2
WHI7 WHIO7
G006 WHIO6
G014 WHI14
5IL4 WHIO4
CHM1 WHIO1
SILOS WHIOS
GOD4 WHIO9
THCO1 BLKO1
THCO2 BLKO2
THCO3 BLKO3
THCO4 BLKO4
YEL3 YEL03
YEL05 YEL05
PUR2 YEL.02
JK11 JAD11
3K12 JAD12
iCK4 JADO4
ORA3 ORA03
ORA2 ORA02
PURI PUR01
PUR3 PUR03
PUR5 PUR05
GRA3 PUR13
BLU6 PUR06
GRA1 PUR11
BRO1 PUR11
107
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
New
Old Name Name
WHI3 PUR12
GRE2 FSCO4
CHM3 FSCO3
CHM2 FSCO2
GRE30 BROO1
ORA4 13R002
PNK
GOD7 GRA07
GRE31 GRA31
WHI4 GRA04
WHI5 GRA05
The cannabinoid and terpene profiles of each TI-IC parental variety were
determined
using both GC-FID and IIPLC as described in Example 1. The resulting
measurements are
summarized in Tables 6, 7, 8, and 9. The GC-FID cannabinoid analysis of Table
6 also included
measurements for THCV, CBDV, CBGV, CBN, and delta 8 TUC, all of which were
measured to
be less than .05% and were therefore not included in the table. Similarly, the
HPLC cannabinoid
analysis of Table 7 included measurements for THCV, THCVA, CBDV, CBDVa, CBGV,
CBCiVA, CBC, CBCA, CBD, and CBN, all of which were measured to be less than
.01%, and
were therefore not included in the table.
108
Table 6- Cannabinoid measurement by GC-FID for TUC color class parental
varieties. Blank values indicate undetectable levels or 0.
,
_______________________________________________________________________________
______________________
GC-Flo THC Color Class Parental Lines
C
N
iPiC CBD CBG CSC Cannabs
by GC THC:C50 by GC Cannabs / Terps (GC) =
,
_______________________________________________________________________________
________________________________ 7.7.
Sample WI /6 95 It CI WI 1,6 95160 WI% 95% C i WI % 95
%CI - Wt% 95 % Cl- Wt 16- -95160 Nbit % - 9511 CI - -
I
' --.
/i
/i
BLKO1 18.82% 0.51% 0.23%
19.56% 13.77 4.
4.
01.1(02 20.23% 1.37% 0.37%
21.97% 18.78
...__
811(03 1634% 0.71% 0.43%
17.67% 12.06
............... 131.1104 20.70%_____ 0.58% 0.19% 21.90%
12.37
_ 13W04 _ 7.52% - I-0.16% , 0.16% 0.10% 7.98%
47.26 5.94
BRO01 12.23% 2.32% 0.52% 0.01% 0.26% 0.07%
13.08% 2.27% 9.01 3.27
BROW. 13.47% 0.97% 0.02% 0.02% 0.74% 0.06% 0.16% 0.02%
14.44% 0.90% 1036.07 1147.94 12.66 2.88
FSCO4 12.49% 0.34/6 0.42%
13.29% 6.62 r.9
,e
FSCO3 16.20% 1.84% 0.29% 0 14% 0.16% 0.03%
16.71% 1.91% 10.08 1.71 =.I-
_ . _ ....
%a FSCO2 17.57% 0.51% 0.19%
18.39% 7.89
'S.
60D13 19.79% 2.10% 0.53% 0.07% 0.18% 0.02%
20.55% 2.17% 7.30 0.56 LI
=
6 -
GOMA 21.12% 0.82% 0.17%
22.19% 10.13 it
GODO2 19.36% 1.70% 0.64% 1.08% 0.16% 0.01%
20.22% 2.75% 8.72 3.85
GOD11 20.45% 1.00% 0.15%
21.65% 10.38
GOD10 21.37% . 0.97% . 0.38%
22.58% 9.00
GRA07 16.07% 1.25% 0.43% 0.03% 0.18% 0.07%
16.74% 1.22% 7./1 O.3
GRA31 11.43% 2.35% 0.13% 0.09% 0.21% 0.09%
11.81% 2.54% 9.19 1.20
GRA04 8.30% 1.56% 0.01% 0.00% 0.06% 0.01% 0.15%
0.01% 8.54% __ 1.56% 1193.88 110 99 8.77 1.65 V
_
(-5
1-3
GRA05 11.52% 1.45% 0.01% 0.00% 0.14% 0.05% 0.32% 0.03%
12.02% 1.50% 850.84 193.14 7.01 1.50 8
r
rt)
............... GRE09 ----- 7.97% 0.31% 0.16% 8.48%
11.30 b.)
GRE01 16.43% 0.83%
1 1.31% 0.08% 0.31% 0.04%
18.10% i 0.90% 9.59 1.57 =
i-i
4:.
....
0
4:.
3A011 12.45% 0.54% 0.25%
13.28% 5.41 ______________ CA
JAD12 $.32% i 0.47% 0.19% 9.03%
5
vs,
4:.
-
M::::: a M a a MO::GC41D'ItiC Color
Class Parental Lines
:IIIC :::::: ::::=Clat)
:::::::: ::::::t13G:: CBC Cannabs bfOCH: ::HTFKMEK,:944,rpC:.
Cannalos 1 Tarps (GC)
0
,...
Sam*
'
.._ :::::::M1.6:::::: ::::05:...!
:::::)Aft*:::: ::::9$.:%0::::: :::::Wt %::::: ::%:A:0:::: :: Mt:* ::
::9516:0:: ::::::::W.t.:X3::.::: :::95%:0:::: :::W:t%:: : :::95:%:C1::: :::::
VOT: %: :: :: ::::::15*(4::::::::
=
7.
.
,
IAD04 , 10.7R% 0.67% 0.18% 11.20%
I SA10 ,
I
5
'../1
OR AO2 11.83% 0.79% 0.50% 0.04% 0.13% 0.01%
12.50% I 0.83% 9.32 1.53 .../1
4.
4.
OR A03 , 11.60%
1.23% 0.03% 0.04% 0.20% 0.04% 0.12% , 0.01% 12.03% 1.25% 818.90
3083.82 7.33 2.92
KJ R03 15.52% 1.12% 0.32% 0.07% 0.30% 0.03%
16.19% 1.17% 9.28 0.64
PUR01 11.45% 1.01% 0.25% 0.0696 0.16% 0.03%
11.91% 0.98% 7.06 0.81
RO R13 16.13% 2.35% 0.75% 0.06% 0.19% 0.02%
17.14% 2.38% 9.45 1.30
PUR06 14.08% 2.66% 0.16% 0.03% 0.17% 0.03%
14.48% 2.70% 9.56 2.93
-
P0805 18.96% 0.92% 0.39% 0.01% 0.32% 0.01%
19.70% 0.91% 6.45 0.30
PUR11 13.49% 0.41% 0.15% 14.09%
9.93
o
to
--------------- P1.1813 9.89% 0.16% 0.18% 10.26%
6.55 to
w
I-
- P1.1812 , = 13.89% 2.42%
0.31% 0.10% 0.15% 0.03% 14.39% 2.43% 12.44 2.26 0)
.
to
o
REDO* 8.42% 0.88% 1.18% 0.67% 0.22% 0.11%
9.86% 1.38% 14.27 2.15 w
u
0
w
S11.04 15.27% 1.28% 0.41% 0.06% 0.19% 0.03%
15.92% 1.36% 7.02 0.63
w
o
50.06 11.25% 1.09% 0.39% 0.03% 0.40% 0.07%
12.09% 1.14% 14.25 1.07
51108 17.15% 1.43% 0.23% 0.11% 0.15% 0.02%
17.59% 1.39% 10.78 2.17 ,
511.03 13.37% 0.90% 0.19% 0.02% 0.16% 0.04%
13.74% 0.96% 11.07 1.80
S8.02 15.00% 2.38% 0.12% 0.00% 0.17% 0.02%
15.30% 2.39% 9.03 0.10
S11.01 14.23% 2.05% ,
0.40% 0.03% 0.16% 0.01% 14.88% 2.07% 10.89 1.36
WHI07 15.44% 1.75% 0.24% 0.03% 0.17% 0.01%
15.92% 1.78% 8.73 1.05 Plo
n
WHI04 15.97% 1.40% 0.50% 0.20% 0.16% 0.02%
16.76% 1.65% 12.93 5.49 ......lq
C
WHI09 15.27% 0.60% 0.19% 16.22%
15.22 CA
_______________________________________________________________________________
______________________ . b.)
0
WH101 14.83% 1.74% 0.23% 0.13% 0.17% 0.05% 15.30%
1.96% ---------- 9.79 2.04 1-1
4:.
---.
0
WHI14 14.40% 4.04% 0.36% 0.33% 0.20% 0.06%
15.01% 4.36% 10.77 5.02
a,
cr,
V1/1-1105 16.15% 0.45% 0.1.8% 16.82%
17.19 _____________ 0
4:.
WM106 ______________________ 14.74% 0.03% 0.40% 0.18% 15.37%
491.23 8.82
nanann?:;pciw:mc Color Class Parental Ones
:CEO CBC Cannabs
Cannabs Tarps (GC)
1,A
Sample :g0Ci.04H =====Wiii 95
% CI
WHIO2 18.72% r, 0.47% 0.2396 19.60% 114.16
11.67
YEL03 13.81% 0.58% 0.58% 0.08% 0.58% 0.05% 15.04% 0.68%
10.61 2.06
YEWS 16.21% 2.20% ----- 1.63% 0.80% 0.29% 0.13% 18.19% 3.13%
7.60 1.66
YEL02 11.10% ............ 1.14% J 0.74% 0.06% 0 24%
0.03% 1212% . 1.14%
=
$1.00 for all cannalAnolcIs was 0.14%. _
0
a.
I.
co
0
0
b
Table 7- Cannabinoid measurement by FIPI:(7. N.TITC, color class parental
varieties. Blank values indicate undetectable levels, ()1Ø
1;
C
i ...... ...
kJ
C.annabInokls (Wing.
=
Cannabs / Terp5
71
THCA C8DACBGA T1-1C
CBG Cannabl by HPLC õ
.. .. .... .... ....
.... .. .... , WPM) = 5
- :
i = '../i
:
: tAI:
Sttrn Pt* Wt % 99 % Ct
::W:%:::i ::9%.:c:Wt% :::::%..:t :::::::W.%::: 95%Cl Wt% I 95%0 Wt%
95%a Rertio 95' 94CI 4.
44
8101 27.24% 0.95% 0.34%
0.07% i i 28.61% 20.15
=
811(02 26.11% 1.94% 0.30%
0.09% 28.44% 24.17
,
111.1(03 26.70% 0.71% 1.10%
0.05% 28.56% 19.50
811(04 26.37% , 0.77% 0.74%
0.48% 28.38% 17.02
- ,
811104 9.94% . 0.25% 0.21% 0.16%
10.60% 7.90
.............. 811001 ----- 15.90% 2.54% 1.08% 0.81% 0.47% 0.21%
17.49% 1.47% 11.99 3.30
8R002 16.77% 0.29% 0.06% 0.85% 0.02%
0.30% 0.15% 0.09% . 0.00% 18.04% 0.51% 15.93 5.04
0
--
=-=
u,
3SC04 16.20% 0.38% 0.33%
16.92% ____ 8A 3
. __
==..
=-
o.
1-k
11
t..> FSC03 18.33% 1.30% 0.38% 0.21% 1.03% 0.2996
15.81% 7.84% 11.96 2.20 h=
0
1..
FSCO2 21.04% 0.72% 1.29%
23.20% 9.96 o
=
1..
0
.............. GOD13 24.52% 2.8.1% 0.74% 0.11% 0.43% 0.42%
.............. 25.82.96 2.54% 9.17 0.64 w
0
60003 24.16% ------------------------------------- 1.00% 0.60%
25.83% 11.79
60002 72.27% 7.2'A 1.29% 0.29% 1.30%
1.47% 0.11% 25.01% 1 .12% 10.70 3.79
60011 23.57% 1.17% 0.57%
0.13% 25.49% 12.22
._
60010 24.32% 1.18% 0.59%
0.13% 26.27% , 10.47
-
i
GRA07 20.21% 1.81% 0.56% 0.05% 0.63%
0.37%21.55% 1.47% 9.93 1.08
1
GRA3I 15.27% 2.82% 0.35% 0.45%
0.29% 0.28% 16.02% 3.47% 12.47 1.60 Mg
_
(-5
1-3
GRA04 1 10.48% 1.51% 0.02% 0.10% 0.02% 0.37% 0.03%
10.96% 1.54% 11.27 1.63
8
w
GRAOS 14.65% 1.63% , 0.02% 0.01% 0.21% ,
0.06% 2.25% 3.17% 17.13% 3.76% 9.97 , 2.62 b.)
.
CM
1..1
GRE09 9.66% 0.40% 0.14%
10.21% 13.61
.....
CD
4:.
CiRE01 20.38% 0 91% 1.55% 0.19% 0.52%
0.27% 0.12% 0.00% 22.55% 0.83% 11.94 1 90 ch
.
...............................................................................
................................ ch
VD
JAD:11 1.70% 0.64% 0.61%
17.05% 6.95 4:.
1
...............................................................................
...
i
Cannabinoids 11.1HPLC)
:
. -
.:.a:.:. E Cannabs / Terps
THCA CBDA CBGA
::::::::::::::::; THC CBG Carinabs by HPIC
(HMI
C
1,A
=
Sample
.% Sit96%9W
:::Mtli::,::%N.Cr: ..: Wt % %.....S.,:i:%0 !MtN..:., ::.::.9.:00. :.:
.:.:.:.Wt . Qk .z.. CI Wt % 95 %CI , Ratio 95 % Cl
7.
,
JAD12 10.88% : 0.61% 0.43%
11.91% 6.91 5
.
-
_
/i
/i
JA004 13.53% , , 0.91% 0.54%
14.98% , 7.76 .1.-
.1.-
ORA02 14.79% 0.50% I 0.71% 0.05% 0.45% 0.18%
15.88% 0.50% 11.78 1.3
0RA03 14.21% 0.01% 0.29% , 0.45%
7.48% , 14.67% 7.67
PUR03 19.45% 1.48% 0.35% 0.12% 0.34% 0.13%
20.26% 1.46% 11.60 0.69
PUR01 14.74% 1.19% I 0.24% 0.07% 0.31% 0.32%
15.31% 0.98% 9.10 1.18
I-
PUR13 21.05% 2.57% 0.93% 0.14% .
0.34% 0.18% 22.41% 2.56% 12.44 1.87
PUR06 18.08% 3.40% 0.22% 0.04% 0.32% 0.25%
18.70% 3.27% 12.34 3.72
-
PL1ROS 23.75% 1.64% 0.43% 0.02% 0.21% 0.21%
24.48% 1.31% 8.02 0.43
0
=.)
0
PUR11 16.36% 0.46% 0.54%
4 17.57% 12.38
:-.
1-
0
Z.: POR13 12.64% 0.26% 0.77%
13.77% 8.78 co
=.>,
0
PUR12 17.55% 2.71% 0.36% , 0.13% . 0.17%
0.11% 18.13% 2.59% 15.74 3.12 1-
u=
-
=
=-=
RED08 11.03% 1.13% 1.37% 0.62% .
0.22% 0.08% 12.67% 1.66% 18.37 3.06 0
...,
0
511.04 19.18% 2.47% 0.55% 0.13% 0.25% 0.22%
20.04% 2.42% 8.81 0.59 .
....
51106 14.39% 1.33% 0.39% 0.04% .
0.25% 0.07% 0.16% 0.11% 12.10% 6.03% 1752 1.07
1-
51108 20.75% 2.44% 0.32% 0.16% 0.37% 0.24%
21.55% 2.33% 13.24 2.96
611.03 16.70% 1.32% 0.10% 0.03% 0.22% 0.15%
0.15% 0.01% 17.20% 1.49% 13.88 2.55
S11.02 19.67% 3.46% 0.07% 0.04%
13.27% 13.04% 754 7.34
:
61101 18.25% 2.53% 1 0.57% 0.03% .
0.38% 0.32% 19.12% 2.63% 14.00 1.73 No
n
WHIO7 19.31% 2.48% 0.24% 0.04% 0.21% 0.09%
19.82% 2.46% 10.83 1.19 .......1q
C
i WHIO4 19.76% 0.77% 1
CA
0.64% _______________________________________________________________ 0.20%
0.40% 0.27% 20.87% 0.63% 16.01 5.74
1
b.)
0
WH109 18.99% 0.80% . 0.11%
4a. 20.01% 18.77 1-1
.
--..
0
W11101. 17.74% 2.25% i 0.29% 0.16% 1.00% 0.44%
19.06% 2.73% 12.13 2.22 4a.
CA
CA
WH114 17.81% 4.40% - 0.46% 0.46% 0.33%
0.23% . 18.67% 4.78% 13.34 5.63 0
4a.
:
...............................................................................
...
I
Cannabinolds (11HPLC)
1
.
-
;
Cannabs / Terps
THCA CEPA CBGA THC
MG Cannabs by HPIC
(HMI
C
1,..)
=
Sample Wt % _ _ 95%11 , Wt % , 95 % CI ........... 514.% _ 95 % Ci .,.. Wt %
_ 95 % CI Wt % 95 % CI Wt % 95 % CI Ratio 95 % CI
7.
,
WHIOS 1).55% : 0.55% 0.20%
0.04% 20.38% 20.84
_
"ii
I
WHIO6 19.25% 0.03% 0.53% 3.97%
I 23.78% 13.65
.I..
1
.1-
WHIM 22.19% I 0.61% 0.15%
23.09% 16.34
:
YEL03 16.71% 0.17% 0.74% 0.03% 0.33% 0.10%
17.99% 0.35% 12.66 1.99
:
YELOS 19.65% 3.39% 1.93% 0.41% 0.85% 0.11%
22.52% 3.81% 9.41 2.03
I :
i
YEL02 13.97% 1.29% I 1.19% 0.33% 0.20% 0.14%
12.62% 5.77% 6.65 3.11
*LOCI for all cannabinolds was 0.14%.
0
ro
,o
1-.
1-.
.-.
1-
co
.1-
1..)
0
I.
0
I
I..
0
W
0
V
el
.....iq
w
ksa
c,
4:.
.....
0
4:.
a,
cr,
vs,
4:.
Table 8- Absolute terpene measurements by GC-FID for TFIC color class parental
varieties. Blank values indicate undetectable levels,
or O.
c
t,..)
=
VI
--,
.5
Telpenes (GC-FD
VI
VI
alpha garrima alpha alpha beta
camphers alpha alpha 4.
terpirenene beta ocimene carene Ornnnene
. tenchni caryapnyi linalnni cary wide myrc=etia: ielentifW
phellandrene Wpmene Ripen terpineno Were e
terpineof Inomnene ::::::::0
---., ---, .
1!...:,..: :M 4 A:* k.. -,s',z.
vs, 4, .4, w, '-::::74:: . lis:,: ,3:%=::
Snmple, vet % 9:i %CI Irt4tX 2.45 %..0i.:Ait::57: 98%c: µ3,1A:%: 95% CI 850
:ti: :.::.%0 ::t1 0:.%:: 041: ::.:0. .e.. ::,3 % li % Q:: ::* :
ci ::% : c; =,(, 0 : ::::0::: % :.:::.e:: :...46 : ..C):: .:..>46:.
:....r.': ..%... ::.:::i :
0.31 0.02 C.05 0.33 i
0.04 3.16 0.46 0.14 0.17 1.42
BLK01 0% 6% 4% 8% 4%
7% 0% 4% 7% 0%
0.23 0.02 0.04 0.03
0.04 0.14 0.40 0.12 0.13 1.17
01807. 0% 2% 4% 6% 0%
2% 6% 0% 7% 0%
0.26 0.01 C.03 0.03
0.04 0.21 0.60 0.14 0.11 1.46
81803 2% 7% 7% 1% 0%
7% 3% 3% 5% 5%
0.27 0.01 0.04 0.04
0.04 0.23 0.68 0.15 0.1.6 1:77
811(94 7% 8% i 2% 0% 6%
8% 9% 6% 1% 0%
0.12 0.24 0.01
0.04 3.04 0.12 0.03 0.20 1.34
8LU04 0314% 3% , , 2% 9% 3%
2% 2% 9% 0% 3% 2
, . .
, , . v
0.02 0.00
0.01 0.00 0.04 0.02 0.05 0.01 1.07 0.18 1.48 0.28 =.1"
'-' BROO1 0.211% 0.070% ________ 5% 1% 9% __ 4%
7% 9% 3% 496 3% 2% 3% 0% 0% 5% O
14.4
4 0)
.J1 0.05 0.00 0.02 0.00
0.02 0.00 0.08 0.03 0.04 0.01 0.00 0.62 0.18 1.16 0.33
88002 0.330%0.089%i 7% 9% 6% 7%
4% 1% 0% 5% 6% 4% 0% 4%=--, 2% 1% 5% 0"
0.04 0.02
0.16 0.46 0.05 0.07 1.02 2.00 01-
=
F5C04 0.035% 0.109% 1 9% 0%
8% 5% 9% 7% 6% 8% O
'
0.21 0.03 0.01 0.00 0.03 0.00 0.02
0.00 0.03 0.01 0.16 0.05 0.45 0.12 0.07 1.01 0.67 0.14 1.71
0.35 ow
0% 0% 9% 3% 1% 1% 1% ' ,
6% 9% 2% 0%
0.25 0.01 ! 0.04
0.03 0.03 0.23 0.59 0.07 1.00 2.33
FSC07 0.026% 7% ; .(- : 1% 0%
9% 0% 4% 6% 5% 0%
,
- 0700.04 0060.00 0.12 0.00 0.07
0.00 0.08 0.00 0.13 0.00 0.46 0.03 0.18 : ; 0.01 0.00 0.930.01 221 0.1,0
001313 6% 0% 3% 4% 8% 7% 2% 2% 6%
1% 0% 9% 5% 2% 1% 0 7% 1% 1% 9% 2% 4%4
0.69 0.05 0.10 0.04
0.05 0.12 0.44 0.11 0.51 2.19
60003 9% 6% 7% 6% 0%
9% 0% 5% 1%. 0%
0.59 0.25 0.05 0.01. 0.09 0.03
0.05 0.03 0.01 0.00 0.06 0.04 0.16 0.04 0.59 0.17 0.13 C . ; 0.01 0.01 0.59
0.03 2.40 0.74'
60002 0.014% 0.009% 9% 6% 0% 9% 856 656 5% 5% 6%
656 8% 7% 7% 3% 2% 2% 9% :' 8% 2% 3% 7% 6% 9%,
0.50 0.04 C.08 0.04
0.01 0.04 0.13 0.46 '1 ' 0.01 0.60 2.08 PIO
G00130.309% 3% 4% 8% 2% 4%
3% 3% 4% '-)..i. : 7% 0% 6% (-5
0.67 0.05 0.10 0.05
0.06 015 0.54 0.3.4 0.67 2.50 =3
G0010 0.012% 1 5% 3% 4% 0% ,
0% 7% 8% 9% 1% 9% 8
. 0.330.04 0.03000 C.07 0.00 0.04
0.00 0.05 0.00 0.04 0.01 0.17 0.05 0.19 0.00 1.22 0.18 2.19
0.21 WI
l..1
GRA07. 2% 7% '2%5%,1% 9% 5% 3% 0%
3% 9% 4% 8% 1% 5% 9% 0% 8% 2% 1% =
,
0.10 0.03 0.14000 0.08 0.03 0.01
0.00. 0.03 0.01 0.01 0.00 0.05 0.01 0.06 0.00- 0.77 0.31
1.30 0.44 I.+
4:.
GRASS 2% 2% 3% 2% = 1%
1% 5% 0% 5% 5% 6% 2% 6% 0% 8% 1% 4% 9% 0% 5% ...,
0
0.08 0.00 0.08001 0.04 000 0.01
0.00 0.01 0.01 0.01 0.00 0.03 0.00 0.03 0.01 0.64 0.02
0.97 0.00
Ch
GRA04 7%, 8%, 3% 1% 9% 1% 2% 7% 6%
6% 4% 2% 7% 4% 3% 4%, 1% 7% 4% 5% cr,
vp
0.11 0.03 0.23006 OM 0.02 0.01
0.00 0.02 0.01 0.04 0.00 0.12 0.01 0.04 0.01 1.05 0.44
1.78 0.59
GRA053% 5% 8% 3% 8% 8% 4% 6% 0%
2% 7% 8% 7% 8% 2% 7% 3% 1% 1% 9%
'
Terpene6 (C3C4:101
beta
OW
alpha gamma alpha alpha beta
camphen alpha alpha
Iarpincaem, beta nchrena =rmene limnnene
fenchal carynphyl. iinafoo1 iary oxide myrcene isiiiiti0ji.id C
paillarocleen.a texpirma pinene tespinene
pingo*: ::::::::::: : ::::::e:::: :::Wpkteol humulene :::::::::::::::::
1w13
h...)
Vit:::.: 95* Att W1E M1 5554 .W: 95 % kli.t 944$ .:384::: 95 14.cAtt 95% ::Wt
SS % W-: SS % kid. 95 % ::M:::19881\::+Ait 9S % We SS % V17t:: 515%
:
::::IA.:: : :: vi
01%ci WI. % 35 %.:t.:'..i W96:: 95%03 :3,f4:: X.i: fi:: :j:1 :A::::C3::
16 .<1 :IC:: :t1: ::::s:!:!:!:0:: :!:%::: ::::0::: ::::$ c %
a % ci : : :,14 :T. ::3f. a %
i 0.3.6 0.02 0.03 0.01 0.01 0.01 0.05 0.02'
0.24 0.75 .:..^..Z
1
GRE09 0.129% 6% 7% 8% 7% 9%
7% 5% 7% 4% __ 0% VI
. VI
o
0.23 0.03 0.10 0.01 0.07 0.01 0.03
0.00 0.04 0.00 0.08 0.00 0.23 0.02 0.09 0.01 0.63 0.16 1.94
0.35 4.
4.
GRE01 0 374% 0.098% :3%2% 4%5% 4% 0% 3% 2%
7% 7% 7% 7% 9% 2% 7% 3% 7% 2% 6% 4%
0.09 0.02 0.06 0.04
0.10 0.04 0.04 0.12 0.08 0.35 2.45
.14011 1.311% 0059% p.017%, 0.046% . 1% 7% 0%
9% 8% 4% 8% 9% 9% 7% 4%
...
i
0.06 0.07 0.04 0.03
0.08 0.03 0.03 0.12 ! 0.10 0.17 1.72
14012 0.916% 0.043% `0.018% 0.034% 4% 1% 7%
7% 4% 4% 5% 0% i 0% 3% 6%
I
0.07 0.02 0.05 0.03
0.10 0.03 0.06 0.22 0.02 0.05 0.21 1.93
JA004 0.977% 0.045% '0.02(3% 0.039% 0% 3% 7%
9% 0% 3% 2% 5% 2% 3% 3% 1%
_
0.07 0.02 0.00 0.00 0.06 0.00 0.01 0.00 0.06 0.01 0.01 0.00
0.02 0.00 0.06 0.01 0.14 0.03 0.02 0.00 0.35 0.07 1.36 0.16
08%02 0.277% 0.04396 0.016% 0.002% 0.212% 0.023% 0.014% 0.001% 4% 7% 9% 1% 8%
9% 6% 0% 0% 0% 3% 3% 5% 7% 2% 5% 4% 9% 4% 7%. 2% 4% 8% 4%
0.06 0.01 0.01 0.00 0.13 0.01 0.01 0.01 0.10 0.01
0.03 0.00 0.02 0.00 0.06 0.00 0.03 0.00 0.02 0.67 0.20 1.69 0.50
08%03 0.480%0.224% 0.024% 0.007% 0.019160.005% 7% 1% 0% 5% 3% 216.11.ti 2%
4% 2% 2% 6% 1% 2% 3% 4% 7% 6% rh 7% 7% 5% 5%
I 0.03 0.00 0 76 0.02 C.06 000 0 08 0 01
0.33 003 0.11 0.02 0.71 0.08 1:75 0 16
PU803 0.12796'0.023% 496 5% ....... 7% 2%
7% 6% 9% 1% 7% 5% 1% 2% 2% 0% 814 1% o
0.390,05' 0.18 0.03 0.11 0.02 0.04
0.00 0.05 0.01 0.05 0.02 0.23 0.03 0.07 0.01' 0.60 0.14 1.71
0.30 ro
34
PUR01 '0.028%0.007% 0% 7% 8% 1% 6% 0% 9% 5%
2% , 0% 7% 2% 1% 0% 4% 4% 4% 3% 1% 1% %
%
ir 0.080,02 0.51 0.02
0.14002 0.07 0.01 0.19 0.04 0.04 0.01 0.72 0.12 1.85 0.31 %
co.
ri
I
co
ON PUR13 : 0.033%0.004% 4% 4% 0% 4% 5% 8%
7% 7% 9% 7% 5% 0% 3% 5% 4% 5% ro
0.06001 0.37 0.07 0.17 0.03 0.01
0.00 0.02 0.05 0.00 0.17 0.01 0.06 0.00
0.00 0.00 0.66 0.20 1.60 0.33 o
%
P13806 9% 2% 8% 8% 5% 7% 4% 1% 3%
8% 5% 8% 0% 1% 9% 9% 2% 9% 8% 9% 9% ut
I
0.04 0.00 0.40 0.00 0.10 0.00
0.10 0.00 0.41 0.00 0.18 0.03 1.52 0.00 3.05 0.00 %
o
P1.31205 0.259560.000% 6% 0% 3% 0% 4% 0%
9% 0% 9% 0% 3% 0% 0% 0% 3% 0% w
o
0.06 0.33 0.09
0.04 0.12 0.03 0.63 1.41
P13811 0.024% 3% 5% 5%
6% 2% 0% 0% 0%
0.18 0.15 C.16
0.08 0.18 0.59 136
P13813 6% 6% 7%
0% 7% 1% 7%
0.16 0.05 0.18 0.07 0.10 0.04 0.02
0.05 0.01 0.12 0.05 0.02 0.52 0.23 1.19 0.43
P13812 6% 6% 6% 0% 1% 0% 2%
6% 5% 8% 0% 5%
0.23001 0.130A34 0Ø5 0.01 0.02
0.01 0.02 0.00 0.02 0.00 (La? 0.03 0.02 0.00 0.02 0.01 0.70
0.17
RED08 0.188% 0.051% 2% 9% 0% 6% 1% 2% 9% 0%
7% 7% 2% 8% 6% 7% 3% 8% 2% 2% 8% 3%
0.70 0.19 0.07 0.02 0.11 0.02 0.09
0.01 0.02 0.00 0.09 0.00 0.13 0.00 0.48 0.00 0.21:002 0.21 0.09 2.28 0.37
511.04 0.011% 0 001% 0 114% 0.027% 2% 9% 3% 2% 6% 5% 4% 0% 1%
3% 2% 3% 8% 5% 796 416 3% ! 3, 1% 0% 5% 4%
1.0
0.29 0,03 0.05 0.00 0.07 0.00 0.05
0,00 0.05 0.00 0.02 0.00 0.07 0.01 00)!( % 0.08 0.01 0.85
0.09
n
511.06 0.106%0.016% 6% 1% 5% 7% .. 4% 9% 1% 7%
0% 5% 1% 3% 4% 2% %, ' 8% 8% 2% 746 ......,q
0570,25 0.0501') 0.10 0.02 0.06
0.02 0.06 0.02 0.05 0.00 0.18 0.a.). 1. . ,,, 0.28 0.10 1.68
0.38
mos. 2% 1% 3% 4% .. 6% 8% 8% 5% 5%
8% 5% 9% 5% 3% % . . 0% 9% 2% 7% cA
.
3390.06 0.03 0.00 0.06 0.00 0.03
0.01 0.03 0.01 0.05 0.01 0.17 0.0$ 0 , , . 4, 0.25 0.03 1.26
0.23 6.9
=
50.03 0.006% 0.004% 396 4% 6966% 096 8% 6% 3%
796 2% 0% 596 596 6% % , 696 9% 096 3% =I
4a.
0.590,11 0.050,00 0.10 0.01 0.06
0.01 0.07 0.02 0.09 0.01 0.37 0.04 0.22tk...01 0.10 0.05
1.69 0.28 ....,
0
$11.02 0% 8% 2% 7% 1% 5% 4% 4% 2%
0% 7% 6% 2% 7% 1% 7% 9% 0% 7% 6% 4a.
01
0.400,01 0.030,00 0.07 0.00 0.05
0.00 0.06 0.00 0.07 0.00 0.27 0.02 0.18 0.00 0.18 0.03 1.36
0.03 01
$11.01 3% 8% 7% 3% ,. .0 2%
1.95 0% 3% 096 , 1% 4% 8% 1% 7% 6% 7% 996 , 0% 5% 9% VD
4a.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
0
0N0 .n*.1* F.iatat -.0m 606"6'r
-
4.-4-44,v*Af4ggg* rqo Ln
C :,,,..;q1/!0 oAor oAodkott
t 0, o'd d'^dr- 0'40m0
..-4; 7 7,', z,! :=1 z! 1; cs,:` ti; ;4; ds; g a,- =,-
,1 4 ',-,1 4 ',-. "s I: ',-,! gti 6" 4
' .
,,,, ., 0 " O'-' d o
= ,
T1 ,
.F. y he 2 ke 8 he :1*=,x8he3ae he qg
- 6'46.6., 6NoNo.A01".c." 00
Eted2-8,-,8,0 86'46 cs46.."6µ',
$
e.21-..therA*.t..1Tht"Z*A*8*V**2*
6.16.06.-8,8N.4060,368dNdododh
.d
9
rot
a,
mg. ,48*',.1,94g4e61e2g.tik2e8g2*
z -- 6 6 6' es 6'1006 d= 6'-'6µ-'6
.a. i 0: ... = 0 do dµcdm dmo'dm .
76t.7k4gf,clf AL0'.**CIA TA(IWg*
6 0mom6".
g, ..
8.8
.1:1Ø..,.. 4 r=I 0
75,v8i.v.1,11cir8q4.- cAo* F.* che,
c T'..... :, na cm et . .4.= na ...I en ..13 na
na
41,:,.:==:.*:.8A6A01,,pAqqA0A0A0A0A0A
4.,6 0"4.6.0 0 0 6,F6'1608606'.1
r.::1::.'; 'Ff 8 v z 8w8he 8A8A8*
6m6m60
0 A ;.Z: d '''' d d c" d ' =-: ' d " d d i;: 'L' 6 '
6 an
r ' "
E .4-1.====" ! : :
õ a:e8egat
. x,,,,,:-= : : 6o6"46r=
e I ..
7i1 :lii,t6-.*8**m*m*V!*8*alegae8x8*
_ 0.0,0.6w6m0.6,n6.6.6m60
6: 2g, _ 8A8X
.., c4 ..
OeOr
,=== d"d
m6". 00r"
0 . =::::=i;::%": . ..-8
E .,,,,,s,,x4aen.helg4:0*.:9,0e:ngg:4*
Aik 8 8 8 g
6 6 '
ri
0
0 0=
. . .
. 0 0 0 d=
= . .
0 6 o 4 g
14 w at *Is
.,-- 2! un on
.: m To E
e. N N y 0
6 6
. *
C, 6 8 8 il
m.'6 41 6 6 6 -
g g g 4 41
. 4.,
z. a gtill
6 6
7.::=T * * * 4:
2 ..:: . :::::!:!:5!= 6 d o ..
A bt he g 'A
'. -
0
, 0 to
JI rilggws4 '
õ:E
nA 3 a 3 3 3 3 3 3 5.7 -g- 5,-*
If
117
Table 9- Relative terpene levels as measured by GC-FID for TIIC color class
parental varieties. Blank values indicate undetectable
levels, or 0.
0
JI
.. .. . . = .. = .. = . . .. = .. =
. =:=:. . . . . . . . .. . .. . . .. .. . . .. . .. . ..
.. . .
...
alpha beta 3858*8 $lpha alpha beta
. . .. . .. . .
. . .. . .. .. . .. . . =========
= = = = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
= = = .= = = = = = = = = = = = = = = = = = = = = = = = = .= =.= = = =
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
= = = = = = = = = = = = = = = = = = = = = = = . .
.......... . .............. . ........... . ........ .
. .........................
.............................. .............................
..........................................
Unalpha alpha betaMO
Sample 1erpinoloomphellac0r.43fle:ANiR3eop:: :3etpleen3): :leminer%:
:KR01p1sekik :11U4402M: mityPpleilknonalo.o.0 my:oxide
1317(01 _ 0% 0% 0% 0% 72% 0% 2% 0% 2% 3%
0% 3% 12% 32% 10% 0% 12%
=
81K02 _ 0% 0% 0% 0% 20% 0% 2% 0% 4% 3%
0% 3% 12% 35% 10% 0% 12%
81K03 _ 0% 0% 0% 0% 18% 0% 1% 0% 3% 2%
0% 3% 15% 41% 10% 0% 8%
811:04 0% 0% 0% 0% 16% 0% 1% 0% 2% 2%
0% 3% 13% 39% 9% 0% 9%
0
1317304 1% 0% 0% 0% 9% 0% 37% 0% 18%
1% 0% 3% 3% 9% 3% 0% 15%
oo) 8RCX)3 3% 0% 14% 0% 0% 0% 4% 0% 2% 3%
0% 0% 1% 3% 4% 0% 73%
0)
op
BR1O2 0% 0% 26% 0% 0% 0% 5% 0% 2% 0%
0% 0% 2% 7% 4% 0% 54% o)
f5C04 2% 0% 5% 0% 2% 0% 0% 0% 1% 0%
0% 0% 8% 23% 3% 4% 51%
8
rsc03 0% 0% 0% 0% 12% 0% 1% 0% 2% 1%
0% 2% 10% 26% 4% 0% 39% 0
f5CO2 1% 0% 0% 0% 11% 0% 1% 0% 2% 1%
0% 2% 10% 25% 3% 0% 43%
GOD13 0% 0% 0% 0% 25% 0% 2% 0% 5% 3%
0% 3% 5% 17% 6% 1% 33%
GOD03 0% 0% 0% _ 0% 32% , 0% 3% 0% 5%
2% 0% 2% 6% 20% 5% 0% 23%
00002 1% 0% 0% , 0% 25% 0% 2% 0% , 4%
2% 1% 3% 7% 25% 6% 1% 25%
001311 0% 0% 0% 0% 24% 0% 2% 0% 4% 2%
1% 2% 6% 22% 6% 1% 29%
60D10 0% 0% 0% 0% 27% 0% 2% 0% 4% 2%
0% 2% 6% 22% 6% 0% 27% r)
GRA07 0% 0% 0% 0% 15% 0% 1% 0% 3% 2%
0% 2% 2% 8% 9% 0% 56% et
0*
GRA31 0% CI% 0% 0% 8% 0% 11% 0% 6%
1% 0% 3% 1% 4% 5% 0% 60%
GRA04 0% 0% 0% D% 9% 0% 8% 0% 5% 1%
0% 2% 1% 2% 3% 0% 66% er5
CA
GRA05 0% 0% 0% 0% 6% 0% 13% 0% 7%
1% 0% 1% 3% 7% 2% 0% 59% C%
%4C
GRE09 0% 0% 17% 0% 22% 0% 4% 0% 5% 2%
0% 3% 2% 7% 4% 0% 33%
GRE01 0% 0% 19% 0% 12% 0% 5% 0% 4% 2%
0% 2% 4% 12% 5% 0% 33%
1AD11 , 54% 2% 1% 2% 4% 1% 2% 2% 4% 0%
0% 2% 2% 5% 0% 4% 15% 0
t4
34312 53% 2% 1% 2% 4% 1% 3% 2% 5% 0%
0% 2% 2% 7% 0% 6% 10% 0.
../i
JADO4 48% 2% 1% 2% 4% , 1% , 3% 2% 5%
0% 0% 2% 3% % 12% 1% 3% , 11% -...
ri.
61
ORA02 20% 1% 16% 1% 5% 1% 5% 1% 4% 1%
0% 2% , 5% , 11% 2% 0% 26% !A
A
A
ORA03 28% 1% 0% 1% 4% 1% 3% 1% 6% 0%
0% 2% 1% 4% 2% 2% 40%
PUR03 0% 0% 7% 0% 2% 0% 15% 0% 4% 0% 0% 0% 5% , 19%
6% 0% 40%
PUR01 0% 0% 2% 0% 18% 0% 11% 0% 7% 3%
0% 3% 793 14% 41% 0% 35%
PUR13 0% 0% 2% 0% 5% , 0% 27% 0% 8% 0%
0% 0% 4% 11% 2% 0% , 39%
PUR06 0% 0% 0% 0% 4% 0% 24% 0% /1% 1%
0% 1% 4% 11% 4% 1% 42%
PUR05 0% OS 8% 0% 2% 0% 13% 0% 3% 0%
0% 0% 4% 14% 6% 0% 50%
PUR11 0% 0% 2% 0% 4% 0% 24% 0% 7% 0%
0% 0% 3% 9% 2% 0% 44% g
0
1201113 0% 0% 0% 0% 12% 0% 23% 0% 11% 0%
0% 0% 5% 12% 0% 0% 38% ro
,o
1-.
1-.
=L PUR12 0%0% 0% 0% . 14% 0% 16% 0%
8% 2% 0% 0% 5% 11% a% 0% 44% 1-
o.
=I
co
YD
i
ro
RE 008 0% 0% 27% 0% ! 19% 0% 18% 0% 7% 4%
0% 4% 3% 11% 3% 0% 3% o
1-.
(A
0
511.04 0% 0% 5% 0% 31% 0% 3% 0% 5% 4%
1% 4% 6% 21% 9% 0% 9% 1.
o
w
3:1.06 0% 0% 12% 0% 4. 35% 0% 6% 0% 9% 6%
0% 6% 2% 9% 3% 0% 10% o
...._ _
5:1.08 0% 0% 0% 0% , 3/1% 0% 2% 0% 6% 4%
0% 4% 3% 11% 16% 0% 17%
8403 0% . 0% 0% 0% 1 31% 0% 3% 0%
5% . 3% 0% 3% 4% 14% 14% 0% 20% .
i liii 0% 0% 0% 0% 35% 0% 3% 0% 6% 4%
0% 4% OS 22% 13% 0% 6%
I
5:101 0% 0% 0% 0% 1 30% 0% 3% 0% 5% 4%
0% 4% 5% 20% 14% 0% 14%
W H:01 0% 0% 3% 0% , 31% 3% 4% 0% 5% 3%
0% 4% 8% 31% 3% 0% 6%
I
e.)
Vi 1%04 0% 0% 0% 0% i 33% 0% 2% 0% 5% 3%
0% 3% , 7% 25% 8% 0% 10%
!
16/11309 0% 0% 0% 0% 1 29% 0% 2% 0% 5% :3%
0% 0% 124 33% 3% 0% 10%
cn
1
na
IN ii I01 0% 0% 0% 0% 27% 0% 2% 0% 4% 3%
0% 3% 11% 31% 0% 0% 17% 0
rl
A
W:4:14 0% 0% 0% 0% 28% 0% 2% 0% 4% 3%
0% 4% 10% 28% 10% 1% 11% 0
.1:.
<T.
W RIM 0% 0% 0% 0% 29% , 0% 3% 0% 5% 3%
0% 2% 10% 37% 2% 1% , 9% 3:A:
µ0
A
Wiii06 1% 0% 0% 0% 1 33% 0% 2% 0% 5% :3%
1% 1% 10% 20% 3% 1% 11%
"7
0
Vi.
=Th
0
.....
`Th
l=
0
est
(0)
MN
o
0
o
..1
=
o
..1
0
44
0
0
est
0
.4
1¨i
.4
.4
0
0
0
'I'
=7
Ir,
lf,
..1".:
< %TT 960 96E %Z. %Z %Z %0 %T %S %T %E
%I %6 = %T %ST 15Z %SE Z0111/4
=
esi 969 %I %0 %U. %V % Z %0 %I %S 96Z
%E. %T %9 95Z 34.ZT %I ' %EV SOW
0 %TT 960 %Z 969 %Z 96Z %0 %S %S WA
%E %0 %0T %Z %TT 96Z %SE 013A
950T 950 %E %VC %ET %0 %0 %Z %S 940
%E 940 %92 940 940 940 940 ' Z 01H M
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 4. Analysis of CBs Parental Varieties.
A. Proprietary CBs parental varieties
One objective of the present invention was to develop cannabis varieties
producing non-
THC (CBs) with high terpcne oil contents and different terpene
profiles to satisfy
unmet needs for various aroma/flavor and medicinal combinations. Chemical
analysis of these
CBs varieties was conducted as described in Example 1. The cannabinoid and
terpene profiles of
each CBs parental variety was determined using both GC-FID and HPLC as
described in
Example 1. The resulting measurements are summarized in Tables 10-22 as
average values and
95% confidence interval ranges based on five replicate measurements. The GC-
FID cannabinoid
analysis of the CBD parental varieties in Table 10 also included measurements
for THCV,
CBDV, CBGV, CBN, and Delta 8 THC, all of which were measured to be less than
.01%, and
were therefore not included in the table. Similarly, the HPLC cannabinoid
analysis of the CBD
parental varieties in Table 11 included measurements for CBCA, THCVA, CBDVA,
CBGVA,
CBC, THCV, CBDV, CBGV, and CBN, all of which were measured to be less than
.01%, and
were therefore not included in the table.
As can be seen in Tables 10 and 11, CBD01, 24, II, and 13 are chemotype lii
varieties,
with a BD/BD genotype responsible for producing CBD, or CBDA (as measured by
HPLC). The
other parental CBD lines (CBD02-05), have been bred to be chemotype 11 plants
with BT/BD
genotypes producing both THC and CBD. These proprietary lines were bred for
more desirable
terpene profiles through multiple rounds of crosses with THC class varieties
and selfing to obtain
desired genetics. CBDO5 exhibits several desirable features such as the
production of both THC
and CBD, as well as a terpene profile that is not dominated by myrcene (Table
13).
THCV-producing parental line THVO1 was also bred for its ability to produce
propyl
CBGV. THVOI does not accumulate CBGV due to its conversion to THCV by THC
synthase.
The GC-FID cannabinoid analysis of the THVO1 parental line in Table 14 also
included
measurements for CBDV, CBGV, CBN, and Delta 8 THC, all of which were measured
to be less
than .01%, and were therefore not included in the table. Similarly, the HPLC
cannabinoid
analysis of the THVO1 parental line in Table 15 included measurements for
CBDA, CBCA,
CBDVA, CBGVA, CBD, CBC, THCV, CBDV, CBGV, CBN, and delta 8 THC, all of which
were measured to be 0, and were therefore not included in the table. CBGV is
produced by
combining divarinic acid and geranylpyrophosphate. This is regulated by locus
A which can
121
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
encode for enzymes to generate pentyl CBG (Ape) or propyl CBGV (Apr) (De
Meijer et al. 2009
Euphytica, 165:293-31). Thus if crossed with a CBD producing chemotype II
plant, the THCV
locus A is expected to produce both THCV and CBDV. As can be seen in Tables 14
and 15, the
parental THVO1 line contains at least one allele encoding for propyl
cannabinoids with THC and
THCV cannabinoids accumulating at roughly equal amounts. The alleles of locus
B appear to be
BT/BT with no significant accumulation of CBD. Further, these THC syrithase
genes appear to be
functioning efficiently converting nearly all CBG and CBGV into THC and THCV
respectively.
In some embodiments, the THVO1 parental line may be crossed with class
varieties to produce
THCV producing specialty cannabis with desirable terpene profiles. In other
embodiments of the
present invention, the THVOI parental line can be crossed with chemotype H
varieties to produce
THCV and CBDV cannabinoids. In yet other embodiments, the THVO1 parental line
can be
crossed with CBG accumulating varieties described to produce CBGV accumulating
plants.
The present invention also teaches the use of two sources of CBG genetics. The
first set
of CBG-producing parental lines are plants BLK02, GOD11, GRE01, RED08, and
YEL05 of the
THC parentals in Table 6. While not wishing to be bound by any one theory, the
inventors of the
present invention believe that the CBG produced by these plants is due to the
incomplete
processing of CBG by the THC and CBD synthasc enzymes. This may be caused by
an over
production of CBG, or the inefficient processing of the THC synthase enzymes
of the plant.
Progeny of these parental lines are expected to produce low levels of CBG in
combination with
other cannabinoids and desirable terpene profiles.
B. Additional CBs parental varieties
Another source of CBG-producing parental lines is CBG variety CBG02 in Table
18.
While not wishing to be bound by any one theory, the inventors of the present
invention believe
that the CBG accumulation in this variety is due to the presence of a null
allele (Bo). Progeny of
these parental varieties are expected to produce higher levels of CBG, alone,
or in combination
with other cannabinoids and desirable terpene profiles. The HPLC cannabinoid
analysis of the
CBG02 parental line in Table 19 included measurements for CBDA, CBCA, THCVA,
CBDVA,
CBGVA, CBD, CBC, THCV, CBDV, CBGV, CBN, and delta 8 THC, all of which were
measured to be less than 0.09, and were therefore not included in the table.
122
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
A CBC parental variety will be obtained by screening plants for CBC
accumulation in
mature tissue. While it is believed that CBC biosynthesis is a feature of
juvenile tissue, several
reports have published reports suggesting the existence of cannabis varieties
accumulating CBC
in older tissue (De Meijer et al., 2009 "The inheritance of chemical phenotype
in Cannabis
sativa L. OM: variation in cannabichromene proportion"). Table 22 outlines
some of the
publications describing varieties with CBC accumulation that will be analyzed
for high CBC
accumulation. The best varieties identified through chemical and phenotypical
analysis will be
designated as CBC01-CBC05.
123
Table 10- Cannabinoid measurement by GC-FID for CBD parental varieties. Blank
values indicate undetectable levels or 0.
.. . . .. . .. . . ...... . . .. . .. . .
..:,::,,,,,,,,,,,,,::::::::::::::::::::::::
Canna binalds1GC TOT::: 0
0
I 1J
TliC CBD ........:.:-..C6G CSC
Can nabs by GC THC;C80 by GC Cannabs i revs IGC) =
7.
,
Sioople... =W.MM,,,.....95%S.:1 ,f,:-, - ,, M9V%V Mi.h.f.k1C -
5.;'f a V4:06 M5.1*::Q :..:.::, ......::::W* .8.51611
:.:..:.:..:. 07.19.O.M 95 % a AallirM 95%S.Z1..:.:.:. ?..4
/i
/i
C8D01 0.42% 0.08% , 11.13k 0.01% 0.41%
0.10% 0.60% 0.05% 12.56% 0.23% 0.04 0.01 5.33 0.36 4.
4.
C8D03 _ 3.48% 0.73% 6.77% 1.37% 0.27% _ 0.06% 0A6% 0.06%
10.99% 2.19% 0.51 0.04 11.90 2.19
CBDO2 1.96% 1.78% 4.53% 3.98% 0.35%
0.28% 7.08% 6.36% 0.43 0.02 3.81 3.37
C8D05 4.13% 0.36%
7.99% 0.75% 0.30% 0.08% 0.55% 0.05% 12.96% 0.56% 0.52 0.09 , 8.06
1.21
CBD04 5.24% 5.74% 0.16% 0.44%
11.65% 0.91 13.19
i .
CESD24 0.19% 8.03% 0.19% , 0A7% ' 8.87%
0.02 9.01
030011 . 0.18% 6.03% 0.10% 1 0.47%'
I 6.78%
0.03 7.76
i
1
C013 _ 0.25% I 8,20% ! , 0.14% I 0.59%
: iR% , 0.01 4.03 , o
h)
,o
1-k "1..0(1 for all cannablnolds was 0.11%.
1..
1..
1...
t4
et
co
.I,
f.>
0
I-.
0
I
I-.
0
Table 11- Cannabinoid measurement by HPLC. for CBD parental varieties. Blank
values indicate undetectable levels or 0. w
canrobinoids (LIMPLC)
_
Canna bs by rt.I.1 .......... 4 ..Cannabs i
THCA CSDA CBGA THC OD C96
D8-TE-IC
14PLCM T.ei)3s: Mg
...A...'...:.HArt...::..:..:s.. 95 %41. ' :V''litt:%: : 9514tI
I:5MsM%*:::.: w:* ....9 .s..:.:1.:e w. 7..,
. w. 40. ;:wt.1..:....:...::O:..:u::%.'...:,t..:,i: 1.:.:..:..44 $..:::
1%4:....:W:...t*: :...:::...,:.....:....m ::::...:...:.......:: .::.:.
,...'....'...:...::::
C0001 0.38% 0.13%, 14.87% , 0.05%, 0.50% 0.17% 0.05% 0.06% 0.43% 0.06%
0.16% 16.34% 0.26% 0.03 0.01 6.94 , 0.48 .
(8003 4.30% 1.05% 9.48% 1.92% 0.34% 0.06% 0.15% 0.09% 0.13% 0.03%
14.33% 2.76% 0.45 0.03 15.55 2.97 Po
n
iq
(8002 . 2.27% 1.94% 6.22% 5.39% 1.18%
0.60% 0.42% 9.35% 8.66% 0.37 0.00 5.04 4.59
C
cn
CBDO5 5.24% 0.19% 10.77% 0.83% 0.30% 0.14% 0.20% 0.13% 0.14% 0.02%
0.11% 0.02% 16.76% 0.74% 0.49 0.04 10.41 1.53 kµa
0
1-1
--------------- CBDO4 832% ---- 7.53% 0.23% Ø48% Ø16%.
16.71% . 1.10 18.93 .O.
_
-43
(8024 0.24% 14.92% 0.38% 0.03% 0.14%
15.71% 0.02 15.97 .O.
C1µ.
------------------ (8011 0.15% 10.29% 0.14% 0.32% 0.32%
0.32% 11.54% 0.01 ---- 13.20 0
4:.
...... ...... ...... :::::::::::: : :
...... : ...... :
Canna bs by THCAttaLV.k.:bY,
DS-THC
. .. : .. .. .
. ..... . .. .. . . .. .. . ... .. . ......
: ..... : : . HPLC:: : ..... =:Terp$ 0
99NCI %
93:16,7.1 99:NCI ....VOW 9516:ki
7.;
8013 0.23% 1367% 0.21% 0.76% 0.36%
0.04% 15.27% 0.02 6.70
*LOQ for all cannablnoids was 0.3.4%.
h)
I.
co
0
0
(i)
Table 12- Absolute terpene measurements by GC-FID for CBD parental varieties.
Blank values indicate undetectable levels or 0.
C
Urpenei. (GC Fli18
=
........^ .,
wrpinolfne r4phaph4landrenc.
11440riiiir14ut carormi. :3rn47ene g'm. '49h'
'44: ' !'...!57.:::: iiii:: `..77:! H:1.:H: :=..41th'
cacyck,8rfile 811640 car,/ 4xis.% myro6ne Identiiiii4
!::
/i
:: : M H M M M H a : :::::::::::::: :::::::
,'", 9='..%'. ::::: :'4..i., At: ::'='. :::::::::::: :nA, :Y.4:
.95::5µ. :::::::::::::::'0=3A ::::::::::: 0::N '.V!!!':: ..'45:At :::::::::::
PSA ::::::::::::!. ::::::::::: PP:.'i ::::::::::: 0,3., :::: ::: 2.5:9.
::::::::::: %.4.9.3., :: : .v,? ../i
4.
::0.4.iitt010. ::N:0:.*: :!r.,=?.sko:
::?til:,...i:: :0'..C. v./.!:.%::0 0,30 ".",.C:
',. r.'.4:: :ii.i4; ::0:: *: :i:1::: ,M.16 0:01::: 4: 0e.*::: s.,901.;
001:0 ..91,.:% :000: :9:0: 0:01. 0 it:f.i.:% :0:,"..!0: .Wi.% 0C1:: i.,i?1,.:*
:0i;i0: O.% 0:010 %Øi.:* :0:,"..!0: .Wi.% 0C1:0 ifti.,1%. :0i".10: 4.
0.0840.011 V.4470.087
0.19S 0.024,0.015 0.026 0.269 C.003 3.029 '2.1340.002
1.122 eatz 2.36O C.&
06003- 36% % % 36% 96 %
36% % 36% 94 % % %
' 0.061 0.017 0.213 0.078
0.035 0.029-0.0160,001 0.023 0.001 0.027p.008
0.077 0.022 0.034 0.005 0.030 0.003 0.419 0.097 0.969 0.2.04
0E1003 36% % % 36% 96 %
96 % % 1 % % % % % 96 36% % 96 %
0.1190.037 2.4210.177
0.1820.068 0.027 0.04610.015 0.146 0.020 /049 0.054 0.877
0.200 1.041 0.139
00001I. % % , % % % % %
% : % % 36% % % % %
. ....-
I .
0.0700,016' 3.458 0.101
0.119110194.223 0.09010.015 0.234 0.048 0.092 0.049 0.014
0.3580.152 4.6350.331
08005 0122% 0071% % % % % % 96 %
% 1 % 36% % % % % % % %
0.189 0.027 0.025
0.049 0.068 9.216 3.065 0.230 9.883
08004 % % 96 %
% % % % %
0.167 0.013 0.030
0.018 0.023 0.0421 0.131 3.057 0.503 0.984
C8024 % % % % *
16 ! % % % *
0.157 0.009 0.021
02113 0.044 0.016 0.060 2.028 0.526 0.374.
08041 96 96 % % 76
% % % % % 0
r4
0.179 0.186 0.100
0.014 0.063 0.062 0.204 3.022 1.450 2.280 ,t)
1.
00013 % % 36 96 %
% % % % % 1.
--
-1-.
8.4 =1.00 for all terpenes V125 ROM except for alpha-pinata. Maloof. and
alpha. w
co
ON terpinsci which ware 0.04%.
w
o
'4
ut
i
I.
o
to
o
No
n
iq
(f)
0.21
0
rl
A
-43
4:6
cr,
a,.
VS.
4:.
Table 13- Relative terpene levels as measured by GC-FID for CBD parental
varieties. Blank values indicate undetectable levels or 0.
Terperes
C
=
7.
,
alpha be t, a : :Atannma alpna alpha
beta alpha alpha hela
Vi
.............,
40xpin len e pheilavcimse ockmene ..M.443t:::::
::1011011034: Airrene . latAgAta.. terpinene pinene : tenttnal CZ, m phene
terptnesal humalene CR ryophyllent% 13/18;001i:i4liZer.110440:bi:iftirai4:::
.../i
I
4-
4-
C801 4% 19% i % 1%
1% i 1% 1% 6% 48%
CBD3 6% 22% 5% 2%
2% , 3% , 8% 4% 3% 44%
CBD2 6% 23% 10%
196 2% 8% 3% 3% 48%
CBD5 7% = 4% 28% 7% 14%
5% 14% 6% 1% 22%
C8D4 21% 3% 3%
6% 8% 24% 7% 26%
C8024 17% 1% 3% 2%
2% 4% 13% 6% 51%
C8D11 18% 1% 2% 1%
5% 2% 7% 3% . 60% .
2
C8013 8% 8% 4% 1%
=.'"
i¨i
0)
-4
o"
01-
=
O
ow
Table 14- C:annabinoid measurement by GC-FID for THCV parental varieties.
Blank values indicate undetectable levels.
carinabinoldsox-Flo
111.4CM:::::. :. CB.D..:..:.:.:.: wca,q a .:.:
CBC:::::::.::.:.:.:.:.: ::: THCV :.: Cannabslay6C
THCAIKVbyeaC:::,::::CantiabS:i:Te1p41GCV
. ____________________ ..... ..,.............. .......... ...... ....
..:..:.:.:.:. . . .. . .. ,.:.:..:..:.:.:.:. . . .. .
.. . e .......................................................
........................................... . . .. . .. . .
......................................... . . .. . .. . . .....
Sample µ&11:9C:: VS:Atf::: ::::Ve/tii::::::::::::9S%t1
Vett%:::::::::::::::::95Ner:::: :!:!:!!!Wt..3.C:!:!:!:!:T95*.cr:!: !!Vg!%
95 5i:a:: !::::Wt:%::::: ::::95:%:tr !N=t.lil :.::95:9KL :.::.:::kk:
:::ASMitt:n
THVO1 4.52% 3.22% 0.01% 0.56% 0.39% 0.0S% 0.03% 3.27% 1.81% 8.40%
5.46% 1.35 0.24 5.36 2.33 No
(-5
=3
*LOQ for all cannabinolds was 0.14%.
8
ct)
b.)
=
4%
-...
CD
4%
ch
ch
VD
4%
Table 15- Cannabinoid measurement by I-IPLC for TIICV parental varieties.
Blank values indicate undetectable levels, or 0.
C
NJ
Canna binc4ds (UHPIC) =
THCA:THCVA by
Cann abs I Tarps =Ji
---...
THCA CSGA THOM THC CG
Cannabs by HPLC
HPLC
1HPLC) .:."..Z
Sample Wt% : 95% a ; Wt% 95 % CI Wl % 95%r.1 WV%
:5:%:C1 %.^.; t '.:,, i '')5 %.:.3 :::ASIt% '15 % CI Wt. %::::.95
% Cl :WM: : 95%C: .1-
4-
THVO1 4.05% 0.58% 3.35% 0.22% --------- 0.05%
4.38% -- 3.58% 1.05 , 6.50
*LOQ for all can nabinoids was 0.14%.
Table 16- Absolute terpene measurements by GC-FID for THCV parental varieties.
Blank values indicate undetectable levels or 0.
:Tar:gem/4%41W
sJpila
beta Totai
liffiffilto A4::::: :: gamma alpha alpha
:::::::::: : ::: ::::: ::::::: :::::: alpha alpha
,i: p.,irerse. limanene ______ _ _ .___ _ ,.
OrrAms.e.\...r4Cfr?St smOihfhe . p3 re ,r,ulene caayophyile linaleal Cary
C.S.C.* ...Tynne identited
ve,F.,.n. P. fl.. =71.,77 :.
=nrIssneut nu
(wt$)
o
P$01.0 !M. W# 4..'4 M.:9 V.% 'il,3.1i ::
g% ,,W't 55 % 95N: :Wi: 9:!... :::::::::::: ::::: :95:9.: :::
:;::::i:':':: i9.,i',6 :W:t:: :,45 A. S:5 'i '35 % :'.g.,:!* 95%
Wt 1 99.:: M WS i 95 % ro
,a
:HV:: .% %=C CI :%41:.::
Vit:%.: Cl ::%:: :tl: : WA i:ii.6: :.). :: Ci Wt % Cl..:: :M: :.C1:: Wtf4: CU:
VCR ii:g :.tk: :Hci ,Vo; `;', q W: % Ci Voit % C! Ar..; % Ci % 1 CI :
Wt% :O :::W8 :0::: e.
e.
ir TWO ' 0.297 0.008 0.192 0.031 0.063
0.028 0.039 0.013 0.023 0.009 0Ø:,, ') 012
0.086 0 020. :, 173 0 k:.9 0.029 ;., 002 0.597 0.115 1.528 0.354
47.
co
- % % % % % 4. . " %.% .
',- % % :Z % % % .., . % , % % %
= . - . . - ..--- ... ...
....=t..)
0
im.
GM
/
Im.
0
7- Relative terpene levels as measured by GC-FID for TTICV parental varieties.
Blank values indicate undetectable levels or 0. ,...
...
Yerperas
i
alpha beta prn rna alpho alpha
beta alpha alryba heia
, Sample ter pinalene phellandrene ocimene carene
nmonene , terpirene . pirene lerpinene pivene feethol tam phene terpiaeol ,
humulme caryaphyliene\ linalon rfay=tbilde myrtene
1 1 1
TH1/01 t : 10% , 13% 4% 3% I IS 1
?.% 6% 11% 2% 39%
n
Table 18- Cannabinoid measurement by GC-F 1 D for CBC; parental varieties.
Blank values indicate undetectable levels or O. C
w
Caanahinokis icsc-Firg
INC COD 080 CSC 11-40.: CEIDV
CBeilf CBN -.' DS-THC
........................ 95 I .......................... '
.;.p:.5
95 ------- , -----
93 Vtlt 95 Wt 9 5 SM. 1 ,
95 Wt. 1 95 CV/ rabs by THC:CISt; Cannabs /
GC,
b'4 GC
r' Terpi !tit)
95
IA' t 95:.. :',)5 o
crIch
vs,
4:.
satn,ple wt X: 1 % V03ia9.:: 's".' 1 4 W, X % A
03 03 03 '% 1 4 AI X % 03 03 5,6 55 4 55 :
:..%.i:::: 4.9::::, .:3:.
F6 40 0%
C
302 65% 9
0.15%
,
1
11A0%
116 -
,..
13.13
C
h.)
=
VI
--.....
Table 19- (.7annabinoid mc.asurement by HPT,C for CBG parental varieties.
Blank values indicate lindetectable levels or (1.
.5
/I
/I
.1..
CannablaakislUHPIC)
.1..
INCA CSGA THC C116 C. nab
by HPLC I HCA:CBGA by HPLC Canna ba / lerps (11PLC)
1
; Saalp3o M% 95 % C W.: % 95 % CI Wt %
i. 95 % Ci Wt % '3S SC! 05%C ''A , Wt % 95% C.: Wt. %
95%C
C8602 8.8A% 1------ 373% 2.53% 0.35% i
227 13.15
=10=4 for ad cannabinoids was 0.14%.
Table 20- Absolute terpene measurements by GC-FID for C;BG parental varieties.
Blank values indicate undetectable levels or 0.
h>
v
....... ...... ......
.......::::::::::::::::::::::.:::::::::::::::::::::::T.e.w11 (GC-FID)
.-.
.:S..:.:..: .:..: .:..:.:P.:.::..:1i..:Pi.:..:
i.:..:ih.:..:.:..:a.1".. i......:...::...:...:........5V..a..i..l...
l.....h....... a.....! ....... ..: ,,:.::. .::.b............, . .7.
.7.... .. ..... .'.... 7..... ... . .. ..... ..........:..:
:..::..::..::..: :..: : .... :9..s.. .::..::..::.::.: ::.: ::..:
:.::..::..::..::..: ..:..:4....?..... . :: ..: 7..:,.7::...:..::.....:
....::1:..'
-;: gs 9 4i 9 3r. 7
; 9 __________
95NW% *208% 4l654n%Wt1 V;)14 pi 4
...::.:7..4 .d..sfs.n4,:3.. 5
.:..::..:..::.:,.7.:... .,.:.,0
mWt*910WtS C 0 4 C VtC
1eh(o10e0-
3.0n...))
0, .?% .?..Ø? :tii.q..%.:, 0.. ?,.4.? ::a..::, :WIC: CC ...A '0: AC ::.:CIH
::!*: WV Mt% .:0 ::!(41.tlf::, :0 W110: .:0: :!* 0 Mitt%, V :,.:WCIC:H:Cr w
0
(8602 0.267% .030% 10.066% C 026% 0.076%
0.200% 0.059% 0.144% 3.868%
1.0Q for ad terpenes was 0.02% except ter
alphasinene, linalool, and alpha-terpineol which
were 0.04%.
Table 21- Relative terpene levels as measured by (3C-F113 for CBG parental
varieties. Blank values indicate undetectable levels or 0.
No
(-)
Terpen es ,
' . . ...,::,.. ..... .... . .....:.:.:.:.:..:..:.:.:.: :.
, ' .....1q
====== ==============".":=:=::::i:::::::::::::========= . '::::
.=.".".======= . = .. = .. = . =====
".======= . = .. = .. = . -v." =========== CA
b.,1
::: ::::K: ::::::::::1::::::::::::: :::::: ::
::::::::: ::::::::::: = 0
=I
alpha bpta .:.:.: .:..:.:.:.:. . . .. . .. . .
.:.:..A.:.:.:. . . .. . .. . . .:.:.:.:..:. = .:.::gatisma.:.:.:
::.:.Aph*.:.:.: alpha beta MO a alpha beta 4a,
.......:::::::::::::::::::::::::::,:::::::::::::::::::::: !
......
Sample teltinelene pheitandrene ocimene i larenc ::i:::lintentste:
:taiipitione: :pinene: terpinene pinene leeched i tarn phone
terpineol huirluleSe Carvephyllene Einalered Saty oxide nwrrene p
i
4a,
c3Ge2 , i 31% 3% 8% q, .
- , 1 9% 23% 7% I 17% cr,
vz
4a,
Table 22- Sources of CBC parental varieties.
C
Reference for Cannabis Varieties Accumulating CBC
Baker, PB et al., (1983) "The Physical and chemical features of Cannabis
plants grown in the United Kingdom of Great Britain and
Northern Ireland from seeds of known origin- Part II: second generation
studies." Bull Narc 35:51-62.
Bender JA, and Der Marderosian AH (1978) "Chemotaxonomy of Cananbis I.
Crossbreeding between Cannabis sativa and C.
ruderalis, with analysis of cannabinoid content." Econ Bot 32:387-394.
Yotoriyama, M et al., (1.980) "Plant breeding of Cannabis. Determination of
cannabinoids by high-pressure liquid chromatography."
Yak.uga.ku Za.sshi 100:611-614.
Holley et al., (1975) "Contituents of Cannabis sativa L. XI: cannabidiol and
cannabichromene in samples of known geographical
origin." J Pharm Sci 64:892-894.
I.
(-5
1-3
8
cr,
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 5. Breeding Scheme for new specialty cannabis varieties
In another objective of the present invention, the cannabis varieties of
Examples 2-4 are
used in cannabis breeding programs to develop specialty cannabis plants and
varieties.
Furthermore, the specialty cannabis varieties developed according to the
present invention have
specific aromas, flavor(s), and entourage effects in accordance with one of
the classes of
cannabis varieties as discussed above.
This approach was designed in part, as a response to the fact that currently
available
cannabis varieties have been skewed towards higher THC production, which has
increased the
likelihood of adverse effects from the elevated levels of psychoactivity that
these conventional
high-THC varieties produce.
Contemporary "recreational" marijuana cultivars have been exclusively bred and
selected
primarily for their THC acid content, secondarily (if at all) for their
tetpenoid aroma and flavor
chemistry, and rarely for their production of the other cannabinoid acids,
such as CBDA.
Cannabidiol (CBD), a cannabinoid that is rare in contemporary cannabis
varieties, has
been shown to reduce and modulate the psychoactivity of THC and also reduce
some of THC's
other adverse effects including tachycardia, anxiety, memory effects, etc.
There is some
evidence that CBD may reduce the buildup of tolerance to the effects of THE
and also reduce the
likelihood of cannabis dependency. Other cannabinoids (CBs) such as CBDv,
THCv, CBG,
CBN, etc have also recently been demonstrated to have a variety of medical and
recreational uses.
In some embodiments, the breeding programs of the present invention were
designed to
combine THC with non-THC CBs. Furthermore, the specialty cannabis varieties of
the present
invention were additionally selected for their ability to produce terpenes
that are appealing to
patients and that may also provide a pharmacological activity that modifies,
enhances or
ameliorates the effects of THC. In contrast, publicly-available contemporary
hemp varieties that
are high in CBD do not produce the pleasing organoleptic attributes of
contemporary high-THC
marijuana cultivars. Indeed, all known chemotype II or chemotype III plants
produce myrcene
dominant terpene profiles which do not have pleasing aroma/flavor, and do not
have the
entourage effects brought on by higher levels of non-myrcene terpenes. Thus,
an objective of the
present invention is to combine THC with higher CBs and diverse terpene
profiles so as to
produce specialty cannabis varieties with these pleasing aromas and flavors
that were unavailable
until the present invention.
131
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In other embodiments, the breeding programs of the present invention were
designed to
produce THC:CBs expressing plants with higher terpene oil content. In some
embodiments, the
higher oil contents of the specialty cannabis of the present invention produce
pleasing
aromas/flavors. In other embodiments the higher oil levels of the specialty
cannabis of the
present invention allows the terpenes reach high enough levels to reduce TI-IC
side effects. In
some embodiments, the higher terpene oil contents of the specialty cannabis of
the present
invention increase the amount of entourage effects of the terpenes in the
terpene profile. In some
embodiments, the specialty cannabis plants of the present invention produce
myrcene dominant
plants with improved aroma/flavor and entourage effects by increasing the
terpene oil content.
One embodiment of the present invention is to produce specialty cannabis
varieties with
high essential oil content, in particularly, mono- and sesquiterpenes. The
breeding objectives of
the present invention are opposite to the face of modem recreational marijuana
breeding
strategies which have focused almost solely on breeding for higher levels of
THC content alone.
According to one embodiment of the present invention a TUC class variety is
crossed to a
CBs producing line to produce Fl seed which were grown to produce Fl progeny.
The resultant
Fl progeny can be fixed through asexual reproduction and/or used in further
breeding schemes.
Five CBD lines were chosen to use in the initial breeding program: CBD1, CBD2,
CBD3, CBD4
and CBD5 (see Example 3). Similarly, THC class varieties can be crossed to the
THVOl, CBC01,
and CBG01 parental varieties of the present invention. According to one
embodiment of the the
present invention, each of these CBD, THCV, and CBG lines is crossed to one or
more cannabis
varieties which are described above and summarized in Example 3. In another
embodiment, the
present invention teaches crosses of any of the parental varieties with each
other. Thus, for
example, one or more GOLD Class varieties are crossed to each of CBD1, CBD2,
CBD3, CBD4,
CBD5, THvoi, CBC01, or CBG plants to produce Fl populations to create (GOLD
Class x
CBD; GOLD Class x THVO1 ; or GOLD Class x CBG) combinations. In some
embodiments,
CBs producing parental varieties may also be crossed among themselves (e.g.,
CBDO5 selfed, or
CBDO5 X THVO1) Following is a list of the iterations for each of the Class x
CBD, Class x THY,
and Class x CBG crosses (Tables 23 and 24).
Table 23- Example crosses between Color Class cannabis varieties and CBD
parental lines.
CBDO1 Crosses CBDO2 Crosses CBDO3 Crosses
CBDO4 Crosses CBDO5 Crosses. j
132
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
CBDO1 Crosses CBDO2 Crosses CBDO3 Crosses CBDO4 Crosses CBDO5 Crosses
AZURE X CB001 AZURE X ( 8002 AZURE X CB003 AZURE X CBL)04
AZURE X C8D05 ,
BLACK X CB001 BLACK X CB002 BLACK X CB003 BLACK X C8004
BLACK X (BOOS
BLUE X CBDO1 -- BLUE X CBDO2 BLUE X CBDO3 -- BUR X CBDO4
BLUE X CBDO5
BRONZE X CB001 BRONZE X CB002 BRONZE X CBDO3 BRONZE X CB004
BRONZE X CBDO5
BROWN X CB001 BROWN X CB002 BROWN X CBD03 BROWN X CB004 ,
BROWN X CBDO5
FUSCIA X CB0O1 FUSCIA X CB002 FUSCIA X CB003 FUSCIA X CB004
FUSCIA X (BOOS
GOLD X CBDO1 GOLD X CBDO2 GOLD X CBDO3 GOLD X CBDO4 GOLD
X CBDO5
GREEN X CB001 GREEN X CB002 GREEN X CB003 GREEN X CB004
GREEN X CBDO5
GREY X CBDOI GREY X CB002 GREY X CB003 GREY X CB004 GREY
X CBDOS
JADE X CBDO1 JADE X CBDO2 JADE X CBDO3 JADE X CB004 JADE
X CB005
LEMON X CB001 LEMON X CB002 LEMON X CB003 LEMON X CB004
LEMON X CB005
MAGENTA X CB001 MAGENTA X CB002 MAGENTA X CEI003 MAGENTA X CB004
MAGENTA X CB005
NAVY X CB001 NAVY X CB002 NAVY X CB003 NAVY X CB004 NAVY
X CB005
OLIVE X CBDO1 OLIVE X CBDO2 OLIVE X CBDO3 OLIVE X CBDO4
OLIVE X CBDO5
ORANGE X CBDO1 ORANGE X CBDO2 ORANGE X CBDO3 ORANGE X CBDO4
ORANGE X CBDO5
RINK )C C11001 PINK X C8002 PINK X CBDO3 RINK X C8004
PINK X CB005
PURPLE X CB003. PURPLE X CE002 PURPLE X C8003 PURPLE x (0004
PURPLE X CBDOS
RED X CBDO1 RED X CBDO2 RF:D X C8003 RED X CBDO4 RED X CBDO5
SEA X CBDO1 : SEA X CBDO2 SEA X CBDO3 SEA X CBDO4 SEA X CBDOS
I
SILVER X CEIDO1 SILVER X CBDO2 SILVER X CBDO3 SILVER X CBDO4
SILVER X CBDO5
TAN X CB001 TAN X CB002 TAN X CB003 TAN X CB004 TAN X CBDOS
VIOLET X CEI001 VIOLET X CB002 VIOLET X CB003 VIOLET X CB004
VIOLET X CB005
WHITE X CB001 WHITE X CB002 WHITE X CBDO3 WHITE X CB004
WHITE X CB005
: YELLOW X CB001 YELLOW X CB002 YELLOW X CB003 YELLOW X CB004
YELLOW X CB005
Table 24- Example crosses between Color Class cannabis varieties and other CBs
(THCV/CBDV, CBC, CBG) parental lines.
THVO1 Crosses CBC01 Crosses CBG02 Crosses
AZURE X THVOI AZURE X CBC01 AZURE X CBG02
BLACK X THVO1 BLACK X CBC01 BLACK X C8602
BUIE X DB/01 KUL' X E8C01 81 UE X C8602
BRONZE X THVO1_ BRONZE X CBC01 BRONZE X CB602
_
BROWN X THVO1 BROWN X CBC01 BROWN X CB602
FUSCIA X THVO1 FUSCIA X CB(X)1 FUSCIA X CBG02
GOLD X rHVO1 GOLD X CBC01 GOLD X CBG02
GREEN X THVO1 GREEN X CBC01 GREEN X CB602
GREY X THVO1 GREY X CBC01 GREY X CBG02
133
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
THVO1 Crosses CBC01 Crosses CEIG02 Crosses
JADE X THVO1 JADE X CBC01 JADE X CB602
LEMON X THVO1 LEMON X CCM LEMON X CB602
MAGENTA X THVO1 MAGENTA X CBCD1 MAGENTA X CBG02
NAVY X THVO1 NAVY X CBC01 NAVY X CEI602
OLIVE X THVO1 OLIVE X CBC01 OLIVE X CB602
ORANGE X THVO1 ORANGE X CBC01 ORANGE X CB602
PINK X THVO1 PINK X CBC01 PINK X CBG02
PURPLE X THVO1 PURPLE X CBC01 PURPLE X CB602
RED X THVO1 RED X CBC01 RED X CBG02
SEA X THVO1 SEA X CBC01 SEA X CBG02
SILVER X THVO1 SILVER X CBC01 SILVER X C8602
TAN X THVO1 .1 TAN X C8C01 TAN X CBG02
VIOLET X MVO]. VIOLET X CBC01 VIOLET X CB602
WHITE X THVO1 WHITE X C8C01 WHITE X CI3G02
YELLOW X THVO1 YELLOW X CEIC01 YELLOW X C13602
In one representative version of this breeding regime the resultant F! progeny
can be
selfed to produce F2 seed which are grown to produce F2 progeny. Selection for
desirable
phenotypes and/or genotypes can be conducted within the Fl, F2, or subsequent
progeny since
the selections can be immediately maintained (i.e., fixed) via asexual
reproduction. Alternatively,
the F2 progeny can be crossed among themselves to produce a bulked F3
population from which
desired progeny can be selected and/or further generations of crossing can be
conducted. In
another embodiment, the resultant Fl progeny can by backcrossed to the TUC
class or CBs
variety to further reinforce the traits of other parent. In yet another
representative version of this
breeding scheme F1, F2, or subsequent progeny may also be crossed to
additional CBs varieties
to create even more complex cannabinoid combinations. For example, Color Class
X TEIV01
F 1 's can be subsequently crossed with a CBD variety in order to produce THV,
CBDV progeny.
Regardless of the exact crossing/selection procedure, selected lines can be
chosen so as to have a
total THC content <90.0%, a total CBs content >1.5%, and a desirable aroma and
flavor profiles.
1.5 In another embodiment of the present invention, regardless of the exact
selfing/selection
procedure, the selected lines can be chosen so as to have a total THC:CBs
ratio of greater than
9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7,
1:9, and lower, and a
desirable aroma and flavor.
134
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
According to the present invention, the lines can also be further selected for
a specific
content of certain other cannabinoids and/or of certain terpenes/terpenoids,
and/or for additional
phenotypic and genotypic characteristics. Desirable phenotypic characteristics
include but arc
not limited to larger plant size (i.e., greater bulk or biomass), higher
production of flower buds,
larger flowers, more trichomes, shorter plant stature, ability to tolerate
lower and/or higher
growing temperatures, greater germination percentage, greater seedling vigor,
more efficient
water usage, disease resistance, pest resistance, and other desirable
agronomic and production
traits. For an overview of diseases and pests of importance to cannabis
production see Clarke et
al. (2000) Hemp Diseases and Pests: Management and Biological Control: An
Advanced
Treatise (CABI Publishing).
In an alternative version of this breeding regime the selected F2 progeny are
backcrossed
to the Class variety as the recurrent parent. Selection for desirable
phenotypes and/or genotypes
can be conducted after this initial backcross, after any subsequent backcross
(e.g., progeny
obtained after 2, 3, 4, 5, 6, 7, 8, 9 or more backcrosses). In some
embodiments, selected lines
will have a total THC content <90.0%, a total CBs content >1.5%, and an aroma
and flavor
profiles typical of its class. In other embodiments of this breeding scheme
selected lines can be
chosen to have a total THC:CBs ratio of greater than 8:1 and approaching 1:1
and lower, and an
aroma and flavor(s) typical of its class. The lines can also be further
selected for a specific
content of certain other cannabinoids and/or of certain temenes/terpenoids,
and/or for additional
phenotypic and genotypic characteristics.
The progeny resulting from any selection stage of either the selling or
backcrossing
versions of the breeding regimes of the present invention can be asexually
reproduced so as to fix
and maintain the desirable THC content, CBs content, the aroma and flavor(s)
typical of the
desired class, and the other desirable phenotypic and/or genotypic
characteristics. The resultant
selected lines will be designated as Specialty Cannabis Varieties.
The progeny resulting from any stage of either the selling or backcrossing
versions of this
regime can also be crossed to other cannabis plants/varieties within, between
or among the
various classes of cannabis so as to produce additional plants for selection
and maintenance
through asexual reproduction. In this way, specialty cannabis varieties with
various, desired
flavor combinations can be produced and subsequently maintained through
asexual reproduction.
135
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The resultant specialty cannabis plants of the present invention also
generally have more
terpene essential oil content (e.g., absolute content of terpenes in each
plant's terpene profile
measured on a dry weight basis) per plant than contemporary marijuana
varieties. More essential
oil per plant means less plant matter is required per
treatment/administration, thereby also further
minimizing any health risks for medical and recreational cannabis smokers.
This would also
further increase production efficiency.
The inventors of the present invention hypothesized that breeding plants with
increased
CBD, or THCV content would alleviate most of the commonly recognized real and
perceived
adverse effects of high THC cannabis. According to the present invention, a
direct result of
increased CBD is lower THC content because THC synthase and CBD synthase are
allelic. Thus,
another objective of the present invention was to create specialty cannabis
varieties with an
'optimal' dose of THC and resulting in the most efficacious ratio of THC:CBD
or THCV:THC.
According to the present invention, it is possible to apply dosage data to
creating custom
blended granular mixes for rolled delivery, pellets for bowls and house one-
hitters, extracts for
dabs, etc. with the flowers of these highly resinous newly-developed varieties
with designed
cannabinoid content so as to reduce adverse effects associated with THC.
Gold Class Breeding Regime for THC':CBD producing plants.
Example Basic Breeding Scheme. The initial cross for the Gold Class CBD
Breeding
Regime that was conducted as follows: 1'! (GOLD Line (GOD02) x P2 (CBD Line
(CBD05).
The hybrid cross between Parent 1 (P1) and Parent 2 (P2) could only be
achieved by induction of
staminate flowers on the pistillate plants by an exogenous application of the
chemical silver
thiosulfate. This process allows otherwise pistillate (female) plants to be
coaxed to produce
staminate, pollen bearing flowers. During this process, to investigate and
exclude the possibility
of maternally inherited genetic factors, reciprocal crosses can be made where
both P1 can be
induced to produce pollen and fertilize P2 (Line 1A), and P2 can be induced to
produce pollen
and fertilize P1 (Line 1B).
These crosses resulted in the production of an Fl population = GOD02 x CBD05.
Individuals from the Fl lines of each Fl population can be analyzed via TLC,
GUMS, GC-FID,
or HPLC to determine their respective chemotypes. It is expected that the Fl
populations
136
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
comprise individuals that show a Chemotype I, II, and II cannabinoid
distribution, with a range
of tetrahydrocannabinol (THC) and cannabidiol (CBD).
Plants with suitable terpene contents and profiles can be 'self-fertilized' to
create a series
F2 segregating populations or families; all non-desirable lines can be
rejected from the breeding
regimen. In this way, a series of F2's can be created ¨ 1AF2a, 1.A.F2b, IAF2c,
IBF2a, 1BF2b,
IBF2c, etc.
F2 families can be propagated and screened via GC/MS to determine individual
chemotypes; it is expected that in the F2 segregating populations we will see
chemotype I,
chemotype II, and chemotype III plants. Chemotype I plants can be discarded
and only
chemotype II and chemotype III plants can be retained and again screened by
GC/MS to evaluate
their suitability in terms of terpene content and profile.
It may also be desirable to mate selected Fl lines via a backeross scheme to
the P1 00D02
to reinforce the GOLD genetic background, although doing so will re-introduce
B(t) alleles (i.e.,
the alleles that encode for THC production) into the breeding population,
resulting in a
population of chemotype I and II plants.
Similar breeding schemes may be followed to obtain additional class-CBD
progeny by
repeating the steps described for GODO2 with other class varieties and/or CBD
parental lines.
Example 6. Development of THC:CBD specialty cannabis varieties
Unique parental THC and CBD lines from Examples 2-4 were selected and one of
the
parental cultivars was treated with silver thiosulfate to coax the pistillate
plant to produce
staminate, pollen-bearing flowers. The THC and CBD lines were then crossed,
the resulting
progeny were screened by TLC to identify plants producing both THC and CBD, or
CBD alone.
Progeny exhibiting the desired chemotype II and III profile were allowed to
reach maturity and
the flowers were harvested and processed. In general, field observations could
detect the crosses
with the desired characteristics, however this was verified by chemotype
analysis and the final
flower was analyzed for cannabinoid and terpene content. Table 25 outlines the
initial crosses
performed with THC class varieties and CBD parental lines. The crosses
produced progeny
approaching ratios supporting the single locus model for THC and CBD synthase.
TLC results
described in the table show the field-determined chemotype of the progeny
(chemotype II- THC
and CBD producing, and chemotype III- CBD only).
137
C
1,..)
Table 25- Crosses performed between class cannabis varieties and other CBD
parental linc,.. TLC result indicates ehemotype T, TT or 11. =
VI
---...
CBDOS
.:..4.,'
P Donor
Vi
Vi
P
4-
C8005 C8003 :C8002 :08002 : : :: :: : C8004 ::
:: : YEL03 PL1101 : W11107 S1108 : : :SHAM : WHIO4 W3001
,Accept0r ::::::::::::::::::
:3-1,C, , , : ::::i::::::::::::::: ::::1-....0 .:::::::::::::::: ::::171:Cõ
:::::::::::::: ::::;-14 :n::::: I TLC ::::: ::::::: , õ
::: :1W: :.: _ I LC , _.::: ::1,w: ::::::::: :::.ii.c Ti..0
, :::::: ..41.:.::::
4.41.Cr: tief=l!it (...11.. 60i 7.1.. 0.4.i:ii.t If!.n. lep.fdatjf.t
.. '''''. ''.'.:''" .,,, '' .'1,7 kik,11.A 1f:'"lr.. ki;,;:f,
C' Rp.s,iir '.:T1.1n Oi.56E:
CBD05411- CI30034P- CB D024P- ,C8002411-
CB0044P YE :.034P- PUR014P- W111074P- SIL0114P. Sii.084P-
14041044P- Wit10149-
_ 1.. 01 ...III_. 01 III 01 - 31 II 01 +
01 - 01 - 01 II 01 II 31 - Cl - 18
rC113054P- CB)034P- -r5D024P- 1C80024P= C80044P- YEL034P- PUR014P- WHI074P-
SILD84P- 511084P- WHI044P- -WHI014(17
2 02 II 02 - 02 - 32 II 02 H 02
- 02 - 02 II 02 == 32 - 02 H 19 II
C90054P= C00034P- CBD024P- C88024P- C80044P-
111.034P- PUR014P- WH I074P- SIL084P, 511084P- WHI044P=
W131014P-
3 03 - 03 II 03 - 33 - 03 II 03 -
03 - 03 - 03 H 33 - 03 1 - 22 II
C50054P- CBD034P= CBD024P- C80024P- C80044P- YE:034P- 4108014P- WHI074P-
511.084P- 511884P- WHI044P= WHI014P-
4 04 - 04 - 04 - 34 - 04 + 04 -
04 H 04 - 04 - 34 II 04 - 23 II
CB0054P- (80034P- C8D024P- =C60024P- C80044P-
YEL034P- PUR014P- WHI074P- 511.084P- 511084P- WHI044P- i
W111014P-
OS H OS H 05 U 35 - OS + 05 - OS - 05
- 05 - 35 - CS 1 - 14 H
o
(113005411- 1:BD034P- C80024P- 4:13(3024P-
C80044P-, YEI.034P- Pl.:ROI:0x WHI074P-
511.08431- 511.084P- W11104 oP- W11101411- co"
6 06 = 06 - 06 - 36 = 06 i +II 06
- 06 == 06 == 06 - 36 == 06 = IS III
1-
=c CBD05417- C801:334P- C80024P- C80024P-
COW4401 YEL034P- PUR014P- WHI074P. 50.084P-
S11080- WHI044P- : WHI014P- o
toe
co
00 7 07 - 07 III 07 - 37 = 07 + 07
=- 07 == 07 II 07 - 37 II 07 1 = 16
'
i I.>
CBD054P= CBD034P- CBD024P- .CBD024P= 7.7. :: :
:: : : :7'::.::: vE:..0341,.. PUR014P- WHI074P- S11.084P-
511084P- WHI044P= W141014P- *
:-.
8 08 - 08 - 08 - 38 =
:::::::::::::::::::::::::: ::::::::::::::: 08 - 08 -
08 II 08 H 38 II 08 = 12 H co
I
C80054P= CES0034P- CBD02.4P- C00024P=
:::::::::::::::::::::::::: ::::::::::::::: vEL034P- PUR014P- WHI074P-
511.084P- 511.084P- WHI044P- 1-
o
9 , 09 - 09 H 09 II 39 - , M, ::::::
09 - 09 1 - 013 - (39 - 39 -
(39 - co
GSM/54P. lal10034P- C8002412- oC8D024P- : ::::::
YE1034P- PUR014P-' WH I074P- 5IL084P-
511.084P- o
10 - 10 II 10 II 40 0 :::::::::::: :::::::::::::::
10 - 10 II 10 - 10 - 40
C80054P- C13I303147- C8D024P- C60024P- ::::
,,,,,,,,,,,, YE it3xP- P:JR014P-1 WHI074P- SILD849- SII.084P-
11 11 - D. - 11 1U 41 - :: ::::::::
1.1 - 11 1 - 11 II 13. - 41 - ::::::::: :
:::1:=::::
C80054P- CI:113034P- cenoliox C80024P- ::::
:::::::::::: YE L(80- ::::::::::::::::::::::::: ::::::::::::: W111074P-
5111:1849- 511.084P-
12 12 - 12 - 12 II 42 - :: :::::: : 12
= :::::::: : : :: ::::::,: 12 - 12 == 42
, -,--
CIID054P- 'C8D034P- CB D024P- C800241-
:::: :::::::::::: YE L03xP- ::::::::::::::::::::::::: ::::::::::i:::
:::::::::::::::::::::::: ::::::::::i:ii 511084P. Sii.084P-
13 13 - 13 = 13 = 43 :::
::::::::::::::: 13 = :::::::::::: . : .. : .. : . :::: :::::::::::::
:::::::::::::::::::::::: :::::::::::::::: 13 = 33 -
C8D05412- CBD034P= CI30024P= CBD024P =
7 ::::: YEL034P- ::::::::::::::::::::::::: ::::::::::".:::: ::::::::: . :
.. : .. : . :::::: ::::::::::::::: SIL0134P- 511.084P-
14 14 - 14 - 14 II 44 -
::::::::::::::::::: 14 _______ -
:::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::
::::::::::::::: 14 II 44 II
CB0054P- CBD034P-1 CBD02411- CBD024P- 'EL034P-
:: .. ::::::::: ::::::: '
::::::::::::::: ::::::::::::::: 50.084P 1.10
15 - 15 - 15 II 45 - 1: - : 15 -
....iq
C80054P- CBD034P- CBD024P= CBD024P- ,
YEL03xP- S;10.8XP,
16 16 - 16 - 16 = 46 - 6 .
:::::::::::: ::::::::::::::: 15 :
CliD054,- 1:BD034P- C80024P- C8D024P- ::,:,:,,,,,,
,,,,,,,,,,,,,,, 30ii.03x1, i S:W81xik .
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 2 !::::.. . ..:.:. :... CA
lsb
0
17 17 - 17 - 17 II 47 II ./
:::::::::::: ::::::::::::::: 11 -
:=::=:=:=:=:=:==:==:=:=:= :. =I
CBD054P- CBD034P- C00024P- CBD024P- , M a
qi.034P- ,,,,,,,,,E a , S11.08411-
----...
18 18 - 18 - 18 - 48 = ..:, ::
:: :: : :::::::: 18 = : :::::::::::: 18 II
:::::::::::::::::::::::: :::::::::::::::
::::::::::::::::::::::::::::1::::::::::=== ::::::=:=:=:=:== =:.: 44-
CBD054P- CBD034P- CBD024P- CBD024P- i
:::::::::::: ::::::::::::::: vE:_034P- :::::::::::::::::::::::::
Iii.084P- :::::::::::::::::::::::: :::::::::::::::
:::::::::::::::::::::::::::::3::::::::::::' 0
01
19 19 - 19 - 19 - 49 = ............. :
19 _________ = ::::::::::::::::::::::::: 19 -
44-
CII0054P- - CBD034P- - C00024P- - C80024P- -
1 "=:::::::: :::::::::::: YE L030- - :::::::::::: . : .. : .. : . ::::
Siia84P-
20 20 20 50 1 20
::::::::::::::::::::::::::::::::::: 20
1
C:8005xP- CEIDO3xP- CIIIX)2x1,- C8002xP- VI ',C3x1,-
::::::::::::::::::::::::::::::::::::: ...... :::::::::::: '; i
i08xP
21 21 - 21 - 21 - 51 - 21 -
:::::::::::: . : .. : .. : . :::: ::: : ::::::: : 21 ::: .....
:::: : ::: : :::: :::: __ C
C8005xP- CEI203xP- CBDO2xP- C8002xP- 'E ..%3xP-
::::::::::::::::::::::::: :::::::::::::
::::::::::::::::::::::::= :: 3',I08xP- nJ
22 22 - 22 - 22 - 52 . - 22
= ::.:::.::::.::::::::::::::: =:....::: ::::::::::::::::::::::: ::::
22 =
..-- -8- -CEIDO
655xP--------3xP- -i-'1D02xP- ------8-5-6-2-x-13
:k
- YEI.03xP- :::::: :::::::::::: :::::::::::.1I:I
::::::. S!1.08xP- . ::::::::::::::: ::::::::::::::.:
:=:::..............:=::=::=::=:::=:::=:::.:=.:........:.... CP
23 23 - 23 - 23 - 53 - .
23 ::: :::::::.:,:.::....::::::.
5
-
C81305xP- tBDO3xP= CBDO2xP- CBDO2Y.P- I,
vELD3xP- I:::. :.:.:.:.:.:.:.
::::::::::::::::.j.::: :::: Si W8x1"-
:::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::
:::::::::::::::::::::::::::::::::::::::::::: :::::::: Vi
24 N - 24 - 24 - 54 - I 24 -
::::::: ::::::::::::::: 24 = ::::::::::::::::::::::::
::::::::::::::: ::::::::::::::::::::::::::::: :::::: VI
4..
C8D02xP- CBDO2xP- vF i.133xP-
5:618xP- : :: :: : .5..
25 25 - 55 II 2. -
25 -
C3002xP- I YE LO3xP-
SIID8xP- :::::::::::::::::::::::: :::::::: . : .. ::.:::::
:::::::::::.::::.::::.::.:::::::::::::::::
26 26 = I 25 II ::::::: :::::
I tõ 26
....::::: . C 8002xP- i rE103xP- ::::.
.::::::::::::: :::::::::: SII.08xP-
27 : . 27 1 27 33
:::::::: =:. ......... ......... 27 II
1 -
.......:::::::. :::: :::::::: :::::: CBDO2AP- -E i
33.P- :::::::::::::::: g:: :::: $:s.08xP-
28 :::: ::::: :::: : : ::::::::: : : ::: 28 II
23 = : :::: :::::: :: : 28
---t
C3002xP i :::::
:::::::::::::::::::::::::,:: SILOUP-
29 29 - ! 29
'CBDO2xP=
1
541.08x1,-
30 30 B 30
0
la
.
.."
c:
1;
vz
6'
t..'
=
18
41
V
n
1-3
8
ct,
=
-
4a.
0
4a.
cr,
cr,
vz
4a.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 7. Chemical analysis of cannabinoids and terpenes of THC:CBD specialty
cannabis progeny.
The new specialty cannabis varieties created through crosses described in
Examples 5
and 6 were subjected to cannabinoid and terpene chemical analysis as described
in Example I.
The levels of carniabinoids were measured by both GC-FID (Table 26) and HPLC
(Table 27).
Terpenes were measured using GC-FID and are presented as absolute content
measurements
based on the percent content by weight of dry inflorescences (Table 28) and
relative content as a
percent of the total terpene profile (Table 29). The GC-FID cannabinoid
analysis of Table 26
also included measurements for THCV, CBDV, CBGV, CBN, and Delta 8 THC, all of
which
were measured to be less than .3% and were therefore not included in the
table. Similarly, the
HPI,C cannabinoid analysis of Table 27 included measurements for CBCA THCVA,
CBDVA,
CBGVA, CBC, THCV, CBDV, CBGV, CBN and Delta 8 THC all of which were measured
to be
less than .08%, and were therefore not included in the table.
Unlike previously available chemotype TT or chemotype III plants, the
specialty cannabis
of the present invention exhibit chemotype II and III genotypes (BT/BD,
producing both THC and
CBD, or BD/BD, producing CBD but no THC) while producing desirable terpene
profiles. That is,
the breeding program of the present invention has produced chemotypc II and
III specialty
cannabis plants with desirable terpene profiles in which the myrcene terpene
is not dominant. For
example, the PUR01 X PO4, PUROI X PIO and PUROI X P05 have limonene-dominant
terpene
profiles. In some embodiments, the limonene terpene is expected to impart the
specialty cannabis
with a citnisy aroma. In other embodiments the limonene terpene is expected to
have added
anxiolytic properties to combat the side of effects of THC. In yet another
embodiment, the
reduced myrcene content of the specialty cannabis will reduce the amount of
"couch lock" effect
produced by myrcene. in other embodiments, the terpene profiles of the other
chemotype II and
III progeny provide diverse terpene profiles designed to produce desirable
aroma/flavors and
organoleptic appeal. In other embodiments, the terpene profiles of the
chemotype II progeny
allow for terpene entourage effects to reduce the side effects of THC.
The breeding scheme described in Example 6 also produced specialty cannabis
plants
with increased terpene oil content. For example, progeny CBDO2 X P-11
(chemotype III), and
SIL08 X P-30 (chemotype II) have terpene oil contents greater than 1.5%.
Several other progeny
such as CBDO5 X P-01 (chemotype 111), and SIL08 X P-34(chemotype 111) have
terpene oil
140
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
contents greater than 2%. In some embodiments, the higher oil content of the
specialty cannabis
varieties provide "smoother" aromas and flavors and will raise the total
terpene levels so as
increase the pharmacological entourage effects of said terpenes. The higher
oil content results in
myrcene becoming the dominant terpene, but it remains less than 2/3 of the
relative terpene
content providing opportunity for the entourage effects of the other terpenes
to emerge. For
example despite having a myrcene dominant profile, the SIL08 X P-34 specialty
cannabis of the
present invention is expected to provide a better organoleptic experience than
that of myrcene
dominant chemotype II varieties currently available which tend to have very
low terpene oil
levels.
141
Table 26- Cannabinoid values as measured by GC-FID for TFIC:CBD and CBD
(chemotype II and III) specialty cannabis varieties. c
1,..)
Blank values indicate undetectable levels or 0. Some zero values are indicated
by "0.000%." =
v.
,
s
: : : :: : :: : :: : :: :: :: :: :: : :: MC:::::::::::::::::::: ::: :::
::::::::::::::: ::: :::::::::::COO:::
::::::::::::::::::::::::: : :::::::::::::::::::::: ::: ::Ca::::::::: :::
::::::::::::::::::::::: ::: :::::::::::: ." .1i
Carsnabs by GC
THC:C8D by GC 4 .
4 .
aBE BRaa MaaBE MBRaBRaaBRaaaaaRB E.
Sampl*
::::::::Vd%::::::: :::::%:gff::: :::::::::::Wt:%:::::::::::
:::::9:16.:O::::::: ::::::::Akt.t%::::::::.:::::::15:1400/::::::::
::::::::WE:%:::::::: :::::::lii.514.6( I W% !9.5%C
:::::::::Wt:%::::::::::::::::::::::::: 9.µ.t %E.. ChemotVP
Wt-0010.1.; 0.13% 4.90% 0.05% _ 0.38% ,
5.46% . 0.03 , : I
CBD02xP-11 0.25% 0.10% 8.49% 0.68% 0.15% 0.05%
0.55% 0.22% 923% 1.04% 0.03 : 0.01 : 1
C131003xP-01 0.16% 0.04% 5.40% 181% 0.06% 0.05%
0.38% 0.07% 6.00% 1.97% 0.03 0.07 III _.
C80030-10 0.26% 8.35% 0.23% 0.60%
9.43% 0.03 , III
f.8003xP-07 0.17% 6.22% 103% . 0.09% . 0.03% 0.47%
0.03% 6.37% 0.87% 0.03 1 : I 2
= c
I-
- C8004xP-01 0.21% 094% 8.34% 0.95% 0.16% 0.00% 0.39% 0.11%
910% 0.79% 0.03 . 0.01 III
t.4
C8004xP-09 0.22% 8.34% , 0.18% . 0.42%
9.17% 0.03 , 1 o"
...............................................................................
.................. - '5
=
C8005xP-01 0.31% 0.76% 11.05% 194% 0.27%
0.17% . 0.56% 0.12% , 12.19% 1.59% , 0.03, ......01
. O
C8D05xP-13 0.21% 0.01% 7.69% 1.92% 0.27% 0.11%
0.36% 0.08% 8.53% 1.95% 0.03 0.01 : I t
MR01)&46 1.59% 4.20% 0.12% , 0.28% .
6.18% 0.38 II .
MR01411-04 2.20% 0.61% 6.00% 1.82% 0.21% 0.02%
0.42% 0.03% 8.83% 2.51% 0.37 0.00 II
PUR0141410 1.57% --- 4.02% 0.21% 0.32%
6.12% 0.39 II
PUROIxP-OS 1.5% 2.43% 0.09% 0.32%
4.40% 0.64 :1
0
-
511.08xP4.31 1.95% 6.20% 0.13% 0.40%
8.73% 0.31 II No
n
S11.084P418 5.60% 0.53%.b 5.05% 0.71% 0.19% 0.02%
0.33% 0.04% 11.17% 1.19% 1.11 0.05 II 1-3
8
S11.08xP-30 6.20% 4.71% 0.21% . 0.35%
1147% 1.32 II . CA
b.)
0
511.084P-14 2.43% 0.40% 837% 1.31% 0.29% 0.06%
0.42% 0.14% 11.71% 1.51% 0.28 0.00 II I.+
-4a,
....
S11.08.0418 2.33% 7.18% _ 0.35% 0.44%
10.30% 0.32 II 0
4a,
Ch
511.084P-34 7.65% 6.56% ____ 0.27% 0.53% ____
15.01% __ 1.17 II cr,
.....___
vp
4a,
$11.016,P-03 :3.86% 10.75% 0.40% 0.65%
15.75% 0.36 II
:::::::::::=::::::::::::::::: : Canrabinclit13(GC-F10)
M M:3:3YEICU:3 1 :::::: =
CLIO ::33333:3:3K:080333:3:3 33333 ::3:3333:3C003 33333:3:3 Cann abs
by GC a THC:C110 by GC
_______________________________________________________________________________
____________________________________ .-2
.
VI
Sa Mph? Wt% " : .,,,,, 1%C:'3i ::?.WtNH H
cµ,%(..1 Wt.% 15%Cl Wt% %%ta: ::%L. GS%C, Chfomstyp*:
VI
SI108.P-37 3.09% 8.34% 0.44% 0.51%
12.37% , 0.37 II ..ii
.i..
-i-
58.08xP-38 4.0% 337% 0.08% , 0.31% ,
8.36% 1.23 II
WHIO4xP-02 2.68% 8.10% 0.31% 0.51%
1160% 0.33 Il
WHI070-07 4.62% _______ 4.11% 0.17% 0.93%
9.2.7% 1.17 II
WHIC37xP-1.1 2.20% 4.62% ---------- 0.15% 0.35% _____
7.32% 0.48 II
WHI070-01 6 14% 5.26% 0.25% 0.47%
1213% 1.17 II
WHI070418 3.27% 3.05% 0.15% 0.37%
622% 1.07 3
W131070-01 2.12% 5.28% 0.22% 0.42%
8.03% 0.40 II
69
YEL03xP-01 6.88% NA 4 3.11% N/A
0.18% N/A 0.59% N/A 10.79% 2.21 II ,, o
=.w
2 YE1.03xP -02 11.11% N/A 0.00% N/A 0.11% N/A
0.12% N/A , 11.34% I
Ca
.
o"
YEL03xP-03 4.54% , NA 4 6.86% NIA 0.24% 1 N/A 1.10%
N/A 12.73% 0.66 II
I
YE1.030-013 10.04% N/A 0.02% N/A 0 i; 2% i N/A
0.41% N/A , 10.81% , 456.18 4 I 6"
ow
YEL030-20 4.13% N/A 4 0.00% N/A
0.12% N/A 0.13% N/A 4.38% I .
YELOIRP-15 3.21% N/A 5.55% N/A 0.21% N/A
1.01% N/A 10.00% 0.58 II
.
1
YEL03x13-26A 3.25% N/A 4 6.13% N/A
0.25% N/A 1.01% N/A 11.15% , 0.61 i II
YE1.03xP-268 10.88% N/A 0.03% N/A 0.36% N/A
0.35% N/A , 11.64% , 350.87
YEL03xP-04 3.02% N/A 4.57% N/A 0.19% N/A
1.07% N/A 8.86% 0.66 II
111.034P-05 2.07% N/A 3.32% N/A 0.19% N/A
0.69% N/A 627% 0.62 II 110
...............................................................................
................... _-...... - n
YEL03xP-06 8.91% N/A 4 0.00% N/A 0.60% ,
N/A 0.17% N/A 9.57% , I 1-3
8
YEL034P47 2.81% N/A 5.46% N/A 0.28% N/A
1.09% N/A 9.64% 0.52 II C/1
L=J
0
wo
YEL03x13-09 3.38% N/A 4 5.20% N/A 0.15% ,
N/A 1.00% N/A 9.74% 0.65 II
0
YE1.03xP-10 3.86% N/A , 6.10% N/A 0.28% N/A
1.30% N/A 11.54% 0.63 , II
cr,
cr,
YEL03xP41 3.66% N/A - 5.32% N/A 0.24% _,..
N/A 1.18% N/A 10.40% 0.69 II 0
4:.
Caorabinoic13 (GC-7l0)
TtIC tea clot. : Cat cant;
abs by t1t: TtIC863 by t.0
C
bJ
=
:
'./1
Sample Wt % 95'4g (.' ;7.0 5 % c.: Wt %
:%6%%1. MO % 4, 4.5% C1 Wt..% ..,1 33 % ti , W114
'3'3'14 t" thersotype 5
VI
*7E103042 _ 5.10% , N/A .02% N/A 0.39% N/A
1.31% 4 N/A 13.81% 0.73 II VI
4-
4-
YE1.030-13 4.91% N/A 6.06% N/A 0.40% N/A
1.20% N/A 12.58% 0.81 8
- --4 -
*7E1030-15 2.61% N/A 3.96% N/A 0.23% N/A
0.79% N/A 7.58% 0.66 II
YE1.030-16 , 3.60% N/A 504% N/A 0.29% N/A 1
1 1% 4, N/A 9.93% 0.69 8
-
4
*7E1030-17 13.26% N/A 0.00% N/A 0.93% N/A
0.51% N/A 14.72%- I
YE1.03x17-18 , 12.20% N/A , 0.00% . N/A
0.33% N/A 0.28% . N/A _ 12.83% .4 I
..
YEL03xP-19 4.80% N/A 5.84% N/A . 0.36% ,.
N/A 1.33% N/A . 12.33% , 0.82 II
YEL03x1)-21 , 3.75% N/A _ 4.56% . N/A
0.24% N/A 0.97%+ N/A ... 9.53% ..1, .4 0.82 8
2
YE1.030-22 1.34% N/A 0.00% N/A . 0.11% ,.
N/A 0.09% N/A 1:54% I I to
.
ot
,--.
4- YEL03117-24 3.47% N/A 0.00% N/A 0.51% N/A
0.27% .. N/A 9.27% I . 4.1-
co
4-
''.1.
, YE1.030-27 8.43% N/A 0.00%
N/A 0.55% N/A 0.39% N/A . 9.40% I r....
.
I
YEL03117-28 9.94% N/A 0.00% WA 0.61% N/A
0.44% .. N/A 11.03% I 6"
I
111.030-29 11.41% N/A 0.00% N/A 0.25% N/A
0.13% N/A , 11.79% I C
YEL03x1,-30 5.37% N/A 0.00% N/A 0.61% N/A
0.18% .. N/A 10.16% I .
VE1.03043 3.52% 0.51% 6.70% 1.38% 0.24% 0.05%
0.50% 0.06% 10.97% 1.78% 0.53 0.03 II
YEL03117-26 2.99% 0.35% 7.23% 1.04% 0.25% 0.02%
0.59% _ 0.06% 11.06% 1.32% , 0.41 0.01 II
WHIOIKP-22 . 2.60%._ ............ 5.20% 0.23% 0.55%
9.58% 0.42 õ
WHIO1xP-12 3.94% 7.67% 0.16% 0.62%
12.39% 0.51 II ma
(-5
WHI03.1(P-14 3.48% 5.09% 0.23% 0.53%
10.34% 0.57 II 1-3
8
WHIOIxP-19 3.89% 5.78% 0.18% 0.59%
11.44% 0.57 II CA
-, 04
WHI010-23 1.48% 4.63% 0.09% 0.35% 6.56%
.4 0.32 II
- . =
4t
CBDO2xP45 2.29% 5.75% 0.25% 0.65% 8.96%
0.40 :I 2
0,
0,
----------- C8002.0-16A 2.93% 9.63% 0.33% 9.8% 13.72%
0.30 II VZ
A
Caorabino1313(GC-FI0)
:::::::::::::::::::::::::::::
!!!!!!!!!!!!!! Pil.C!M! U!!!!' cep :ff M=46..4 Mmg.gc
:: ::: Cannabs by Gt: ::::::::::Tf=lt:40,0!ii.i31c
0
kM:.:::
nJ
=
EEHHEEHHER ffiNg IgH HHERõ,:,:: : a EHHHE
SHEHE HHEBH Ogg:: Li'
::7:49t?":6: : 9V,K (.' _.t :::11`;:t:%:::::: :: 91 %
c.::::::: :::::::WVN::::::: :.:?.!il:t: : ::Vir::::
CODWAP-17 1.41% 0.34% 4.83% 0 12% 0.20% 0.05%
0 VI.31% 011% 621% 0 62% 0.29 0.06 II VI
A
A
C80020410 2.62% 7.07% 0.30% 0.55%
10.54% 0.17 , II .
CEID02.041 2.39% --- 7.11% 0.42% 0.50%
10.42% 0.34 II
C80020414 1.83% 6.40% 0.13% 0.44% 9.00%
0.29 II
C13002048 2.48% 6.42% 0.15% 0.55% 9.61%
0.39 II
i
C8002xP-31 1.79% --- 4.63% 0.16% 0.38% 7.02%
0.38 II
C8002.0-05 1.56% 0.31.6 = 5.80% 1.94%
0.28% 63.16% 0.40% 0.07% 8.0416 71i7).5 0.27 0.04 II
C18002xP-30 1.53% 5.00% 0.25% 0.44% 7.26%
0.32 .......... II
------------------------------- cr-
2
C130024432 2.14% 0.11% 4.67% 0.52% 0.15% 0.06%
0.40% 0.13% 7.35% 0.57% 0.46 0.03 II co
6.1-
.., CBDO2xP-40 1.86% 3.85% 0.23% 0.37% 6.31%
0.48 Il 6-
co
3/3
C8002043 1.64% 3.47% 0.16% 0.32% 559%
0.47 II tit
-4
61;
I
C8002.44-09 1.93% 7.15% 0.36% 0.46%...µ 9.90%
0.27 il
-------------------------------------------------------------------------------
------------------- ---4 __ . 6-
C80020-28
2.06% 0.74% 630% 1.82% 0.19% 0.14% 0.40% 0.21% __9.15% 2.91% 0.32
703 II CI
C8002xP .47 1,57% 6.15% 0.15% 0.50% 8.67%
0.30 II
C80030-03 2.12% 5.39%
i. 0.39% 7.90%
0.39 II
C81003xP-05 1.35% 3.90% 0.14% 0.30% 6.69%
0.35 II
C1310030-09 1.66% 4.63% 0.31% 0.29% 6.90%
0.36 II
_
C8001xP-02 2.29% 3.86% 0.13% 0.30% 6.57%
0.59 II ma
(-5
C80040403 3.36% S.0% 0.22% 0.32% 9.21%
0.63 II 1-3
8
113004xP-06 2.46% 0.24% 4.33% 0.11% 0.12% 0.03%
0.29% 0.06% 1.60% 01 Ph 0.52 0.06 II C/1
- . - ,
- -
.
Oba
C80054402 1.14% 0.44% 3.34% 0.37% 0.16% 0.05%
0.24% 0.13% 427% 0.98% 0.34 0.09 :1
0
C80C15x13-05 1.57% 0.20% 4.87% 0.05% 0.32% 0.09%
0.31% 0.12% 7.23% 0.03% 0.32 0.04 II A
---4
0
0
CBDOSxP-09 1.65% 358% 0.10% 0.40% 5.73%
0.46 II 0
A
CBDOSxP-OS 127% 0.569. 5.13% 0.31% 0.11% 0.06%
0.35% 0.06% 7.16% 0.38% 0.31 0.13 II
. . -
1/)
==1.
=I=
II 5.5008D
P0 5:70 96E C*0 %0V9 %Or0 1613f-0
9600'0 30 0 343E' C. %T.: 17 %50 0 %All
aldwkS
"Alsma1/43 %SI, 14% S6 90,16 0%56. ,%"'1%
13 '11'56 %Mk - µ" /00,
f`J
0
''AqQ.1173"4. " 74"
al 1.11
(s3t1-.3.1) 4110u!qc,lut.3
Table 27- Carmabinoid measurement by FIPI.,C for THC:CBD and CBD (chemotype II
and III) specialty cannabis varieties. Blank
values indicate undetectable levels or 0.
c
N
I
=
....................................................... Canna010P10.4 t.014PL4
:::::::::::: 'JI
...... : : : ,:
-. --,
THCA CIIMV ::::C.1318;k:g; :::::;.1430
:::: gtfiCt C8G . Cann.ai.1C. by HPLC T NC 11.:C8DA fay
H PLC .5
Vi
Vi
4.
4.
:9. %(: 'OP. % .*!:, 0(I Wt % I q`i% C: WI N CS %Xi
:::::::::R*16::::::: :::::::::::::::::::::45:%C3:::::::::::::::::::
oCisismotypit
... r
WHIO1xF.-1S 0.14% 7.33% 0.06% 0.03% 0.53%
8.10% 0.02 18
:
CBDO2xP .11 0.27% 0.12% 14.83% 0.28% 0.18%
0.02% 0.01% 0.03% 0.15% 0.08% 0.06% 0.05% 15.51% 0.55% 0.02
0.01 111
....
C8D03x1)-01 0.18% 0.07% 7.90% 2.35% 0.09% 0.06% 0.02% 0.00% 0.10%
0.02% 8.29% 2.50% 0.02 0.00 111
p.--.
C80030-10 17.20%
1220% III
C13003xP477 , 0.19% 9.29% 0.79% 0.15% 0.08%
9.50% 0.39% 0.02 18
(8004x1L01 0.24% 0.08% 13.37% 4.30% 0.22% 0.06% 0.02% 0.00% 0.11%
0.08% 0.05% 13.99% 4.15% 0.02 18 . 2
tt,
1: C8004xP-09 0.77% 12.00% 0.27% 0.00% 0.06%
0.06% 12.70% 0.02 10 O
co
---1
C8005xP.01
0.36% 0.12% 18.31% 3.37% 0.32% 0.15% 0.33% 0.61% 0.24% 0.11% 0.11%
0.10% 19.68% 3.48% 0.02 0.01 18 . o"
O
I
010050 .13 0.29% 0.09% 12.78%
5.50% 0.40% 0.24% 0.20% 0.22% 0.13% 0.09% 0.03% 0.01% , 13.83% _
5.77% 0.02 _ 0.02 111 O
. PUR01xP-06 2.35% 6.29% 0.19% 0.09% 0.08%
0.03% 9.03% 0.37 : : O
PUR01xP-04 3.29% 1.07% 10.39%
5.43% 0.21% 0.09% 0.07% 0.03% 0.05% 0.01% , 0.08% 0.01% 14.09% 6.57%
0.33 0.07
PUROIxP-10 1.76% 6.17% 0.26% 0.02% 0.05%
8.26% 0.28 11
PUR0IxP-05 2.01% 3.63% 0.10% 0.08%
5.81% 1 0.55 11 ,
%06P01 2.93% 914% 0.30% 0.04% 0.C4.24
12.55% i 0.32
51108.0 -08 7.94% 0.60% 8.40% 2.93% 0.48%
0.37% 0.20% 0.30% 0.05% 0.03% 17.06% 342% 0.97 C. 27
:: V
(-5
SIL08x11-30 6.21% 617% 0.26% 0.25% 0.06% 0.08%
8 1.5.65% _ 1.21 , = =
= . 3
_
_
w
51E08xP-14
:3.38% 0.35% 14.12% 4.73% 0.42% 0.05% 0.07% 0.01% 0.07% 0.02% 0.06%
0.04% 18.13% 5.02% 0.24 C..06 11 b.)
0
I.+
511.08xP-18 3.28% 10.58% 0.48% 0.12% 0.09% 0.05%
14.65% 0.31 11
....
0
4:.
511.08xP-34 00.49% 9.58% 0.27% 026% 0.07% 0.16%
20.91% I 1.09 11 ON
-
1
cr,
I
vs,
SIL080-03 5.38% 15.95% 0.68% 0.05% 0.06% 0.08%
22.21% i 0.34 !I
-
Mk::::::::::::::::::: ::::::::::::::::::::::6ea4:::::::::::::::::::::
:::::::::: CIRIA :::::::::::1*::::::::::::::::::::
::::::::::::::::::::M::::::::::::::::::: ::::::::::::::::::::00:::::::::::::
ttinnaig.tsy NPIC THCA.C.BOA by 1-13,IC
C
1 ----------------------------------------------------------------------------
-------------------------------------
N
=
Mg MHUH MUM MUM MHHF:...
VI
::::::W:::::::::,%2 :00 .715:,4S0.: %it% 05% 01
Wti:.14: lt5:36:47: :.:0:N.5/1:: :X*540:1:: :::.:Nt5i. 05% Ci 00t %
'35 % Ci :::::::R00:::::::
_ 511.084P-37 4.37% 12.36% 0.56% 0.04% 0.05%
0.09% __ 17.45% 0.35 VI
I
VI
I 4-
4-
511.080-38 _ 6.39% 4.55% , 0.10% . 0.11% 0.04%
11.18% 1.40 '
.. .
- 1
1
I
WHI04oP-02 3.91% 12.23% 0.41% 0.02% 0.05% 0.08%
16.71% 0.32 .. --..---
WHI07xP-07 6.66% 6.43% 0.22% _ 0.10% _ 0.03% _
0.04% 13.58% _ 1 03 = . .
5.101107xP-11 334% 8.05% 0.20% 0.0/34 0.05% , _
0.04% 11.77% 0.47 0 ,
WH10704:11 8.95% 3.73% 0.35% 0.05% 0.10%
13.14% 2.42 il
tfiA00730.418 5.12% 4.73% 0.19% 0.02% 0.05%
10.06% 1.09 il _
WHI070-02 3.22% 8.46% 0.33% 0.09% 0.06% , 0.03%
12.20% 034 II .
-
ro
to
YEL03xP-01 10.68% 0.04% 5.74% 0.17%
0.13% 0.08% 0.48% 0.10% 0.02% 16.85% 1.86 II ,,
=.w
-
.141'
00 YEL03xP-02 16.92% N/A 0.03% N/A 0.09% N/A 1.08% N/A 0.00% N/A
0.04% N/A 18.13% N/A %/A I et
ow
YEI.133xP-03 6.98% N/A 1194% N/A 0.29% N/A+
0.33% N/A 0.24% N/A 0.04% N/A 19.82% N/A 0.S8
N/A 0 I
ow
111030.08 _ 15.53% N/A ... 0.00% _ NIA 0.42%
NjA, ,. %39% , %/A _ 0.00% , %/A 0.09% N/A 16.43% N/A _ NIA
.......... YE1.03xP-20 6.69% N/A 0.00% _ N/A 0.22% N/A
i 112% N/A 0.00% N/A 0.00% N/A 7.03% N/A WA
YE1.03xP-25 5.12% N/A 9.92% N/A 0.30% WA ic
122% %/A 0.16% .. N/A 0.01% N/A _ 15.73% N/A _ 0.52 _
N/A
YEI.03xP-26A 5.93% N/A 10.74% NIA 0.34% %/A _l_
3.18% N/A 0.15% N/A 0.02% N/A _ 17.36% N/A _ 0.55 _
N/A
11103xP=260 _ 16.99% N/A , 0.03% N/A ., 0.57%
N/A _________ 3.57% , N/A , 0.00% , N/A 0.09% N/A , 18.22% N/A _
N/A
,.._.,
.
1
YEL03x1%04 4.93% NIA_ 824% N/A 0.11% %/A i
3.00% N/A 0.21% N/A 0.00% N/A 14.09% %/A 0.56 N/A
(-5
.......... YEL03xP-05 _ 3.19% N/A 6.04% N/A 0.06% N/P 4
u.00% N/A 0.16% N/A 0.00% N/A 9.46% N/A 0.53
NA ,, 1-3
8
YE1.03xP-06 , 14.26% ,._ N/A _ 0.04% _ NIA 0.35%
..r NjA 0, s.oc96%/A 0.02% NIA 0.00% NA 14.66% N/A
356.55 , N/A =
_ .. _ CA
.
N
0
YE1.030,07 . 4.43% N/A _. 10.17% _ NIA _ 0.08% N/A
i 100% N/A _ 0.24% , N/A 0.00% N/A , 14.92% ,.. NIA _ 0.44 1
14/A = '
.
1.4
44
0
YE1.03xP-09 5.03% N/A 9.46% N/A 0.02% WA_t__
100% %/A 0.23% N/A 0.00% N/A 14.74% NIA 0.53 N/A
0 44
cr,
cr,
YE403xP-10 6.05% WA 11.32% %/A 0.15% %/A 1
3.00% N/A 0.20% N/A _ 0.00% N/A 17.72% N/A 0.53
N/A II 0
44
The..iii ::: ::::: :::::::::::t SW ::::::::::::::::::
:::::: CIRIA ::0:1NC:M:: ::::11,,iik :13,0e :::
C.Rnnaig.ksy MM. THCA.C.BOA by 1-0,IC
C
=
ag aHMH REHE a HF:...
'JI
;I:I;;;I:I;I:I;I:100744C; ; : ;
;;I:I;I:W.t%I.;;I;;I:15;I,Ki; ;I:I:I:I:Wilk ;I;;I;I I95%(1: Vv't % '35%
CI Wti:%:::: AS14:0: EWM.:: :: ,.1:5 St i ttlt% .;.'; % Ci Wt
VI
YEI.03xP-11 5.75% N/A 9.95% N/A 0.10% N/A 0.00% N/A 0.22% N/A 100% N/A 16.02%
N/A 0.58 WA V:
4-
4-
YEL03x0-12 8.07% , N/A 12.98% N/A 0.26% N/A 0.00%
N/A 0.13% N/A 0.00% N/A , 21.44% N/A 0.62 N/A .
YEL03xP43 7.94% N/A 1165% N/A 0.22% N/A 0.00%
N/A 0.11% . NIA 100s N A 19.92% N A 0.68 N 'A ----
YEL03xP-33 4.07% , N/A 7.10% N/A 0.03% N/A 0.00%
N/A 0.23% N/A 0.00% N/A r 11.48% _., N/A _
0.57 _. NIA .
YE103xP -16 5.48% , N/A 8.99% N/A 0.13% NjA ..:6.00s
%/A 0.37% N/A 0.00% N/A 14.96% N/A _ 0.61 NIA
YE1.03xP -17 20.14% N/A 0.09% N/A 0.31% N/A 3.00%
N/A 0.00% N/A 0.00% N/A 20.54% NIA 221.34 WA
YEI.03xP-18 18.59% N/A 0.(N% N/A 0.16% N/A 3.00% N/A 0.00% N/A 0.00% N/A
18.79% N/A 502.38 N/A =
=
i
YEt03xP-19 , 7.61% N/A 10.85% N/A 0.24% N/A1
0.0C% N/A .. 0.15% N/A 0.00% N/A 18.84% N/A
0.70 N/A II 2
.
YEL03x0-21 5.88% N/A 8.41% N/A 0.20% N/Aii, .
3.00% N/A 0.18% N/A 0.00% : N/A 14.68% N/A 0.70 N/A
oliol t
I
oil
0 EY =1.03xP-22 11.43% N/A 0.03% N/A 0.03%
N/P : Z..00% N/A 0.00% N/A 0.00% N/A 11.49% N/A
439.62 N/A .. : .
o
tit
ow
YEE:COUP-24 13.19% N/A 0.04% N/A 0.11% WA 4
::.00% N/A 0.00% N/A 0.00% N/A 13.34%
N/A 299.86 N/A =
ow
YE1.03xP-2? 12.0(1% , N/A 0.03% NIA 0.11% NjA t
..:600s %/A 0.00% N/A 0.00% N/A 13.03% . N/A _
415.97 NIA . . ow
YE1.03xP-28 15.33% N/A 0.04% N/A 0.20% N/A i 100%
N/A 0.00% N/A 0.00% : N/A 15.57% NIA 414.43 WA
YE1.03xP-29 17.85% N/A 0.05% N/A 0.17% WA i
3.00% NIA 0.00% N/A 0.00% ' N/A 18.07% WA 379.70 N/A
-
YEt03xP-30 14.70% N/A 0.08% NIA 0.10% N/A 1
3.00% N/A .. 0.00% N/A 0.00% N/A 14.88% N/A 181.42 N/A
=
YEt03xP-31 5.47% N/A 10.30% N/A 0.11% N/A 4,
3.00% N/A 0.00% N/A 0.00% N/A 15.88% N/A 0.53 N/A
= = .
YEL03x0-23 5.04% 0.89% 11.25% 4.39% 0.46% 0.01% 0.04% 0.01% 0.04%
0.05% 0.00% 16.84% 5.33% 0.46 0.10 No
(-5
YEL03xP-26 4.93% 0.69% 12.44% 5.33% 0.22% 1-'4
0.09% 0.03% 0.07% c , = ' ' alms 0.00% 17.20% 5.73%
0.36 0.10
5.101101xP-22 4.20% 10.44% 0.34% i:=.15% 0.10% 0.04%
15.28% 0.40 .. 8
ct,
. .
=
WHIOIxP42 5.08% 11.58% 0.29% 3.04% 0.32% 0.05%
17.38% 0.44
44
0
W11101xP-14 3.6496 8.4596 0.33% 1.06% 0.58% 0.08%
14.1994 0.43 0 44
cr,
cr,
WHIOIxP -19 5.12% 10.41% 0.28% 345% 0.21% 0.04%
16.51% 0.49 II VZ
44
i:EHEMEH:HE:::MH:H:MEH:HEETH: Catinabir451.9 0.04PLCI ,
:::,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,...,,,,,,,,,,õõ
114c.4:::::::::::::::xgo:.wn CMIA
:::::::::::1K:::::::::::::::::::: ::::::::::::::::::::04:::::::::::::::::::
::::::::::::::::::::04::::::::::::: ttintasig. Isy 49PIC THCA.C.BOA by
ili'IC
C
=
VI
3:::::a:IgOffiltikC:::::: ::a9.41:*:::::9AiNCI: 1...=.:AIVIIF:::::H.95,CCi:
iSt5i. ';;.c:i Wti:.%::::::::9,5.16:0::Mt:W .1.55¶:1 iNt% 1 ?
.i./.;Ci %Sit% '35 %Ci
!
5
VI
WHIOIxP -23 , 2.67% 8.46% 0.17% 0.12% 0.09%
11.50% 0.32 VI
4-
4-
CBC352x17.15 3.60% 9.63% ..__ .2.24% 0.06% 0.06%
0.09% 13.68% 0.37
:
C8002.0-16A 4.73% 15.65% 0.33% 0.06% 0.08% 0.11%
20.96% 0.30 _____ --..
C8002xP-17 2.19% 0.57% 8.91% 0.19% 0.23% 0.06%
0.06% 0.06% 0.06% 0.05% 0.09% ..... 11.50% 0.91% 0.25
CB002xP-19 3.91% 11.79% 0.38% 0.1935 0.14% 0.11%
1636% 0.33 0 ,
C80020.12 3.59% 12.96% 0.36% 0.13% 0.13% 0.26%
17.48% 0.28 II
03002x9-14 2.82% 11.68% 0.46% 0.13% 0.13% 0.08%
15.35% 0.24 il .
C8062,iP-18 3.35% 10.26% 0.18% 0.30% 0.25% 0.05%
14.43% 0.33 II . 59
u,
CBDO2xP-31 2.24% 8.74% 0.22% 0.11% 0.12% 0.03%
11.49% 0.26 II ,, 5.1-
5/ol'
0 C8002AP-05 2.43% 0.31% , 10.51% , 3.02% 0.43%
0.38% 0.80% 1.44% 0.09% , 0.01% 0.03% 0.01% 14.29% 5.13%
0.23 0.04 il . o"
ow
5:8002KP-30 3.82% 13 70% 02% u16% 0.14% ctoass
18.17% 02i 8 =
ow
53002A7-32 3.05% 0.18%
8.29% 0.50% 0.26% 0.11% 0.10% 0.02% 0.07% 0.03% , 0.03% 11.79% 0.40%
0.37 0.04 0 ow
C8002xP410 2.44% 7.03% 0.29% '109% 0.07% 0.04%
10.02% 0.34
C81902x1LS3 2.08% 6.73% 0.16% 1.13% 0.13% 0.07%
9.26% 0.31
C13002xP-09 2.97% 11.37% 0.50% 1.11% 0.13% 0.05%
15.14% 0.26 if
CBDO2k5,28 2.58% 1.77% 11.01% 2.27% 0.34%
0.18% 1.21% 0.09% 0.15% 0.10% 0.05% 14.35% 431% 0.23 0.11
= =
, CBD025P 47 2.81% 10.21% . 0.32% .1.15% 0.16%
0.03% 13.72% _. 0.28
(-5
C8003xP,03 2.54% 7.83% O.23% j.09% 0.09%
10.90% 1 0.34
8
03003xP-05 1.99% 5.93%
7.98% 0.33 ,
..
WI
,
l=J
0
CF3003xP-09 2.40% 6.63%,
9.02% 0.36 = '
.
1.4
4:.
CBDO4xP-02 2.7296 5.43% 0.93% '1.15% 0.08%
9.32% 0.50 il 44
03
CA
03004xP-03 4.70% 7.55% 0A0% 1.13%
12.79% 0.62 11 VZ
4:.
_________________________________________ CaenablaaMS
CIY8A
Ce11118 lsy I3 .0 73iCA.C.BOA iyI3 IC
MHEE ann PHHE
Sample :AA% % %
C8D04P-06 3.54% 0.09% 7.76% 1.88% 0.22% 0.06% 0.05% 0.04% 0.04%
0.03% 11.60% 1.73% 0.46 0.12
CBDOSAP 1.42% ..9.5991. 6.13% 0.90% 0.24% 0.01% 0.05% 0.04% 0.07%
0.05% 0.03% 7.92% 1.64% 0.23 0.06
CBD05x P.05 2.01% 0.93% 8.85% 0.12% 0.35% 0.01%
0.48% 0.73% 0.07% 0.04% 0.13% 0.05% 11.89% 0.16% 0.23
C. 11
CBDO5NP=09 2.74% 6.81% 0.13% 0.11% 0.09% 0.04%
9.93% _ 0.40
CESEX/SaP-05 2.06% 1.34% 8.78%
1.24% 0.16% 0.10% 0.10% N01*8% 0.09% 0.06% 0.02% 11.24% 0.44% 0.24
0.19
CBDO5a5-11 2.11% 0.55% 7.63% 1.56% 0.13% 0.06%
0.13% 0.03% 0.12% aic9c 10.12% 2.05% _ 0.28 0.02
7,
I.
(-5
1-3
8
4
4
0
4
Table 28- Absolute terpene measurements by GC-FID for THC:CBD and CBD
(chemotype II and III) specialty cannabis varieties.
Blank values indicate undetectable levels or 0. Some zero values are indicated
by "0.000%."
..
0
TerpenesiGC-FiD)
h...)
C:
tropinale
::,t:,:,:,.=:i,: n .r3nPe17 Lseta e gatlmkma n! pila
arplpfla beta ail arbeta
"e!,""re "ter limonne it
õAnthoi,,ph, caphyl inalaol y oxide myrrene ntfe
d
ocintene terene pinen tenere pinene
uvineolmulene %V..I.
4 , r
I
ime
'ttrr--
.
...i.,'
VI
1:.:... ::
...t1
4
_.._M
.
Wt 2514 :Wt: !# S A.Vt: r4:%. ::WK: PS '1i Vft
% Vill:P.a % t''' `-'5 % ::$.1 0:5.*
:.:0&: '13% Wt 95% :VCi1::: :9. . :!`4:.: P$...% k.i?;t: 0.$1.4 ::::ft: ay>
wt 19s s v.t::: o.:s iwt oN:mc:o$:% at011iot 4.
Sample % CI tIC :CF: :.3C::CE :?3.C: CI %.:11:<":
56::.=:::.:1:7:1 % CH: .?:*.:.: .:.:m .16 C % Ci.:
WHIO1xP 0.13 0.01 7.1.C.2. 1.01
0.02 0.04 0 04 01)2 0.76 111
-15 6% , 1% 4% 6% 5% 5%
5% 7% 8% 7% ill ,
CBD02:0- 0.12002 0140.05 0.07 0.02 0.01 0.(XI
0.02 0.00 0.04 0.00 0.16 OM 0.02 0.00 0.93 0.16 1.55 0.27
11 0%4% 6%i% 4% 2% 1% 0% 9% 3% 4%
4% 6% 0% 6% 2% g% 4% 4% 8% ill
,
CI3D034P. 0.05 0.00 0.1.5 0.02 0.06
0.01 0.00 0.00 0.00 0.01 0.00 0.02 0.00 0.63 0.13 0.96 0.17
01 7% 5% 8% 9% 7% 0% 9% 8% 0%
9% 1% 0% 1% 0% 5% 2% 1% ill
CI30030- 0.07 0.17 0.07 0.01
0.75 1.08
4% , 1% 6% 1% 4% 6% ill
CBDO3xP- 0.10001 0080.02 0.20000 0.05 0.00 0.01 0.00
0.02 0.05 0.00 0.0 0.01 0.03 0.00 0.30 0.10 0.95 0.18
07 0%2% 9%5% 3%0% 3% 3% 0% 3% 2% 1%
2% 5%, 7% 0% 3% 7% 5% 1% 0% 111 ,
. ..
CBDO4xP- 0.13 0.03 0.09001 0250.0? 0.07000
0.05 0.00 0.03 0.00 0.08 0.00 0.05 0.01 0.62 0.09 1.41 0.10
o
01 8% 1% 4% 4% 3% 0% 5% 5% 7% 7% 0%
0% 6% 1% 1% 1% 8% 4% 0% 7% III co"
CBD040- 0.19 0.01 0.02 0.01 0.02
0.18 0.06 0.06 053
1-,
71 09 7% 2% 2% 7% 4%
4% 8% 0% 4% 111 1-
co
co
tc..7 CBD05sP- 0.23000 0260.11 0.13 0.04 0.02 0.00
0.06 0.00 0.05 0.01 0.15 0.02 0.06 0.00 1.48 0.26 2 49 0.06
01 9% 5% 7% 1% 5% 1% 0% 4% 4% 8% 9%
9% 6% 1% 8% 4%. 4% 3% 0% 7% !II o
1-.
. ,
. ul
CBDO5xP- 0.12 OM 0.11 0.00 0.26 0.06 0.08 0.02
0.01 0.00 0.02 0.00 0.11 0.00 0.08 0.15 0.05 0.00 0.38 0.13 1.26 0.41
0
1.
13 , 8%7% 2% , 8% , 6%4% 1% 2% 3% 1%
2% 1% 5% 2% 6% 1.56 8% 8% , 4% 6% 3% 6% ill 0
PUR01xP- 0.12 0.10 0.05 0.03. 0.02
0.05 0.22 0.04 0.86 1.50 w
o
06 6%, 4% 7% 3% 0% 7%
, 8% 1% 2% 8% p
.
.
PUR01xP- 0.10001 0560.02 0.08001 0.08 0.00 0.04 0.00
0.01 0.00 0.04 0.00 0.08 0.02 0.26 0.08 0.07 0.00 0.16 0.00 1.54 , C 1:
04 3% 8% 9% 0% 7% 2% 7% 5% 4% 6% 0% 0% 9% 1%
3% 5% 5% 5% 9% 1% 8%,5%. 2%j
PUR01xP- 0.06 0.33 0.05 0.05 0.02 0.03 0.03
0.14- -0.03- -0.09 0.88
10 8% I 8% . 2% 6% 0% 9%
3% 9% 6% 4%
PLIFt01xP- 0.11 0.27 0.02 0.03 0.02 0.02
0.06 0.22 004 0.18 1.01
os _ 3% 6% 2%.. 4% 3% 8% 7%
3% 7% 2% 5% =
.. . . .
. . .
50.08xP- 0.19 0.01 0.02 0.01 0.02
0.09 0.37 0.07 0.14 0.971
01 4% 3% 6% 5% 3% 8%
9% 9% 5% 2% 0
SIL08.0- 0.20 0.01. 0.01. 0.00 0.02 0.00
0.01 0.00 0.02 0.00 0.13 0.03 0.40 0.11 0.05 0.(30 0.07 0.00 0.95 0.13
110
40 8% 2% 3% 3% 7% 5% 7% 3% 3% 1% 9%
8% 2% 3% 5% 3% 0% 4% 1% 4% 3 . n
511.080- 0.17 0.20 0.10 0.01 0.02
0.03 0.09 004 0.98 1.68 ......lq
30. . 7% 3% 8% 8% . 5% 0%
6% 2% 4% . 3%
.
C/1
5I109xP- 0.14005 0110.00 0.40020 0.10 0.04 0.01
0.02 0.00 0.04 0.01 0.15 0.C3 0.06 0.01 0.70 0.08 1.76 0.45
k4
14 2% 0% 1% 8% 0% 6% 9% 6% 0% 1% 2% 7%
0% 8% 7% 7% 7% 6% 5% 4% 1% P 0
=I
511.08xP- 0.12 0.11 0.33 0.09 0.01 0.01
0.03 0.11 0.04 0.50 1.38 4a.
.......,
18 1% 0% 8% 3% 0% 9% 5%
6% 4% 3% 9% h 0
4a.
5Ø08xP. 0.16 0.20 i 0.49 0.14 0.01
0.02 0.05 0.13 0.08 0.83 2.15 ON
34 2% 0%
I 9% 0% 7% 5% 7%
7% 7% 2% 6% l: 01
44
SILD8xP- 0.04 0.41 0.02 0.05 0.02 0.03
0.06 0.24 0.13 0.14 1.20
03 6% 7% 7% 2% 6% 8% 9% 7%
2% 7% 1% ::
ler ptaw., i0C-(:10)
a lptn =
ben 'WM
terpittolonõ.. . Lvta .. gmrstria alpha alptspl betA
i ,. . . a lpto alpha
e p0.1rikare eelmeee ca terse lurenene teepa,eee pineee
terpineõ oneee ! ennos camphene ,temineel tumweee caryraphyll 3rsalool can/
oxide myrrene ide.nt.illeti C
Ile :=:=::= = : .:::.
0 ,.... .
. ..............
.=::: :::::::::::..
.=
.= .:::::::::::: ::::::::::: :::::::::=. .,.: ::::::i=:::.,. .: .:.
,= K:::: ::. =:==::K: K:: :=:=:=:=:=:: :=K::: K=:.
.:=:::: ::: =::::::: K :::::= :. VI
-......
.. 15H111
Wt 95% !1*.:= 0.5 '" ". ''''.:4=:=. ::=..:4=.=::.=. ::J.=::*.::=
Hi11Ø=*.= .:*.J1:::104'..* ..... *..3.% V''' 95% `!,... 't
35=$.=:4i.:t=:.;=. :..µ=^=4*.:.: ..1'1.= 95 X: 'M.::: .05*....:. .j..*:.
AH;.:...*:: ..:.(Nt:.:.::.:-."$:...%.'N.:4.,..c. 0..5.*=-A*..........i::4*: %4
:..5 X Cher.,ot
?...=v,
::.0i:.:. .:.:%.:.: .:.:V:.::.: ::.96.: ::Cl:: :.:16::::: I ::0::::::
:..1V.4::0F.: ::::==%:::ti `.:4 :: ::::=Cr ::µ',C:: ::0: :E:%: ::X!:::::
::1C: C1:: ::%:: .C::: ::,%: ===la:: :* C.: "4 ype VI
I 0...03 i.)5.0,62 .
VI
58.08xP= 0.70 0 01 0.03
0.09 0 24 0 C:,3: 0.13 0 96 .1..
37 , 9% , 9% , 9% 5% 1%
7% 4% 2% 5% _ 1% : .1..
,
,
SIL080- 0.28 I 0.02 0.04 0.02 0.03
0.07 0.17 0.10 0.32 1.07
1
38 7% I 0% '94 1%
2% 6% 2% 3% 5% :
_ = - . - ,....
- _
WHI04xP 0.25 0.01 0.03 0.02 I
0.03 0.05 0.19 0.12 0.05 0.78
:
-02 8% 7% 2% 2% 1%
4% 4% 2% 0% 0%
+
WHI07zP 0.17 0.18 1 0.28 009 0.01 1
0.02 0.05 0.14 0.03 0.54 1.53
.07 6% 2%, =
. 6% 1% 6% 1% 0% , 5% 0% , 0% 7% i=
WHI070 0.10 0.08 0.20 0.06 0.01 0.02
0.08 0.04 0.63 1.25
-111% , 7% 4% 7% , 1% 6%
4% 6% 6% , 8%
.
.
WI1I07xP 0.38 0.02 0.04 0.02 0.03
0.03 012 003 0.28 1.05
-01 6% 5% 9% 8% 3%
7% 5% 5% 9% 7% :
WHI0.70 0.18 0.01 0.02 0.01 0.02
0.06 0.23 003 0.05 0.64
-08 8% 1% 2% 2% 3%
4% 6% 3% 9% 8% '
i - 0
WH I07xP 0.04 0.20 0.13 0.07 0.02 0.02
0.05 0.14 003 0.86 1.61 14
V
-02 2% 8% 9% 5%= 0% 9%
6% 2% 7% 7% 5%
1-.
7
.. . -.. -.. . .
1 YEL03 - xP- 0.07 0.13 0.06 0.02
0.06 0.04 0.00 0.29 0.71 Cn
co
r.... 01 N/A N/A N/A N/A 0% N/A I WA 9% N/A N/A 7% N/A
N/A N/A N/A 8% N/A 2% N/A 6% N/A 0% N/A 7% N/A %
NIA I;
h.)
Y63.03xP- 0.00 0.00 0.15 0.00 0.16 0.00 0.61 0.00
0.18 0.02 0.00 0.00 0.04 0.05 0.13 0.00
0.63. 1.99 o
1-=
02 0% NIA 0% N/A 6% N/A 0% WA 6% N/A 0% , N/A 6% N/A 0% N/A 316 N/A
6% WA 0% N/A 096 WA 2% N/A 0% N/A 2% N/A 0% N/A, 4% N/A % WA I u.
I
1-=
YEL03xP- 0.00 0.00 0.15 0.00 0.14 'P0 0.22 0.00 0.07
0.00 0.00 0.00 007 0.12 0.06 0.00 0.39
1.26 o
03 0% WA 0% N/A 996 N/A 0% N/A 6% N/A 0% N/A 1% N/A 0% N/A 7% N/A
0.34 N/A 0% N/A 0% N/A 2% N/A 1% N/A 3% N/A 0% N/A 6% N/A % N/A II to
o
VEL030- 0.00 0.00 0.12 0.00 0.11 0.19 0.00 0.06
0.00 0.00 0.00 -- 0.05 -- 0.13 -- 0.07 -- 0.00 -- 0.29 -- 1.05
011 0% N/A 0% N/A 6% N/A 0% N/A 3% N/A 0%
5% N/A 0% N/A 9% N/A 0% N/A 0% N/A 0% N/A 1% N/A 0%
N/A 3% N/A 0% N/A 7% N/A % N/A :
YB.030- COO 0.00 0.00 0.00 0.14 COO 0.05 0.00 0.03
0.00 0.00 0.00 0.05 0.09 0.00 0.00 0.04 0.42
20 0% WA 0% N/A 096 N/A 0% N/A 8% , WA 096 N/A 4% WA 0% N/A 2% N/A
0% N/A 0% N/A 0% N/A 0% N/A 156 N/A. 0% WA 0% N/A 1% N/A % N/A ! .,
YEIL.3xP- 0.24 0.00 0.08 0.00 0.06 0.001 0.02 0.00
0.04 0.00 0.00 0.00 0.03 0.08 003 0.00 0.10
0.72
25 2% N/A 0% N/A 2% N/A 0% WA 0% N/A 0% 1 N/A 9% NIA 0% N/A 5% N/A
0% N/A 0% %/A 0% N/A 7% 141/A 0% N/A 6% N/A 0% N/A 4% N/A % N/A
IT.I.03xP- 0.22 0.00 0.07 0.00 0.05 0.00 0.03 0.00
0.04 0.00 0.00 0.00 0.03 0.08 0.03 0.00 0.09 0.69
26A 5% N/A 0% N/A 3% N/A 0% WA 994 WA 0% N/A 0% N/A 0% N/A 7% N/A 0% N/A 0%
N/A 0% WA 8% N/A 8% N/A 3% N/A 0% N/A 8% N/A % Al/A
YE.1.03xP- 0.00 0.00 012 0.00 0.1.3 0.00 0.26 0.00
0.09 0.00 0.00 0.00 0.06 0.14 0.08 0.00 034 1.27
268 0% WA 0% N/A 9% N/A 0% WA 2% N/A 094 61/A 7% N/A 0% N/A 596 N/A 0% WA 094
WA 0% WA 1% N/A 9% N/A 3% N/A 0% N/A 9% N/A % 131/A I
51.1.03xP- 0.00 0.03 0.14 0.00 0.09 0.00 0.21 0.00
0.06 0.00 0.00 0.00 0.05 0.12 0.06 OLO 0.30
1.06 el
04 0% N/A 0% N/A 6% N/A 0% N/A 4% N/A 016 !NM 1% N/A 0% N/A 5% N/A
0% N/A 0% N/A 0% N/A 4% N/A 5% N/A 0% N/A 0% N/A 5% N/A % N/A l; .....1
YEL030- 0.24 0.00 0.07 0.00 0.03 0.00 0.02 0.00
0.03 0.00 0.00 0.00 0.04 0.09 0.03 0.00 0.10 0.69
05 6% WA 0% N/A 796 N/A 0% N/A 7% N/A 0% N/A 3% N/A 0% N/A 4% _ 3;/A
096 N/A 0% N/A 0% N/A 3% N/A 3% 61/A 0% N/A 0% N/A 9% N/A % N/A I: CA
64
YEL030- 0.00 0.00 0.28 0.00 0.23 0.00 0.09 COO 0.05
0.03 0.00 0.04 0.09 0.20 0.09 0.00 0.43
1.58 0
=4
06 0% N/A 0% , N/A 2% N/A 0% N/A 7% , N/A 0% 1 N/A 1% N/A 0% N/A 8%
N/A 5% N/A , 0% N/A 8% , N/A 7% N/A 5% N/A 5% N/A 0% N/A 4% N/A , % N/A
......
YR.03xP- 0.60 0.03 0.19 0.02 0.11 0.01 004 002 0.06
0.02 0.00 0.04 0.04 0.06 0.04 0.00 0.22
1.57 CD
4.
07 0% N/A 4% N/A 1% N/A 5% WA 5% N/A 7% N/A 4% NIA 0% N/A 6% N/A 1%
N/A 0% N/A 8% N/A 8% NIA 9% N/A 5% N/A 0% N/A 5% N/A % N/A :: 0
0
3/6.1.03xP- 0.62 0.03 0.1.8 0.02 0.09 0.011 0.04 0.02
0.06 0.00 0.00 0.00 0.03 0.07 0.02 0.00
0.24 1.48 0
09 6% N/A 5% N/A 5% N/A 7% WA 6% N/A 7% I WA 0% N/A 0% N/A 1% N/A 0%
N/A 0% N/A 0% NIA 8% N/A 1796 N/A 7% IVA 0% N/A 1% N/A % N/A
CA 02911168 2015-10-30
WO 2015/065544
PCMS2014/046694
_
== .,
. .. .. .. .. _ _
=,.
...
0, ^ g õ..., c., =-.. -... -, -.. =-=-. ====.. --..
-... -, -,.. --.. --. --. , -, -, - .-= ,n1 or..
2 2 2 2 2 z 2 2 2 z 2 z z 2 2 z6,06,1)
sl ;:a- ,,l. _
,-- a. ,
ct;
. .3:=4. 1". i .1 :.-I .:2. 1- 1. li. .'I 1.1. 1-
'.2 lis ?i. 'Fi- 200 0C'1
0 ,......1.4,_,.. ______________________________________
k
o ch :4 c. LO CO
V * Os g< in X el at ,-, at ...! * .1* n * r.-) * t; * 8r :!..t w :-.' at al.
at `Al x V=1 at ',I
E ..?". 6"o"o0orsor"ow6"606"6"6'-'6"6"6 26"Ow6w6`26 ".40,40
,, c, ..... --. -.. =-. -.... -.. =====.. -.... -
.. , ===. -... ... .... -... ,
8 ..,,,, Z Z Z 2 2 Z Z 2 Z Z 2 Z Z Z Z Z .
t '' Pat8at8at8x8*8*Qe8*8*8*Sat8at *8*8*8*
0*z..,06060c.;06060z4060606060,50!30606060
at < .ic < a 4 4 4 4 < < 4 4 4 ef 4 4 ,n1 s =
1g t..0 on on CO tr, te= CO 00 ..O tO
ft, '''
ato*o*6 *o*oA AADAogto*o*o*i5*8* 3 at 8 * 8 * r8 at 8 at 'cl at '8 *
.:-.. 0 On 0 On
c; Lo c; OI
'1.-.,:, ' Y: -4. .1 < < < < < 4 4 4 4 =4
4 tr tc.. tr, :55,.. 0 jz 8
CO3 II., 1.4,c,-az si: 1 1 1 1 1 -1 1 1 1 1 g 2 7 7 0 µ0 0 g
'2 Z. ''''' g * ?F= at
6- at g at :.9 e 8 * 8 * 71 gT. 8 *
. f'3 0 0' 0 co 0 4.4 6 w
6 " 6 w 6 ' ci ' 6 " c; w 6 " 6 6 o d " ..C; " cS! 6 . 6 w Cl w 6
. ,
t 'c a a a gc a a a a a < 8 * 8 *
2 . g i 1' 1 1 1 1 1 1 1
1 1 1 1 1 1 1,3,-,3,-.
mg = ge.,..*3*8*G*0*0*0*.*0*8*gat8at13*,9*8*8*8*23*8*8*8*
a. 6 w 6 =-= o w 6 ' o " o ' 6 " o r" o o w 6 0 --: " 6 w 6 0 6 " 6 " 6 " 6 "
6 r" 6 w
-E 0 - 't .'.5 :5 fic '1 .."5 .5 5 < < < < < < 8 * 8 *
c*v 1 g g g .::a. 1 1 g g g 1- .1 1 1 1
_
= g ez * $ *
ri * -4 ak 3 * '8 * g * 3 * 3 at 8 ak 8 * 8 * 8 at 8 * 3 at 3: at 8.* 8 at
Un CO
q * CI *
Oe0e OMOe Ci ' 606w6wo0606" 0 0 0r**0.n OM 0.40 N
0 0
0: 0 7727777777777727
t..
E .8g0
lg2.g8.g"3g8g8g8.gg2=C`3g8g8g2ig8.g
.--"' c-, 6 o .T.= o o 6 -' 6 co a o o 6 6
o a
2 2 2 2 --- ' 2 -- '. 2
2 2 2 2 '"== :`, `, '':.- -:=.- ' Z
2 ... :*==== ' 2 `--- -z- 1==== =-: p .-: 0-'
t = 4, 2 2
.-. ;7. 5`;,r '8w8*S'at.Sat8e.8*2*8;k8*Es*Se8g8g8*8*8C8*8at8g8xF:laat
O -- 0 4. is 0 a 4- 6 w 6 =-= 6
''''' C...; n' d .4. Cf. .) a N 6 =-= 6 =-, el ' ci w ci - 6 w d '" 6
el rs 6 "
\ \ \ \ \ , \ \ \ ,
*
Z600"
,'I II,It
o ow 60 0' 6" o''' ci 00 6w ow dw omorn ow 6" 60060 6' cis'
,ii c: * - 4 .1 < 4 ¾ 4 d
.1 < < 4 d =L 4 < 4 8 *
g...a . .- A "^ at 8 * 8 * 8 * 8 * 8 * 8 A 8 * 8 * 8 * 8 * 8 * ' - ' * 8 * 8
*8* 8*
t ,- -606.d0...000000d.d00d0doZ.doc.s0..,..* .,-..
'f. '4 , 0 . , --. , -... -... . -... =-=.. =-
.., -... -... -.... , ,.. ,, o
2 2 2 2 2 2. 2.. 2 2 2 2 2 2 2. 2 z6
Ta t
8*
-I' I' -I 1 - i .1. i 1. -I -1 -I Z.' si .1 -1 -1. 6 r 4 _
_ _
;z e- ;;;-*2,gg$g"sg$ggg$gEigs'gggg'z-ig 0 *
..,.,
2.. ," c, : -1.-.!..c *. zf.
& 0.= z z z z z z z z z z z z z z z zomom
g --- _
E .^ =1:.;AMAgiA 1:.*8at'lliatiatN*9atnx`Oat8Amat Ae?., at8*fgw"'*'9*Maku)
A
-
3::*.6'26w 6"60 6"6"O'nOwc;'26"6" 60 8226', ci"Ow60Ol'cOw 6"g'
li gvz 8*8at8e8e8*8*8*8*8*8*8*81.*8*8*8at8e 6 A
' 60 6- do ci 60 60 60c-i-do cio d"o" 60 do do 6-2 a"'
.,,u ===== =====. -.. =-.. ===.. -... ...
=====. -.... ...... .... =-=... -... ..... --..
......QA q 0-. I
2 g -
''.6 a:* izi at :II* 7-i' at i';=: g 8 g * i'-.:;* 1i at '8
* g at ::.' e 8 g 8 3 ak -i' at O. at 'A at P.1*
7. '* 4 4 4 µC < < 4 .4 4 .2 4 < 4 4 4
7'13 ...'w,f34t 8 at 8 at is: * 8 * 8 at 8 * 8 at 8 * 8 * '8 * 8 at 8 * 8 r
8 * 8 * m
0 0
11. - 0 0 6060c:06 6 6 6 6 606w ow 6.6 6 0 o
' * - < a a < < a < a 8 A
2 0 V .1 .1 sl' i 1 - i -I .2 .2 1. 1.- -1 i 2. sis
9 +6)
.... o..
... .... OtR,) g 1, :6 66 5,6 g1c 1:5gI,gac;µ)ccirp,gI,gIg3
f,
2 co"
ci- sli I: 1 li i ch I,- i li 1 i li 1 i 42
fig)- vg.. gg.. mr)- gr.r,-. g).- r.g)- 4 g. r...mLal' mg.mg.mg. mga- riggga=
m4 t t 4t
154
CA 02911168 2015-10-30
WO 2015/065544
PCTMS2014/046694
I , ______________________________
74. g 4r. : :: .0=, : 6 :4: 6 - 6 ea 0
:si 6
::::!.....:"..:: ..-. Ln .4 ''' 6 " .4 " 6 " ,. " m " .4 =-= r.i - r.i '= ..-;
.4 " i4 0 ,. " .4 '-'' .4 " mi '-' .-4 '-' i-; 01 .4 '2 .4 =
, N
. = ::=ciy.'...)6 **...-
c ' " o ul
k
c
:::::::::7...:. õi wi= 6 o 6 m 6 .1. 6 ar. 6 r.. 6 cr. 6 o .õ; o ,..: N. 6 m
õi rq 6 m õi cl= 6 m õ: ,. ,...; va õ.; 0 ,i o 0 Lrt 6 ....
i t=ii 1
'15 i 1
õ ..., . -4 -.... .. . .... .=
N -.= t i
B , p 8* 8* 8* 8* 1
6 " 6 " 6 " 6 .2
,..C:. en === =it u) m N CY , 1.1
N ln
oiR oiR q*q*CiA oe oigo*q* owtoatoe gig
:.=-' 0..4 or, 6 W N ..(1 0 IN d 0..-.606o600 or- .DD 0 N 6 (4, 6 ea .)O 0
.4t 0o6m6e.., el
'7-=.:. ' -+ m
0 a! =a=
o at
0* 0
Q
'a; -E= r.: :::":'
H:: :=...:::: o cs co 8 -' d " ci
" 6 2' 6 ' 6 "" ci " cl= e d " c; ce 6 22 c; ' c; '''' cl= =-= d 'a ci " 6
'''' 6 "2 ci ^
. . . . . . . . .
.g..::::.:::::,...:-4 8* 23* 8* 3* 8 at ';:3* 8* ;=:1 at 81* 8* 3 at 23 at 3*
'8* 3* 8* 8* 8* 8* O* 8*
"a= .::A'...: 8 at 8 at 8* 8*
z Y
- O "" at 8 at S*Zatxat 8
q --- * iN 14) r=I I-1
q It q* q q*
,, ,.......
or-ow o ''' 6 " 6 " o e 6 r` 6 " 6 e 6 "" 6 " o ca o e o " o a'
. - ..
t _______________________________________________________________
E t=-=:::::
8
8 8* T
at g
.c ::::::::::::::::::::4,:::: 6 = 6 '''' 6 6 " . ;
'a' .;;r:EtEtE ;;; . ----= ¨
::: ...) 6 " 6 " 6 " 6 " 6 " =-: " 6 " 6 "2 6 .r. 6 a 6: m. 6 OD 0 fn a .1.
6 cr. 6 W 6 m
......
o ZR R 4K 8* q
,... ,.,._. t A p = ... ,,, ,-.
,i.. ...m E
1.,.'' yer.::::: 1'9., * Lte * gm * ''' ig q At S at S e gc * cf: at 8* S e 8
at ..,:='* 8* 8 at S* 'A' * rel at 9* 8* tc.1 e
....( Z.
6 " 6 "" C.': " ct::: ' 6 " 6 - o " '6; ''' 6 " 0 " 6 " 6 '''' 6 as 6 I' 6 e 6
" 6 ''' 6 '''' 6 ' 6 '
..%; ,...- ...
= õ.
m r-1 .= = .= .-,
.. ¨ ¨
0 at 0 * ci= r., . *
Ts. 2 _______________________________________________________
..ii i ' = ;--!. IR P. * 8
at m * 8 * :s",.' PLI* 9* 3* 9 * .` al at S* III g t:1 at 9* .1', * RI
g :::1 * 3 CA*
`'`` o ':., 0 ' 6 ca .8 e 6 " 6 6 " 6 22 6 " 6 " 6 = 6 r'l ci ''' 6
6 µ1' 6 " 6 "7 6 6 c oi ci ''
g E : ::;...7:`.".' - ¨ _______
:
2..'= 'Ø:::: .-1
Q A 8 e
8 _______________________________________________________________
E
::::::==,...'''':,k,::: 'LI * 8 * n * Z * a * at 0 * 9*.IatSxnat9AfRat
4*SatS*wr,-1*9*8*Se
-
.
m = ,-. = m = o = o = er = to = r.. = 47 = .41. , = M = IT = e-I cr. =
µs= = .... = m = W = M = .0
. : .,:q Z
Li W 41.i4
: : ::::::
I .
, :4.,.:.::::
Ei .., 0
,,,,'t c: ____________________________________________________ .;..
Z
C t.:
r., < t ci 0 6 ' 6 "t 1 (.." '''' ,
'=
. i .. + ........ 4. ..........
i
. i
= = Z.I %.1:::: i
. . ¨
j
7, Tie ::=g:::*, !
a
2 ::: ,
..2...=
: : :3 :: . 0.. 1
22
-
g 1 vElging,,28:48-,8-8 . g: 4 8 g is $ 8.'8-'8 4 8 .A888...184,808086
155
ler ptaw., itiC-H0)
ban
Total
terpittaien '11Ptl Lviagamma alpha alpts a beta I
alpha alpha
ph.allandre carprse
litretienai =anzilo3 campt,ene caryraphill 3nalnal can,/ oxide myrrene
idantift
::::.eti C
a ocailarta .. t..i,rplsiene
pinelw. terpinerm pinarta :: tarpineril hutht&ha
Ile :=:=: = .:.
elle oil (1,41%) 1=.)
r..--- f = :::: ;
...7-1 , `..--- =
VI
: . :: . : . .. . :::: ..
..:... ... . . .:.:. ..:..:.:.:.
: .K.:. ...:..:.:;.::.:.: === ======= ---..
=
. Wt: :95 % 4A. ;35 % ve % ::Wt::: OA :M:
:% :W1:15% Vvt: .9:$ % '69'. '',Y> ',''' \ VT. ;
35 .0er .,.:.'4...µ Ma ),/ Wt.. :.:.% Aft: M:% :NlVt:: 95% Wt 195 '4A4i OA
*f 0-% Vit 195 X Che010:
.:.4Z= .........
%==:C: % C . '%.= i C
A; ::rCi: * :::Cl.:.: :..le & V AY=N: C % 1.:Xt N ....).. . c!
% a we
r
VI
VI
1780040- 0.07 012 i ;) ( E.. :.Cri
0.07 006 0C2
i
0.72 I 210
02 5% 2% 1% 0% 6%
5% 1% 7% 7% '
= 4.
. .
CB004413- 0.09 0.12 0.06 0.01 0.03
0.02 0.05 0.05 0.85 1.33
03 4% 5% 5% 3% 9% 6%
9% 3% 8% 2% :
CBDO4xP- 0.18 0.06 0.01 0.00 0.02 0.00
0.01 0.00 0.02 0.00 0.10 0.00 0.29 040 0.05 0.00 0.09 0.00 0.80 0.09
06 8% 4% 2% 6% 3% 8% 6% 4% 3% 0% 2%
2% 8% 6% 1% 2% 6% 3% 8% 4% l,
C8005xP- 0.33 0.07 0.14 0.04 0.04 0.00 0.02 0.00
0.01 0.00 0.02 0.04 0.01 0.04 OCI 0.04 0.01 0.44 015 1.14 0.13
02 6% 5% 5% 8% , 3% 3% 7% 5% 5% 5% 3% 1%
7% , 4% 0% 1% 0% 3% 3% 4% 2% a
C131:05xP- 0.53002 0160.05 0.08000 0.03 0.00 0.01 0.00
0.02 0.00 0.08 0.00 0.16 0.03 0.04 0.00 0.74 0.17 1.98 0.24
OS 4%.5% 4%6% 3.%8% 9% 2% 7% 7% 3% 496 5%
0% ,. 0% 7% 0% 2% 6% 0% 8% 1% ii
CB0050- 0.10 0.06 0.11 0.04 0.07
0.20 0.04 0.67 1.30
09 0% 0% 5% 0%0%
6% 4% 3% 8% '
...--... t
C80050- 0.34 0.02 0.00 0.00 0.46 0.27 0.11
005 0.05 0.00 0.11 0.00 0.04 0.01 0.61 0.08 1.75
05 2% 5% 7% 8% 7% 1% 6% 4% i 7%
1%3% 8% 4% 1% 6% 3% 3% 3'41 :
--, --------------------------------------------------------------- 4
_ ..,-..... .:,
CB005:0- 0.29 0.02 0.0000 0510.43 0.12009 0.05
0.02 0.11 0.03 0.03 0.00 0 ,13 0.03 1.57 C SS "
.4
31 4%9% . 5%4% 7%2% 5% 9% , .
. 7% 7%
_ 2% 5% 7% . 8% ______ 1 % 8% 7% 1% : 1.
._
1.
(71
1-
v.
CO
ON
r..)
0
I-.
U.
I
I.
0
Table 29- Relative terpene levels as measured by GC-FID for THC:CBD and CBD
(chemotype II and III) specialty cannabis varieties. w
..
Blank values indicate undetectable levels or 0. Some zero values are indicated
by "0.0%."
Te,3penex
---------------- ,
3
alpha beta gamma alpha
alpha beta alpha alpha bete ear?
Sample.
, terpinolene phellardrene oelmene carene.
Smonene lerpinene Otter,* terpinene pinene. lettchel camphere terphleol
burldene caryopltyllene ;Maloof <mine .myreerte Chemotipe "10
\ n
WI3101XP-15 14% 1% 2% 1% 2% 4%
, 4% 2% 69% IV
CA
CBCO2xP-11 = 8% 9% 5% 1% 2% 3%
11% 2% 60% II l'.4
......., 0
i
=I
C80030-01 6% 16% 7% 1%
":% 2% 2% 65% !II 44
......,
.
.............., 0
44
CB DO3x P-10 7% 16% 7% 1%
69% 31 al
--------- 01
VD
Ct3tYPNP-07 , 3.1% , ,)% , , 71%: 5% 1%
2% 5% : 10% '3% ... 12% . A
. __________________________________________________________________ -,
T Teti:caries
i
C
1,1
=
alpha beta gamine alpha
alpha beta alpha alpha beta C-111,1 'JI
terpineleno pheilardrene ecimene ca tette limpeepe terpineno pinono terpirione
Worm leochel eariphene torpineol bumiene caryppbyliene Ileatool oxide rnymerte
Chemety. pc %....
.5
CBD04x VIP-01 10% ------------- 7% 18% 5%
4% 2% -- 6% 4% __ 45% ill VI
._.
.I¨
.1¨
C130040-09 34% 2% 4% 3% 4%
32% 12% _ 10% HI .
CBD05xP-01 10% 11% 5% 1% 3%
2% 1 6% 3% 60% HI
--+
CEIC05x?-13 10% 9% , 21% 6% , 1% ,
2% 9% 7% ... 5% 30% !II ..
PUR01xP-06 8% 7% 4% 1% i%
4% 15% 3% 57% ¨.
PLIR01.xP-04 7% 37% 6% 6% 3% 1%
3% 5% 17% 5% 11% .
¨
PUR01xe-10 8% 38% 7% 5% 3% 3%
4% 16% 4% 11% ....'.--=
Plik01 zP-05 . 11% 27% 2% . 3% 2% 3%
7% 22% , 5% 18%
o
o)
=c Sil 05x9411 20% 1% 3% 2%
1% 10% 39% 8% 15% co
oc,
. oc,
0-
th 5:1.084418 22% 1% 3% 2% 2%
15% 42% 6% 7% ec
co
--1
oc
Sit 08x9-30 33% 12% 5% 1% 1%
7% 6% 2% $8% o
o.
, uc
I
o.
6108xP-14 8% 6% , 23% 6% 1% 1%
3% 9% 4% 40% o
_
...
o
51108x9-18 9% 8% ;4% 1% 1% 1%
3% 8% 3% 36%
Sli.08xP-34 8% 9% 23% 6% 1% 1%
3% 6% 4% .. 39% ,
S3L08xP-C3 4% 35% 2% 4% 2% 3%
6% 21% 11% 12%
58.08xP-37 _, 32% 2% 4% 3% 3%
10% 25% 6% 14% .
5108xP-38. 27% 2% 4% 2% 3%
7% 16% 9% 30%
-
W11104oP-02 33% 2% 4% 3% 4%
7% 25% 16% 6%
el
W11070-07 , 11% 12% 19% . 6% 1% 1%
3% 9% 2% 35% . ....,..iq
WHIO7x1,-11 8% 7% 16% 5% 1%
2% 7% 4% 51% 1CA
bo)
0
WHI070-01 , 37% 2% , 5% 3%
3% 4% 12% 8% 27% =i
4:.
......,
0
WHIO7x1,-08 29% 2% 3% 2% 4%
10% 36% 5% 9% : . 4o.
0
0
WHI070-02 3% 13% 9% 5% 1% 2%
3% 9% 2% 54% _________ 0
.P.
---------- ................... ......... .........
Tzpetsts :::::::::::::::
RP
==:=="' . = .. = .. = . :=::=???RH=k= .. == H== = ..
= .. = . =:=:=:'
n
. .. .. . . .. .. . . : .. : .. .
: .. : ..
... .. nolo* alpha
:: ::::::: ::::::::: . : .. : .. .tetPitH4en*:
:PhONANOMM:: ::terploon4: fl r.1$fl6w he :lenchoJ: :orilthekke.
1003001 . hum /alone.: .:11aaicka oxWe.: .:mitteri0
YELOIxP-01 9.8% 19.7% 9.5% 3.9%
8.8% 6.5% 41.8% 0
YEL.030,02 0.0% 0.0% 7.9% 0.0% 8.4%
0.0% 31.0% 0.0% 9.2% 1.3% 0.0% 304 2.1% 2.5% 6.5% 0.0% 30.9% !
YEL0IxP-03 0.0% 0.0% 12.7% 0.0%
11.6% 0.0% 17.6% 0.0% 6.1% 0.0% 0.0% 0.CY:i 5.7% 9.6% 5.0% 0.0%
31.6% 0
YEL.030,08 0.0% 0.0% 12.0% 0.0% 10.7% 0.0% , 1813%
0.0% 6.5% , 0.0% 0.0% _ 004 4.8% 12.3% 6.9% p.095õ 28.2% !
YEL03xP-70 0.0% 0.0% 0.0%
0.0% 35.6% 0.0% 13.0% 0.0% 7.7% 0.0% 0.0% 0.0% 12.0% 21.9% 0.0% 0.0%
9.9% i
YE1.030`-25 33.8% 00% 11.5% 0.0%
8.4% 00% 4.1% 0.0% 6.3% 0.0% 0.0% 00% 5.2% 1.1.2% 59% 0.0%
14.5%
YEttlIcP-26A 32.6% 0.0% 10.6%
0.0% 8.4% 0.0% 4.3% 0.0% 6.8% 0.0% 0.0% 0.0% 53% 12.8% 4.8%
0.0% 14.2% :
VEI.03xP-268 0.0% , 0.0% 10.2% 0.0% 104% 0.0% ,
71.1% 0.0% 7.5% 0.0% 0.0% 0.0% 4.8% 11.8% 6.6%
.Ø0%_ 77.6% ;
YE1.030-04 00% , 0.0% , 13.8% 0.0% 8.9% , 0.0%
19.9% 0.0% 6.1% 0.0% 0.0% _ 0.0% , 5.1% _ 11.8% 5.7% _0.0%_
28.8%
1-;
1-;
1-;
YEI.03xP-05 35.5% , 0.0% 11.1% 0.0% 5.3% 0.0% ,
3.3% 0.0% 4.9% 0.0% 0.0% 0.0% 6.2% 13.4% 4.3%
_0.0%, 15.8% ;
co
r4
YE1.03xP-05 00% , 0.0% , 17.8% 0.0% 15.0% , 0.0%
5.8% 0.0% 3.7% 2.7.96 0.0% _ 3.0% , 6.1% _ 13.0% 6.096
_0.096_ 27.4%
YEL03x-07 %3% 22% 12.7% 1.6% 7.3% 1.1% _
2.8% 1.3% _ 4.2% 1.3% 0.0% 3.1% 3.1% 4.4% 2.9%
Ø0%_ 14.3% :
c.4
YEL03xP-09 42.2% A.4% , 12.5% 1.8% 6.5% , 1.1% 2.7%
1.3% 4.1% 0.0% , 0.0% 0.0% , 2.6% , 4.7% 1.8% _0.0%_ 3:
9E1.030-10 0.0% 0.0% 16.2% 0.0% 11.1% 0.0% , 19.1%
0.0% 5.9% , 1.6% 0.0% 0.0% 5.0% 1.3.6% 5.896 _0.096, 21.7%
YE1.03xP-11 0.0% , 0.0% 14.0% 0.0% 11.4% , 0.0%
20.5% 0.0% 6.4% 0.0% , 0.0% 2.0% 3.8% 6.2% 5.6%
0.0% 32.1% :
961.03xP-12 0.0% 0.0% 12.1% 0.0%
27.6% 0.0% 5.4% 0.0% 4.5% 3.3% 0.0% 4.8% 7.3% 19.0% 5.3% 0.0%
10.8% ;
YE1.03xP-13 0.0% 0.0% 10.2% 0.0% 31.6% 0.0%
3.6% 0.0% _ 4.6% , 3.7% 0.0% 5.0% 7.8% 15.9% 5.7%
0.0% 11.9% :
961.03xP-15 , 25.3% 0.0% 14.4% 0.0% 1.8%
0.0% 6.3% 0.0% 4.8% 0.0% 0.0% 0.0% 5.3% 9.8% 5.6% 0.0% 26.8%
;
(-5
YE1.03xP-16 0.0% 0.0% 14.1% 0.0%
15.2% 0.0% 20.6% 0.0% 6.7% 2.4% 0.0% 3.6% 5.2% 8.8% 5.8% 0.0%
17.6% ;
a
961.03x1)-17 0.0% 0.0% 13.6% 0.0%
11.3% 0.0% 18.3% 0.0% 6.6% 1.7% 0.0% 2.5% 3.7% 7.0% 7.6% 0.0%
27.8% ;
6.41
YE1.03xP-18 0.0% 3.0% 8.6% 0.0%
18.7% 0.0% 3.0% 0.0% 4.2% 2.8% 0.0% 3.9% 8.4% 19.9% 7.5% 0.0%
22.9% ;
46.
0
VEI.03xP-19 0.0% 0.0%
6.7% 0.0% 26.1% 0.0% 4.4%!0.0% 5.1% 4.6% 0.0% 6.3% 8.6% 19.5% 11.0%0.0%
7.8%
01
YE1.03xP-21 0.0% 0.0% 8.4%
0.0% 30.3% 0.0% 3.1% 0.0% 4.6% 4.3% 0.0% 5.8% 10.6% 19.3% 6.5% 0.0%
7.2% ;
46c.
= C
::::::::::MOR::::::::: . : :: : :: .tetPitH4en*: lthONANOMM:: ::04:3Mne::
:came:: 1Mowen:::terpkien4::099m:::terpin9o8phwile: lemi9A: :c9r4itheile:
1994mi: tunviiiene t:arioptyilieng: linakko; oxisie.: :rcti# Chetinit, --
.....
.5
YELOIxP-22 44.5% 2.6% 9.9%
2.1% 6.9% 0.0% 3.0% 0.0% 5.2% 0.0% 0.0% 0.0% 2.3% 7.7% 3.1%
0.0% 12.7% VI VI
4-
.1-
YE1.03xP-24 , 29.8% 2.1% 7.7% , 1.9% 6.7% 0.0%
3.7% 0.0% . 6.1% 0.0% 0.0% 4.6% 6.7% 15.3% 3.3%
0.0% 11.7% ---.0
YELOIxP-27 31.9% 0.0% 12.1%
0.0% 6.0% 0.0% 4.1% 0.0% 7.1% 0.0% 0.0% 0.0% 5.0% 13.2% 6.0%
0.0% 14.6%
YEE.03xP-28 0.0% 0.0% 12.3% 0.0% 9.0% 0.0%
, 12.6% 0.0% .... 5.5% , 2.0% 0.0% 0.053 9.2% 23.5% 5.4%
0.0%, 20.6%
YEL03xP-29 0.0% 0.0% 9.7%
0.0% 34.3% 0.0% 3.5% 0.0% 5.0% 3.3% 0.0% 4.5% 4.8% 17.4% 4.5%
0.0% 13.0%
-
YE103xP-30 37.4% 23% 10.7% 2.0% 5.653 00% 3.6%
1.2% 5.7% 0.0% 0.0% 389' _ 4.8% 1.9% 0.0% 0.0% 13.1% :
YEL03xP-23 14% 29% 3% 4% 2% 3%
5% 15% 7% 19% 3
Y111.03xP-26 41% 7% 13% 1% 8% 1% 2% 1% . 4%
1% 2% 2% 1 ic% 2% 14% :
o
o)
1-k W8101xP-22 34% 2% 5% 3%
7% . 5% 49%
1-,
1-,
1-
th WHI01.wP-12 7%. 7% 4% 1% 3%
0% 1% 77% : o
co
o
W8101xP-14 10% 12% 5% 1% 1%
0% 3% 1% 66%
o
I
%
WHIOlaP-19 8% 8% 4% 1%
0% 3% 1% 75% ! 0
...)
o
W8101xP-23. 8% 7% 4%
1% , 3% 13% 2% 62% :
.
CBDO2xP-15 35% 2% I 4% 3% 3%
9% 24% 6% 14%
I
CBDO2xP-16A 36% 3% : 5% 3% 3%
5% 23% 7% 16%
CBDO2xP-17 26% 2% 3% 2% 3%
10% 21% 7% 26% :
CBDO2xP-10 12% 4. ____________________ 8% 16% 5% 1% 1%
4% 11% 3% 40% :
CBDO2xP-12 9% 1 8% 18% 5% 1% 1%
2% 4% 3% 49%
el
CBDO2xP-14 10% _________________________ 7% 16% 5% 1%
3% 9% 2% 48% ....,.1q
CBDO2xP-18 5% 6% 6% 5% 1% 1%
1% , 3% 2% 70%
bal
0
CB1102xP-31 , 6% 4% 9% , 4% 3%
3% 8% 2% 59% : =i
---..
0
CBDO2xP-05 9% 12% 5% 1% 2%
3% . 9% 2% 57%
0
01
CB1102x15-30 - 8% 8% 4% 1% 2%
2% 7% 3% 65% : VD
4.
gp .. nn i
C
1,1
=
.,M
alpha beta gamine ::004.::: :::::::010a
bet4 ::::::::::::::::::::: :: alpha alpha
5ampal
...............................................................................
.................... terpinelen pheilardrene odmenecame 3monen4 lefp.31444
Sii0KC I44:00ne . p14900: :10441i0J: :camphene terpineol humlene caryophyliene
Ilnatoo; o3W myirmw Chemotype:: ---
Vi
CBD020-32 8% 3% 4% 1%
4% 4% 9% 3% 59%
.6.
.4.
CBCO20-40 10% 9% 656 1% 1%
1% 4% 3% 66% ..=
..
0311020-53 9% 11% 6% 1%
4% 10% 2% 56% :1
CEICO20-09 6% 12% 5% 1% 2%
1% 2% 2% , 70% ..=
..
CBD020-28 5% 17% 7% 1%
1% 0% 1% 1% 65%
----/'
CBIX)2xP-47 6% , 14%, 6% 1% 1%
1% 2% 1% 68% _
C130030-03 6% -. :% 5% 1% 1%
1% 4% 1% 68% ..-¨.
C8D030-05 5% 2214 5%
2% 6% 2% 69%
o
to
C130030-09 6% , 14% 7%
1% 5% 2%- 65% : ce
..
. :-.
:-.
=c
0.
ON CRI3040-02 7% 11% 6% 1%
2% 6% 2% 66% en
co
=
14
(13004x9-03 7% 9% 5% 1% 3%
7% , 4% 4% 64% : o
1-
cn
i I
:-.
CODO4xP-06 23% , , 1% 3% 2% 3%
13% 1 37% 6% 1216 , o
. ,
.2,
o
C131705x9-02 29% 13% 4% 1.16 1% 2%
4% 4% 4% 39% :
CBDO5xP-05 28% 9% , 4% 2% , 1% 1%
5% 8% 2% 39%
.
¨ .
CBI:050,09 8% 5% 9% 3%
5% 16% 3% 51% : ,
CEIG05xP-05 19% 0% 27% 7%
3% 6% 2% 35%
CBI:050,11 19% 0% 33% 8%
4% 7% 2% _ 27% :
PO
el
....iq
WI
kna
0
=I
4:.
---.
0
4:c=
05
ON
NO
4:.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 8. Phenotypic analysis THC:CBD and CBD specialty cannabis progeny.
The new specialty cannabis varieties created through crosses described in
Examples 5
and 6 were subjected to phenotypic analysis as described in Example 2. Seeds
were allowed to
germinate in indoor facilities for 10 days and were then transferred to grow
in an outdoor
growing facility. Plants were allowed to grow for 120 days after germination
until maturity and
were analyzed as described in Example 2. Measurements were conducted as
described in
Example 2 unless noted otherwise.
The progeny of this example were grown during the "short season" defined as
November
through February in California (-36.67 N). The short season applicable here
was marked by
record lows and a run of cloudy days that dramatically reduced growth, flower
production,
trichome formation. These factors combined with low light angles reduced
yields and oil
production significantly. However, the cooler temperatures combined with
higher precipitation
weather also provide excellent conditions for fungal pathogens and provide
researchers with a
great environment to select for resistance to both cold weather, low light
levels and fungal
pathogens. Table 30 outlines the results of the phenotypic analysis.
Node Branching- Node branching was visually determined by inspecting nodes and
determining the amount of branching at plant maturity at 120 days post
transfer. For this example
branching was notated with a Y to indicate branching at nodes and N to
indicate low or no
branching at nodes.
Apical Inflorescence Size - For this example, inflorescence size was visually
estimated
and assigned a score of 1-10 with higher numbers corresponding to larger
inflorescences. Due to
the short growth season, relative comparisons were used for assessing progeny
for future
production and/or breeding schemes.
Floral Cluster Density - Floral cluster density is a measure of how tightly
packed floral
buds are in a plant inflorescence. For this example, floral cluster density
was visually estimated
and assigned a score of 1-10 with higher numbers corresponding to denser
clusters. Due to the
short growth season, relative comparisons were used for assessing progeny for
future production
and/or breeding schemes.
Ripening Mode- Ripening Mode was determined by tracking the ripening of mature
inflorescences. All progeny exhibited relatively short and uniform ripening
times. The ripening
161
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
for all progeny was even among all the inflorescences. This is in contrast
with other cannabis
which can exhibit staged ripening in which various inflorescences ripen at
different times.
Average Calyx Length- Calyx length was measured in centimeters from the base
of the
calyx to the tip of the leaf but not the pistil. Measurements were taken from
mature plants at 120
days post germination.
Initial selections were conducted based on measured phenotypes and chemical
analysis
described in Example 7. Cuttings of desirable progeny were preserved for
subsequent growth
trials during a longer warmer season. These cuttings are also being used for
subsequent breeding
as described in Example 5, 19, and 20. Phenotypic results for these cuttings
and their F2 and S2
progeny will be grown outdoors during the upcoming season as described in this
example or
through indoor growth as described in Example 2. Year round production to
maximize natural
light production is greatly dependent upon short season trials to select
progeny that perform well
in the conditions outlined above. Many of the selected progeny of several
lines are being
propagated and flowered in controlled indoor environments to determine more
standardized
growth metrics.
162
C
1,..)
Table 30- Phenotype table of THC:CBD, and CBD (ehemotype II and HI) progeny.
=
'JI
--...
I
....4.,v
E 4-= 7.- , 2 **6 ; r! a -0
o
1
'Ji
Cultivar ID = 5 m ., E ...i ,.-t 1: 9
a c t.". t F. ri- il -14, '7)-0, :" t g bp
..
.. 0
. .-.. IS g _.,=,. E tz : I.) E.-,
a = o < o .. 5 ii
=47.. 0 'E
i --' _.., c lo z ¨ E..
A. A.
i z
a 0 c 1.--. `'` g. 2,?
Z ii.
Normal color
S1108,1P-01 65 45 7 il 7 N L 2 9 8
Short, Even
Normal color
$11.01UP-03 78 72 7 3 9 Y ita 2 9 7
Short. Even
Normal color
SILOUP-08 96 62 7 3 a 1' M 3 8 7
Short. Even --
Normal color
S11011xP-14 74 39 5 3 7 N M 3 9 3
Short, Evers
Normal color
SRORKP-27 80 54 5 8 8 v H 3 10 9
Short, Even o
ro
Normal color
o
ro
511.0803-30 , 72 40 5 8 8 N M 4 9 9
Short. Even ro
ir
1-
eN
Normal alio, ,Vigor+ o
co
Ca Sil.080-34 120 49 7 3 8 sr M 2 8 8
Short. Even ro
Normal color
o
v.
SIL080-37 97 48 5 5 9 N M 3 9 8
Short, Even ur
,
ro
Normal color
SILOSvP-38 97 47 5 a 11 Y M 3 8 9
Short, Even
Normal color
o
YEL030-16 99 48 9 8 10 Y M 6 , 7 8
Short, Even
Normal color
YELI33YP-23 110 30 11 3 9 Y NI 5 6 8
Short. Even
Normal color
YEtD3xP-26 , 92 , 39 9 3 9 N 6 6 7 ,
Short. Even
Normal color
Y11.034P-17 95 60 , 9 5 9 N M a 7 7
Short, Even
Purple Flowers
PUR01xP-04 65 48 7 B 7 N H _ 1 5 5
Short, Even
Normal color
PURDIKP-136 50 30 1 8 a Y no 2 4 6
Short. Even iv
el
Slack Leaves, Vigorous growth
.....iq
_ RIRO1xP-10 62 51 9 B 3 N M 3 6 7
Short. Even
_
Leaf Serrations
KRYA-1 82 42 5 B 8 r Ns 5 7 7
Short, Even C/1
tvo
Normal color ,Vigorous growth
0
=I
WH107-02 90 39 7 B 7 'V H 5 5 8
Short, Even 41.
.......
Normal color
0
WH107-03 , 93 50 7 8 7 1' M 3 5 6
Short. Even 41..
01
Normal color
01
WH107-07 80 60 7 3 9 1' H 5 6 6
Short. Even VD
41.
¨ . _________________________________
t .".. t b4
C 4/ a- ......
a
st ?e' 4.. M
..-- ..... ,.., 1
... F., v z=
.51 - E .g -5 :,
.1-: t E. Va
"6 it :2
u
c c 0 0 43
'6 t 7.,74. '?' 7' aa
Cuitivar ID - c a. E 0: 1 5 s* g
W ti; 2
-4 at, ex
0
1,1
--......
Normal o)lor
.....4Z
WHI070-11 45 28 5 B 6 N M 5 6 6
Short. Even VI
-..- ¨
Normal color ,Sweet ter pane smell
4.
SIL04xP-01 47 40 7 B 7 V M 7 8 7
Short, Even 41.
Normal color
SILO4rP-02 50 31 5 B 6 N L 6 8 8
Short, Even
Normal color ,Sweet and mint terpene smells
03004xP-1 70 64 5 8 9 V H 4 5 8
Short, Even
Normal color
CB1004xP-2 74 40 5 B 6 Y M 4 8 8
Short, Even
¨
Normal color
iltD04x1,-3 77 40 7 B 7 r M 6 6 7
Short, Even
Normal color ,Production, High Yield
(BM4xP-4 83 67 7 , B 8 Y H , 4 5
7 Short, Even
Normal color ,Vigorous growth
CBIDO4xP-6 96 46 7 B 6 Y H 3 8 6
Short, Even
Normal color
o
CBC103xP-01 55 27 5 B 6 N M 6 4 5
Short. Even ro
co
Normal color ,Vigorous growth
1-,
ir CBDO3xP-03 100 100 7 B 9 V M 4 8 7
Short, Even
e N
Normal color ,Vigorous growth o.
co
4:.
CBDO8xP-05 82 76 5 8 10 Y H 6 7 5
Short, Even o"
Normal color
Lx
CBDO3xP-07 , 73 56 7 B 8 V H 7 6 ,
7 Short, Even 1
1-.
Norma! color ,Vigorous growth, Sweet smell
o
CBDO3xP-09 96 70 ii 0 8 Y Ni 6 7 8
Short. Even w
o
Normal o,lor
CBDO3xP-10 93 42 5 B 6 Y M 7 6 8
Short. Even .
Normal color
CBD011icP-11 84 42 7 B 7 V M 5 5 5
Short, Even
Normal color ,Vigorous growth
CBDOLLP05 100 74 7 B 8 Y H , 7 5 7
Short, Even
Normal color
C801270-3.0 80 61 7 P 9 1' ii 5 7 6
Short. Even
Blue flower iminr
C60020-11 , 78 62 7 H 10 N , M 5 5
7 , Short, Even .
Blue flower coior
110
COD020-12 80 69 7 H 9 r H 5 6 6
Short, Even
(-)
Normal color ,Production, High yield
.....iq
CBD07.0-15 87 RS 11 . H 11 V H , 7 6
6 Short, Even
Normal color
EA
C8002xP-180 78 60 7 H 10 V H 7 6 6
Short. Even l...1
0
Normal color
=L
CBDOUP-16 84 56 5 H 8 N M 7 6 6
Short. Even 4a-
0
Normal color
A-
CBDO2xP-17 81 40 5 H 6 r M 4 5 6
Short, Even 0
01
Norma! color ,ProductIon. High yield
VD
CBDO2xP-18 92 64 5 H 11 V H 4 4 5
Short, Even A-
_ . _________________________________
% ..." {7 let
C
a
t _ ....." a
'd ?e' 1
c 0 0 ,-I .
... F., v z=
il ¨ E .g -5 :, E. v)
..6 t3 :a-
u
. .6 =.'41 7'24. ti -,-
: a a
Cultivar ID H iIIE 14.õ . g 2
tr, i
0
.ga t-- izs I
ar g ili
o z ze-7 r.-. 0, g c
t= - E 3 =
el. Ct. Z 1.7 E = 8 2
12 vi
---...
Normal oolor
.:..i.v
CBDOUP-28 89 59 9 H 8 Y M __ 6 7--- 6
Short. Even Vi
....¨ .--- ...... ¨ 'al
Normal color
44
CBDO2KP-30 76 86 5 H 3 v H 4 7 5
Short, Even 4.1.
Blue flower co:or
CBDOUP-31 81 96 5 H 9 Y H , 6 7
?BD Short, Even
Normal color
C8005)&411 92 81 5 H ii Y M 5 9 8
Short Even
Normal color
CBDOSicP-02 , 120 105 7 _ H 9 Y , M 7
5 7 , Short, Even
Normal color ,Vigor,
CBDO5xPa0S 150 125 7 H 6 r M 7 5 a
short, Even
Normal color
C13120535-05 71 54 7 8 7 Y M 7 7 i
Short Even
'
Normal color ,Cherry Pie
03005;15-11 86 39 7 8 9 N M 7 8 7
Short, Even
Normal color
o
CBDO5x5-1.3 59 33 7 3 7 1' M 7 8 7
Short. Even r4
.r)
Normal color Astringent Cherry
4
4
ir CBDEGLicP-32 80 53 7 H 5 N L 6 6 6
Short, Even 4:
en
.
th
Normal color fe
CBDO2xP-40 49 33 5 8 6 N M 6 6 6
Short, Even 4.)
o
Normal color
1...
La
01002xP47 72 SS 5 8 6 Y M 4 6 6
Short, Even 1
4.
Blue flower color
o
C11002xP-55 73 48 5 3 6 Y H 4 6 E.
Short Even i...
o
Normal oolor
WHIO1xP1il 80 64 5 3 9 Y H 4 5 6
Short. Even .
Norm! color ,flubblegum flavor
WHIO3xP19 79 59 7 5 10 'I H 3 3 4
Short, Even
Normal color
WHIO1xP-22 81 61 7 5 9 1' H 4 3 , 5
Short, Even
Normal color
W1ila1xP-23 65 50 5 e 10 N I. 32 6 4
Snell, Even
Normal color
C8D24 59 47 5 13 10 Y H 2 3 3
Shen, Even
¨
NOnnal OCrior
V
CBDII 61 45 7 H 7 N M 2 4 6
Short, Even
el
Normal color
......1q
C13013 60 31 7 H 8 V M 3 6 4
Short, Even
Normal color ,Production, High yield
EA
WHIO1xP-15 100 57 5 li 10 'Y H 3 7 4
Short. Even ba
0
=L
........
0
4:4
Ch
01
VD
4:4
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
Example 9. Volunteer trials using THC:CBD specialty cannabis. Effect of added
CBD.
In order to demonstrate the added utility of the specialty cannabis varieties
of the present
invention, volunteer comparison trials were conducted. During these trials,
volunteers were
provided with cannabis flower blends with varying terpene and cannabinoid
profiles to determine
the effect of cannabis with CBD, effect of higher terpene oil content, and the
effect of diverse
terpene profiles with reduced myrcene contents. The trials were split into two
parts. The first
part (Weeks 1-2) compared volunteer responses to THC-only cultivars and
cultivars that
contained THC plus a small amount of CBD.
The volunteer trial for CBD was conducted over 2 weeks. Volunteers were split
into six
groups (1-6). Each volunteer in the group was given two samples (a control and
a comparator
blend). For instance, they were given al and a2, or bl and b2, or cl and c2,
or dl and d2, or el
and e2, or fl and t2 (see Table 31 for trial design). In this trial, the
control (i.e., 'Control ID'),
and comparator blends (i.e., 'Comp ID') were prepared to contain nearly
identical levels of THC
and terpenes, but each week the comparator had either 1.5% CBD, or 2.5% CBD
added in. For
the higher percentages of CBD, a cannabinoid rich form of hash known as kief
was used rather
than flower so a higher concentration could be added without affecting the
terpene profile as
significantly as adding whole cannabis flowers.
Table 31- CBD Effect Trial Overview for Weeks 1 and 2.
Week
1. 2
THC or THC or
THC*1.514 1HC41.514 Tommy Class Control and COMparatest
Terpones ease CultIvar Control ID Comp ID
ato
Group 1 Group 6 a myrcene, pinene GRA8 al a2
Group 2 Group 1 b hmonene, linalool, caryophyllene, humulene
WHI2 b2 bl
Group 3 Group 2 c ocimene, myrcene GRE1 cl c2
Group 4 Group 3 d terpinolene, ocimene PDR2 d2 dl
Groups Group 4 e myrcene, pinene, otimene, 'Maloof caryophvilene
PUPS el e2
Group 6 Group 5 f limonene, caryophyllene, myrcene, linalool
RED1 f 2 fl
166
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The samples were prepared by first assaying the individual cultivars for their
cannabinoid
and terpene levels. Once levels were determined the mass ratios of the
cultivars needed to attain
the desired analyte levels could be predicted. The appropriate amounts of
materials were
combined in a coffee grinder. A finer grind was needed during the first four-
week section to
mask the addition of the kief, which was added for the higher percentage of
CBD. The material
was split into 1.0-1.5 g samples and stored at -20 until distribution
(typically within 24 hours).
Enough of each blend was made to analyze the samples in triplicate to verify
the cannabinoid
and terpene levels (See Table 32 and 33 for terpene and cannabinoid analysis
of blends given to
patients). The controls (THC only) are in bold face and it can be seen. that
the levels of THC are
roughly similar within a group. It also can. be seen that the blending process
produced consistent
levels of cannabinoids and terpenes that were close to predicted values.
Table 32- Cannabinoid levels of cannabis blends for Week 1 and Week. 2 trials
as measured by
GC-F1D and EIPLC. Blank values indicate undetectable levels or 0.
08994131808% (Gt430)
C80 TH0:C.Sil by C.C. :
::::::::::::C8A::::::::: : ::
n
M::aqfuam
ape % 1% % % Ci
.logoo-3,101--ofp-$/.... 20.90% 0.91% 74 04% 044%
M>CM.13A-002 a2 18.14% 0.50% 1.82% 0.14% 9.95 0.24
21.32% 0.40% 2.14% 0.10% 9.96 0.34
r4PCM-134.-002-1)". 15.82% 1.11% 1.60% 16% 9.30 0 98
19.17% 0.71% 1.90% 0.14% 10.14 1.01
fir4P0M-1302-n 17.r.1% 0.58% 20 80% 0.65%
NIKA.4,134452.4. 19.10% 0.19% 22.91% 0.27%
MPC.M-1.34-002-r2 17.24% 0.66% 1.65% 0.07% 10.50 0.66 7067% 1.04% 2.02% 0.02%
10.22 0.58
-d: 10.67% 0.31% 1.75% 0.04% 6.11 0.16 1324% 0.2% 2.17% 0.17% 6.11 0.44
1s4PO4-134-602-...12 12.22% 0.95% 15.27% 13.5%
84POnaffit412.4V . 20.90% 0.56% 24,69% 0.47%
114,CM-13A-002-62 18.41% 0.99% 1.80% 0.08% 10.23 0.74 21.86% 0.85% 2.23% 0.16%
9.84 0.67
rim:m-134-002-31 15.83% 0.58% 1.83% 0.07% 8.68 0.45 19.30% 0.87% 2.28% 0.11%
8.46 0.37
....'titt. 17.92% 0.55% 21.21% 0.62%
MPCM-13A414334V 19.17% 0.84% 25.48% 1.14%
M'CM-.P.-O3.7.20.09% 0.68% 2.76% 0.16% 7.28 0.25 25.45% 1.00% 3..31% 0.33%
7.72 0.67
MPCM-134-003-61 16.81% 0.19% 2.69% 0.04% 6.26 0.05 21.46% 0.76% 3.18% 0.14%
6.75 0.53
N4P0Y1-13.AAD034r_ 16.67% 0.69% 22.28% 195%
jyTsm-lsA-oce-a 1592% 0.55% 24.57% 0.35%
MiI1,4-13A-003-62 18.59% 0.34% 2.9:3% 0.30% 6.37 0.63 23.56% 0.11% 3.53% 0.43%
6.72 0.85
167
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
GInnabinoids tiC-1,10) C:innabinaids (ibiPLC)
THCA;CSDA by
THC (81)4.384.F.433.64414i.c. 114cP,
CBDA
HP1C
Sample % Wt % 01%..: 45%(: W3 41%C% %
M:,CM-131.-001-4: 14.50% 0.67% 2 33% 4.27% 4.97 0.48 18
51% 0.71% 3.47% 0.!,.0% 5.37 0.62
MPC84-384-068-42 .1145% 0.63% 16.03% 0.60%
ft48088-134403-4/ 20.97% 1.09% 27.28% 0.60%
M2CA4=13A 003-42 20.18% 0.53% 2.80% 0.15% 7.21 0.21
25.58% 0.78% 3.24% 0.22% 7.90 0.30
1.3A.003.11 17.77% 0.24% 3.05% 0.10% 5.82 0.13 22.96% 0.24% 3.62% 0.20% 6.39
0.40
:1140Attskitaik1883W: 17.07% 0.16% 22.80% 0.26%
168
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
- -
k - A-
.....;
..-. '74 ., =-ia * f * g *
at g * * * 4 g * * r A at *
:-, ,- .4;
..
....0 0
....
-, 1.1 ti,i 8'
at 8* ;lat Z-1 at 3 e 8 at 8 e :1* P * 3 A .9 at 8 at 8 at 8 A 8' at ,t1 at 8,
at 8 at 8 e
= ;a., ,-.4:
..,--::.,:-..:.:: 6 IN 6 .-! 6 01 6 0- 6 V 6 01 6 N 6 0 6 4-4 0 04 6 =-= 6 0,
6 Cr: 6 on 6 0 6 ,r1 6 0 oo 0 6 .-o
''-' a:t:;44 = -- = .. = ...... 40 40 m
co ::::,....::::.. ::H:: -I " -
i .0 .41.0 ,-.i .0 c,i .0 ca " .-1 . .-1 ' ===,) " is,o "' M a o-; ri " A
0, A V, N V. A .-. A vi. A .
414)
03 t k 1N
> -
-
6 " 6 " d do 6 " 6 " 6 " 6 " 6 6 ' 6 ''' 0
"1 d = 6 `7 6 " 6 "
rd
....... 4 a. 72.:v::5':::*
.::::::::::: 6 N 6 - ai 0 a; ^4 6 " 0 V'' 0 V' 0 '-' 0 M 0 "" 6 = 6 " 6 ' 6 =
= o in 6 'I' 6 " 6 ''' 6 "
I--
o 5 e. :, 6 '4 6 " 0 ci ' ci '' ci ''''' 6 ' 6 'n o
o 0 d 0 o 6 0 6 " ci ,'"' ci =-= 6 " ci 'T ci "
U
C., ,,, -g:4:& 8 at 8at.8 at 8e8e8at 8*8 at
, 1 P : : 6 " 6 " 6"6"6"6"6"6" 8 at 8 at
ci " 6 "' 8 at 8* 8 at 8 at 8 at
õ
4.4 ==== ...,AV,O*C=*4-% acoac, oac,,a6 cl µ12
q * q * iii at 2 at t'i at 74 r 8 *
-0 - 6 " 6 " 6 '''= 6 '''. 6 6 " . 6 ' 6 0 " 0 r"
0 " 6 "'' 0 ' 0 6 41.
õ
"0 "
6 ' 6 '''= 6 " 6 " 6 " 6 " 6 " 6 ' 6 m 6 0, 6 "
4
on ... co .. m ... 01 ... 04 ... N -
0 GO 01 .-
qa,oa,oa,oa, 0 4, 0 *
A q *
0 .0 Al = CT = IA = IA = I, = N
0 0 0 0 0 0
- 0 = A
0 0 0, ili
q.! Irf, :10 0 01 0 0 4.= 0 .... . õ . .
0 . 0 .
- - 0*0*g* q )t 0*0*6 at 4 =-)A0164sat1 o * 4' * S'
I: . at
E.9 0 0 Cs' 0 00Ø0.0M0m=O. + 0.
0.0v. 0 N 0 ,== 6 0 6 ,-4
.'.=
cn ',....-...c.:cargAri4q4""r .-
:A,.=1.--1,1.=== .-.. 4 ..,., 4 .1 g 1 g 4. e p at
at 0 0 o 6 6 16".6µ.0 0"lo o=
0Ø6"0"
8A8A8 at 8 at 8 * 8 * 8 A 8 g 8* 8* Sat
8 g
'-' "
6 " 6 " 6 " 6 " 6 6 .d......"_'6.....____ 6 " 6 " "
d
='" o -1717 6
: 0
I-. I. Z. * qActAoAgAinlit alas 9 ." 9 .'= 9 A 9 a' 0
* fl *
...., :-:
. .
Cl
6 6 '
8 -4
0 .- .=== *
qz g oe
.-. = No
6 6
ti- z..7 ',',',. - c; -, 6 c, 6 m 6 c. 6 deoc 6 6 6 " 6=46"e 6*6
"0 ====-=
0 =-. * PI *
el * .p. *
:*:::: 0 0 ns en o o o = . o o Al IN 0 0 4.I 0-0-0_,I
4--I W M : : :
o4:i'.3 A 7"Rgqg 4 g0A A"ggq?! W4g4g. g *: r
" &t:::::6 on'oo o 6 6 6 0'46 ci'no o= 0';"6"'o o 0 0"0
,1
a : ''.'..: :::`..1.0 1... r... . 0 . 04 _ ..,4 4==== 4 =a=
a= fn N t.0 %.0 RP
E::::::::ro::::e 0f: lei it.r.;riAr=se.A.A6A0AwitAte) oat eat
..,1 b p.,,,, ,-; 0 ;,-, . ,-, e
....I, ..
=i. 8 w 8 V,
6 " 6 " i
- -
f+- ----
0 i^ .V,1:=.!.' 0 µo 0 co i
, _ ,
. . .
=
Fs - __ -,-- -:- ! - ------ :
,...
6 0 "
.6 do
''' ... :.:',,. =A ro. m
9 ;t
.:15 c'.' .
:=:Og CI* eat 8* 8 atOg 8*8 at 4 A r. * 8*8*Ogg*8* 8*Oatlig 8 A
t.10 ,,, 7; ' 0
0 " 0 .4 0 " o " a 6 " d 6 ci 0 ci " :=ri 0 6 6 0 6 6 0 a " 6 ci 0
cu ='.1. ,: w
SgSat&lat3e!.ligPgAglat11g 843g,r.e1f1g 4g glatgatSgro'at'Ae
o - " - 6 d " 6 ''' 6 d d 6 6 .4 4 6 = 6 "'Ici ei ci -' ci ''', d
d 6
- , -
ocic;
2
40. õ i,c -= * -I * =-. * -I *o*qatqat 8g 8*8*8g8*!'-ig Sat 8*.:latrig8gri*
C = " 6 c 6 'n 6
'n 6 " o ' o '" o " c.; 6 ". 6 `n 6 6 ' 6 6 ' 6 ' 6 " o o o "
O C 8 at 8 * 8 *
t.a 3. Id , ,== 6 " 6 " ...: 14
E ' .
= oo,. av= 8. *
a.) (L) 45 - o o
El ti, . ''' ,-.
8e 8g 8r 8e$4848 at 8*Ig 848 s 8g 8x8te 8* 8* 8*8484
..... 2 ., ;-.,-, - 6 '40 010.0 6 6 'n .6 'n
6 6 4 o = ' 6 '''' o: ' 6 " 6 " 6 " 6 6
.2- c
',.) .. oso o
:',...e *gag 8at 8* 8A:1*$ at 2 attflat1;1*rcIA 3* :le:Cie. :-.:iArc*iAASAci A
- ei ei 0 0 0
m 6 m 6 L. r.: '. -) ' 0 M ea c` 6 " d " 6 " o 0 6 " ,-, " o " 6 " 0 "
4 4 4
a., tgi:-..4,-.4:,-,, Ø0, r .4 ',1 :-.4 Ti oi , =-= "I N . .4 0, 04 . 4-
. N . 44 0, N . e -1 . N '44 . Ai L." TR
43.) ::::::: ..,,,,I, . ili =I .:2 n' vc. y 7 ,? T
itolrely7''..:1'÷*".'77',P7'...'"='.7 TlY7'?
.,...,
B. ,,5., A ZS. cµ= 8 s.) 8 k. 8 L., .._=) 0 ..'_ ^ k 8 k' 88
,S).,k.'=?,,.'8 a., 8 8 Y. 8 ,4,'2'. k.'8e8
F. = 1 Aft -='. >1,-',,\^.
169
Yes-inns:5(44-61W
alpha
hem Total
alpha beta alpha beta
gamma terpirialen . alpha alpha easy flelail
pirtelii. cmP$111en'' pineni., Pheil"dr : :77.!!' tetpineho limoneno
otiotem totplo 69hho Isnalool fer.chol taripphyll
terpineol ::::::: :
homuia,ne 0x81P identitipd C
a
=
W: 95 % V.,.. 195% 0': 9S% 1.6.A 95% Wl 9S* 3?Ft P.T.0,1 ',V.: 195% Wt 95.%.
AST:t 9S AVC 9;1% .5,,Wi....9.3* Wt 9E.: % Wt 95%. Vvt 195 ''.:4 A.'le '..,%
Mit 95% W95 % Vs't 95:% .:1YrC
SampiP % (I % ( i % 0 s ci x
CT:: :%!!::k.F !%!!! .3.-:.1 % !!..:r !96!!! Cl 9C!:..iii:
96I:.:C3.::::::. !!6: ct :*. Cl s ::: !!V :..c:i s (1
%!1:,'i .j! i!!b: :::::::: =./1
--,
MPCV14:14,. J.05 00) ' C.07
0.0, 0.33 0000..0Z 0.00 0 II. 0.00 0.18 0.00 0.36 0.01 0.05 3.0C.) 0.0::
0.00 0.040.00 0.09 C.,..)0 J02 L. 1.31 0.03 5
, 043-02 0% 3% , 8%
4% 0% 7% 2% 1% 4% 0% 9% BY 7% 9% 5% 24 3% 1% 2% 1% 7% 3% 5% 1% 8% 0%
14%
'al
'PAPCM.121/4, 0.33 0.01 C.08 0.00 1.06 0.04 0 04
0.00 0.17 0.00 i 0.1513.00 0.34 0.01 008 0.00 7.29308 4.
.I.
7%6% , 7% 5% I% 8% 0% 1% 7% 6%
! I% 5% 6% 2% 896 3% . 1% 9% 46%
. .
=
hilKM-13h- 027 0.00 0.07 0.01.3 0.81 0.01 0.04
0.00 0.14 0.00 0.11 0.00 0.01 0.00 0.02 CI.00 029 0.00 0.07 000 1.95 OM
003-e2 6% 6% 2% 1% 9% 9% 6% 0% 5% 2% 7%
1% 3% 1% 4% 1% 0% 6% 6% 1% 5% 9% 45%
IVIPCM-13A- 0.05 0 00 C.07 0.00 0.14 0.03
0.4013.00 i 0.16 0.00 0.05 000 0050.00 0.29 0.00 007 0.00 1.32 3 02
003-fl 1% 2% 2% 1% 8% 2% - i
2% 294 0% 1% 796 0% 7% 5% 8% 1% a% a% 11%
mmykw oxyi ow o.oi 0.00 0.08 0.00 0.14 0.00 0.4713.01 0.18
0.00 0.05 C00 0.06 0.00 0.31 0.00 008 -676=3 -fig 0 03 -
i310,34E 0% 1% 3% 0% 1% 2% 6% 4% 4%0% 4% 2% 4%
1% 1% 1% 9% 7% 1% 2% 5% 0% 10%
0
6)
0
6.
6.
1-=
6-
-.1
0
0
0)
6)
0
6.
0
=
6.
0
...)
0
P 0
A
d
w
k..)
=
i-i
4a,
...,
0
4a,
0
cr,
0
4a,
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The controls (al, b2, cl , d2, el, and f2) had only THC while the comparators
(a2, hi, c2,
dl, e2, and fl) had approximately the same amount of THC plus a small
percentage of CBD. In
Week One approximately 1.5% of CBD was added, in Week Two 3% of CBD was added.
These
non-THC cannabinoids have demonstrated pharmacology (such as CBR antagonist
and 5HT-1 a
agonist) that were hypothesized to attenuate some of the negative side effects
of THC by
blocking the action of THC itself or by activating alternative pathways.
The controls and comparators in Weeks 1-2 were also blended to have very
similar
terpene profiles in order to ensure both samples had similar aroma, flavor,
and putative entourage
effects, so as not to predispose the volunteer to thinking one or the other
would be different
based on organoleptic properties. Both Table 33, and Figure 1 (with comparison
pairs indicated
with brackets) of relative terpene content show the precision with which the
blends were
engineered to have comparable terpene profiles. The blends were always
prepared so the
nxyrcene content was below 60% and the total identified essential oil content
was about 1.5%.
The amount of added CBD was kept below 3% since adding more of the myrcene-
rich
CBD cultivar would have significantly altered the terpene profile and all the
groups would have
become myrcene dominant. Adding more of the myrcene-rich CBD cultivar would
have also
diluted the relative amount of THC, and at this stage it was desired to ensure
any changes in
effect were due to the addition of CBD rather than a significant reduction in
THC content.
Thirty volunteers were recruited and asked to fill out demographic surveys.
Each week the volunteers were given a control and a comparator, two
corresponding surveys
(Figure 2), and asked to fill out the survey forms as they self-administered
the samples over the
following week. This was designed to be a head-to-head comparison and the
results were then
tabulated in Excel and analyzed both as absolute ratings and as differences
between the control
and comparator. The results of Weeks 1 and 2 (control vs. comparator) are
summarized in Table
34 as averages followed by 95% confidence intervals.
Table 34- Combined feedback results for Week 1-2 trials.
AVerar $1,14Pr.. FRIMS r %wk. 1-2
1:114e,Aion A 9s4s, c osi4c: 3)slii 95% g
8µ.514t: ItTrAt. 85% a
Afcrfqi = 1 142 0 0.98 -0.9 1.59 am 127 2
176 -0.5 2.07 Ø23 0.65
23z,:nr 86 1.98 -013 1.14 -1 6 1.5.5 -7, 1 24
0.857 145 -0.83 171 -0 8 06)
Mi'nd 1 57 1.12 -0 11 1.40 -L 6 1.61 .1 63 074
-043 127 0429 170 -0 85 ass
171
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
904V -0.43 0.72 0.222 1.52 .1.2 1.62 4.38
1.33 1.143 1.93 -1.14 1.79 -0.5
-1.14 1.00 -056 1.27 -1 1.13 -35 0.74 0.286 1.02
-0.57 1.41 -0 22 0.46
Ø71 2.13 0.444 1.09 -0.6 1.06 2.25 1.73 1.143
0.79 0.286 0.70 0.438 039
1.42 -0.33 1.27 1 1.87 -038 132 1.143
1.00 0371 1.53 0 333 0.62
-0.29 0.93 0.333 1.03 0.6 , 1.14 -3 1.74 -0.86
0.79 -0.71 1.95 -0.58 , 0.61
.7 .
0 016 0.222 0.91 -0.7 1.40 0.75 1.65 0.857 0.51 0.957 1.45 0.271 0.51
2.43 1.70 0.222 0.79 -1.4 1..1 0.13 1.14 0.714
0.56 1 2.01 Ø38 0.63
0.143 1.31 1.111 0.89 -0.3 134 0.25 1.03 0.236 1.02
1.143 1.84 0.417 0.51
H0.90Ø -0.71 217 1.222 1.30 0.4 1.81 -0.38
1.23 0 1.54 -0.43 2.45 0.083 0.71
li3WE MO UM -0 .1 4 2.16 4156 1.14 -0.7 1.94 -1.5
1.23 -0.57 1.34 -0.29 1.90 -0.65 0.66
-0.51 1.53 0.667 1/2 -0.1. 0.8.5 0.5 1.48 1.143
1.00 -0.29 2.21 0.229 0.56
:3043Mali -1.43 1.34 0 0.86 , -0.3 114 0.625
1.28 1429 1.04 1.143 2.03 0/08 , 037
9.714 1.33 -0.33 1.22 0.8 0.96 -038 1.11 1.429 1.04
1.286 1.85 0.542 032
:== -0.57 -0.57 1.70 Ø22 0.63 -L7 1.73 -
113 130 -0.57 153 -0.43 1.81 Ø81 0.61
-1 1.54 0 1.70 -0.44 0.93 -0.79 1.95 -
0.1 1.46 -0.67 1.31 -0.43 0.57
0.71 2.08 0.778 136 , -0.6 1.68 0.75 1.47 1 0.74
1.143 2.23 0.354 0.69
Ni46A3,CMMEM 1286 21,1 -0.67 0.92 1.6 1.92 -1.5 1.85
0.143 1.51 -0.43 2.93 0.125 0.82
The results are presented as the difference in feedback scores between control
samples
with just THc cannabinoid, to comparator samples with added CBD cannabinoid
(see Table 34
and Figure 3). Several feedback trends can be seen in the comparison of the
two samples. Most
notably, there appeared to be an obvious decrease in the level of "mind high",
"body high",
"intoxication", "sedation", and "duration" for cannabis blends containing CBD.
There also
appeared to be an increase in the ability to "function normally" for cannabis
blends containing
CBD. There was also a decrease in "anxiety" and an increase in "energy" level
for these blends.
Each comparison control and comparator sample contained equal amounts of THC
and nearly
identical terpene profiles. Thus the differences outlined in Table 34 and
Figure 3 are attributed to
the relatively small amount of CBD added to comparator samples.
The observed trends suggest that the addition of a non-THC cannabinoid, such
as found
in chemotype II cultivars, can help reduce the feelings associated with being
"high", reduce
intoxication, reduce the duration, reduce sedation, and improve the ability to
function normally
while under the influence of TIIC. Thus in some embodiments, the specialty
cannabis of the
present invention with CBD has the potential to reduce adverse effects and
provide a larger
172
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
margin of safety for a number of applications wherein the specialty cannabis
is provided as a
blend or as flower material from an individual variety. In some embodiments,
the CBD
containing specialty cannabis can be used at times when users wish to still be
able to function
after smoking. In other embodiments the specialty cannabis of the present
invention can be used
for medicinal applications. Many times patients attempting to use cannabis for
medical treatment
discontinue use due to the aforementioned "negative" side effects, such as
being "high" or
intoxicated, and these ratios have demonstrated a clear potential to mitigate
these effects.
The decrease in flavor feedback for the CBD blends was likely due to the
addition of
unpalatable CBD-rich plant material and kief to reach the desired cannabinoid
levels. This result
further reinforces our original hypothesis of the need for specialty cannabis
varieties which
contain CBD with desirable terpene profiles to create pleasing aromas/flavors
and reduced side
effects. In some cases, patients discontinue use of previously and currently
available medicinal
CBD marijuana due to unpleasant aromas and poor organoleptic feel. Currently
existing
TI-IC:CBD cultivars have terpene profiles and total oil content that result in
organoleptic
properties and entourage effects that are less appealing than the THC-only
cultivars. In one
embodiment, patients wishing to use the specialty cannabis of the present
invention for medicinal
purposes will prefer the improved aroma and flavor, which results from the
present invention.
While it has been known that CBD is an antagonist to the CBI and CB2 receptor
(Mechoulam et al., 2007 "Cannabidiol-recent advances" Chem biodivers 4(8) 1678-
92), studies
between CBD producing varieties have often compared varieties with high CBD
contents and
varying THC contents. Thus it has been difficult to distinguish the effects of
the addition of CBD,
to that of the reduction of THC. In this study, we have shown that beneficial
trends can be seen
with the addition of small amount of CBD, and that, unexpectedly, these
effects do not require a
substantially diminished THC content. Furthermore, this study indicated that
volunteers
preferred THC/CBD blends with aromas and organoleptic properties normally
associated only
with high THC content.
Example 10. Volunteer trials using specialty cannabis. Effect of added high
terpene oil.
The fifth and sixth week of the trials were designed to test the effect of
higher terpene oil
content on cannabis plants. For this trial, the same groups (1-6) used in
Example 9 were asked to
compare the more oil rich profiles of (a-f) to the "typical" terpenc profile
of (g) found in
173
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
currently existing THC:CBD or CBD varieties (Tables 35 and 36, and Figure 4).
This "typical"
profile was represented by a known chemotype II variety "Harlequin" (Week 5),
or by
mimicking the tap= profile with a blend of CBDOI and BLUO6 varieties (Week 6),
which
allowed the THC:CBD ratio to be adjusted. For each week, the control and the
comparator
samples had nearly identical ratios of THC:CBD. On Week 5, the THC:CBD ratio
of the samples
being tested was ¨1:2 (Harlequin). On Week 6, the THC:CBD ratio of the samples
was ¨2:1
(BLLT6 and CBD1 blend). The terpene profile of the control was the typical low
oil myrcene-
dominated profile of the mixed cannabinoid cultivars, while the comparators
had higher oil
content representative of the specialty cannabis plants of the present
invention.
Samples for the trials were generated as described in Example 9. However, for
this
example, samples were ground by hand. As before, each sample was analyzed via
GC-FID and
EIPLC before being provided to volunteers in order to ensure consistency
(Tables 35 and 36, and
Figure 4). The same questionnaire that was used in Example 9 (i.e., as
provided in Figure 2) was
used to assess the volunteer feedback on the tested blends.
The sample ID of the control sample is highlighted (Tables 35 and 36) and the
relative
terpene profile is labeled in Figure 4. Week 5 of this study compared a
typical low oil 1:2
THC:CBD variety (Harlequin in this case) to higher oil blends prepared from a
parental CBD
line (CBDOI) and various parental THC lines. Because the mass ratios required
to create the 1:2
THC:CBD ratio were approximately 1:4, the terpene profiles were all dominated
by myrcene
from CBDOI, and this is observed in the analytical results. While all the
relative terpene profiles
were similar and dominated by myrcene, the absolute content was significantly
different, with
the control (Harlequin) having less than 1% and all of the comparators having
greater than 1.5%.
Week 6 compared a typical low oil 2:1 THC:CBD variety (mimicked by blending
BLU06:CBD01) to higher oil blends prepared from a parental CBD line (CBDOI)
and various
parental THC lines. More diversity can now be seen in the terpene profiles of
the comparators
and the control. The control samples had lower terpene oil contents of ¨1%,
while the
comparators were generally between 1.5-2%.
Table 35- Cannabinoid levels of cannabis blends for Week 5 and 6 trials as
measured by GC-
FID and 1-PLC. Blank values indicate undetectable levels or 0.
Can binaids it5C-1,101 Cannabitsoitis (MVO
174
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
::A33J82V
= : :: :: : :: :: :
Sample
MPCM -13A-006-a 3.24% 0.09% 10.37% 0.11% 0.31 0.01 4.65%
0.05% 14.20% 0.24% 0.33 0.00
MPCM-13A-006-b 3.49% 0.53% 869% 0.16% OAD 0.07 4.93% 0.75% 11.539% 0.33% 0.41
0.07
IMPCM-13A-06-c 3.65% 0.09% 8.87% 0.51% 0.41 0.02 5.29% 0.09% 12.24% 0.93% 0.43
0.03
MPCM-13A006-d 3.42% 1.38% 10.41% 3.61% 033 0.02 4.90% 1.86% 13.56% 2.99% 0.36
0.05
MPCM-13A-006-e 4.04% 0.48% 9.26% 0.24% 0.44 0.06 5.99% 0.60% 12.906 0.13% 0.46
0.05
MPCM-13A-0064" 3.13% 0.07% 9.64% 0.47% 033 0.01 4.71% 0.07% 13.29% 0.57% 0.35
0.01
';40.1%;AkinAllait=C 4.57% 0.12% 9.97% 0.15% 0.46 0.00 6.59% 0.00%
14.15% 0.08% 0.47 0.03
MPCM-13A-007-a 9.79% 0.35% 4.58% 0.39% 2.15 0.15 14.66% 0.94% 6.99% 0.03% 2.10
0.14
MPCM-134-007-1:: 9.09% 0.44% 4.70% 0.22% 1.94 0.16 12.33% 0.67% 6.40% 0.28%
1.93 0.16
MPCM-13A-007-c: 9.63% 0.41% 5.90% 0.30% 183 0.15 13.04%
0 40% 8.12% 0.50% 1.61 315
kb
MPC.M-1.34-0(17-d 7.39% 0.31% 5.14%: 0.27% 144 0.13
ii.1.00% 147% 7.74% 1.95% 1.44 3.16
MPCM-134.007-e 10.53% 0:71% 7.14% 0.38% 1.52 0.18 14.61% 1.66% 9.60% 0.69%
1.52 0.18
MPCM -13A 007. f 2.06% 0.57% 5.27% 0.30% 153 0.02
13.05% 1.42% 8.38% 1.10% 1.56 0.04
ikilP.08/1,0Milfffije 8.13% 0.37% 4.10% 0.07% 1.98 0.11 12.94% 0.85% 5.33%
0.58% 2.43 3.15
175
CA 02911168 2015-10-30
WO 2015/065544
PCTMS2014/046694
row 2.,.: at at e e e at e at r * e at at
at
..: 49. __ N.A..0,,......4
jeittr/40*4gn*qtqCOR4*4*44t4Ait
.....
0
,--U ,,= ____
4...
0
'''''
A,:Aftilt4*RIti;8.4t8*ggIti;)/t4)/tg*8*8*
=
.p.
'6.1.4480*4*4*SO4tg*420tri***401C4W;!*
CA .0 = .'::0; CiV0=30Lnd 0"
0.''0001.3dvo o'ovom
780 , __________________________________
Z
>. =Ogga*4*40*C11.10*R*4*4*3*S*40*
,..E.w.it:,,,o dvovo dmovovovovovdvdvo 6v
."14A*4"101"14"14t6f4"0"!*710t4"Oercilt
... 5 -.*oNcoto ol'o'new.a-
'o*o^o"oNo*c^o^
0 8 z,r,$at$at$e8g8g$at 8* 8r $g$g 8g
lir, '"e`c;le2at2e2we'-'4e2at 2at , 2*8*
. ... .6cocic.60.S.Or46.0 2ig 6.x.c.im al.
0 .
r."... . 0 =0-.0-0,-0 0,-0-.0 0 0-.0 0g0,-.
.
0 5.0q.:IggC6 4":
ovo.-o 6 dmovdc= 6v gA,(gCgaqg
o
0
- "-8e8e8e8e8e8e8e 8e8e8e8e8e8e
2 "c;u6v6v6v6v6v6v6v d..od.6.6Ø
.10 7,' rn 0 Cr W A kD rn 0 W V PI 0,õ,
"0 N. 5gyeoatoAqAcOftgeq
, o'ad'Id'eom0'0.aroa' "Ig."ktgeot g-'''''''
-.8g¨ - i .
F A,
i
I
________________________________________________ - *
E.,..; ...... z, .
I
0 .
:,...
6m
Ts c.c i
. 4 ,..1
8 1 __
S5t..*'111*19. i
,...<
4 t e8r8at,at git 8e8atr2g8at8e8e8at Sat
,L. V; 6v6m6,6v 0N6"60,0 0m6081N606^
kr) a ... m o m r. tgeOgglie,lee8*7.148e
g z'atqr-Oeqrqe
, 0W,N0A0A dv6v6 dv6v6v6mo 60
1..) .
.z.`'
C:,
0 cir`
8*
w il _____________________________________
q*
la 0
8*
om
C , 1 _____________________
A0g
_ ________________________________________________
c.b
5a6li*WOX"""MglgOe'tgq00at
4 r18*$*$*$*$*4* 8e$It$at$at$*$at$eQe
L..., a = -
6vou'omovomovcivovevovo'^ovevom
=
0
4.
C :.,:&.:;L:o ovov606
6v6vovovo^ovdmov6v
0
. . .7,
0 . r
a..)
E.'
'S a c,
...? .
-----.4 ____________________________
. c; ,....... o ovovovo-
ovOvovovdvo ov
4P s. -- = r:5::: = = = = = =
1::5:::
et.a 0 UVI?-
9My"17t1'717;¶Y;T;v7.4.T41
=.::-2pYRicogmot. .m18mmr-m,-';
= T.; Ak le6kekc'k k Ak5kc'k
ko0oEM
k'm U 54,0M 9.1a0M
176
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The survey results are shown in Table 37 and Figure 5.
Table 37- Feedback results for Week 5 and 6 trials.
1
i .... A.,/,'IiI=II:
....
= =
= = n
__________ CiLI,II.:1,1=:, .II ,;...I'Ii C :.::.3:.:.:. .5)µSs'/,
I., L.. .?::, Ik C: L, ,.../ ,I.....,.,. c; E ..-..,.:: ,
=...,...3,1 i : fi; .I.,L :<95%(
3 0.80 4 5.88 1.2 1359 0 667 5.58 4 '
4.08 L667 1.73 2.25 1.21
33 H33
L75 0493 III 3 1.37
3 2.99 3 2.99 1.333 1.73 2.105 0.90
'
. 139 -1 1.96 0.25 0.49
2.333 2.85 0.333 1.73 2.667 3.27 , 1 0.87
8."...4 3 0 75 1.67 -0.5 0.98 0 0.80 0 2.26
2.333 2.85 1.667 4.28 _ 0.737 0.93
'
iHH:H
175 094 0 1.96 0.2 1.14 0.667 2.36 0.667 0.65 1.333 0.65 0.8 0.54
..
33:3:3:::3:3333:
c.003.3.::::::::::: 0.5 0.57 -0.5 0.98 2.4 1.92 0 4.53
2.333 2.36 -1.67 3.27 0.75 1.11
'
HH
H=3,k7ti`..44: H3 0.75 2.32 1 1.96 0.3 0.73 -
0.33 3.97 1.333 2.61 -1.33 3.64 0.4 0.97
433e -0.25 Ø25 049 -1.5 2.94 -2 1.64 -2.67
2.85 1.333 2.61 2.333 5.58 =0.55 1.24
...iiM MMM
1 2.12 1.5 2.94 2.2 2.66 0.333 457 0 1.13 -233
2.85 0.6 1.21
1.5 127 , 3.5 0.98 -OA 3.37 2.333 2.85 0 2.26
1 1.13 1.05 1.10
0.25 049 1 1.96 0.3 1.14 -0.33 6.63 1 1.13 0.667
1.31 0.55 0.94
L....;;;....;;Ma;
1.5 1.27 1 1.06 .2 2.06 0.667 1.31 -0.67 1.31
2.667 2.85 0.3 1.01
I141. 3".3.3.M ';'':'. 375 094 4.5 2.94 -2.4 2.37 -1.67
9.27 -2 0.00 2.667 2.135 -0.15 1 34
025 0.94 -1 1.96 -0.2 2.03 0.333 1.73 1.333 1.73
1.333 1.73 0.35 0.71
. . 1
1 113 1.6 0.98 1 0.61 1 1.96 0.667
0.85 1.667 1.31 1.1 9.77
255 2 3.92 0.6 018 2.333 2.85 0.667
2.36 0.333 0.65 1.05 u.8"..
'
am 123 0.5 0.98 0.75 2.45 1 2.99 ..... 0.333 0.65 .
2.333 4.71 0347 33,
.64..'...::.: :HH 0.3 037 0 0.00 0.75 1.47
1.333 1.73 1.667 1.73 2.333 2.36 1.105 0.63
FM0Ø,=Hg 2 0.80 0.5 2.94 1.2 1.44 1.667 2.36 0.667
2.36 0.667 1.73 1.2 0.68 .
UN M
iii3516&13,-6 : : : 3 -1 1.13 -1 1.96 -02 2.00 -3
3.39 0.333 5.10 0 1.96 -0.75 1.07
i'.i:*9333'OHH HH 0.4 139 3 1.13 3.333 2.85 3.25 0.94
2.333 1.31 2.667 1.73 2.143 0.87
0.4 048 3 1.13 2.667 5.10 0 4.08 3 3.92 2.333
0.65 1.684 1.10
. ........
i:1=44,,i gA a -3.6 1.71 0 1.13 0.5 4.90 1.25 2.45
4.667 3.64 1 1.13 1 1.14
0 OAS 1.667 1.11 13 636 3.25 2.93 3 5.89 1.733
1.73 1.3 1.16
333:3:::3:3:3333:
=li3613.. .8ØHH 0.2 21/9 0.333 1.13 0.333 2.61 2.5 3.05 3.333 5.58 1.667
0.65 1.333 1.16
3333 H3333
'.0::::::
..g 3 04V03"..s.: 3 ::::3: -0.2 2.03 0.667 1.31 -0.67
1.73 0.25 1.47 1.667 0.65 -033 3.97 0.19 0.81 .
....74......: H -az 039 -0.67 2.85 0.567 0.65 -33 2.47 0.333 1.73 0.667 1.31 -
0.57 0.89
33 3333
FM346.MM -1.8 3.12 -1.33 1.73 -2 2.26 =1.5 3.80 = 1
1.96 2 1.96 -1.05 1.24
ft.3.33HME .1.2 0:73 -1 3.39 1 1.13 -2.75 0.94 -1.67 719 -2
2.99 -1.1 1.18
*i=ii=eiMMA .Ø8 1.14 , 2 2.99 1 3.92 0.5 1.70 0.667
3.46 1.667 1.73 0.476 0.96 ,
::Sr.ssitniMM 0.7 0.39 -1 1.96 1.333 7.36 -2 2.53 1.333
0.65 -033 1.1 -0.14 0.79
:.3.3.:3:......33:,:,:,:,3,3,3,:,:
i1,40/3.0i:"33 0 0.62 0 1.96 0.333 035 1.75 2.17 ,,.
1 _ 1. ; 3 Ø33 2.95 0.476 0.67_
177
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
1
03M.1 9 95%C1 t 9540 95560 696%ti 95'.5 CI 70-/-,
S5'.4 C
D 2 073 -033 2.36 -1 2.97 3.25 2.58 -3 2.99 -
0.67 4.28 -0.14 1.22
Phy<:Nt: 0 4 0 78 -0.67 a65 -2 1 '6 -1 79 1
667 4,3 1 1 1 3 -01
-3.2 157 -0.67 0.65 -1.33 131 0.25 3.34 1 1.96
1.96 0 0.83
a4nctlrm -1 1 52 -1 1.13 1.333 1.73 -2 1.79
1.333 1.31 -033 1.71 -0.43 0.78
5e400n. 0 153 2 299 e 1.96 0.75 2.81 0.333
0 65 1.667 0.65 0.75 076
0:srm3i,a,; 0.2 0.73 1 2.26 3.5 4.90 2.25 2.17
0333 2115 2 2.26 135 031
Po>itiv'e 0.6 0.48 2 1.13 0.667 0.65 I 2.65
1.333 131 0 667 2.85 1 0.65
Nbvitivis -0.6 0.78 -1 1.13 0.333 225 -1.75 1.47
0 2.99 -1.33 0.65 -0.76 0.67
For Week 5, both the control and the comparator had nearly the same levels of
THC and
CBD, so that any observed change in effect can be attributed to the higher
terpene oil contents.
The major trend observed in this case is that volunteers experienced a more
pleasing aroma,
flavor, and overall positive assessment of the high oil blends compared to the
currently available
low oil chemotype 11 "Harlequin". Additionally, high oil blends showed
increased scores for
ability to focus, calmness, energy levels, emotional comfort, and ability to
function. This result
demonstrates that our hypothesis that the higher terpene oil contents of the
specialty cannabis of
the present invention mixed THC:CB cultivars will be found more appealing to
cannabis users
than the currently available low oil varieties.
Example 11. Volunteer trials using specialty cannabis. Effect of added diverse
terpene
profiles.
The seventh Week of the trials was designed to test the effect of diverse
terpene profiles
on cannabis plants. For this trial, the same groups (1-6) used in Examples 9
and 10 were asked to
compare the diverse terpene profile of samples (a-f) to the myrcene dominant
terpene profile of
(g) found in currently existing THC:CBD and CBD varieties (Table 38 and 39,
and Figure 6).
This study compared a 5:1 THC:CBD cannabinoid ratio with a myrcene dominated
terpene
profile (a blend of BLU06:CBDO1 in this case) to blends prepared from a
parental CBD line
(CBD01) and various parental THC lines. Samples for the trials were prepared
as described in
Example 10 by hand grinding and blending cannabis. As before, each sample was
analyzed via
GC-F1D andl1PLC, before being provided to volunteers in order to ensure
consistency (Table 38
178
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
and 39, and Figure 6). The same que.stionnaire that was used in Example 9
(i.e., as provided in
Figure 2) was used to assess the volunteer feedback on the tested blends.
The sample ID of the control is highlighted in (fables 38 and 39) and also
labeled in
(Figure 6). This study compared a typical high myrcene terpene profile to
higher more desirable
terpene profiles with other terpenes. Samples b, d, and f in particular
exhibited desirable terpene
profiles in which myrcene was not the dominant terpene.
Table 38- Cannabinoid levels of cannabis blends for Week 7 trials as measured
by GC-FID and
U PLC.
Canrsabinoid; (GC FID) C1nr1binoic:(0%43'1C)
'MC am VIC C130 3r & THCA
CODA THCA:C804. Ix? 11PLC
Sample WI 95'X Cz 7%c3 11 W! X 15 X :S. I X
15%1;i Vtiz !6' 9!,
MPCM=13A.008-a 16.59% 0.65% 2.10% 009% 7.92 0 21.20% 0.42% 2.57% 0.16%
.:.25 0.57
MPCM-134.008-b 1437% 1.27% 2.02% 0.20% 7.3e 2.38 18.82% 0.91% 2.43% 0.41% 7.71
1.60
MPCM 13A-508 c 15.47% 0.60% 1.86% 0.18% 8.39 0.99
20.27% 0.17% 2.32% 0.10% 8/5 0.32
MPCM-134,008 d 11.10% 0.80% 1.53% 0.06% 7.27 0.81
14.99% 0.60% 2.09% 0.10% 7.17 033
MPC44-13A.420Ki-e 17.24% 1.03% 2.1.5% 0.12% 800 0.79
22.86% 1.22% 2.86% 0.08% 7.98 0. 3
3
MPCM 134.0084 13.21% 0.54% 2.07% 0.14% 6.22 0.69 17.62%
1.04% 2.46% 0.14% 7.19 0.65
MPCM-1.34..0061 14.67% 0.62% 160% 0.22% 5.25 131 19.75% 0.54% 1.87% 0.26%
10.67 1.28
179
Table 39- Terpene contents of cannabis blends for Week 7 trials as measured by
GC-FID. Blank values indicate undetectable levels or c
1...)
0 ,
=
VI
--,
.5
Terpene: 03C-FID) Vi
VI
alpha gammv
beta Total 4-
alpha tamphen beta aipila beta terpinoten
aipba alpha cary Relati 4-
. myrrene phellandre carene ,,,.
,_ . 8mnnene otltrelle: terpinen ,i, linakm1 tenant rarvophyli
klentiffen
pinene e p:nero, t, pmr.riv
1eitsineol b*mulene oxide
et e
-- ------- - .,-,,,.,,-
.,-,...,, rrnace
HM 95% WI' 95% 95% 95 % Wt :% Wt tasv wt
9s s i 95:S. :3(1,0'. 95:90 1(0s 95 % 95 % WI 95 % l0( 95 % 403 95 %
9S% 957 WY 9.5% 9S%
, ne
i6.010: wt II \ a % a lot ss,. a tvt ,,,,\ n
% 1 :: 0 ::: ::%, :::::q::: ::::%:: q:: wl ,,,,,,: :0:::: :::%:: : 0:::,
Y. CI Wt X:: Cl. % CI % : Cl. % CI I.90 %.4. CI Wt 56 CI %
C3 Wt % CI .
NIPC.10.13A- 0.33 0.00 0.10 0.00 0.48 6.00 1 0.06
0.00 0.03 0.00 i 0.04 0.00 ! 0161040 0.0*i0.00 1.31 0.01
008.a 3% 8% 5% 2% 7% 8% 1% 2% 7% 1%6% 1%
3% 1 6% 0% i 2% 3% 6% 37%
1
e
i
NIPCM-13A- 0.09 0.00 0.10 0.00 019 0.00 0.49 0.01 0.08 0.00
0.16 0.00 0.06 0.00 0.07 0.00 034 0.01 0.09 0.00 1830.07
.. 008-b . 8% 5% 3% 2% 3% 7% 0% 4% 0% 2%
4% :39( 9% 2% 2% 2% 7% 13% a%8%
N4PCM-13/11 0.11 0.00 0.05 0.00 0.55 0.02
0.15 0.00 0.24000 0.08 0.00 0.02 0.00 0.04 0.00 0.1710.00
O.060.00 1.49 0.03
008-c 3% 6% 8% 3% 1% 1% 8% 3% 0% 4% 3%
1% 8% 1% 3% 0% 5% I 1% 1% i 0% 7% 0% 37%
MPCM-13A- 0.08 0.00 0.07 0.00 0.24 0.00 0.01 0.00
0.01 0.00 0.10 0.03 0.13 0.00 0.33 0.01 0.05 0.00 0.07 0.00
0.04 0.00 0.1110.00 0.03 0.00 1.29 0.02
008-d 2% 2% 9% 2% 3% 5% 8% 1% 0%
0% 9% 1% 1% 3% 8% 1% 3% 1% 3% 1% 1% 1% 2% 5% 0% 1% . 0% 7% 19%
MPCM-13A- 0.29 0.01 0.08 0.00 0.95 0.04 0.06 0.01 013 0 00
0130.00 0.32 0.01 0.0810.00 2.07 0.10 0
0080 1% 9% 8% 5% 3% 8% 6% 1% 6% 7% 2% . 534
0% 2% 4% i 4% 0% 4% .
9,
M0C3.4.13A 0.07 0.00 0.013 0.00 0.26 0.01
0.31 0.01 0.15 0.00 0.05 0.00 0.')5 0.00 018 0.02
0.0710.00 1.35 0.06 o.
o.
1..k 008-f 7% 3% 1% 3% 0% 0% 8% 1%
1% 9% 0% 3% tl'A . 3% 6% 2% 5% 1 5% 1% 4% 19% P.
<P,
00
ce
i
0 .t.00..14.* 0 V 0.00 012
OA) 0.46 0.020.05 0.00 0.06 0.00 0.3.4 0.02 0.04 0.00 ktb.:
.13iØ5 PP
=0044.N % 73 3% 6% 0% 3% 594 3% . 334
5% 0% 3% 5% 7% ::40%:=:41k::'7% 0
1-
L.
=
1-
o
w
.
No
(-5
d
w
NI
o
I.+
4:.
...,
0
4:.
CA
cr,
vp
4:.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The survey results are shown in Table 40 and Figure 7.
Table 40- Feedback results for Week 7 trials.
.:=:z0,s?fot4g#,OOVA.07g
9.:=:;;;- c.: C ;959k; .;;;;;;;;;Z; En 9.51CC;
-2 : 4.08 ; .5 4.3.5 I 333 1.73 2.5
0.98 -0.75 1.47 -0.67 0.65 0.059 1.04
3.5 6.86 0 -2 2 3.92 -1 1.13 -
0.5 0.93 0.455 1.59
3.333 538 13 0.98 1.667 2.85 -0.67 131 -1 2.40 -0.25 0.49 0.579 1.20
3.337i; ....
1.667 2.36 2 1.96 2 1.96 0333 131 1.2.12 -0.5
1./0 0.942 0.81
1.667 4.28 1 0.00 2 3.39 0 2.26 -0.5 1.7C 0
0.80 0.579 0.96
CroIrn' 0.667 2.36 1 0.00 0.333 1.31 1 0.00 -
0.25 1.23 0.5 0.57 0.474 0.48
Aiiiii.44immHu 2.667 6.23 1 0.00 -0.33 2.61 2.667 1.73
-1.75 2.17 1 1.96 0.737 1.31
0 0.00 0.5 0.98 -0.3.3 0.65 -.3.39
3.27 0.25 0.94 -0.25 2.45 -0.56 0.93
"
.31kikUMN -0.33 6.23 0.5 0.98 4.67 2.36
1.667 0.65 -1 1 0.8C 0.5 0.98 0Ø53 1.01
Mood 3.333 538 1 1.96 3.333 1.73 -0.33 3.27
-0.25 2.45 0.25 0.49 1.105 1.24
2 276 0 0.00 0 2.99 1.667 2.36 -
0.511.68 1 1.39 0.684 0.85
.0 87 0.65 1 1.96 3 2.26 1 1.13 =0.75 1.23 0.25
0.94 0.526 0.75
-+
ThN
-1 1.13 1 1.96 1.333 0.65 -1 2.26 0.5
1.71 -0.25 1.47 0.053 0.69
1.:367 1.73 0.5 0.98 2 1.96 -0.33 2.36 -0.5!057
0.25 1.23 0.444 0.68
538 0.5 0.94 1.333 1.31 0.667 3.46 0 0.80 0.75
2.17 1 1.11
________________ a333 0.65 43.5 0.98 -0.33 285 7 1.96
0.5 1.70 0.25 1 23 0.421 0.71
1.333 .3.64 '1 0.00 2.647 535 -0.67 2.36 0.5 330
1.5 2.33 1.053 1.32
Dwatio,1: 2.333 3.64 C 0.00 2 4.08 0.667 0.65 -
0.5 1.27 13 2.47 1 1.02
3 5.38 03 0.98 4333 0.65 1.667 2.36
0.25 1 1.86 1.25 1.67 1.789 1.17
________________ -0.33 2.85 0.5 0.98 -1.67 2.36 -1.67
3.27 0 1.39 0 1.39 -0.53 0.84
Since both the control and the comparator had nearly the same levels of THC
and CBD,
any observed change in effect could be attributed to the varied terpene
profiles. In general, non-
myrcene dominant profiles showed increases in energy and alertness, associated
with less "couch
lock". Moreover, analysis of each terpene profile separately revealed several
terpene specific
effects. For example, there were large increases in the aroma preference for
classes b and d
which had profiles dominated by terpenes other than myrcene (limonene and
terpinolene,
respectively). There was also an increase in calmness for all classes except
e, which was the only
class to have substantially more myrcene than the control sample. Terpinolene-
rich d is more
anxiolytic which agrees with studies showing terpinolene to have a calming
effect on mice (Ito et
al. 2013 "The sedative effect of inhaled terpinolene in mice and its structure-
activity
181
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
relationships" J Nat Med 67:833-837). Increased ocimene in C always improved
mood
enhancement. Ocimene has been suggested to be an anxiolytic in mice (Okoli et
al., 2010
"Anticonvulsant and anxiolytic evaluation of leaf extracts of Ocimum
gratissimum, a culinary
herb). Our results show that non-myrcene dominant profiles can increase the
amount of energy
and alertness after consuming cannabis by overcoming the "couch lock" effect
of myrcene. In
addition, our results show that the reduction in myrcene also allows for
entourage effects of other
terpenes to create unique specialty cannabis tailored to a desired medicinal
or recreational effect.
Example 12. Development of THC:THCv/CBDv specialty cannabis varieties
Unique parental THC , CBD, and THC:THCV lines from Examples 2-4 were selected
and one of the parental cultivars was treated with silver thiosulfate to coax
the pistillate plant to
produce staminate, pollen-bearing flowers. The THC:CBD, or THC class varieties
were crossed
with THVO1 lines. The resulting progeny were screened by TLC to identify
plants producing
more than one cannabinoid (e.g.. THC:TEICV, or ITICV:CBD'V). Progeny
exhibiting desired
cannabinoid profiles were allowed to reach maturity and the flowers were
harvested and
processed. In general, field observations could detect the crosses with the
desired characteristics,
however this was verified by chemotype analysis and the final flower was
analyzed for
cannabinoid and terpene content. Table 41 outlines the initial crosses
performed with THC class
or CBD varieties and THCV parental lines. The crosses produced progeny
approaching ratios
supporting the separate loci for the control of THC/CBD and THCv as suggested
by de Meijer et
al. I, II, III, and IV (I: 2003, Genetics, 163:335-346; 11: 2005, Euphytica,
145:189-198; 111: 2009,
Euphytica, 165:293-311; and 1V: 2009, Euphytica, 168:95-112). TLC results are
indicated as +
or -, where + indicates the production of THCV with at least one other
cannabinoid.
Table 41- Crosses performed between THC:CBD parental and THCV producing
parental lines.
TLC result of + indicates presence of THCV with at least one other
cannabinoid.
vol
CRIX:5
P Dartar
S13.08xP GRE:01 VE3.03 THVO1
Acceptor
"¶: Fr , Code 1.1C
I SILO8/1?-01 - GREWAP-01 - VEL03x7P-01 - THV01OP-01 = +
2 511.08kTP-02 GREO1,CrP-02 - YEL03xTP-02 -
THVOl.:7?-02
3 SiLO8xTP.03 - GRE01xTP.03 - YEL03xTP.03 - THVO b
P.03
182
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
THVO1 COWS
P Doctor
SILONNP GREcn. YEW: Ili V01
Acceptor
VA-Aie r C.hie 13C Pest& Cod% l=lt4su11 CC:it C
4 G RE,3 0 Yi 13xTP-0,1 1HV014CIP-
(J4
YE11336TP-0S + TFIV014P-OS
6 Yh I 3,4 f' W-136
7 T 88018TP-07
11480187P-08
.............
9 1-15201xTP-09
THV01871). 10
11 [WA:1xW-13.
2.2 THVO1x7P-12 +
- -.---
13 111901879-13 +
14 TlisAl1xTP-14
TH1/01x1P-15 -
16 THV01819-16 +
17 THVO1xTP-17 -
18 THVO1xTP 18
19 UW01819-19
THVO1x1P-20
21 TH801879-21 +
22 THVO1871,22
4
13 THVO18P-23
24 T19/018117-24 I +
Example 13. Chemical analysis of cannabinoids and terpenes of Tlii(::THCV
specialty
cannabis progeny.
The new specialty cannabis varieties created through crosses described in
Examples 5
5 and 12 were subjected to cannabinoid and terpene chemical analysis as
described in Example I.
The levels of cannabinoids were measured by both GC-F1D (Table 42) and HPLC
(Table 43).
'rerpenes were measured using (iC-FID and are presented as absolute content
measurements
based on the percent content by weight of dry inflorescences (Table 44) and
relative content as a
percent of the total terpene profile (Table 45). The GC-FID cannabinoid
analysis of Table 42
10 also included measurements for CBGV, CBN, and Delta 8 THC, all of which
were measured to
be less than 0.06% and were therefore not included in the table. Similarly,
the HPLC
cannabinoid analysis of Table 43 included measurements for CBCA, CBGVA, CBC,
THCV,
183
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
CBDV, CBGV, CBN and Delta 8 THC all of which were measured to be less than
0.08%, and
were therefore not included in the table.
The specialty cannabis produced by the crosses described in Example 12 contain
THCV
or CBDV cannabinoids while also producing desirable terpene profiles. For
example, the YEL03
X TP05 plant of Tables 44 and 45 has a non-myrcene dominant terpene profile.
Thus in some
embodiments, the specialty cannabis of the present invention has THCV with a
non-m.yrcene
dominant terpene profile. In some embodiments, the reduced myrcene content of
the specialty
cannabis will reduce the amount of "couch lock" effect produced by myrcene. In
other
embodiments, the terpene profiles of the other THCV and CBDV progeny provide
diverse
terpene profiles designed to produce desirable aroma/flavors and organoleptic
appeal. In other
embodiments, the terpene profiles of the THCV and CBDV progeny allow for
terpene entourage
effects to reduce the side effects of THC. For example the TITVOI X P07, THVO1
X P02,
THVO1 X P18, and THVO1 X Pll have increased levels of ocimene terpene. In some
embodiments higher ocimene levels will impart woody and floral aromas/flavors
to the specialty
cannabis of the present invention.
The breeding scheme described in Example 12 also produced specialty cannabis
plants
with increased terpene oil content. For example, progeny plant THVO1 X P-03
has a terpene oil
content greater than 2%. In some embodiments, the higher oil content of the
specialty cannabis
varieties provide "smoother" aromas and flavors and will raise the total
terpene levels so as
increase the pharmacological entourage effects of said terpenes. For example
despite having a
myrcene dominant profile, the THVO1 X P-03 specialty cannabis of the present
invention is
expected to provide a better organoleptic experience than that of the myrcene
dominant THCV
varieties currently available which tend to have low terpene oil levels.
184
Table 42- Cannabinoid values as measured by GC-FID for TIIC:TIICV and CBDV
specialty cannabis varieties. Blank values indicate c
6..)
undetectable levels or 0.
=
,...
,
0000i0Ø0*wio:?E:::::
ti.
...... :DK : ...... 480 .. : : : ......
CBG ::: ::c8.C: THCV : . ..CIIDV...=:::. . : .. : . :::
:CaIiii:496 biiriC:: :::ItiCatiCV.:.liVOC::
::::::::::::::.W.:::::::::::::::: Mit%
Tli%010941 4.81% i 0.41% 0.09%
0.80% 6.10% 6.00 4.26
mv03x1P-06 1.63% 757% 0.17% 0.25% 0.27%
0.32% 5.51% 6.15 4.53
THVOlx7P-08 5.63% I 0.35% 0.06%
1.04% 7.08% 5.39 4.31
IHVOIxTP-16 1.78% , 3.58% 0.20%
0.32% 0.21% 6.09% 4.55
!
7/N0167947 6.42% _I. 0.00% 0.43% 0.08%
1.01% 7.93% 6.35 5.89
-__ _
-_ .
THVOIc79-19 1.83% 410% 0.16% 028% 0.29%
0.45% 7.10% 644 6.29 1 3
c c
. t
or THVOlx7P-20 2.18% _I. %. 5.21% _ 0.44%
0.32% 0.24% 0.39% 8.77% 595 5.20 O
00 - .- _
co
CA I
THVO1xTP-21 2.27% I 4.54% 0.28% 0.31%
0.42% 0.52% 8.34% 5.42 5.37
c
' 0-
THVOlx7P-10 I 1.77% 3.79% 0.44% 0.29%
0.29% 6.57% 3.65 I
_
-
__ . O
THVO1x1P-22 6.11% I 0.69% 0.10%
0.87% 7.76% 7.06 4.61 ow
i
THVOIx7P-23 4.10% 0.48% 0.07% 0.91%
5.56% 4.48 4.33
-- -r ._ _
i
7,11/0167P-071
5.36% 0.56% 0.22% 0.53% 6.67% 10.17 4.04
i
TliV01oTP42 3.94% 0.40% 0.05% 0.40%
4.78% 9.84 3.50
. . .
THVOlx7P-18. J *-
1.26% 4 17% 0.27% 0.27% 0.24% 0.57% 6.76% 5.30 .
5.45
_. ,
111V01.c7P-24 2.02% 464% 0.23% 0.32% 0.64%
1.00% 8.86% 3.14 6.92
_- _ _
:
i
NO
THVOIxTP-14 3.24% , 0.36% 0.29%
0.05% 3.94% ____ 63.55 4.02 (-5
...... 1--- 4
1 - 3
IHVOIxTP-15 :
= 5.67% 0.01% 1 03% 0.26% 0.66%
7.63% , 8.54 4 62 8
w
THVOlx711-095.39% 0.01% 0.60% 0.17% 0.63% 6.81% 8.58
4.55 b.)
0
loor
THVOI.VP-03 7.01% 1 000% 0.77% 0.23%
0.35% 8.37% 19.87 3.88
%-.
0
4or
THVOlx1P-04 1..._ 1.54% . ________ 4.17% 0.24%
0.28% 0.27% '.) 49% 6.98% 5 73 3.74 0
.
cr,
vp
7hVOIxTP-05 1.65% I 3.32% 0.15%
0.26% ".) 48% 5.56% 3.76 4:.
Cannabineids (GC-F10)
c.30118b81:TtOt:
CEO :::::::::::::
::::::::::::::::::::C86i:::: C. I %CV :::Cift37 Cannairi by GC
YNC:114L-11 by tie:::::
1,..)
=
Sam* W.: % Vt.';'.% .. ::::::: A,IT:%:::......... ,.. IA.t.`14
W t: % V., t ''.4; Wt %
'
'JI
--,
INVO1 rt TP-11 5 0 %I. 101% 0 64% n 21% 0 189;.
6 no,',34. ):: 4 = 3 SO .5
Vi
TIIVOixT3-12 1.58% 3.87% 0.23% 0.32% 0.19%
:.30 'A 6.49% 8.33 4.11
_4.
4-
-Frivol. TP-13 5.49% , 1.06% 0.21% 0.30%
7.06% 18.17 3.55
S:1.08.7P-02 11.14% 001% 0.33% 0.15% 0.25%
11.93% 44.74 7.35
98103k17.09 4.92% 0009; 0.53% 0.06% 4.12%
, 9.59% 1.17 8.78
1 .1.0Q for all cannabinows was 0.1496.
"
Table 43- Cannabirloid measurement by HPLC for TH(3:CBDV and CBDV specialty
cannabis varieties. Blank values indicate
undetectable levels or 0.
2
.
g.phisoinoio:tutipt..c*:
0
K:__,,,,,,,,,,,,,,,,,,K,,,,,,,
1"HC.Ai: :Ci1DA::: ::C11W4.:.: :: :33it'VK :
:cgi.rivw 1.1.fic ?COP:. :: :: :::: : ::: :::.:006:::::.
: : : : : : : : : : : : : :
0
5-3mp9F: ::::::: ::::::.:Wt:.94::.:::::: R.:W:t W
n n tii.9t5CH n3,0 96: n)1StIC n n.5. 1,t1N
:::::A1,49.1C::::: :: ::Vit:IC ::::: HSIV.tAn =11.44.:%n :.3..11:0
O
t
THVOlx1P-01 7.50% 0.00% 0.74% 1.45% ___________________ 0.07%
0.04% 9.80% 5.16 6.85
THVOUTP-06 1.96% 5.05% 0.29% _ 0.46% 0.69%
0.03% 8.48% 4.24 6.97
TI4V01TP-08 8.00% 0.60% 1.78% 0.14%
10.53% 4.49 6.40
\
T HVOIx IP-16 2.08% 6.17% 0.28% 0.27% 0.46% 0.04% 0.01%
0.05% ... 9.39% ....... 7.70 7.01
Th4VOIx111-17 9.31% 0.82% 1.77% 0.09% 0.03%
12.02% 5.25 8.92
THVO1x7P-19 2.06% 5.96% .. 0.25% 0.48% 0.77% 0.02% 0.04%
._.., 0.05% 9.62% 4.28 8.53 No
(-5
3141/01x7P-20 2.46% 7.47% 0.55% , 0.41% OM % 0.05%
0.12% 11.73% 5.97 6.97 1-3
8
THVOIx1P-21 2.71% 6.53% _ 0.47% 0.70% 0.97% 0.32%
0.04% 0.04% 11.52% 3.87 7.41 C/2
---- --'
b.)
0
TI4V01x11,-10 2.29% 5 59% 0.63% 0.34% 0 59% 071% 0.04%
, 0.04% 10.56% 6.65 5.86 I.+
4:.
.....
0
TI4VOIx7P-22 8.49%0.93% _________________________ 1= 20% 0.08%
____ 10.71% 7.08 6.37
_________. ::: .... _________
:::::::::: _______. ___ - . ch
cr,
niV0IxTP-23 5.60% 0.74% 1.49% 0.19%
8.03% 3.75 6.26 0
4:.
70/01x7P-07 7.90% 0.82% 1.96% 0.08% 0.09%
10.85% 4.04 6.58
Cartrab3noid5(1111PLC)
rmi!:!:!: !:!!:!:!:!::!::!:!:!:!:tisiti::!::!:!:!!!!!:!:
Carmen by 714CA:THCW !!critty604:44
Ttie-A! !N: CBDPC!!!!!!!!!! C6143A !! !
!!!!!37660/4 !!`!!!Ca0V16!!!!!!!! 111C:
Tei1664MC) :
C
NJ
=
INt-15 , :.::::691%. Wt %
:
VI
t
---
1 ........ T Walt:IP-02 6.14% 0.60% 0.80% 0.07%
0.06% 7.66% 7.7 2 __ , 5.60
. __________________________________________________________ ......4.Z
'..11
TliV01x7P-18 1.23% 5.94% 0.29% 0.34% 0.91%
0.07% 0.04% 0.09% 8.91% 3.59 7.18 VI
.1-=
4-
THVOIx7P-24 2.30% 6.67% 0.47% 1.05% 1.85%
0.09% 12.43% 2.19 9.72
_.- - .
THVO1xTP-14 5.13% 0.64% 0.93% 0.08%
0.06% 6.84% 5.51 6.97
THVOIxTP-15 8.54% 1.58% 1.21% 0.15%
0.13% 11.60% 7.07 7.02
_
_
THV01x7P49 8.15% 0.99% 1.15% 0.12%
0.11% 10 52% 7.07 7.04
114V01x7P-83 10.25% 0.01% 1.20% 1.49%
0.19% 0.10% 13.25% 6.89 6.14
THVOUTP-04 1.79% 7.49% 0.36% 0.51% 1.26%
0.03% 0 34% 0.10% 11.61% 3.50 6.21
T33VOIx1P-05 1.79% 5.92% 0.19% 0.57% 4
1.10% 0.06% 0.06% 9.69% 3.16 6.21
o
TliVOU1P-11 7.33% 0.02% 1.02% 1.18%
0.12% 0.06% 9.79% 6.29 5.63 to
to
1-
1-
1-
.t THVOlx1P-12 00 1.93% 6.81% 0.36% 0.38%
0.75% 0.03% 0.04% 0.07% 10.36% 5.08 6.56 o co
THVOL,t7P-13 8.13% 1.61% 1.30% 0.20%
0.17% 11.41% 6.26 5.73 0
1-
ut
I
YEL03x1P-05 6.19% 0.17% 0.70% 6.44%
0.72% 0.09% 14.36% 0.96 13.15 1-
o
ot
o
Table 44- Absolute terpeile measurements by GC-FID for TF1C:CBDV and C;BDV
specialty cannabis varieties. Blank values indicate
undetectable levels or 0.
gamma , , alpha
,s,õ, 4 ,,,: 4,,,. alpha alpha t.i..::::
õ,44,,,,44.4::.:::.: ;
tprene limontaze terpiren 8'P"a
terpinen w" 'enC:7P: 1.!1/:''''''' lerpiner hutrulen carpaphylifirl 77:7, r:`.
9". "tun
110
. :: ptettandrene acimene
pirtenk, plrene 1 e : s: titisite e n OH
4 8
i e e .::::::: :::::::::el
...............................................................................
...................... IPA%)
.4.441q
:Wt36:: : ::: :::::::Wt %.:.:::::::: :::::::::Wt16:::::::::: ::::::. 61, t 16
W,. "k W: % Mit:%::::: ' Wt.% µ.Vit:iC: : 3VZ %
Wt % :81: % W z. % LI, : %=,. AtVOC :: WIC : : MN:: : CA
0.073 0.044 0.015
0.028 b..1
0
1541401x7P-01 0.120% 0.137% % % %
0.021% 0.063% % 0.934% 1.431% =I
4a.
0.060 0.034 0.012
0.022 .....
0
THVOLCIP-06 0.10916 0.103% % % ..... 16
0.017% 0.026% % 0.834% 1.217% 4:6
----
05
0.095 0.053 0.017
0.030 cr,
711VO1i1P-08 0.124% 0.157% % 56 16
0.023% 0.036% 0.052% 96 1.058% 1.645% 0
4:6
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
_
g r * g A A A 4 4 4 4 A r g
A A * A A
&"AA;.1.8)884,1,34c,83 41 '4 00 ,T, f.,:. 01 fL,
. B 7z --- - eti e-i iti 14 eti r-i .4 .--; 14
.4 .-4 ni 0 ni ni ni .4 .4 .4 ni .4 t=-=
F'
- w
E
e ii A
.0 d
,
4 .
-2 =^
% -- 0 V ni 0
i0 V nl cn en I 00 I-1 e4 s. OD .0 1-. ul
CO CO 0 0 CO CO 6 Co CO CO 6 CO CO CO 6 ci CO CO
1
lit. r 3" A" 4" A g 'v: g g A r; g. A Pp', GI g '-'05. tl, g t..= g g
. 0 0. 0. q q q , ,..! q =-! ...! q
0. 0. , c:,.. -, q q ,I ,I ,1 ,1
. ,
.2 f, if k g
4 g g ?: AA4gAArf,*4*A*A
("4s! QEi CO z q t, gi 6: ti El CO C)a3 R K-' 4
0 0 0 0 0 0 0, 0 0 0 0 . 0 0 0 0 0 0, 0 0 0 0
* * * * * * * * * * *
r4 r=I CV I'
1 i ''. 'el. q CI Ct q 9 0 9 q q q q q
q q CO 9 Q Q
CO 0 CO CO 0 c.; 0 0 0 0 0 0 0 0 0 0 0 0
P I i i
2 w g
F5 c;
c
. :-11 3 3 tE " 3 --= 3 n n ,.. .:4 I.:, 3 3 3 " *:`? :LI A "4
E ¨ ggleodroWolt E.:*Ei*ct*::ieq*cORq*cdtc:deq*gitgitc:t*Ci*ci:tq*q* 8 *
,..,
E' n
,,,abto*o.Aotd*d*o*o*oVtoroe 6*0*0*6=*0*0*c..,*0*0*0e.-c*
7 Z. 6 6 6 6 6 6
6 d 6 e 6 6 6 6 6 6 6 ci 6 d 6 6
k.,
e. I
8
4.
8 i SI
C' V . v * ra :-/ ca"" PI 9 8 41
fc, ''CI* rci * * Ei *n*E* *ki* g *::-3,, fg,
-.51 d c; d d 6
6 c; c; c; d d d ci d d 6 6 6 c; c; o o
m $
W
,00'
" ...
A ¨
FtCo
. 5 ..r. " ,.,- !!! 7-1 ,-. 'A 8 3 7-cr n µ,., .1 3 7-1 3 =,. '.:1 3 3
.-c P-'.
E
'''''
T -
I i
,
1
* i
E
. .
,
a,
cc
V; E " '
0 ¨
4 ---
m
.c 3,,
'
o. = 1
To ..g. - -'',. 1
t
a
f * 1g ,,t =
e ¨
1 1 1 I
:
1 t t p. p. ca. p. p. a. a. a. a ti. ti. . 4. 0. 0.
0. 0. a. ii. di. 0.
i i Tc Ti 74 Si P; tl ti ',1 Si 'ri ',I 174- 17( 1;
, 1 :
188
Terpenes (GC-FIDJ
1
-
Total
gamma alpha
alpha beta alpha beta
tench%) camphen alP" a39h4 l'W Malay cary myrren ;dentine
C
. t0.30;3.4.ette ra rene limonene terpir en
terpinen terpinee humultm caryophyllen
...ptellan theft ocimene pinch e pleene
I e i oxide e d oil
8 8
i e 2 =
(WtX4
'JI
---...
, .:::.184:*: :W.C:% :ltSit % . Al.t.ICi :!Ait % Wt. %
......4.Z
0.077
0.330 0.093 VI
YEL03xTP-05 0.175% 0.052% 0.117% 0.394% %
0.086% 0.035%; 0032% % % 1092% Vi
.6.
....................................................... -L----
*IDO for all terpenes was 0.02% except for elpha-pinene, Ilnalool, and alpha-
terpineel whkh werti 4-
0.04%. =
Table 45- Relative terpene levels as measured by GC-FID for THC:CBDV and CBDV
specialty cannabis varieties. Blank values
indicate undetectable levels or 0.
Terpenes
BE 1
i:
! ::
:.:.:::::::1:: :1: 0
to
w
alpha hma gamma alpha , alpha
beta aloha alpha beta:.::i:i:.:i:-:: :=::::::::::::::eary::::::::
=L
: .. . .. . . ...::.::.:::.:.: . : .... . . . .
....:.::.: 1-.
Sample terpinalene ptleliandrene acimene cameo
limanene terpinert, p invsse i terpinene pinene !verbal ramphenet
terpicseni humulene caryophylicime i:iltulthei..t.:.:414cla..treyrrene e.
co
i
i to
THVO1x1 P-01 l
1 8% 10% 5% 3% 1% i I
1% 4% 2% : : 65% c
1...
ut
I
THVOlxTP-06 __ 9% 8% 5% 3% 1% .
1% 2% 2% 'i 69%
i
to
1
THVO1xTP-08 1 8% 10% 6% 3% 1% 1
1% 2% 3% 2% 64% 0
THVO1xTP-16 =11% 8% 716 496 6
____ _ 19 +¨
2% 2% 5% 61%
I
THVO1xTP-17 .1% !?% 5% 3% 1% 1
. 1% 1% 3% 70%
THVO1xTP-19 3% 9% 5% 3% 1%
2% 4% I I 67%
THVOlxTP-20 10% 8% 7% 3% 1%
1% 1% 4% 2% ,
I
! , 62%
I
!
THV)1x7P-21 1% ex 6% 9% 1%
1% 2% 4% 2% i i 64% No
el
THVO1x7P-10 10% 7% 5% PA 1% .
1% 3% 8% 2% 60%
.....,q
T11V01(TP-22. 11% 7% 7% 3% 1%
1% 3% 9% 2% 55%
! ! CA
bol
THVO1xTP .23 10% 6% 9% 4% 1%
3% 7% 1% 57% 0
=I
4:.
.....
NvO1sTP-07 25% 9% 3% 2% 1%
1% 4% 7% 3% 43% 0
I
4:.
ON
THVO1x7P-02 25% 11% 2% 2% 1%
3% 10% 2% 44% cr,
vs,
4:.
THVO1x1P-18 I 23% 12% 1% 2% 1%
2% 3% 3% 3% 41%
C
N
=
VI
:::::: : : :: .......õ........_
4 I
:::::
0:94.Y!R
VI
,.,1u.penes i
1::::.a1pti1::HarnIpuhle.,n.b,leill..7,11,4ne
al ph.n r'1,. h'n .. _ineõ, 1 Ulm.
3%
4.
:: ::13Eta:
2%
74
=
45%
tune 0.00: : 840114) r ,Itioitri* canxi,
lim,,,,,,,,,, teerts*"134gte 1 pit:e t.2rpl:mo.ti ,,,b2,1: 13,hul :Pe1.:*.
1 twi***: : 2%, 36:
3%
atl!Ple 'ArPinu 70% 13%
1% i
2%
42% .,
2%
10%
4%
3%
4%
1%
THVO1xTP-24
13%
49%
1%
2%
24%
2%
!
4%
3%
!
2%
2% I
48%
THVO1xTP-14
9%
1% !
1%
24%
3%
5%
6%
1%
3%
52%
THVO1xTP-1.5
8%
1%
a%
24%
3%
3%
9% !
2%
THVOLJP-09
7%
!
1% !
1%
55%
23%
2%
2%
3%
5%
3%
THVO1xTP-03
8%
1%
3%
38%
22%
2%
11%
2
THVO1xTP-04
8% ---------------------------------------------- i 5% _.-
!
:
1% =
1% 4%
40%
0
21%
2%
9%
3%
=.w
3%
2%
4%
ii
THVO1xTP=05 r
9%
42%
29%
2% 1% 1
4%
_13% 1---
3%
10%
0"
THVO1 xTP-11
11% --------------------------------------------------
1%
5%
ow
27%
7% 1%
8%
0%
I
3%
I
10%
3%
ow
THVO1xTP-12
10%
6% i 1%
6%
11%
24%
7%
3%
0%
9%
30%
ow
THVO1xTP-13
45%
3%
mr
5%
5%
VZ
16%
=
511.08xTP=02
9%
7%
YEL03xTP-05 8%
No
(-5
1-3
8
=
-
4.
,
c,
4.
0,
0,
.0
4.
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Example 14. Volunteer trials using THC:THCV specialty cannabis. Effect of
added THCV.
In order to demonstrate the added utility of the specialty cannabis varieties
of the present
invention, volunteer comparison trials were conducted. During these trials,
volunteers were
provided with cannabis flower blends with varying terpene and cannabinoid
profiles to determine
the effect of specialty cannabis with added TTICv.
The volunteer trial for THCV was conducted over two weeks. Volunteers were
split into
six groups (1-6). Each volunteer in the group was given two samples (a
control, i.e., 'Control ID',
and a comparator, i.e., 'Comp ID' blend). For instance, they were given al and
a2, or bl and b2,
or ci and c2, or di and d2, or el and e2, or fl and 12 (see Table 46 for trial
design). In this trial,
the control comparator blends were prepared to contain nearly identical levels
of TI-IC and
tetpenes, but each week the comparator had either 1.5% THCV, or 2.5% THCV,
added in.
Table 46- THCV effect trial overview for Weeks 3 and 4.
is
Week
4
'MC or
THC or Base Control Comp
THC+2.5% Terper!e Ca s Control and Comparator Terperses
11101.1.5%TMCV Cl4tivar oID
Group 5 Group 4 a yrcene, pinene GRAB
al a2
Group 6 Group 5 b limortene, InaocI,
caryophyliene, humulene WHI2 b2 bl
Group l Group 6 ocimene, myrcene GRE I
cl c2
Group 2 Group I d erpinolene, ocimene PUR2
d2 dl
Group 3 Group 2 myrcene, pioene, tximene,
linatool, catyophyllene PUR5 el e2
Group 4 Group 3 1 limonene, caryophyllene,
myrcene, liralool 11E1)1 12 Ii
Samples for the trials were prepared as described in Example 10 by hand
grinding and
blending cannabis flowers. As before, each sample was analyzed via GC-FID and
HPLC before
being provided to volunteers in order to ensure consistency (Table 47 and 48,
and Figure 8). The
same questionnaire that was used in Example 8 was used to assess the volunteer
feedback on the
tested blends.
191
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
Table 47- Ca.nnabinoid levels of cannabis blends for Week 3 and Week 4 trials
as measured by
GC-FID and HPLC. Control samples highlighted. Blank values indicate
undetectable levels or 0.
Carn4bMokt1044401.-- ''''' Cannableuids 1t33PIX.)
'11.14Z THCV THC:THCV by GC THCA THCVA
THCA:THCVA by HPLC
Samyle U9,$5CIg '33V.6W
00015335=::C,
MPC.s/1-13A-004-41 19.02% 056%
V- I.? 2 16.36% 0.49% 1.42% 0.03% 11.05 0.53
13.96% 1.15% 1.38% 0.04% 10.11 0.51
I MP(244-2313.1.42 It 34% 1.85%
' '17.04% 0.61% H PLC
measurements not conducted for Week 3 samples
; -134-004-c2 14.85% 0.86% 1.33% 0.05% 11.17 0.70
k4PCM-134-004-d1 10.46% 0.26% 1.37% 0.10% 7.64 0.40
3iORNM fflgMn
Wiattlidatilarraiiiiii3i3 10 34% 0.91%
1961% 0.42%
IVIPC34-134-004-,32 16.46% 0.56% 1.41% 0.04% 11.50 0.49
34Payl-134-004-fl. 14.12% 0.69% 1.4C% 0.03% 10.12 0.43
301PC3V34444.034&ii 15.50% 0.59%
............. . .
19.02% 0.56%
MPCM-134-005-e2 21.03% 0 3:I% 2 .7 .7).> 0.26% 7.68
0.60 27.38% 0.68% 4.45% 0.39% 6.17 0.46
r.P.pcm 13A 001 l 19.31% 1 13% 2.72% 0.20% 7.12 0.98
24.96% = 1.53% 4.44% 0.33% 5.64 0.55
6.18CIA-73A4705.42 16 34% 1.85% 24:27% 2.32%
64PCM-1340.6VOM 17.04% 0.61% 25.16% 0.79%
IYIPCM-13/3,005-42 20.83% 0.63% 2.99% 0.12% 6.97 0.50
26.09% 1.32% 4.83% , 0.16% 5.41 0.39
MPC34-334-005-di 1529% 0.52% 2.67% 006% 57:3 032
20.57% 0.20% 4.34% 0.07% 474 0.12
34PCM-3.334.90S-e2 10.34% 0.91% 16.06% 0.98%
MPC64-13A=0135,A. 1961% 0.42% 28 10% 0.26%
IVIPCM-134-005-e2 22.93% 1.44% 2.96% 0.04% 7.76 0.58
28.72% 1.10% 4.70% 0.02% 6.11 0.12
-.4
3APCM .134.00541 19.00% 0.79% 2.7.5% 0.45% 7.02 1.25
24.70% 0.36% 4.37% 0.79% 5.75 1.01
*nli4kMii.M.i0054ZU. 15.50% 0.59% 23.47% 0.79%
192
Table 48- Terpene contents of cannabis blends for Week 3 and Week 4 trials as
measured by GC-FID. Blank values indicate c
t,..)
undetectable levels or 0.
=
,...
--.
s
TeoppesNC-F0)
,..),
alpha =
= :.: n.:.
gar!.ma teminoler, ) beta Total vi
4-
alpha carnphen bale a lph a
õ _:.::.: .i.i.i.:16e9a , alpha a lpha... nary
Wati .1.
myrome pt0ellandre carene timonenv.
:._.:,:::::0..:.:.: terpirter. linaino! ferchoi teloto carynphy8
t.3ww*ii.0 gi,,o4te icier:90ml we
pinoie .4. ..... .....pipepe ....... terpintme
.::.::::::::iii iigclipene Q.
:::::::::::::::::::::::::.:::.:.::. . . ..:::::.:::::, . . Be
.... ...... ...... ==== ====
..0::::::.0:::::::::::::::::,.::::.:0 . . . . e
:=0=6W::::.:::::::::..::::::.::.:.:::::::::::::..:.:.:.:.:.:
______________ , .
'4', % 0.4: 95% :AA*ii';..16 )...C: Al% wt. .4.51µ. :11'.4* .% :::Wt:::
41,:WW)iiiNli.k*:1:..;i3.5% vv7 .gs% WI: 95 % .:.:*., 9-. % Wt 9S )..,if
.4i:4 i.ii..i Ø.-4i:. .44 .4.....i *..CØ.!.34 7: e
snmp % ' a Iv :43.:.:4:::,:::0%a::: W:: 'TT' 96::. ::::C:1:::
::::g:::: ::::c1::::::::%:::::::.t?%0 % n %:. = :.:.0:. .4.4
(.:,... :.....,, . :.40 ..1, .:. .fi.:. *: .:..6 * w %
. t - _
_
. mpcm-u.A. 3420.01 0.11 0.00 0.57
0.00 0.07 0.00 0.04 o.oe 004 0.00 0.17 0.00 0.06 0.00
1.52 0.02
004-e1 8% 1% 7% 2% 8% 2% 0% 0% 1% 1% 7%
1% 7% 3% 8% 1% 3% 6% 38%
Mr'f=`,/ -13A 0320.01 0.09 0.00 0.67 0.03 0.11
0.00 0.1010.00 0,040.00 0.20 0.00 0.07 0.00 1670.07
C04,2 (3%9% 996 6% 8% 1% 3% 4% 5% 3% 7%
0% 0% 8% 5% 3% 0% 4% 40%
=
0060.00 0.08 0.00 0.35 0.01 0.53
0.03 0.14 0.00 0.14 0.00 0.06 0.00 0.07 0.00 0.39 0.02 0.11 0.00 1970.11
CC,:: -i; 1 796 5% 5% , 6% 7969%
1% , 2% , 8% 6% 0% 7% 3% 3% 0% 596 , 0% 096 , 6% 6% 3%
4% 18%
MPCM-13A; 0.0i 0.00 0.11 0.01 0.25 0.01 0.71
0.06 0.12 0.01 0.18 0.01- 0.08 0.00 0.08 0.00 0.39 0.03 0.11 -0.01
2200.24
994-1)2 9% 9% 5% 2% 2% 9% 0%
9% 8% 2% 8% 8% 2% 7% 6% 7% 5% 9% 1% 1% 8% 5% 11%
:Ifk4P6:A.,1:;13*. 0.09 0.00 0.06 0.00 0.67 0.02 0.21
0.00 0.36 0.01 0.09 0.00 0.03 0.00 0.05 0.00 0.19 0.01 0.07 0.00
1840.0? o
i:0.044:Z: 3% 3% 6% 1% 2% 0% 2%
6% 1% 5% 8% 5% 1% 3% 196 3% 3% 6% 0% 7% 8% 2% 36% ro
u,
MPCM.13A.. 0.08 0.00 0.06 0.00 0.63 0.00 0.20
0.00 0.31 0.00 0.08 0.00 0.03 0.00 0.04 0.00 0.21 0.02 0.07 0.01
1750.05 o.
o.
m.i
mo-
0 t 004-c2 5% 3% 1% 1% 0% 8%
5% 5% 8% 8% 4% 6% 2% 2% 6% 4% 3% 8% 7% 1% 1%
8% 36% v.
0
G.) 4 6,1PM43A- 0050.00 0.06 0.00 0.28
C.00 0.17 0.00 0.18 0.00 0.26 0.00 0.04 000 0.02 0.00 0.04
0.00 0.13 0.00 0.04 0.00 1320.0?
==>
CCA -c 1 4% 1% 6% , 1% 4% 8% 3% , 3% 5% 3%
6% 7% 7% 0% 4% 1% 0% 2% 2% 3% ,1% 1% 6% 0% 21%
1..
'Pll).cW43:k 0-04 OM 0.06 0.00 0.17 C.01 0.10
0.00 0.16 0.01 0.37 0.02 0.04 0.00 0.02 000 0.04 0.00 0.08 0.00 0.02 000
1220.05 =.6
=
1..
...3973,07: 7% 5% 9% 5% 0% 1% 5% '
9% 3% 3% 9% 8% 9% 2% 1% 1% 0% 2% 5% 3% 3% 1% 'A% 8% 14% 0
00.004.4 0.31 0.01 0.08 0.00 104001 0.06
0.00 0.16 0.00 013 000 0.31 aoo 048 aoo 117 0.05 4..
o
H6.6+WH:1 6% 3% 2% 3% 2% 8%= 0% 1% 6% 4% 896
2% 1% .5% 0% 1% 1% 1% 47%
=
MPCM-13A- 023 0.01 0.06 0.00 0.90 0.01 0.09
0.00 0.19 0.00 0.11 0.00 0.29 0.00 0.08 0.00 2.01 0.03
004-e2 9% 5% 9% 2% 0% 8% 3% 2% 0% 1% 0%
1% 2% 7% 3% 1% 5% 8% 45%
6,1PCM-13A- 0.04 0.00 0.07 0.00 0.25 0.01 0.38
0.02 0.06 0.00 0.13 0.00 0.04 0.00 0.05 0.00 0.29 0.01 0.08 0.00 1.43005
(V.-fl 7% 2% 1% 3% 8% 0% 3% 2% 5% 3%
8% 6% 7% 2% 3% 2% 5% 5% 3% 3% 9% 9% 18%
RIPP/KAIN= 0 04 0.00 0.08 0.00 0.15 0.00
0.48001 0.17 0.00 0.05 0.00 0.05 000 0.30 0.00 0.07 0.00 1.440,03
00801,42::00 :%l% , 4% . 2% 4%, 2% ,
396 .. 3%, /46 3% 4% 1% 9% 1% 6% S% 996 2% 696 796 11%
M60M41V 0.42001 0.11 0.00 0.57 0.00 0.07
0.00 0.04 0.00 0040.00 0.17 0.00 0.06 0.00 1.52 0.02
...13054100' 8% 1% 7% 2% 8% 2% 0% 0% 1% 1% 716
1% 7% 3% 8% 1% 3% 6% 38%
6.42CV 1.3A= 0.41 0.01 0.12 0.00 0.66 0.03 0.14
0.00 0.11 0.00 0.04 0.00 0.02 0.00 0.02 0.00 0.28 0.01 0.10 0.00 1.95008
V
005-a2 , 0% 3% 896 5% 7% 1%6% 8% 3% 6% 9%
1% 0% 1% 9% 1%6% 4%7% 5% 7% 1% 34%, (-5
..... . .
MPCM-13A- 0.10 0.00 0.11 0.00 0.37 0.00 0.63
0.03 0.17 0.00 0.17 0.00 0.07 0.00 0.07 0.00 0.47 0.02 0.14 0.00 2410.09
...==3
,
005-b1 2% _ 3% 8% 4% 496 8% . _
9% 6% 2% 5% 0% 9% 7% 3% 8% 2% 6% 0% 9% 3% 8% 2% 15% d
.* _ , ,
i *WM* 0.07 0.00 0.11 0.01 0.25 0.01 0.71
0.06 0.12 0.01 0.18 0.01 0.08 0.00 0.08 0.00 0.39 0.03 0.11 0.01 2200.24
C/1
l..1
16ilk8iM 9% 9% 5% 2% 2% 9% ..... 0% 9%8% 2%
86 8% 2% 7% 6% 7% 5% 9% 1% 1% 8% 5% L.%=
1-1
114191:hA6:1Mi 0.09 0.00- - -0.06-0.00-0.67- - - 0.0i 0.21
0.00 0.36 0.01 0.09 0.06 0.03 0.00 0.05 0.00 0.19 0.01 0.07 0.00 1840.0?
............õ,....................,
MittiaiR a% 3% 6% 1% 2% 0% 2%
6% 1% 5% 8% 5% 1% 3% 1% 3% 3% 6% 0% 7% 8% 2% 36% ...,
0
4:.
MPCM-13A- 0.11000 0.08 0.00 0.68 0.01 =
0.25 0.00 0.34 0.00 0.08 0.00- 0.03 0.00 0.04 OM 0.30 0.00 0.11 000
1750.01 06
005-c2 9% 1% 0% 1% 6% 2% 2%
1% 5% 4% 8% 3% 5% 1% 8% 1% 5% 3% 4% 2% 9% 5% 39% cr,
vp
MPCM-13A- 0.08 0.00 0.08 0.00 0.33 C.01 0.01 0.00 0.01 0.00
0.01 0.00 0.22 0.00 0.21 0.00 0.35 0.01 0.05 0.00 0.02 0.00 0.04 0.00 0.22
0.01 0.07 0.00 1420.05
005-51 3% 1% 9% 3% 3% 0% 9% 1% 3% 1% 0% 1% 2% 8% 4%
6% 2% 9% 3% 2% 9% 1% 4% 2% 5% 0% 5% 3% 2% 5% 23%
_
. -
CA 02911168 2015-10-30
WO 2015/065544
PCMS2014/046694
- õ *
71-1. tts 4 t=i
1*
:"5
6"6"6c"6"6"
go ff, r-=
8 * 8 * * at 8
oti den 6 tr, d os rO .0 01
== * 4 * r?, *
g at It
0 0,-0-
CO NO ol
7,1 g oclatqf
6 o 0
8 A 8 A 8
qgqgq*
o = o o
8 * 8*8e8*8 *
- = = r=4 =rn =0:0 =er,
C (rk 0 0 0 0 0
* 3 * w =
¨ cs 00 6 c'= 6 "ici
" g=
6 ON,
4Z=
3 a
oo
q
m 0 o
T;=; ______________
PC:
a "-
70 r====
t
::HV4
t
ov<:
E. a
t0 0c' r" 6 ".
,õ o.1
0 0
rs.0 0 0 0trtµ
t.; c>
8 g 8 at 8 at 8 at 8 ;a
ci ===== ci op 6 in 6 =Or
8*8*
u]02 s"- 6 " " ci
t -%1** * at ^ *
="' 0 90'.Ø.0===
< .4(
e e -
aHEEEEEE,a
194
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The controls (al, b2, cl , d2, el, and f2) had only THC while the comparators
(a2, bl, c2,
dl, e2, and fl) had approximately the same amount of THC plus a small
percentage of THCV.
In Week 3 approximately 1.5% of THCV was added, in Week 4 2.5% of THCV was
added.
These non-THC cannabinoids have demonstrated pharmacology (such as CB2 agonist
and mild
antagonist to CBI) that we hypothesized may attenuate some of the negative
side effects of THC
by blocking the action of THC itself or by activating alternative pathways (RG
Pertwee. 2008
"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:
delta 9
tetrahydrocannabinol, cannabidiol and delta 9 tetTahydrocannabivarin" Br. J
Pharmacol.
153(2):199-215).
The controls and comparators in Weeks 3 and 4 were also blended to have very
similar
terpene profiles in order to ensure both samples had similar aroma, flavor,
and putative entourage
effects, so as not to predispose the volunteer into thinking one or the other
would be different
based on organoleptic properties. Both Table 48 and the Figure 8 (with the
controls and
comparator sample pairs labeled with brackets) show there is little difference
in the terpene
profiles of the control and comparator within a group. The blends were always
prepared so the
myrcene content was below 60% and the total identified essential oil content
was about 1.5%.
Thirty volunteers were recruited and asked to fill out demographic surveys.
Each week
the volunteers were given a control and a comparator, two corresponding
surveys as described in
Examples 9 and 10. The results were analyzed as the averages along with the
95% confidence
intervals (Table 49).
The results are presented as the difference in feedback scores between control
samples
with just THC cannabinoid, to comparator samples with added THCV cannabinoid
(see Table 49
and Figure 9).
Table 49- Combined feedback results for Week 3 and 4 trials.
Ageracrs. for Wsteln
s?ion A .)SO (1 95%0 32 9SIE (5443 E
053C3 f 56(19 "fUfAl. 95% c
AMMO. 2 167 .. 245 1 :13 0.65 -3. 13 0.78
C141 1.00 0.236 I 2.21 -0.25 1.27 0.262 I_ 0.62
FEI3ice 1 209 -1.25 167 0.556 1.14 -1.4 131
0.833 106 0.625 r 1.23 0.237 071
"'33 246 0333 0.83 0 032 -143 153 .133 251 05 1.96 .024 072
1 1 87 -0 67 0 83 3,444 123 -043 113
4.33 1.78 0.75 1.42 41.05 0.64
0 2.37 -0.33 0.83 -0.11 089 4 1.86 -
1.57 2.30 0.375 1.77 -0.58 0.71
195
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
:95,14:CF
=1 139 0.5 2.07 0.125 1.01 a714 2.03
-1 1.05 -2.13 i 1.55 4.49 0.63
Mortrx.xl 0 1 52 -1.5 1.21 0 0.65 1.714 1.58
0 286 1.54 -0.63 1.97 0 0.68
Ø67 120 0.833 1.38 0.56 0.74 -1 176 0.14 1.45
0.5 2.22 0.19 0.65
Focut. ::..167 1.78 -2 334 0.444 133 1.429
1..27 0.143 1.79 1 2.19 0.279 0.70
0.833 2.17 .1.83 1.55 0 1.08 0.714 133 -1.57 1.34
-1.75 259 0.6 0.76
Ene:gy -05 131 -0.33 0.94 0.778 1.63 2.286 140
0.714 1.26 -0.13 0.58 0.442 0.58
How,: :837
224 1.167 1.28 0.333 1.39 0.714 1.99 0.143 0.90 -1.13 1.67 0.349 0.67
3Isir0. 0 1.01 0 1.07 0.333 1.03 0.711: 1.11
0 2.05 0.25 2.18 0.238 0.61
= 2 2.73 -0.33 1.49 0.111 0.83 0.571
1.27 -0.29 0.93 -0.13 1.01 -0.28 0.57
frnmkOiEMEMM -0.83 1.18 0.5 1.50 -0.11 0.39 1 1.05 -0.43 0.58 -1.13 2.58 -0.19
0.62
figletiMininiiMni 0.333 165 0 2.68 -0.33 065 1.857 168
1.148 117 -0.88 131 0.302 0.64
1.167 2.05 0 1.01 0.11 1.44 -1.14 1.08 Ø71
2.25 05 1.85 C07l 0.69
tWkfiz.r. 0.667 2.46 -0.83 0.94 -CM 0.89 -0.14
211 -1.43 0.94 -0.63 0.82 -0.42 0.57
0333 2.36 -0.83 118 0 0.86 0.714 1.26 -171 1.53 .4.25 0.61 -0.47 0.56
0.6 1 00 1167 (11 -0.33 0.57 -1.29 146
0.857 1.79 1.625 0.90 0.405 0.59
Several feedback trends can be seen in the comparison of the two samples. Most
notably,
there appeared to be an obvious decrease in the level of "mind high",
"intoxication", and
"duration" for cannabis blends containing THCV. There also appeared to be an
increase in the
ability to "function normally", "energy", "focus" and "hunger". Each
comparison control and
comparator sample contained equal amounts of THC and nearly identical terpene
profiles. Thus
the differences outlined in Table 49 and Figure 9 are attributed to the small
amount of THCV
added to comparator samples.
The observed trends suggest that the addition of a non-TIIC cannabinoid, such
as found
in THCV cultivars, can help reduce the feelings associated with being "high",
reduce
-intoxication", reduce the "duration", reduce -sedation", and improve the
ability to "function"
normally while under the influence. Thus in some embodiments, the specialty
cannabis of the
present invention with THCV has the potential to reduce adverse effects and
provide a larger
margin of consumer safety for a number of applications. In some embodiments,
the THCV
containing specialty cannabis can be used at times when users wish to still be
able to remain
functioning normally even after smoking it. Another use for specialty cannabis
of the present
invention is in medicinal applications. Many times patients attempting to use
cannabis for
medical treatment discontinue use due to the aforementioned "negative" side
effects, such as
196
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
being "high" or intoxicated, and these ratios have demonstrated a clear
potential of the present
invention to mitigate these effects. In some embodiments, patients could use
the specialty
cannabis of the present invention to experience the hunger inducing effects of
cannabis, with
reduced effects of feeling "high" while maintaining an increased ability to
function.
THCV has been shown to be a potent CB2 receptor agonist but a mild antagonist
for CB1
receptors. THCV's response with the CBI receptor is also dose dependent as
higher doses of
THCV allow the molecule to become a ail agonist (Pertwee, R.G. 2008 "The
diverse CBI and
CB2 receptor pharmacology of three plant cannabinoids: A9-
tetrahydrocarinabinol, cannabidiol
and A9-tetrahydrocannabivarin"). The experiments will also be repeated at
higher THCV
concentrations.
Example 15. Phenotypic analysis THCV specialty cannabis progeny (prophetic).
The new specialty cannabis varieties created through crosses described in
Examples 5
and 12 will be subjected to phenotypic analysis as described in Example 2
(indoor growth) and
Example 8 (outdoor growth).
Initial selections will be conducted based on measured phenotypes as well as
the
chemical analyses already conducted in Example 13. Cuttings of desirable
progeny will be
preserved for subsequent breeding as described in Examples 5, 19 and 20. The
data gathering
sheet shown in Figure 2 will be used to guide these phenotype assays. Data
that will be collected
will include plant height at maturity, plant diameter at maturity, number of
leaflets, leaf type,
average number of internodes, leaf color, node branching, number of
inflorescences, average
non- apical inflorescences, apical inflorescence size, flower cluster density,
ripening mode,
average calyx length, and flower color. Notes about growth and resistance to
pests will also be
recorded.
Example 16. Development of CBG specialty cannabis varieties (prophetic).
Unique parental chetnotype I 11, 111 and CBG lines from Examples 2-4 will be
selected
and one of the parental cultivars will be treated with silver thiosulfate to
coax the pistillate plant
to produce staminate, pollen-bearing flowers. The chemotype 1, 11 or 111 line
will then be crossed,
the resulting progeny will be screened by TLC to identify plants producing
either THC:CBG or
CBD:CBG. Progeny exhibiting the desired cannabinoid profile will be allowed to
reach maturity
and the flowers will be harvested and analyzed via GC-PID and HPLC. Table 50
outlines the
197
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
initial crosses that will be performed. Progeny from these crosses will also
be allowed to "self"
to produce CBG producing cannabis with desirable topene profiles and high
terpene oil contents
of the parental varieties. Progeny will also be backcrossed to parental lines
to reinforce parental
chemical and morphological phenotypes. For a more thorough description of
expected breeding
schemes, see Example 5.
Table 50- Prophetic crosses with CBG02 parents.
, I
Aoceptor Pompon Acceptor I
L. 1
P Donor Catiscar 'Trak tilMvat %mit Colthser Tait I
fted Botch Clatte
1
C860265 G0013 1,2,3,12 G0002 1,2,3,9,10 'GOD:2
1,2,4,10 C81.1026 =XGOLD
i .
C8G02x5- 51104 1,3,7,10,12 51101 1.3,12 51108 1,2,3,9.12
1C8G02x5. XSI :NE R
!
066026S- W102 1,3,5,8,9,12 WRO7 1,3,5,6,12 WI1103
1,1,5,6,12 C.130.02x.5- X Vvioll:
C8602+6- pL=RCrt 1,6.8,10 PUR03
1,2.3,6,12 CI3G02xS-X6011611
1
!
CSG0265- 6E002 1,3.4,5,12 RED01 1,3,4,5,12
CBS32x3-XRED i
C860 24- YE103 1,2,3,8,9,10.12 YEI.04 1,2,4,5 YEA.05
1,2,4,5.6,9,10 C13:302x5-XYMOW
:::.260265- ORA02 1,4,7,8,12 OR4:13 1,4,7,8,9,10+
1:1:1.02,6=XORANGE
C13602eS- 81K03 1,2.3,6,10,12 ICI3G024-X3IACK
CSG02.65- FSCO1 1,2.4,9,10 . F502 1,2,4,9,10
,C8G024=XFUSCIA
i
(8G0265- GRA01 1,2.4,7,8,10 GRAO 3 1,2,3,7,3,9.12
IC81:101):5- XGR At
C860265- 13ROD1 1,4,5,6,12 ;R 1,2,5,6,10,12
C8G02xS-X8RONZE
. OM I
C3G02x5- GRE01 1,2,3,4,6,8.9,12 GRED2 1,2.3,7,8,9,10 GRE 30
3,2.4,5,9.10 CBG02x.5-XGREE61
C860265- 81008 1,2.4,6,8,10 61.1.105 1,2.3,4,6,9,12 81006
1,2.4,5.6.7,8,9.10 CBG02x5-XBIGE
(8602,45- JADO7 1,2,4,5,8,9,10 JA021 1,2,4,5,8,9,10 1A004
1,2,3,9,12 CBG02x5-X1ADE
1.1160265- C9004 1,2,6 CBDO5 1,2,3,6,8,12
CBG:12x5-XCI3Dcrype 2)
C6G02x.S. C8024 1,2,3,6,8,12 C800466-09 1,2,3,6,8,12 C8D05x1) -
01 1,2,3,6,8,12 CBG02x.S-XC3Dcrype 3)
i
,23002x5= C8005 .1,2 1,6,6,12 i ci3G02xS-
XCEI002J: S. !
i
cg0224, CM:$2"1- A.2,4õ5,1,0,11.
in these crosses, the CBG02 line was selected for its accumulation of CBG
carmabinoid.
Table 50 also lists the some of the major traits (in trait codes) for which
the other parental lines
were chosen and the expected phenotypes of the progeny. Table 51. lists each
of the desired traits
alongside the trait codes used to represent them.
Table 51- Non-limiting list of traits important for specialty cannabis
breeding programs.
I rlroait .1
Description
I
198
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Trait
Description-.:
' . '' '' ' ' '' '' ' ' .. .. . . .. .. . . . . .. . .. . . . .
.. . .. . .
essential Oil Content (either terpene or overall content) - Seiection based on
overall oil content >1.5% and/or a singe terpene that
accounts over half of total terpene content and/or a determined range of
terpene concentrations designed specifically to treat
ailment.
2 Cannabinold Content (either rare cannabinoid or overall content)-
Selection based on overall oil content >1.5% and/or a singe terpene
that accounts over half of total terpene content and/or a determined range of
terpene concentrations designed specifically to treat
ailment.
3 Structure for Manual Trim/Market - Selections are based on the relative
ratio by weight of finished flower: Whole plant This usually
is directly related to dense trichome morphology with very few sun leaves.
4 Structure for Automated Trimming - Selection based on flower morphology
that is more tots with many sun leaves protruding from
large inflorescences. Overall flower size is typically large, but trichomes
are less densely packed and overall inflorescence is less dense
than what is traditionally selected for manual trim.
5 Structure for Extraction - Selection for this trait is conducted post
harvest and post drying. Positive selection is based on copious
shedding of trichome heads and stalks.
6 Color- Selections are based on, but not limited to unique coloration of
stem, leaf, inflorescence, calyx, stamen, trichome bodies and I
finished products including extracts and hash.
7 Root Structure Positive root selection is marked by overall root vigor
and adventitious root growth, ease of transplant, rate of root
development on clonal propegations, and root shooting from tissue culture
samples. Also resistance to soil end hydroponic pathogens
including pythiurri.
8 Vigor - Selection for plant vigor are marked by tremendous growth rates
and robust stem/stalk infrastructure. Often times, selection
display morphologies that are very much enlarged compared to sibling progeny.
9 Fungal Resistance - Selections based on plant that exhibit Immunity or
partial Immunity to fungal diseases and pathogens Including
but not limited to powdery mildew, botrytis, downy mildew, etc.
10 High Yield Natural Light Production Long Season - Selection teed on
yield performance fin early ripeeing varieties during long
season.
11 High Yield Natural Light Production Short Season - Selection based on
yield performance of late ripening varieties during long season
and/or yield of 'Merits that ripen in winter months and at low light levels.
12 High Yield indoor Production - Selection based solely on plant yield
performance in artificial lighting (HID).
Example 17. Chemical and phenotypic analysis CBG specialty cannabis progeny
(prophetic).
The new CBG specialty cannabis varieties that will be created through crosses
described
5 in Examples 5 and 16 will be subjected to cannabinoid and terpene
chemical analysis as
described in Example I. The results of the chemical analyses are expected to
show that the
crosses described in Example 16 generated specialty cannabis that accumulate
CBG and have
higher oil contents and "desirable" terpene profiles.
The new CBG specialty cannabis varieties will also be subjected to phenotypic
analysis
10 as described in Example 2 (indoor growth) and Example 8 (outdoor
growth).
Initial selections will be conducted based on measured phenotypes as well as
the
chemical analyses. Cuttings of desirable progeny will be preserved for
subsequent breeding as
described in Example 5, 19 and 20.
Example 18. Volunteer trials using THC:CBG, CBD:CBG, or CBG only specialty
cannabis. Effect of added CBG (prophetic).
199
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In order to demonstrate the added utility of the CBG specialty cannabis
varieties of the
present invention, volunteer comparison trials will conducted. During these
trials, volunteers will
be provided with cannabis blends with varying terpene and cannabinoid profiles
to determine the
effect of specialty cannabis with added CBG.
a The volunteer trial for CBG will be conducted similarly to the trial of
Example 9. The
trial will split volunteers into groups. Each volunteer in the group will be
given two samples (a
control and a comparator blend). For this trial, the control comparator blends
will be prepared to
contain nearly identical levels of non-CBG cannabinoids and terpenes, but each
week the
comparator will have either 1.5% CBG, or 2.5% CBG, added in. Volunteer
responses will be
measured using the questionnaire of Figure 2.
CBG has been shown to be a CBI antagonist (Cascio et al., "Evidence that the
plant
cannabinoid cannabigerol is a highly potent alpha(2)-adronoceptor agonist and
moderately potent
5HT receptor antagonist" British .1 of Pharma. 159 (1): 129-141). The addition
of CBG into
cannabis blends is thus expected to reduce the side effects of THC.
Example 19. Development of additional cannabinoid producing specialty cannabis
(prophetic).
In order to develop specialty cannabis with unique cannabinoid profiles,
additional
crosses among the parental varieties disclosed in Example 2-4 will be
conducted. These
prophetic crosses are indicated below with expected breeding charts describing
specific crosses
and the traits each cross is expected to produce. Traits for each cross are
represented by trait
codes which are described in Table 51 of Example 16.
Table 52 is a non-limiting list of expected crosses using parental lines of
the present
invention to generate new CBD producing specialty cannabis. Table 53 is a non-
limiting list of
expected crosses using progeny CBD lines previously developed in Examples 5
and 6. Each of
these crosses will also be followed up by one or more back-crosses to further
reinforce the
transfer of desired traits.
Table 52- Additional example crosses to be conducted for CBD parental lines.
iliwommm __________________ 111804644:]:::98
200
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
C6D24 G0013 1,2,3,12 00302 1.2.3,9,10 GOD12 1.2.4,10
CBD24XGOLD
C8D24 54104 1.3,7,10,12 51101 1,3,12 51108
1,2,3,9,12 C8D24XSILVER
C8D24 WHIO2 WHIO7 1,3,5,6,12 W1113
1,3,5.6.12 CBD24XWHITE
C8024 PUR01 1,6,8,10 PUR03 1,2.3,6,12 CI3D24X
PURPLE
C8024 YE1.03 1,2,3,8,9,10,12 0E104 1,2.4,5 1E105
1,2,4,5,8,9,10 C6D24 XY ELWIN
C8D24 0RA02 1,4,7,8,12 ORA03 1,4.7,8,9,10
C8D24X0RANGE
C3324 81K03 1.2,3.6.10,12 C8024XBIACK
C8024 F511 1.2,4,9,10 F5f202 1,2,4,9,10
,..0024XFUSCIA
C.8024 RA01 1,2.4.7,8.10 GRA03 I 2 . ,
7,5,9,12 11:fiE/24 XGRAY
C6D24 6RE01 1,2,3,4,6,8,9,12 GRE02 1,2.3,7,8,9,10 0RE30
1,2,4,5,9,10 CSD24XGRE EN
C9324 BW06 1.2,4,521,10 61.1/05 1,2,3,4,6,9,12 811306
1,2,4,5,6,7,8.9,10 C8024791.0E:
C1324 jA307 1.2,4,5.8,1,10 JAD21 1,2,4,5,8,9,10 iAOO4
1:2,3.9.12 CS324X1A DE
C8024 CE1305 1,2,3,6,8,12 C81/04 1,2.6
C111)24XC80(Type2)
(6024 SILOS xP-02 1,2.3,12 C9D24x
S11.08Y.P
C:3024 CBD04xPr09 1.2,6,9,10,12 C8005xP.01 1,2,3,9,9.10,12
CBD24 1,2,6,9,10,12 CBD24xCBD(Type3)
Table 53- Additional example crosses to be conducted with CBI) progeny lines
of the present
invention.
tttilit):=
C80040..09 00013 1,2,?, 12 =11932 1,7,3,9,10 013012
1:1,2,4,10 03004xP-093001.0
C8304xP-09 51104 1.3,7,10,12 511.01 1.3,12 $11.08
!1,2,3.9.12 CBDC4x?-09XSILVER
C8DO4xP-09 WHIO2 1,3,5,8,9,12 WHIO7 1,3,5,6,12
WH 103 i1,3,5,6,12 C8004 xP -09)(WHITE
CBD04 xP-09 PUR01 1,6,8,10 P12103
1,2,3,6,12 C8004 xP-09XPURPLE
C8004 xP YEL03 1,2,3,8,9,10,12 YEL04
1,2,4,5 YE LO5 1,2,4,5,8,9,10 013D04xP.09XYELLOW
C8004 xf,09 ORA02 1.4,7,8,13 ORA03
031304xP-09X0RANGE
C6004xP.09 31.K03 1,2,3,6,10,12
CBDO4xP-09XEILACK
C6004 xPj..)9 FSC01 1,7,4,9,10 F SCO3
1,2,4,9,10 CBD04xP419r612SCIA
C 8004 xP .09 01001 1,2,4,7,8,10 RA03 1,2,3,7,8,9,12
CBDO4xP.09XGRAY
C8004xP09 GREW. 1,2,3,4,6,8,9.12 01602
:1,2,3,7,3,9,10 1311.30 CBD04x9 09XGREE:t4
C8004xP-09 BLUM B WO5 51V06 I1,2A CBDO4xP-09XBLIJE
C11004 xP-09 JADO7 1,2,4,5,8,9,10 )A921 1/1094 11,2,3,9.12
C0004 x P-09 XJA0::
C3D04xP9 CBDO5 1,2,3,6,8,12 C8004 1,2.6 CBDO4xP.09XCBD(Type2)
C8004xP-09 SI L08xP-02 1.2,3,12 CBDO4xP-
09x51108xP-02
C6004 W-09 C60040-09 1,2,6,9,10.12 C8 005xP-01
1,2.3,8,9.10,12 C8024 1,2.6,9,10,12 C:E1004.xP -09 xCEID<Type3
201
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
µ ___________________________________________________
Acceptos $14:4e1416( ACe1161:r
P Dom CL.11Ix-oa -Pail WORN Ir:331 tuttivat 'WA
%MUM CKY48) I
1
CBDO5xP 01 60013 1,2,3,12 60002 1,2,3,9.10
60012 1,2,4,10 C8D050-01XGOLD I
CI1D05xP-03. 91.04 1,3,7,10,12 91.01 1,312 Sii 011
1,2,3,9,12 COD05x941 XSI WEI?
C8D05KPOI WHIO2 1,3,5,8,9,12 WHIO7 1,3,5,6,12 1:194103 1,3,5,6,12
CBDOSxP=01X.WHITE
CW050-01 PUR01 1,6,8,10 PUR03 1,2,3,6,12CBD03xF-01XPI.PRPl E
:
:
:
C800Sx17:01 8E002 1,3,4,5,12 _______________ RED01 1.3,4,5.12
CBDO5xP-OIXRED
-:19:15x17-1*, 1E103 1,2,3,8,9,10,12 VE1.04 1,2,4,5 1E105
1,2,4,5,8,9,10 1'RD05xP-01)01111.01N
'...6i.)05)(114,1 ORA02 1,4,7,8,12 ORA03 1,4.7,8,9.10
(.81:105xP-01X0FtANGE
C8005P-01 811(03 1,2,3,6,10,12 CEID050-
01)(EXACK
C6005xP-01 FSCO1 1,2,4,9,10 FSCO2 1,2,4,9,10
CEIDO5xP-01XFUSCIA
CODO5x15-01 GRA01 1,2,4,7,8,10 GRA03 1,2,3,7,8,9,12 : :CBDO5xP-01)(GRAY
C5D05x17-01 BROM 1,4,5,6,12 8R004 1,2,5,6,10,12.
:CBDO5xP-01X8RONZE
CBDO5xP :01 GRECO. 1,2,3,4,6,8,9,12 6RE02 1,2,3,7,8,9,10
GRE30 1,2,4,5,9,10 CBDO5x12:01XGREEN
C8005xP-01 812,308 1,2,4,6.8,10 1311105 1,2,3,4,6,9,12 30.106
11,7,4 5,6,7,8.9,10 CB1105x17-01XE11. UE
C6005xP=01 2A:107 1,2,4,5,8,9,10 2A021 1,2,4,5,8,9,10 1A0C4
1,73 9. t 2 C.B0050-01x1A0E
C8D05xP-01 C6005 .:,'.'1.x0 C.204 3,2.4
,CE1005x9-013C13003
i I
450050-05 U0850-01 1,2,3. a,S,12 .,. , i 00050-017(.581F
Table 54 is a non-limiting list of expected crosses using parental lines of
the present invention to
generate new THCV producing specialty cannabis. Table 55 is a non-limiting
list of expected
crosses using parental lines of the present invention to generate new CBDV
producing specialty
cannabis. Table 56 is a non-limiting list of expected crosses using parental
lines of the present
invention to generate new CBG producing specialty cannabis. Table 57 is a non-
limiting list of
expected crosses using parental lines of the present invention to generate new
CBC producing
specialty cannabis. Each of these crosses will also be followed up by one or
more back-crosses to
further reinforce the transfer of desired traits.
Table 54- Additional example crosses to be conducted for THCV lines.
Acceror Acceptor Arcerar
i
.-.1P Donor Cultivar Trait Cultivar Trott kolti,,a,
Trait St,nri Batch Ulric>
i 1
THVOUS- Godn 1,2,3,12 G0002 1,2,3,9,10 60012 1,2,4,10
11111/01x5-XGOLD
THVO1xS- 51104 1.3,7,10,12 51101 1,3,12 St1.08 1,2,3,9,12
THVO14 )(SILVER
THVOlxS- 1N1-002 1,3,5,8,9,12 WHIO7 1,3,5,6,12 WH 101
1,3,5,6,12 THV01 x5-XWHITE
THVOlxS- PuR01 1,6,8,10 PUR03 1,2,3,6,12
THV31 x5. x PURPLE
THVO1x3- RE 002 1.3,4,5,12 RED01 1,3,4,5,12
THVOUS-XRE 0
202
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
CiiltK4e TrAit
"71-11101x.S. 'YE1.03 1,2,3,8,9,10,12 VE01.4 1,2,4,5
YE105 ITHVOIKS-VEL:..OW
1-11V01x5- DRAG? 1,4,7,8,12 RA01 1,4,7,8,9,10
iTiikR1` xS-XORANCE
THN,'01x5 81.603 1,2,3,6;10,12
THVO1x.S.X6LACK
11-11101xS- 15C01 3,2,4,9,10 15(:07 1,2,4,9,10
11-11/01x.5-X$1.:SC:IA
THVOlxS= GRA01 1,2.4,7,8.10 3A03
1,2,3,7,8,9,12 THVD1xS-XGRAY
08001 1311004 1,2,5,6,10,12 THVO1xS-X13111N211
THVO1x5.. 08E01 1.2,3,4,6,8,9,12 GRE02 1,2,3,7,8,9.10
6RE30 1,2.4,5.9.10 ITHVOIY.5 7:GREEN
THVOlx5- 81.:108 1,2,4,6,8,10 81.1.:05 1,2,3,4,6,9,12 1311306
1,2,4,5,6,7,8,9,10 THVOlx.5-X8LUE
THVO1x5- JAD7 1,2,4,5,8,9,10 .1Ad21 1,2,4,3,8,9,10 JADO4
1,2,3,9.12 THVOlx5-XJADE
TH3/01xS- C.8004 1,2,6 CR1305 1,2,3,6,8,12
THVOltS-XCBD(Typen 2)
TIIVOlx11- C8024 1..2,3,6,8.12 C111304xP-09 1,2,3.6,8,12
C13005x11-01 THVOIRSACBD(Type 3)
THVOln.5- CBDOS 1,2,3,6:8,12
,T31V01,..5=XTHVO1nS-
THVO146;:
Table 55- Additional example crosses to be conducted for CBDV lines.
At:cep:or Acceptor :::::::::::::::::::::::::::
P Donor C4tivzr Cultia2r Tpait Crilthior
60013 1,7,3,17 60002 1,2.3,9,10 60017 1,2,4.10 ICBDV3.35-
X601.130
C6CIV1x5- 511.04 1.3,7,10,12 S1101 1,3.12 3:1268
1,2.3,6.12 1C13EW1x5-XSILVER
C9CA/1):5- WH102 1.3,5,8.9,12 WH:07 1,3,5.6,12 WH103
1.3.5,6.12 CBEW1xS-XVVH1TE
C80V1xS- P11801 1,6,8,10 PUR03 1,2,3,6,12
CBDV1x5-XPURPLE
C81W1x5- 8E002 1,3,4,5,12 RED01 1,3,4,5,12
CEIEW1x.i-XRED
CEDV1x5- YE103 1,2,3,8,9,10,12 YE1.04 1,2,4,5 VOIDS
1,2,4,5,8,9,10 CBEW1x5XYELLOW
Ci3DV1xS- :DRAW 1,4,7,8,12 DRAW 1,4;7.8,9,10
C131W1x5-XORANGE
C8OV1r.S- 81.1:03 1,2,3,6,10,12
CBEW1xS-XBLACK
C80V145- P5C01 3,2.4,9,10 15(2)2 1.2.4,9õ10
1:80V1R5-XIUSCIA
C801/1x5. GRA01 1,2.4,7,8,10 GRA03 1,2.3,7,8,9.12
...._,C6DV1x5-XGRAY
CSCIV1x5- 8RCK/1 1,4,5,6,12 811004
1,2,5,6,10,12 1131W1x5-X13110NZE
CP,DV1x5- GRE01 1,2,3,4,6,8,9,12 ,GRE02 1,2,3,7,8,9,10
168030 1,2,4,5,9,10 1030V1RS-XGREEN
C.:80V1AS- 1311.108 1,2,4,6,8,1(3 BLUO5 1131.1:06 130V1x5-
XDLUE
CSDV1xS- JAD07 1,2,4,5,8,9,10 1AC121 1,2.4,5,3.9.10 17,1004
1,2,3,9.12 EICA/13S-K1ACIE
CaDV1x5- C8004 1,2,6 CB005 1,2,3,6,8,12
CBDV1x5-XCE1D(Type 2)
(.8EIV1x5- (.8024 1,2,3,6,8,12 C13004):P=09 1,2,3.6,8,12
CE1005x13-01 IC130V1xS-XCBD(Type 3)
1
C.:80V1x5- Ciii.Y.Y3 1,2.3,603.12
(:8LA/116-K1:801f1x5-
RR Rg gR
C80V31c5. : ri3IN156,0CSFli, :
203
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Table 56- Additional example crosses to be conducted for CBG lines.
Acceptor
I :
1
. P Donor _ Cuitiear Trait : TraR
:
C.8(31x5- 00013 1,2.3,12 G0002 1,2.3,9,10 10.0012 1.2,4,10
CI3GlxS-XGOLD
C5G1xS= 51104 1,3,7,10,12 S11.01 1,3.12 SI108
1,2,3,9.12 CBG1xS-XSILVER
C8G1aS- WH:02 1,3,5,8,9,12 WHIO7 1,3,5,6,12 W H103
1,3,5,6,12 CBG14-8WHITE
L'.:3Glx.S- PUR01 1,6,8,10 _____________________ P12803 1,2,3,6,12
CEIGUS-XPURPLE
C8G1x-S- RE DO2 1,3,4,5,12 RE001 1,3,4,5,12
CBGlx.S-X RED
C3G1xS- YEL03 1,2.3,8,9,10,12 YE104. 1,2,4,5 YELOS
1,2,4,5.8,9,10 CEIGUS-XTELLOW
C8614- ORA02 1,4.7,8,12 ORAO3 1.4,7,8.9,10
CB03x5-803AN6E
C.861xS- B1K03 1.2.3.6.10,12
CBGlx.SIBIACK
CBGlx.S- FSCO1 1,2,4,9,10 FSCO2 1,2,4,9,10
CEIGUS-XFUSCIA
Ci831xS- CRAM 1,2,4,7,8,10 611403
1,2,3,7,8,9,12 CI3G1xS-XGRAY
CBGIrS 68001 1,4.5,6,12 1311004
1,2,5,6,10,12 CBG1x.S-XEIRONZE
... ................................................... ...__ _
:
C8G1aS- GRIN)] 1,2,3,4.6,8,5.11 0RE02 1,2,3,7,8,9,10 It05E30
1,2,4,5.9,10 CE1G1xS-XGREEN
i
C6G16- 81008 1:2,4,6,1,10 613.105 1,2,3,4,6,9,12 I81I.I06
1,2,4,5,6,7,8,9,10 C8G1xS,XBLUE
CBG1xS- A8)1 1,2.4,5,8,9,10 JAW: 1,2.4,1,8,9,10 *1400a
1,2,3,9,12 c !MI6-X.:AM
C.1161/5- C8004 1,2.6 ,C8005 1,2,3,6,3,12
C13:31x5=XCE1D(1y9e 2)
-
C8614- C5024 1,2,3,6,8,12 031)04KP-09 1,2,3,6,8,12
CBD05vP-01 1,2:3,6,F:: 2 IC:8:510=8te9(TyPe 3)
i
CEIG1x.5- C5005 L2.3,6.8,12 ____ t
C8G1x8XC8G1x.S- 1
CNIi,i=n::::C41(31.:..::.:::n:,,I.,;20.1.,5=;30õill.n:::::.::,:::::n:
Table 57- Additional example crosses to be conducted for CBC lines.
'''''''"
P Donor CatiVai:::::::::::::::::: Ti'AiVMan rattiver hail' Callivitr
Trait
!
C3C1xS= C0017 1,2,3,12 G0002 1,2,3,9,10 <8)012 1,2,4,10
COCIxS-X.G0t1)
CBC1.6 SI LO4 1,3,7,10,12 SIL01 1,3,12 SIL08 1,2,3,9.12
CBC1xS )(SILVER
_
C8C1x-S- VvH:02 1.3,5,8.9,12 WHI07 1.3,5,6.12 W H103
1,3,5,6.12 CBC.1 x5-XWI4r11
C8C1xS- PUR01 1,6,8,10 P12803 1,2,3,6,12 CBC1xS-
XPURPLE
CBC1x5- RE DO2 1,3,4,5,12 11E001 1,3,4,5,12
CI3C1x.S-XRED
C6C1xS- YEWS 1,2.3,8,9,10,12 YEL04 1.2.4,5 YELOS
1,2,4,5.8,9,10 Cilt: Wi )(YE ;IOW
CerCbt& ORA02 1,4,7,832 ORA03
_1,4,7,8,9,10 CBC1x.S-XORANGE _
_ ...__
C8C1xS- 13103 1,2,3,6,10,12
CBC:lx$,XEILACK
C3C1,5- FSC01 1,2,4,9,10 FSCO2 1,2,4,9,10
CI3C1x.S-XFUSCIA
ci8:14- GRA01 1,2,4,7,8,10 08403
1,2,3,7,8,9,12 CI3C1xS-X6RAT
CSC1x8 88001 1,4,5,6,12 BROO4
1,2,5,6,10,12 CBC1x.S8SRONZE
-
18C1xS- 05E03 1,2,3,4,6,8,9.12 GRE02 1,2,3,7,8,9,10 65E30
L2,4,5.9,10 CB61xS-XGR( :EN
204
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
C6C1xS= 13a.:08 1.2,4,6.8,10 BLUO5 _________ 1,2,3,4,6,9,12
BLUO6 .CBC1x5-XBLUE
c3C1x5- JADO7 124,5,8,9.30 IAD04 1,2,3,9,12 CBC1x5-
X1A0E
C8CU4 C8004 1,2,6 CBDOS 1,2,3,6,8,12
CBC1r5-XCBDI:Type 2)
8C1xS- Cii024 1,2,3,6,8,32 (110040.09 CI30050-01
11%3,6,0,12 CEiC16-XC8D(Type 3)
C 3C1x.S. C.0005 1.2,3,6.8,12
C8CIAS-XC8C1xS
CBC1a5 CDC14, 1,2,44,8,94/ CliC1,44CiELF
The progeny of each cross described herein will be analyzed as described in
Examples 1
and 2. Progeny with desirable cannahinoid and/or terpene profiles as well as
desirable
morphologies will be used for production of specialty cannabis.
Example 20. Development of additional terpene profile producing specialty
cannabis
(prophetic).
In order to develop specialty cannabis with unique cannabinoid and terpene
profiles,
additional crosses among the parental varieties disclosed in Example 2-4 and
the progeny
varieties disclosed will be conducted. These prophetic crosses arc indicated
below with expected
breeding charts describing specific crosses and the traits each cross is
expected to produce. Traits
for each cross are represented by trait codes which are described in Table 51
of Example 16.
Table 58 through 64 are non-limiting lists of prophetic crosses using parental
and
progeny lines of the present invention to generate new specialty cannabis
varieties with terpene
profiles dominated by selected terpenes. Each of these crosses will also be
followed up by one or
more back-crosses to further reinforce the transfer of desired traits.
Table 58- Additional example crosses to he conducted for ocimene rich terpene
profiles.
Acceptor Acceptor Atteptor
P Donor Cuttrat Trt Cultivar 1Tra0 !Cottliair
Trait Seed tot
YE L3x1i-23 YE LO3 ,2,3,8,9, i0,_2 1E104 11,2.4,5 YEWS
1,2,4,5,8.9,10 YE L30-23)(tii LOW
YEL30-23 c0D13 1,2.3.12 G0002 1,2.3,9,10 60012 1.2,4,10
YE L3KP-23XGOLD
:1130-23 1RE01 .1,2,3.4,6,8,9,12 YEL3xP-23XPURPLE
YE 1.3xP-23 011<03 1,2,3,6,10,12 TEL110-
23XBEK
,E1.30=23 caws 1,2,3,6,8,12 CBDO4 i2,6 YEL3x12-
23XCBDType2
I 30-23 C8004xP-09 1,2,6,910,12. C13005xP-01
1,2,1,8,9.10,12 19613,0-23XCBD1Nioe3
YEL3xP= 23 WI-::0P==02 1,2,4.9,10 YE
L30.23XHighllinorione
f1.3xP-113 1,2õ.4,9,10
?13133P?338ELf.111111
205
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Table 59- Additional example crosses to be conducted for terpinolene rich
terpene profiles.
,,:::::.:.: ..... .......
Acceptor Acceptor s::::::::::::
:.1*.i.00.10c:::::::::::::::::::::::::::
.:i:=::::Ps:00130K::::::::
COltiv.at::::::::::::::::::Tr.aft::::::::::::::::::::::::::::::::::::
alitiVar:::::::::::::::::::Tr44:::::::::::::::::::::::::::::::::::
aittbrat..:.:.....Tr.olt ::::::::::::::: ::::::::.....5.ee.l.Lot ....
...... ... Qty W..... . ...::
1
YE L3xP-26 vEL03 .1.2,3,8,9,10,12 YE LO4 1,2,4,5 YEL05
1,2.4.5,8,9.10 YEL3xP-26XYELLOW
YE L3xP-26 60013 !i1,2,3,12 G0002 1,2,3,9,10 60012 1,2,4,10
YEL3xP-25X60L0
YE1.3xP-26 G11E01 1,2,3,4,6,8.9,12 YE13xP-
26XPURPLE
YEL3xP 26 BLK03 41,2,3,6,10.12
YEL3x026XEILK
..__ ¨
YE 13x9-26 C111/05 1.2,3,6,412 CB DOA 1,2,6 YEL3 xP-
25XE:80 Tyne?
YEL3xP=26 CSD04xP 09 1,2,6,9,10,12 Ci3D080.01 :1,2,3,8,9,10,12
VEL3xP=255C80Type3
1
Yli I 30-26 MiFii0i,-0.7 1,2,4,9,10 Ylii 32P-
25X1righl !mom-mi.
ii iiiii iiii ii Mil ni ii iiiiii iiiii iiiii
iiiiiii iiii iiiiiiiiiiii ii; = i:::::::::::::::::::::::::::
::::::::::::::::::::::::::::::::i*il
Y.EOXRi26:=:=:=:=:=:. 'I'(l.iUR -2 ,., i , ., ' ":,: .?
=:=:=:. . = .. = .. = . =:=:=:=:==:==:=:=:=:=:=[=::=:=:=:=:=:==:==:=:=:=:= . =
.. = .. = : =:=:=:=:. = :=:=:=:. : = :: = :: = : =:=:=:=:. =:. = =:=:. :
= :: = :: = : =:=:=:=:==:==:=:=:=:. : = :: = :: = : if : '--..' _,
-=.: . :=:=:=:=:==:==:=:=:=:=:=::,:=:=:=:=:=:..:..:,:, : = : ....i
Table 60- Additional example crosses to be conducted for Caryophyllene rich
terpene profiles.
Accepter Acceptor kceptor
, ____________________________________________________________________
P Donor Coitivar Trott ::: = :: = : =h:???h=h hvaillIvor :
= :: = :: = : =:=:=:=:=Tita= :: = :: = : =h=h=?': Cistiiyar __Trait .
:::::: .... . ...... ....h..? =????? ?SiKititrieC ?????:': 'eV (6)
I
S11.08xP-01 'VIE:se:3 1,2,3,8,9,10.12 'V5iO4 1,2.4,5 YEL05
1,2,45,6,9,10 Si i080.4.11X*AilOW
SIL08xP.01 ,G01313 1,2,3,12 rG00O2 1,2,3:9,10 .60)12
1,2,4,10 SI W.Sxp:01X60:.D
i11.08vP-01 \6RE01 1,2.3,4,6.8,9,12 SI W8x
P-01131;2314
51108aP=01 yvii;07 1,3.5,6,12
511.080,01XWHITE
511.08xP-01 51104 1õ3.7,10,12 sun]. 1.3,12 SILOS L2,3.9,12
5110(0,01KSVER
511.08xP-01 EI1K03 1,2,3,6,10,12 511.08xP-
01KBLK
SIL08xP-01 C0EY.).5 1,2,3,6,8,12 CBDO4 1,2,5 SIL080-
01XCBDType2
511.08vP .01 C80040 09 1,2.6,9,10,12 CB De5xP 01
1.2,3,8.9,10,12 91.08xP01XCB0Type3
511.08xP.01 Wiii0lx?-01 1,2,4,9,10 _ . Si
i080,01XHigstUrnomerte ...
S1508.09a::: SPMXPg;ili: d:1,7AAa:9
::: M: ::::::::: + :: . ...... ... ... . .
. =
AtOgiti?A: .5/W.txPA.V::::::::::13aM;S=i) : .: Illi804.M1P,St:
Table 61- Additional example crosses to be conducted for limonene rich terpene
profiles.
... ______________________________________________
1
Atreptisr AcC.ptOr Accepter
P Donis, Cutilwar :Trait ist".t:ttivzr Trail Ctiltivar
;Trait Seed int Ctili (a)
i
S11.08xP-37 Y',.1.03 1,.,.3.6,9,10,12 'YEi..04 1,2,4,5
?-(J5 1.,2,4,5,8,Li 0 9In80.37XYE1L0W !
SIL08xP-37 4GOD13 1,2,3,12 00002 1,2,3.9,10 G0012
1.2,4,10 SIL080-37XGOLD
5808KP-37 GRE01 1,2,3,4,6.8,9,12 SILO8KP-
37XPURPLE
SIL08xP-37 WI-807 1,3,5,6,12SILO8AP-37XWHITE
. .
S11.08x13-37 SIL.04 1,3,7.10,12 511.01 1.3,12 Sit.08
1,2,3,9,12 511.08xP-37X511.VER
SIL08x1137 BLKO3 1,2,3,6,10.12 SIL080-
37XEILK
__.
206
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
Acteptor !:!
P Donor Cull:tat Trait 1:43.33tbit
V:1:11111:TtAlt1:1:111111 :21:111111 1:15teeittrt
51108),P-37 CBDO6 1,2,3,6,8.12 CED04 1,2,6 511.086P-
37XC80Type2
S11.08xP-3? C8004xP49 1,2,6,9,10.12 0C13005xP-01 1,2,3,8,3,10:12 511.08xP-
37XCBDTvoe3
511.08xP-37 WHI0L:KP.02 1,2,4.9,10 $11.08KP-37XHiahllmoneqe
s*oggmm sp.4.4*rm 1,40,0:ga
Maaa
WHO3aP4.033: 31V.I:r0ONF's.,081:49,11(UnU nUn
mmEmNi
Table 62- Additional example crosses to be conducted for huinulene rich
terpene profiles.
Aoxptor
Trait Cultivar ra4 ....... ..... MY
31108xP-03 YEL03 11,2,3,8,9,10,12 YEL04 1,2,4,5 4E035
1,2,4,5,8,9,10 '..,.=84,-03XYELL0W
311.08KP-03 GC)1/13 1,2,3,12 00002 1,2,3,9,10 s00012
1,2,4,10 (8.P-03X001.0
SILO8kP.03 GRE01 1,23,4,6,8,9,12 :0S2P-
03XPURPLE
S11.03xP-03 WH:07 1,3.5.6,12 =,...G3KP-
03XWHITE
SILO8aP-03 51104 1,3.7,10,12 511.01 I1.3.12 SILOS
1,2,3,9,12 :.C8xP-03XSILVER
51108W-03 811(03 11,2,3,6,10,12 (!8gP-
03X8LK
311.08x12-03 CBDO5 11,2,3,6,8,12 ,C131304 1,2,6 :.C3cP-
03XCEIDType2
S11.08xP-03 CODO4vP-09 1,26,9,10,12 CI31)05xP-01 1,2,2,8,9,10,12 os*P-
03XCBDType3
;108xP.03. W,4!04x0-02 õ1,2,6.9,10
SIL03KP-03XHighllmonone
UHMM HHMUM MMUHHM MHHM HHHMHM HEMHHMMUHHMMU
ML0,80-011 5111.3.. '..,3 "" . .. .. .
. .. .. .
5llOANP-17 SI108x3.27 1 " "" 531080-
274E1F:" " " 1
Table 63- Additional example crosses to be conducted for linalool rich terpene
profiles.
Acceptor Ameptor _ ______________
0.sttivar Trait Cuttivar TrMt Cuttivar Trait
lot rat/
WI .9-4)2 4)01111 , 1.2,3,12 (0002 1,2,3.9,10
(101)"."2 ).2,4,10 (2024X1101
_WH:04xP-02 9104 1,3,7,10,12 S:U31 1,3,12 3i1.08
1.2,3.9.12 C8D24XSILVER
WHi04rP.02 WH:02 WHIO7 1,3,5,6,12 Wrne3 1,3,5,6,12
CBD24XWHITE
WHi04.KP-02 PUR01 1,6,8.10 PLIRO3 1,2,3,6,12
CBD24XPIJRPLE
W11I04xP-02 YEL03 1,2,3,8.93042 YE LO4 1,2,4,5
YEL05 C6024XTELLOW
WHIO4.P-02 08A02 1,4,7,8.12 ORA03 1,4,7.8,9,10
CEID24X0R4NGE
EILKO3 1,2,3.6.10,12 CBD24XEILACK
WHIO4xP-02 FSCO1 1,2,4.9,10 FSCO2 1,2,4,9,10
C8D24X;LISCIA
WH:04xF,02 GRA01 1,2,4,7,8,10 GRA03
1,2,3,7,8.9,12 03024XGRAY
W11:04x9-02 03E01 1.2,3,4.649,12 G131102
1,23.7,8,9.10 GRE:30 1.2,4,5.9,10 C8024X6REEN
WH;04>P-02 , 1,2,4,6.840 BLUO5 BLUO6 1,2,4,5,6,7,8,9,10
CBD24XBLUE .........
JADO7 i .IA021 1,2,4,5,8.9,10 J4004 1,23,9,12
CBD24KIADE
207
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
W11:04.P.02 _ C8005 _ 1,2,3,6,8,12 .SBDO4
_ 1,2,6CBD24XCBD(Type2)
Wic04xP-02 WliiO4xP-02 1,2,3,12
C8024611.084,02
Whi :Os KP .02 CBDO4xP-09 1,2,6,9,10,12 CBDO5xP-01 1,2,3,8,9.10,12
CBD24 1,2,6,9,10,12 CBD24xC9D(Type3) 1
Table 64- Additional example crosses to be conducted for pinene rich terpene
profiles.
I
AcrqstOS ACriffOr /UMW
..
,
=:.:.:.p Donor C.Pi,÷ ;.:z.,,it CLAtivar 'iota Culane
Titit Seed Battll Cvde City (g)
i
CE;00s (c)D1 1 1 ;,-., 1, G0002 1.2,3,9,0
GOD; 2 1,2,4,1C s rBMixGO: r) ',2 1
1
--t--
(.800S s:Lue. $1101 1,3.12 13.08 1,2,3,9,12
CEIDOi=XS:IVER
C8005 M-1102 i 1,3,5.8,9,12 WHOI7 L3,5.6,12
.....A: 11103 1,3,5,6,12 CB005XWHITE 15.1
C1D05 2tIRC1 1,6.8,10 PUR03 1,2,36,11
C111105XPU RPM 104
a:Dos R302 1,3.4,5,12 RED01 1,3,4,5,12
CBDOSXRED 59
C8005 71103 1,2,3.8,9,10.12. YELO4 1,2.4,5 YE LOS
1,2,4.5,8,9.10 C8305r/i11. LOW 130.7
08005 ORA02 1;1,7,8,12 ORA03 1,4,7,8,9,10
CBDOSXORANGE 66.6
C:1005 81803 1,2,3,6,10,12 CBDOSXB LACK 12
i
C9905 F5C01 1,2,4,9,10 FSCO2 1,2,4,9,10
CI3DOSXFUSCIA
_08005 GRA01 _1,2,4,7,8,10 GRA03
_1,2,21,12,12 ._ CBDO5XGRAY ...
08005 BROO1 1,4,5.6,12 6R004 1,2.5,6,10.12
CBDO5XBRONZE 6.1
C1E005 6RE01 1,2,3,4,6,8,9,12 GRE02 1,2,3,7,8,9,10
6RE30 1,2,4,5,9,10 CBDO5XGREEN 56.6 .
CBOOS _ BLUO8 1,2,4,6,8,10 BLUM 1,2,3,4,6,9,12
BL1106 1,2,4,5,6,7,8,9,10 ., CBDO3XEILLIE 190.7_
capos 1A007 _1,2,4,5,8,9,10 1A21 _1,2,4,5,8,9,10 JADO4
1,2,3,9,12 CBDO5X;ADE 87.8
--
C8005 C11002 1,2,4,5,7,8,942 CEiD05XCB002 5.4
CODOS 08003 2,4,9,W CBDO5XCBDO3 2 2
¨
04905 C11004 1,2.4 CIIIMSXC8004
i
1 C8335 011305 1,2,3,6,8,12 t CBDOSXSEV
The progeny of each cross described herein will be analyzed as described in
Examples I
and 2. Progeny with desirable cannabimid and/or terpene profiles as well as
desirable
morphologies will be used for production of specialty cannabis.
Example 21. Tracking of cannabis plants during production, processing and use
Specialty cannabis must be easily distinguished from each other as well as
from
1.0 traditional recreational cannabis and hemp, allowing it to be tracked
from seed to plant to
processing to sale ("seed to sale" tracking). This can be accomplished by
tagging the seeds or
cutting, harvested material, and marketed product in a variety of different
ways. According to the
present invention it is possible to provide instantaneously the use of
forensic-style audit
208
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
capabilities to indoor horticulture. For example, the compositions and methods
of the present
invention can be used to track specialty cannabis plants, plant parts, ground
plant material,
compressed plant material, extracts, etc. Thus, according to the present
invention, one can track
the chemotype for an individual plant or group of plants from seed to flower
and beyond.
a First,
the seeds and plants may be implanted with a tracking device, such as via
radio-
frequency identification (RFID) using an REID tag or chip, a telemetric
thread, a microchip, or a
magnetic tag, which will allow real-time identification of the seed, plant,
harvest, or final product.
In one non-limiting example, the seeds and plants are implanted with a very
small active
RFID tag or chip which will emit a unique address for each seed and'or plant
to a reader. REID
is a wireless data collection technology that uses electronic tags for storing
substantial amounts
of data that can be used for tracking individual items. There are two basic
types of RFID tags:
passive and active. "Passive" tags have no power source but use the
electromagnetic waves from
a reader (e.g., the receiver) up to approximately 15 feet away to transmit
back their contents.
"Active" tags use a battery to transmit up to about 1,500 feet. The RF1D tags
are read when they
are within the proximity of two-way radio transmitter-receivers, or readers,
which send a signal
to the tag and read its response. The handheld devices can easily be used to
track the RFID tags
integrated into the cannabis seeds, plants, and/or product.
Alternatively, the specialty cannabis plants can be tagged by recombinantly
engineering
them to express a phenotypic trait unique to the strain. For example, a strain
can be stably
transformed to express bio-markers, generally proteins, that directly, or on
contact with suitable
substrates, yield a characteristic color, optical density, light emission, or
fluorescence.
Fluorescent bio-markers can include green fluorescent protein, red fluorescent
protein, yellow
fluorescent protein, blue fluorescent protein, or variants thereof that, when
expressed, will emit a
color under a particular wavelength. Other examples of color tagging include
the bioengineering
of cannabis with enzymes for the production of anthocyanins or other colored
biosynthetic non-
active colored Chemicals. Detection devices for fluorescent bio-markers can
have one or more
excitation light sources for emitting light of a wavelength or a range of
wavelengths suitable for
inducing the fluorescence. In a non-limiting exampleõ an expression cassette
comprising green
fluorescent protein is stably transformed into the plant cells using standard
laboratory techniques.
This protein will be expressed by the seed and/or plant, and when excited by a
particular
209
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
wavelength produced by a simple device, such as a hand-held light, can be
easily identified by
the red color.
Example 22. Horticultural Practice (Consistency)
All cannabis germplasm and cuttings of cannabis germplasm. are established in
identical
environmental conditions (-80`C, 80% Humidity, CO2 variable, 3000k lighting).
Once roots are
established, plants are transplanted into 1 gallon pots using a proprietary
soil mix #1 heavily
laded with beneficial microbes, nematodes and predator mites. Our soil system
is crucial to
establish consistent growth patterns and secondary metabolite production.
Plants are grown under 18 hours of light with 50% Metal Halide & 50% High
Pressure
Sodium Light bulbs generating the spectrum. The environmental conditions,
distance from light,
pots and soil are all proprietary.
Once roots are bound, or plants are approximately 12"-18", they are
transplanted into 3
gallon pots with proprietary soil mix #2. Again, microbial content of soil and
beneficials are a
crucial contributor to the consistent production of specialty cannabis.
Plants are induced into flowering by undergoing a period of 72 hours of
darkness which
is followed by the light cycle of 12 hours of light and 12 hours of dark (20%
Metal Halide and
80% High Pressure Sodium). Plants are trimmed, pruned and topped similar to
fruit tree industry
(i.e., a healthy number of budding sites distributed evenly throughout the
canopy). The specific
techniques employed are cultivar specific.
Environmental conditions, pots, distance from light, trellising techniques,
carbon dioxide
concentration and nutrient regimen are all proprietary.
Flowering period can last between fifty and ninety days. While plants can
exceed 5' in
height, canopies are 'shaped' in row crop tradition and kept at 18"- 24".
Plants are culled if they are showing expressing stress genes and/or if they
are showing
any signs of variations. Ripeness is specifically determined by genetics.
Example 23. Feedback-Based Cultivation System
Some embodiments of the present invention are directed to systems,
apparatuses, and
methods for feedback-based cultivation of the herbal specialty cannabis
described herein.
210
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Figure 10 illustrates a system 100 for feedback-based cultivation of the
herbal specialty
cannabis described herein, according to some embodiments. The system 100
includes at least a
computing apparatus 102, an environment management system 104, and a patient
management
system 106. The various components of the system 100 can be in communication
as indicated
by lines in Figure 10 via a network (wherein a dotted line indicates an
optional connection),
which may be any type of network (e.g., a local area network or LAN, a wide
area network or
WAN, a virtual network, a telecommunications network, the internet and/or the
like)
implemented as a wired network and/or a wireless network. Any or all
communications may be
secured (e.g., encrypted) or unsecured, as is known in the art.
The environment management system 104 can be configured for production of the
specialty cannabis plants disclosed herein. In some embodiments, the
environment management
system 104 can be configured for managing a controlled environment for
production of the
herbal specialty cannabis disclosed herein. The controlled environment can
include one or more
software and/or hardware components monitored and/or controlled by the
environment
management system 104 including, but not limited to, one or more sensors, one
or more
controllers, one or more fertigation systems, and/or the like. For example, in
some embodiments,
the environment management system 104 can include controlled environment grow
rooms,
sensors, fertigation devices, and further computer networks and interfaces for
monitoring/control
of these aspects. In this manner, the disclosed embodiments are configurable
to implement a
smart grow room, where sensor technology and artificial intelligence-based
software combine to
assist cultivators to monitor the dozens of parameters that must be optimized
to grow the highest
quality and healthiest plants producing consistent levels of secondary
metabolites (as will be
described in more detail later). In some embodiments, the sensors can include
soil sensors for
taking soil measurements such as, but not limited to, soil moisture,
electrical conductivity (EC),
available soil moisture, potential gravity, temperature, and/or the like.
In some embodiments, where grow rooms are employed, multiple sensors per room
can
be employed. For example, the total density or number of sensors in each
'cell' (or room with 5
4'x16' rows, ¨150 plants, 15 plants per 4'x8' table) can vary from 2-4 per
room. The number of
sensors in a room can be dictated by the density of plants in each table. Two
sensors are needed
for each density, whether it is 15 or 21 plants per table, one on a boundary
plant and one on a
211
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
middle plant. Additional pairs of sensors can be added for a specific cultivar
if it is known to
have substantially different water usage than surrounding plants in the cell.
In some embodiments, the sensors can include sensors for air
particulate/contamination
measurements. In some embodiments, the sensor(s) includes a Thermo Scientific
TEOM 1405
continuous particulate monitor. In some embodiments, the air sensor(s) can
include
environmental controllers having sensors associated therewith, such as the
Sentinel CHHC-4 that
measures, in real time, temperature, relative humidity, and carbon dioxide
content. In such
embodiments, the controller can also be employed for environmental control.
For example, the
CHFIC-4's ability to hold a set point within a certain range of accuracy can
be exploited.
In some embodiments, water and/or fertigation parameters can be measured by a
variety
of sensors, including pH, EC, flow rate, TDS, NPK, ppm of certain compounds,
and/or others if
desired. Some of these parameters can be determined via direct measurements,
while other, such
as ppm of some compounds, can be determined via dilution calculations. In some
embodiments,
water and/or fertigation parameters can be controlled using systems such as,
but not limited to,
the Hanna Instruments computerized fertigation system (Model HI 10000) that
allows for mixing
of four nutrient zones and one acid/buffer zone for pH control, and uses
reliable and accurate
Dosatron 08R vcnturi style injectors. The HI 100(X) can also be hooked to a
reservoir style
system or in-line flow mixing, where the preferred method is likely reservoir
for compost teas
and inline for fertigation.
In some embodiments, the environment management system 104 can be configured
to
track active ingredients from their concentrations on the plant in the field,
through production
and processing. In some embodiments, the environment management system 104 can
be
configured to measure the production of key secondary metabolites and/or
monitor their flux in
concentration over time to better understand and control the mechanisms
underlying their
biosynthesis. In this manner, aspects of the environment management system 104
overcome
challenges associated with the production of herbal specialty cannabis that
have multiple active
ingredients, where consistent production of these active ingredients typically
varies from crop to
crop. Additional benefits are realized when a highly monitored controlled
cultivation
environment can be utilized in conjunction with timely chemical fertilizers
that trigger the plants
to produce these metabolites at the desired concentration. As a result,
harvesting at the optimal
time can guarantee consistent cannabis. In some embodiments, the environment
management
212
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
system 104 can be further configured to optimize for individual metabolites of
interest with
troubleshooting mechanisms to identify issues before they impact a plant's
primary or secondary
metabolite production.
In some embodiments, the environment management system 104 can be structured
in a
multi tier maxmer and particularly in a three tier manner, with. the primary
order being a central
control center/database, second order being an on-site pc interface station,
and third order being
an individual station such as a tablet interface. The data processing and
analysis can be carried
out by the more powerful control center computers, which can be equipped with
the latest
microcomputer needed for bidirectional data transmission, allowing them to
communicate with
the on-site PC stations and/or to th.e individual stations. The bidirectional
data transmission
between different facets of the network, such as the individual stations and
on-site PCs, can be
accomplished in the manner outlined in Figure 11, which illustrates an
exemplary and non-
limiting embodiment of the environment management system 104:
As illustrated in Figure 11, environmental sensors ("actuator") sense
environmental
parameters and take in raw data ("data") from their respective system and
location therein. This
data is then location and time stamped and sent to the on-site PC station ("on-
site PC").
The raw sensor data can then be received at the on-site PC. Decision making
data
analysis may be done on the on-site PC, and/or at the central control center
("central PC"),
and/or other network computers as well. The data received at the central PC is
sent to the control
center, and changes to the data can be made by the on-site PC in conjunction
with the applicable
system hardware.
In some embodiments, a wireless system of sensor-to-PC communication can be
used. In
some embodiments, as best illustrated in Figure 12, a wireless mesh network of
sensors can be
employed that feedback to a centralized pc system.
The wireless system can contain at least three main components; intelligent
sensors/actuators, wireless mesh network of routers and gateways with
intelligent routing
algorithms, and control and actuation.
In some embodiments, functionality and/or data associated with the environment
management system 104 can include, but is not limited to, one or more of the
following: number
of plants put into veg (date, variety); assign lot and plant number; track
development ¨ ability to
ascertain Inventory of plants at any given time; assign date of flowering
(date flowering
213
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
initiated, variety, lot #, plant #, location); track feeding schedule during
flowering (date, six
nutrient fields); track environmental conditions (linked to various sensors in
the room: soil
moisture, temperature, humidity, CO2 level, and Light intensity); cultivator
notes field (Date,
Note field for cultivator to make notes on specified date, e.g., 'lights were
mistakenly left on
form 0200 until 2300'); cannabinoid/terpenoid testing log (results, testing
date, point in
flowering); harvest (date, B&T weight); processing (trim date, weights); bulk
packaging; transit;
acquisition from MPC ¨ lot #, variety, production reimbursement, total weight,
form; receipt
(entity, name, date); safety screening results (pass/fail) - molds,
pesticides, aflatoxins, microbial;
weighing; assembly (units); allocation information (amount, avg. allocation,
reimbursement);
and popularity indices (rank, velocity, potency/reimbursement ¨ via cross-
references with
"Patient" data). Table 65 illustrates exemplary and non-limiting embodiments
of the cultivation-
related information that can be collected.
Referring again to Figure 10, the patient management system 106 can be
configured to
acquire patient data in any suitable manner. In some embodiments, the patient
management
system 106 can be configured to record patient data within the context of a
method as illustrated
in Figure 2.
Figure 2 used in Example 9 illustrates exemplary and non-limiting embodiments
of the
patient-related information that can be collected, including prescribing
physician information.
In some embodiments, functionality and/or data associated with the patient
management
system 106 can include, but is not limited to, one or more of the following:
standardized and
compliance messaging to visitors (clients, elected officials, healthcare
providers and media) by
using recorded images/messages transmitted electronically via tablet (this can
include all
agreements and consents); collect biographical, contact, health history, and
prior non-cannabis
treatments electronically (currently collected on handwritten forms); set up
patient record
automatically; immediately upon completion of registration process, prior to
first transaction;
assign patient ID automatically and associate that ID with all future
activities related to the
patient; swipe driver's license upon subsequent visits ¨ swipe can bring up
patient's record and
enable dispensary staffer to immediately see "attached" scans of physician
recommendation,
photo ID as well as recommendation expiration date; recommendation date can be
color coded to
quickly draw attention if out-of-date or if within X days of being out of date
so that dispensary
staffer can inform patient on the spot that either the recommendation is no
longer valid or that it
214
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
will be invalid in X days/weeks/months and that s/he should take steps to
renew it; information
regarding allocations to specific patient can be captured (date, variety,
amount, $, lot) and
accessible by staff by doing a patient "name" query; feedback regarding prior
allocations can be
captured (noted effects) and ratings of medicines; follow up, correspondence
to physicians can
be prepared automatically by pulling data from allocation database fields; the
ability to query
database by age, gender, strain, lot #, feedback (feedback itself and/or
condition), etc, and cross
reference with production fields below; and the ability to predict/recommend
medicine based
upon prior ratings/preferences cross-referenced with strain chemistries.
System access can be a concern in such multiuser environments. Accordingly,
embodiments directed to system access will be described with respect to the
system 100, and
unless explicitly stated otherwise, are understood to be directed to aspects
of operation of the
environment management system 104 (also referred to as the production side),
and/or the patient
management system 106 (also referred to as the patient side), and/or the
computing apparatus
102. In some embodiments, system access (production side and patient side) can
include four
components of hierarchy; master administrator, regional manager, on-site
manager, and
cultivator (production side)/counselor (patient side). Communication structure
can be cloned
from one tier to the next, e.g. from cultivators to master administrators. In
some embodiments,
the communication structure can include alerts, decision tree confirmations,
and/or other
clearance restrictions¨most restrictive at the cultivator level and least at
the master control
level. This 'overlapping' of communication in each sector can bring continuity
between the
chain of command so that major decisions are always cleared on multiple
levels. Integrating
with the on-site PC and individual PC can condition operation patients to use
open
communication that they know is backed by system-checked accountability.
The on-site PCs and the individual PCs can have a private communication system
therebetween, such as encrypted 1M and/or some form of closed/private network.
In some
embodiments, emails are encrypted for patients that can send notifications to
users' email of
choice when a new email arrives in their encrypted box.
PC Computer Terminal Interface
Master Administrator platfOnn:
215
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, the master administrator platform (e.g. the central PC)
can be
characterized in the following exemplary and non-limiting manner: access to
all real-time
databases, archived data sets/analysis results, patient information, cameras,
etc. No access
restrictions, access can be heavily encrypted and access codes can be very
limited in number,
only to key company patients for example. Access to certain aspects of the
master platform can
be partitioned off for limited access to other manager(s) if needed. For
example, lab managers
can have access to analysis data, certain production managers have access to
some production
data, etc.
Regional Manager platform
In some embodiments, the regional manager platform allows for control over a
number of
sites, and over selected parameters that can be delegated by the master
administrator platform.
For example, the person responsible for formulating fertigation solutions in
the lab can have
regional access over the fertigation/soil water parameters, but not full
'master' access to all sites.
This access can be restricted further to be allowed from on-site network
computers.
Site Manager platfOrm
In some embodiments, the site manager platform (e.g. the on-site PC) provides
an access
point for data compilation/entry, Excel, Word, system specific software,
and/or the like. System
access/control will encompass control over master 'filtered' parameters such
as fertigation time
series/allocation and/or the like. Any independent changes made by the site
manager either via
their individual PC interface would be sent back to the necessary upper
management in the form
of an email, 1M, and/or other chosen alert method. In some embodiments, a two
method
minimum, and preferably three alert methods are preferred for adequate
redundancy and
accountability.
in some embodiments, no cultivator/counselor access is permitted to on-site
PCs or
otherwise, and cultivator interaction can take place through the individual PC
only. Counselor
access will take place through a separate individual PC intended to provide
product information
to inform counselors and, through the counselors, consumers.
Individual PC pla?fonn
The individual PC will serve different needs for different levels of
management and
operators, but the main purpose can be for use as a company specific interface
and
216
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
communication tool. At all levels users can populate, manage, and track their
tasks, as well as
enter data and notes. In some embodiments, all users can also send and receive
messages to
other users within their realm. At higher levels, users can track data trends,
view real time data,
and analyze various data components in different graph formats and analysis
methods of their
choosing. This analysis will tap data on the master database for all sites,
allowing regional
manager and master administrators to track multiple site data from one device.
The level of interaction at each level can happen via applications in some
embodiments,
some shared by all users and others only for those with special permissions. A
majority of these
applications can be specific need-based adaptations of preexisting native apps
(i.e.: notepad) or
proprietary apps.
Master Access platform: Data input for all areas of production and/or patient
side. In
some embodiments, the master access platform allows viewing of each site(s)
critical data 'at a
glance'. The 'at-a-glance' data can be changed in both content and form. For
example, one
patient may want to compile yield data for all sites that are displayed in a
monthly time series
linear graphs over a prior year, with a year-to-date production trend graph
for comparison
(underlined portions represent changeable variables in the at-a-glance
screen). Any analysis done
by algorithms could also be accessible at the individual PC level, but not
necessarily as in depth
as is available at the on-site PC level. In some embodiments, the master
access platform includes
the ability to make changes/overrides that update to selected individual PCs
(i.e. a master access
change to nighttime temperature schedule for a certain cell would send
notifications of the
change, if desired, and create a permanent change). In some embodiments, the
master access
parameter set points, and other system parameter elements that are outside of
the regional
manager/site manger security clearance will require an encrypted password to
change. If needed,
this would allow master administrators to grant lower management access to
certain elements on
per case basis.
In some embodiments, the master access platform includes the ability to access
patient
records, surveys, survey group data, blood sample data, and all other aspects
of the patient side
of the system. At-a-glace home screen for patient data will have the ability
to show output of
algorithmic data mining. A patient system example would be when a patient's
makes their first
visit and submits their information into the patient database, that
information is cross-referenced
with an array of other patient 'data points' (such as ailment, age, gender,
survey responses,
217
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
chemovar preference, etc.). Based on the results of one or a few simple data
mining algorithms,
tailored recommendations can be made and generated on the counselor's
individual PC in real
time (e.g. a recommendation engine can be implemented).
In some embodiments, the master administrator platform can include the ability
to set the
recommendation parameters for the algorithm's decision process, but whatever
chemovar
recommendation parameters are chosen, in some embodiments, they can remain
constant for all
new patients. In this manner, a consistent reliable database can be built over
time, which will
increase the `accuracy' of the system. This ability for the system to `learn'
using AI (artificial
intelligence) software programming, likely with evolutionary algorithms, will
require a certain
amount of time of patient response data to be entered before the programs(s)
can discern which
decision pattern yields the favorable result a statistically significant
amount of times. The
eventual result of this system component at the patient/counselor interaction
level can be an
accountable and consistent decision tree process that is tied in to all levels
of management,
removing counselor recommendation variance from one to the other and possible
misinformation. Although this example pertains to chemovar recommendation, it
is understood
that it can also be applied to other patient/counselor interactions such as
patient/P0A (point of
allocation) and others.
Regional Manager Platform: The individual PC regional manager platform can
allow
RMs to have at-a-glance data viewing/comparison capabilities similar in
function to that of the
master administrator, but restricted in content to that which is job/project
related or delegated
otherwise. Data inputanalysis and system monitoring can be the main use of the
individual PC
for RMs. Selective control over certain `master delegated' system parameters
could be altered
by RMs via the individual PCs similar to the way it would be on the on-site
PC, but via a
comparatively 'deconstructed/refined' tablet interface.
Site Manager Platform: Can allow for site overview and management of multiple
cultivators or cultivation teams.
Cultivator/Counselor platform: Can allows for cultivator notes to be entered
into the
system, and the system can digitally 'tag' the notes with date, time, batch
number, plant number,
etc. in the system to be referenced at a later point if needed. Cultivators
will need to have fields
in the notation application that will be filled out with the appropriate
information to create a track
record for the entry tag.
218
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Having described system access, referring again to Figure 10, embodiments
directed to
software tools will be described with respect to the system 100, and unless
explicitly stated
otherwise, arc understood to be directed to aspects of operation of the
environment management
system 104 (also referred to as the production side), and/or the patient
management system 106
(also referred to as the patient side), and/or the computing apparatus 102.
Decision Tree Analysis Help Tool - Designed with the cultivator/counselor in
mind, this
application can serve both as a communication pathway between managers and
cultivators/counselors as well as a help tool for them as well. A
troubleshooting function is in
the form of a series of searchable common issues that arise either in daily
procedure or possibly
on rare occasions. If such an issue arises that someone doesn't know the
correct flow of action
for a particular task, they can reference this application to see a decision
tree/flow chart on how it
should be done according to management.
This application can become a communication tool when the managers, whether
transitory regional or permanent on-site, choose to upload decision trees into
the system. For
example, if a regional manager comes through and makes changes to operating
procedure or
wants to reiterate procedure, they can quickly create a simple decision tree
chart (possibly pre-
formatted entry fields) while on-site and upload that system onto the network.
Once uploaded, it
is available for others to view when needed, and managers could even make it
into a checklist
format in which operators must check off steps in the process until
proficient.
Data Entry Portal - The data entry portal can be the data entry application
for the
individual PC that will have different 'forms' for different operator
positions. For example,
patient-based entry fields (i.e.: POA data, patient feedback data, etc.) for
counselors and plant-
based entry fields (i.e.: plant number, lot number, package number, etc.) for
cultivators.
Data Analysis Tool - The data analysis tool can allow managers and technicians
the
ability to alter their at-a-glance home screens and run other analysis on
their data in the field.
The range of this analysis can be limited in comparison to the pc interface.
The results of such
an informatics system can be directed and displayed in many ways, to be chosen
by the user.
Genetics - Terpene Profiles - System is designed to analyze, characterize and
codify the
subtleties in terpene differences across a large number of separate genetic
groups (as per the
color coded system), different populations within those groups, and time
series analysis tracking
where applicable (i.e.: terpcne ratio and/or quantity variation during final
weeks of flower
219
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
development). Individuals will be grouped into different color groups based
initially on some
qualitative characteristics such as 'nose' (piney, fruity, etc.), and later
quantitatively.
Quantitative analysis will allow for each individual to be profiled into the
database.
Chemotype Profiles ¨ These can have the same framework as the terpene program,
but
can include cannabinoids and other secondary metabolites of interest.
BioinfOrmatics ¨ The use of evolutionary algorithms to run computer models of
mass
breeding programs that can allow for increased efficiency in parent material
selection as well as
accurately estimating required population sizes for field trials.
Algorithms for Data, Systems and decision Making - Numerous algorithms can be
used at
any point either singularly, simultaneously or in conjunction to produce new
data, maintain
system functionality and/or optimization, compilation and execution of fuzzy
control programs,
analyzing and/or processing data, making system updates and 'intelligent'
decision/changes, and
monitoring system components/sensors to name a few. Some of the algorithms
used to address
dynamic data sets and problems can include, but are not limited to; least
squares algorithms,
direct and/or indirect control evolutionary algorithms, pattern recognition
algorithms, data fusion
and/or data clustering algorithms.
Referring to Figure 10 again, the computing apparatus 102 (also referred to as
the
"central computer", the "central PC", etc. See Figures 11, 12) can handle the
acquisition,
processing, and analysis of data from different components of the system 100,
including the
environment management system 104 and the patient management system 106. In
some
embodiments, the computing apparatus 102 can be configured to track both crop
and patient
trials of chemotypes of potential interest. For example, the computing
apparatus 102 can be
configured to track the production of metabolites of interest in a crop, while
also being
configured to track the metabolism of those eventual plant-produced
metabolites as they are
metabolized by consumers. Thus, active ingredients can be tracked from their
concentrations on
the plant in the field, through production and processing, to the eventual
concentrations as
metabolites in the blood of patients, post consumption. In this manner,
aspects of operation of
the computing apparatus 102 can define the complete chemical relationship
between plant and
human. In some embodiments, this defined chemical relationship can be used to
create maps,
multi-dimensional scatter plot to examine and/or analyze patterns within a
host of metabolic
variables throughout the incredibly complex system.
220
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
In some embodiments, once data is received at the computing apparatus 102 any
number
of actions can be taken, based on a user's needs and based on a user's
associated system access
parameters as discussed above (i.e. a user of the computing apparatus 102, of
the environment
management system 104, and/or of the patient management system 106). In some
embodiments,
the computing apparatus 102 can be configured to implement one or more
algorithms to analyze
various types and forms of information including, but not limited to; genetic
data, breeding data,
tissue culture data, field trial data, all computer system-related data,
greenhouse data, indoor
grow data, environmental sensor-sourced data, environmental data from other
sources, all
patient-related/sourced data, allocation/reimbursement data, and all other
types/forms of
proprietary sourced data.
The resulting information can then be transmitted back to the user that
requested it in the
form of their choosing via bidirectional data transmission. This transmission,
either wireless or
wired in signal, can be routed through the network (not shown), and/or can be
encrypted. The
user can then choose to make changes or updates to the controllable/accessible
aspects of the
system 100, if applicable. For any alterations to system parameters or any
other significant
system aspect, a feedback system can exist for alerts, timestamps, updates to
currentlfuture
computational processes, referenced data sets, and other signals.
In this manner, patient feedback data can fuel the production of specialty
cannabis. For
example, the patient feedback data can be used to optimize pharmacologically
active plant oil
content through a host of breeding and cultivation techniques. In some
embodiments, the
computing apparatus 104 can be configured to monitor market trends and
identifies products'
appeal, efficacy, and sell-through as the products' chemotype evolves over
time refined by
consumer feedback and research studies. In some embodiments, the feedstock
that is used to
create these products can be selected in response to real-time feedback
collected by this system
from consumers. The coupling of chemotype development and selection with
consumer
feedback can enable the identification of market trends of selected chemotypes
at the earliest
possible stage in product deployment. For example, principal component
analysis can be used to
identify synergies between groups of pharmacologically active constituents
that are gaining
traction with consumers for their medicinal effectiveness, their aesthetic
appeal or combination
of both.
221
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
Table 65- Exemplary growth data for storage in growth system.
[Ifferittalatiftiet:TableISL : :::
lot identifier (relates to Coiiective Table and Patient Table) collective
lot arrival date/time
collective lot identifier (relates to Lot
lot location identifier Table)
=
lot plant identifier (relates to Plant Table) collective break lot up
into units date
lot date began veg collective units
inventory
lot date began flowering patient unit allocation
date
lot feeding date(s) patient unit allocation
identifier
lot feeding date(s) nutrients (six fields) patient unit allocation
reimbursement
lot environmental condition(s) (dates) (soil moisture, temperature, humidity,
CO2, light
intensity) Seed to Plasma
Constituent Analysis :
lot cultivator notes
lot cannabinoid/terpenoid testing (results, testing date, point in flowering)
lot safety screening results (pass/fail)
lot harvest date
lot harvest date weight
lot trim date
lot trim date weight
lot bulk packaging date
lot bulk packaging date weight
lot transit departure date/time ngE gE gE gE
Example 24. Multiplexed Cannabis Mixtures
Some embodiments of the present invention are directed to the production of
multiplexed
cannabis mixtures (MCM). In some embodiments the MCM comprises at least one
cannabis
plant base and one or more stock fortifier(s) to create custom medical
cannabis mixtures for the
treatment of a particular disease or disorder. In some embodiments, said
cannabis base comprises
one of the cannabis varieties of the present invention or any other cannabis
variety known in the
art. In some embodiments, the variety chosen as the cannabis base is selected
for its cannabinoid
profile. . = In other embodiments, the cannabis base is selected for
its terpene profile creating a
desirable aroma/organoleptic feel or desired entourage effect.
In addition to the cannabis base, the MCM includes one or more stock
fortifiers. In some
embodiments the stock fortifiers enhance the MCM by supplementing the cannabis
base with
THC, CBD, CBG or other cannabinoids (for example the addition of CBD
fortifiers to
supplement a high THC cannabis base). In some embodiments, the stock
fortifiers enhance the
222
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
MCM by supplementing the cannabis base with terpenes such as limonene, pinene,
myTcene,
linalool, beta-caryophyllene, phytol, terpinolene, terpene, ocimene,
caryophyllene oxide, alpha-
humulene, or combinations thereof.
In one embodiment, the fortifying stock comprises plant material that can be
blended into
the cannabis base. Cannabinoid fortifying stocks can include one or more of
the cannabis
varieties of the present invention or any other cannabis known in the art. In
some embodiments,
the variety chosen as the cannabis stock fortifier is selected based on its
carmabinoid profile. In
other embodiments, the cannabis fortifier is selected based on its flavor
profile. In some
embodiments the cannabis fortifier is selected based on its ability to reduce
side effects due to
THC.
In one embodiment, the fortifying stock comprises herbs such as basil,
oregano, rosemary,
sage, or other herbs with desired terpene profiles. In one embodiment, the
fortifying stock is
selected based on its flavor profile (for example, to provide the patient with
a mixture tailored to
their flavor, aroma, and organoleptic preferences for their medicinal or
recreational use). In other
embodiments, the fortifying stock is selected based on its ability to treat a
disease (for example
the addition of pinene-containing rosemary for its anti-inflammatory
properties). In other
embodiments, the fortifying stock is selected based on its entourage effects
with cannabis
(British Journal of Phannacolov 163.7 (2011): 1344-1364).
In some embodiments, the cannabis stock fortifiers are in the form of extracts
such as
cannabis sludges or essential oils (EO). Any means commonly used in the art to
isolate particular
cannabis agents may be used may be used to prepare the fortifier stocks. For
example, stock
cannabinoid fortifiers with high THC (1), CBD (11), and/or CBG (1V) contents,
can be produced
by removing the extract from phenotype 1, II, or IV plants that are high in
THC, CBD, and/or
CBG. The terpenes are distilled from the extract by supercritical extraction
to provide a crude
sludge, which is then winterized to remove waxes.
To prepare the high terpene EO fortifiers, plants are produced that have the
desired
concentrations of terpenes: these include, but are not limited to,
terpinolene, alpha phelladrene,
beta ocimene, carene, limonene, gamma teipinene, alpha pinene, alpha
terpinene, beta pinene,
fenchol, camphene, alpha terpineol, alpha humulene, beta caryophyllene,
linalool, cary oxide,
myrcene, and/or phytol. The high terpene extract is removed from the plants,
and is then steam
distilled to provide stock terpene fortifiers with high limonene, pine=
myrcene, Linalool,
223
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
caryophyllene, and/or phytol. Since these compounds may extract together it
might be necessary
to fractionally distill the crude to further enrich for the desired compound.
For small scale extraction of terpenes, a 500 tnL round bottom flask is
charged with 50-
100 g of ground cannabis flowers or other terpene producing plant and
approximately 300 InL of
water. The flask is fitted with a claisen adapter, a distillation head, a
water cooled condenser, a
250 mL receiver, a thermometer, and a separatory funnel. FIeat is applied
until a constant rate of
distillation (one chnp every 2-5 seconds) is achieved. As the water in the
flask is depleted more
is added via the separatory funnel. Continue this process until approximately
150 mi., of cloudy
condensate is obtained. The condensate is transferred to a separatory funnel
and extracted twice
with 30 mI, of diethyl ether. The ether extracts are dried over sodium sulfate
and evaporated
with very gentle warming on a rotovap or under a gentle flow of nitrogen. The
condensate is
stored in the dark at -20 C. The neat steam distillate is misted onto the MCM
to fortify the
terpene content.
In some embodiments the cannabis base to which the high cannabinoid or terpene
fortified stock is added is prepared from any and all of the various strains
described herein, or
others known in the art, by supercritical extraction. This provides the
foundation cannabinoid
ratio which retains the subjective qualities of the strain since all the
eannabinoids, terpencs, and
waxes are still present.
Although cannabis can be used to treat several symptoms, it is not a one size
fits all cure.
Diseases may treated more effectively if the cannabis medicines used to treat
the symptoms are
tailored to each disease with specific cannabinoid and terpene compositions.
It has been
suggested for example that various THC: CBD ratios would be most effective at
tmating a
variety of diseases (Table 68, and U.S. Patent Application Serial No.
11/628,814). In addition,
the present invention has discovered the effect of several terpenes on
volunteer mood, anxiety,
emotional comfort, etc (Examples 9, 10, 11, and 14). In some embodiments, the
tailored
medicine is provided through breeding of specialty cannabis of the present
invention. In other
embodiments, the specialty cannabis of the present invention are used in MCMs
to further
enhance the cannabinoid and terpene profiles. In some embodiments, the MCMs
are produced
using other known cannabis varieties. In some embodiments, the MCMs are
tailored to a desired
medicinal or recreational effect.
224
CA 02911168 2015-10-30
WO 2015/065544
PCT/US2014/046694
The concentrations of the various active agents present in the multiplexed
cannabis
medicine will vary depending on what has been determined to be the optimal
dosing for any
particular disease or disorder being treated. Depending on the condition being
treated and the
subjective qualities desired (such as aroma, flavor and organoleptic feel),
the base is then
fortified with. high cannabinoid and/or terpene stock to give the final
preparation according to the
following flowchart in Figure 13. A. non-exhaustive list of examples of MCMs
to treat various
diseases are outlined in Table 66. in some embodiments, MCM's are a
macroscopic method of
dosage control through the manipulation of ratios of agonist¨antagonist blends
that exploit the
relationship of each cannabinoid to the cannabinoid receptors of the human
body. In some
embodiments the MCMs further tailor the effects of the cannabis blends through
the use of each
terpene's unique individual, and entourage effects.
Table 66- Fxample Multiplexed Cannabis Mixtures.
MISEASEi HCBSASEMa
HiMaCBTORTIFIERMi;TEENI FOIZTIELEIV
Brachial Plexus Avulsion ! THC variety CI-1DV variety
myreene and eucalyptol
Arthritis ______________________ THC variety (.:BD
variety linalool
Motion S ickness TFIC variety C1.31-)
v;kriety limoriene
Seizures TIICV variety CI iDV
variety pineue
Nettropathie pain Fit variety
myrcene and linalool
Weight Loss IIICV variety CBDV
variety cineol
Depression I CBG and CRC varieties THC variety linalool
Irritable Bowel Syndrome CBD varieties THC
variety I inxinene
Cancer Pain THC variety CBD variety
myrcene and eucalipto] .1
Low II DL Cholesterol *Ft (CV variety CBD
variety. tnyrcene
Example 25. Blended Bubble Pack Doses
It is important that the specialty cannabis and MCMs of the present invention
be stable
and possesses a long shelf-life when prepared for distribution to users for
medicinal and
recreational uses. This is achieved through proper drying and curing of the
processed specialty
cannabis product. In one embodiment, the shelf-life of the specialty cannabis,
MCMs, or
cannabis extracts of the present invention can be increased by proper airtight
packaging such as
in a bubble pack or a blister pack. One embodiment of the blister pack is
diagramed in Figure 14.
In some embodiments, the blister packs of the present invention can be used
with any cannabis
product.
225
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The longevity (i.e., shelf-life) of the packaged cannabis can be further
extended by
Modified Atmosphere Packaging (MAP), a technique used for prolonging the shelf-
life of fresh
or minimally processed foods. In this preservation technique, the air
surrounding the product in
the package is removed by vacuum or modified to contain different levels of
nitrogen, oxygen,
and carbon dioxide.
The specialty cannabis products of the present invention, including the
blended cannabis
compositions described herein, can be packaged in a bubble pack in either
multi- or single-dose
units to increase product longevity. Each single-dose unit packaged in the
bubble pack will
comprise the optimum cannabinoid and terpene dose identified by the instant
invention. In one
embodiment, the compositions of the invention are packaged as single-dose
units to ensure the
patient receives a correct, standardized dose and to protect the product
integrity.
Example 26. Use of the Invention as Expectorant
When vaporized and inhaled, the specialty cannabis varieties of the present
invention are
an effective expectorant. Use of CBs containing specialty cannabis varieties
described herein can
be used, for example, in the treatment of congestion and upper respiratory
diseases.
One mechanism through which specialty cannabis may act as an expectorant is
through
the activity of terpin hydrate, a precursor to terpineol which has been
identified in several
cannabis strains (See, Ross and ElSohly, (1996). J. Nat. Prod. 59:49-51 and
Fischedick et al.,
(2010) Phytochemistry 71:2058-2073). The presence of terpineol, instead of
terpin hydrate, in
the samples after the cannabis is dried and heated may be due to a dehydration
reaction of terpin
hydrate to terpineol under thermal conditions. This chemical process may not
occur if the
cannabis is exposed to the lower heat of a vaporizer.
inhalation of the vapors produced by high CBs containing specialty cannabis
exposed to
a lower heat can act as an effective expectorant and can be useful in the
treatment of congestion.
Terpin hydrate was commonly used in the treatment of acute and chronic
bronchitis, but it was
removed from the market by the FDA, which cited a lack of efficacy (See, Code
of Federal
Regulations, Title 21, Volume 5, April 1, 2009). However, the formulations
studied were oral
formulations comprising terpin hydrate, not vaporized, inhaled terpin hydrate
which may prove
more effective.
Example 27. Pelletization of Specialty Cannabis for Bowls, Pipes, or
Vaporizers.
226
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Specialty cannabis of the present invention will be used to create pre-pressed
bowls of
blended and pelletized cannabis. In some embodiments the MCMs of Example 24
may also be
pelleted. Novel design and pellet density were used to optimize dosage for
vapor and combusted
cannabinoid delivery. The purpose of this invention is to maximize the exposed
surface area of
the pelletized material to maximize contact with heated air to achieve optimal
vaporization. In
one embodiment, the shape of the cannabis pellet is a very thin 'coin' shape.
In another embodiment, the shape of the cannabis pellet of the present
invention is a
"truncated cone" (Figure 15). In some embodiments, the dimensions of the
cannabis pellet shape
can vary for use with various smoking methods. In some embodiments the
"truncated cone"
pellet has a smaller base diameter "t" of .5mm, 1 mut, 1.5mm, 2mm, 2.5mm,
3.5mm, 4mm,
4.5mm, 5mm, 5.5mm, 6mm, 6.5mm, 7mrn, 7.5mm, 8mm, 8.5mm, 9mm, 9.5mm, lOrnm,
10.5m.m,
Ilmm, 11.5mm, 12mm, 12.5mm, 13mm, 13.5mm, 14mm, 14.5mm, 15mm, 15.5mm, 16mn.t,
16.5mm, 17mm, 17.5mm, 18mm, 18.5mm, 19mm, 19.5mm, 20mm, 20.5mtn, 21mm, 21.5mm,
22mm, 22.5mm, 23mm, 23.5mm, 24mm, 24.5mm, 25mm, 25.5mm, 26mm, 26.5mm, 27mm,
27.5mm, 28mtn, 28.5mm, 29mm, 29.5mm, 30mm, 30.5mm, 31mm, 31.5mtn, 32mm,
32.5mm,
33mm, 33.5mm, 34mm, 34.5mm, 35mm, 35.5mm, 36mm, 36.5mm, 37mm, 37.5mm, 38nun,
38.5mm, 39mm, 39.5mm, 40mm, 40.5mm, 41mm, 41.5mm, 42mm, 42.5mtn, 43mm, 43.5mm,
44mm, 44.5mm, 45mm, 45.5mm, 46mm, 46.5mm, 47mm, 47.5mm, 48mrn, 48.5mm, 49mm,
49.5 or 50 millimeters.
In some embodiments the "truncated cone" pellet has a larger base diameter "b"
of .5mm,
lmm, 1.5mm, 2mm, 2.5mm, 3.5mm, 4mm, 4.5mm, 5mm, 5.5inm, 6mm, 6.5mm, 7mm,
7.5mm,
8mm, 8.5mm, 9mm, 9.5mm, lOmm, 10.5mm, limm, 11.5mm, 12mm, 12.5mm, 13mm,
13.5mm,
14rnm, 14.5mm, 15mm, 15.5mm, 16mm, 16.5mm, 17mm, 17.5mm, 18mm, 18.5mm, 19mm,
19.5mm, 20mm, 20.5nun, 21mm, 21.5mm, 22mm, 22.5mm, 23mm, 23.5mm, 24mm, 24.5mm,
25mm, 25.5mm, 26mm, 26.5mm, 27mm, 27.5mm, 28mm, 28.5mm, 29mm, 29.5mm, 30mm,
30.5nun, 31mm, 31.5mm, 32mm, 32.5mm, 33mm, 33.5nun, 34mm, 34.5nun, 35mm,
35.5mm,
36mm, 36.5min, 37mm, 37.5inm, 38mm, 38.5mm, 39mm, 39.5mm, 40mm, 40.5mm, 41mm,
41 .5mm, 42mm, 42.5mm, 43mm, 43.5mm, 44mm, 44.5mm, 45mm, 45.5mm, 46mm, 46.5mm,
47nuri, 47.5mm, 48mm, 48.5mm, 49mm, 49.5 or 50 millimeters.
In some embodiments the "truncated cone" pellet has a cone height "h"
of limn, .2mm, .3mm, .4mm, .5mm, .6mm, .7mm, .8mm, .9mm, lmm, 1.1mm, 1.2mm,
1.3mm,
227
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
1.4mm, 1.5mm, 1.6mm, 1.7mm,1.8mm, 1.9mm, 2.0mrn, 2.1mm, 2.2mrn, 2.3mm, 2.4mm,
2.5mm,
2.6mm, 2.7mtn, 2.8nun, 2.9mm, 3.0mm, 3.1nun, 3.2mm, 3.3mm, 3.4mm, 3.5nun,
3.61rmi,
3.7mm, 3.8mm, 3.9mm, 4.0mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5nam, 4.6nun, 4.7mm,
4.8mm, 4.9mtn, 5.0nun, 5.1mm, 5.2mm, 5.3rrun, 5.4mm, 5.5mm, 5.6mm, 5.7nun,
5.8mm,
5.9mm, 6.0mm, 6.1mm, 6.2mm, 6.3mm, 6.4mm, 6.5mm, 6.6mm, 6.7mm, 6.8mm, 6.9mm,
7.0mm, 7.1mm, 7.2mm, 7.3mm, 7.4mni, 7.5mm, 7.6mm, 7.7mm, 7.8mm, 7.9mm, 8.0mm,
8.1mm, 8.2mm, 8.3mm., 8.4mm, 8.5mm, 8.6mm, 8.7mm, 8.8mm, 8.9mm. 9.0mm, 9.5mm,
lOmm,
10.5mm, ilmm, 11.5mm, 12mm, 12.5mm, 13mm, 13.5mm, 14mm, 14.5mm, 15m.tri,
15.5mm,
16mm, 16.5mm, 17mm, 17.5mm, 18mm, 18.5mm, 19mm, 19.5mm, 20mm, 20.5mm, 21mm,
21.5nun, 22mm, 22.5mm, 23mm, 23.5mm, 24mm, 24.5mm, 25mm, 25.5mm, 26mm, 26.5mm,
27mm, 27.5mm, 28mm, 28.5mm, 29mm, 29.5mm, 30mm, 30.5mm, 31mm, 31.5mm, 32mm,
32.5mm, 33mm, 33.5mm, 34mm, 34.5mm, 35mm, 35.5mm, 36mm, 36.5mm, 37nun,
37.5mn.t,
38mm, 38.5mm, 39mm, 39.5mm, 40mm, 40.5mm, 41mm, 41.5mm, 42mm, 42.5mm, 43mm,
43.5mm, 44mm, 44.5mm, 45mm, 45.5mm, 46mm, 46.5mm, 47mm, 47.5mm, 48mm, 48.5mm,
49mm, 49.5 or 50 millimeters.
In another embodiment, the shape of the cannabis pellet of the present
invention is a
"donut shape" (Figure 16). In some embodiments, the dimensions of the cannabis
pellet shape
can vary for use with various smoking methods. In some embodiments the "donut
shape" pellet
has a outer donut diameter "od" of .5mm, 1mm, 1.5mm, 2mrn, 2.5nun, 3.5mm,
4rnm, 4.5mm,
5mm, 5.5mm, 6nun, 6.5mm, 7mm, 7.5nun, 8mm, 8.5mm, 9mm, 9.5mm, lOmm, 10.5mm,
Ilmrn,
11.5mm, 12mm, 12.5mm, 13mm, 13.5mm, 14mm, 14.5mm, 15mm, 15.5mm, 16nun, 16.5mm,
17nun, 17.5mm, 18mm, 18.5mm, 19mm, 19.5mm, 20mm, 20.5mm, 21mm, 21.5mm, 22mm,
22.5mm, 23mm, 23.5mm, 24mm, 24.5mm, 25mm, 25.5mm, 26mm, 26.5mm, 27nun, 27.5mm,
28nun, 28.5mm, 29mm, 29.5mm, 30mm, 30.5mm, 31mm, 31.5mm, 32mm, 32.5mm, 33mm,
33.5mrn, 34mm, 34.5mm, 35mm, 35.5mm, 36mm, 36.5mm, 37mm, 37.5inm, 38nun,
38.5mm,
39mm, 39.5mm, 40mm, 40.5mm, 41mm, 41.5mm, 42mm, 42.5mm, 43mm, 43.5mm, 44mm,
44.5mm, 45mm, 45.5mm, 46mm, 46.5mm, 47mm, 47.5nun, 48mm, 48.5mm, 49mm, 49.5 or
50
millimeters.
In some embodiments the "donut shape" pellet has a inner donut diameter "b" of
.5mm,
lmm, 1.5mm, 2mm, 2.5mtn, 3.5nun, 4mm, 4.5mm, 5mm, 5.5mm, 6mm, 6.5mm, 7mm,
7.5nun,
8mm, 8.5mm, 9mm, 9.5mm, lOmm, 10.5mm, linun, 11.5mm, 12mm, 12.5mm, 13mm,
13.5mm.
228
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Mnim, 14.5mm, 15mm, 15.5nun, 16nmi, 16.5mm, 17mm, 17.5mm, 18mm, 18.5rmn, 19mm,
19.5nun, 20mm, 20.5mm, 21mm, 21.5mm, 22mm, 22.5mm, 23mm, 23.5rmn, 24nun,
24.5mm,
25mm, 25.5mm, 26mm, 26.5rmn, 27mm, 27.5mm, 28mm, 28.5mm, 29mm, 29.5rmn, 30mm,
30.5nun, 31mm, 31.5mm, 32mm, 32.5mm, 33mm, 33.5mm, 34mm, 34.5rmn, 35nun,
35.5mm,
36mm, 36.5mm, 37mm, 37.5mm, 38mm, 38.5mm, 39mm, 39.5mm, 40mm, 40.5mm, 41 mm,
41.5nun, 42mm, 42.5mm, 43mm, 43.5mm, 44min, 44.5mm, 45mm, 45.5mm, 46mm,
46.5mm,
47mm, 47.5mm, 48mm, 48.5mm, 49mm, 49.5 or 50 millimeters.
In some embodiments the "donut shape" pellet has a donut height "dh"
of .1mm, .2min, .3mm, .4mm, .5mm, .6mm, .7mm, .8mm, .9mrri, imm, 1.1rnm,
1.2mm, 1.3mm,
1.4mm, 1.5mm, 1.6mm, 1.7mm,1.8mm, 1.9mm, 2.0mm, 2.1rnm, 2.2mm, 2.3mm, 2.4mm,
2.5nun,
2.6mm, 2.7mm, 2.8mm, 2.9mm, 3.0mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm,
3.7mm, 3.8mm, 3.9mm, 4.0rnm, 4.1min, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm,
4.8mm, 4.9mm, 5.0mm, 5.1mm, 5.2mm, 5.3mm, 5.4mm, 5.5mm, 5.6mm, 5.7mm, 5.8mm,
5.9mm, 6.0mm, 6.1mm, 6.2mm, 6.3mm, 6.4mm, 6.5mm, 6.6mm, 6.7mm, 6.8mm, 6.9mm,
7.0nun, 7.1mm, 7.2mm, 7.3mm, 7.4mtn, 7.5mm, 7.6mm, 7.7mm, 7.8mm, 7.9mm, 8.0mm,
8.1mm, 8.2mm, 8.3mm, 8.4mm, 8.5mm, 8.6mm, 8.7mm, 8.8mm, 8.9mm, 9.0mm, 9.5nun,
lOmm,
10.5mm, llmm, 11.5mm, 12min, 12.5mm, 13mm, 13.5mm, 14mm, 14.5mrn, 15mm,
15.5mm,
16mm, 16.5mm, 17mrn, 17.5mm, 18min, 18.5mm, 19mm, 19.5mm, 20mrn, 20.5mm, 21mm,
21.5mm, 22mm, 22.5mm, 23mm, 23.5mm, 24mm, 24.5mm, 25mm, 25.5mm, 26mm, 26.5mm,
27mm, 27.5mm, 28mm, 28.5mm, 29mm, 29.5mm, 30mm, 30.5mm, 31mm, 31.5mrn, 32tnin,
32.5nun, 33mm, 33.5mrn, 34mm, 34.5mm, 35mm, 35.5mm, 36mm, 36.5mm, 37nun,
37.5mm,
38nun, 38.5mm, 39mm, 39.5mm, 40mm, 40.5mm, 41mm, 41.5mm, 42mm, 42.5mm, 43mm,
43.5mm, 44mm, 44.5mm, 45mm, 45.5mm, 46mm, 46.5mm, 47mm, 47.5mm, 48nun, 48.5mm,
49mm, 49.5 or 50 millimeters.
in some embodiments the cannabis pellets of the present invention are made
with dies to
form the specialty cannabis, MCM, or extracts into shapes (Figure 17). In some
embodiments the
dies of the present invention is a coining die or a blanking die. The dies of
the present invention
may be made from any material capable of withstanding the pressures of forming
pellets such as
steel, hard plastic, wood, or ceramic.
In some embodiments, the cannabis pellets of the present invention are made
with a die
press. In some embodiments, the cannabis pellets of the present invention are
made with
229
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
commercially-available die presses such as the Across EP40 Pellet press (sold
by Across
International). In some embodiments, the dies of the present invention are
designed to work with
the pellet press. In other embodiments the pellet press already includes the
shaping tool for
cannabis pellets.
Example 28. Cannabis Extracts/Products.
The specialty cannabis and MCMs of the present invention can be used to create
various
extracts or cannabis products. Cannabis extracts or products include:
Kief- refers to trichomes collected from cannabis. The trichomes of cannabis
are the
areas of cannabinoid and temene accumulation. Kief can be gathered from
containers where
cannabis flowers have been handled. It can be obtained from mechanical
separation of the
trichomes from inflorescence tissue through methods such as grinding flowers,
or collecting and
sifting through dust after manicuring or handling cannabis. Kief can be
pressed into hashish for
convenience or storage.
Hash- sometimes known as hashish, is often composed of preparations of
cannabis
trichomes. Hash pressed from kief is often solid.
Bubble Hash- sometimes called bubble melt hash can take on paste-like
properties with
varying hardness and pliability. Bubble hash is usually made via water
separation in which
cannabis material is placed in a cold water bath and stirred for a long time
(around I hour). Once
the mixture settles it can be sifted to collect the hash.
Solvent reduced oils- also sometimes known as hash oil, honey oil, or full
melt hash
among other names. This type of cannabis oil is made by soaking plant material
in a chemical
solvent. After separating plant material, the solvent can be boiled or
evaporated off, leaving the
oil behind. Butane Hash Oil is produced by passing butane over cannabis and
then letting the
butane evaporate. Budder or Wax is produced through isopropyl extraction of
cannabis. The
resulting substance is a wax like golden brown paste.
Tinctures- are alcoholic extracts of cannabis. These are usually made by
mixing
cannabis material with high proof ethanol and separating out plant material.
E-juice- are cannabis extracts dissolved in either propylene glycol, vegetable
glycerin, or
a combination of both. Some E-juice formulations will also include
polyethylene glycol and
230
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
flavorings. E-juice tends to be less viscous than solvent reduced oils and is
commonly consumed
on e-cigarettes or pen vaporizers.
While these types of extracts have become a popular form of consuming
cannabis, the
extraction methods often lead to material with little or no terpene profile.
That is, the harvest,
storage, handling, and extraction methods produce an extract which is rich in
cannabinoids, but
often devoid of terpenes.
The extraction methods of the present invention are designed to preserve both
the
cannabinoids and the terpenes. In some embodiments, the specialty cannabis of
the present
invention is extracted via methods which preserve the cannabinoid and
terpenes. In other
embodiments, said methods can be used with any cannabis plants. The extracts
of the present
invention are designed to produce products for human or animal consumption via
inhalation (via
combustion, vaporization and nebulization), buccal absorption within the
mouth, oral
administration, and topical application delivery methods. The present
invention teaches an
optimized method at which we extract compounds of interest, by extracting at
the point when the
drying harvested plant has reached 15% water weight, which minimizes the loss
of terpenes and
plant volatiles of interest. Stems are typically still 'cool' and 'rubbery'
from evaporation taking
place. This timeframe (or if frozen at this point in process) allow extractor
to minimize terpene
loss to evaporation. There is a direct correlation between cool/slow/dry and
preservation of
essential oils. Thus, there is a direct correlation to EO loss in flowers that
dry too fast, or too hot
conditions or simply dry out too much (<10% H20). The chemical extraction of
our cultivars can
be accomplished employing polar and non-polar solvents in various phases at
varying pressures
and temperatures to selectively or comprehensively extract terpenes,
cannabinoids and other
compounds of flavor, fragrance or pharmacological value for use individually
or combination in
the formulation of our products. The extractions can be shaped and formed into
single or
multiple dose packages, e.g., dabs, pellets and loads. The solvents employed
for selective
extraction of our cultivars may include water, carbon dioxide, 1,1,1,2-
tetrafluoroethane, butane,
propane, ethanol, isopropyl alcohol, hexane, and limonene, in combination or
series. We can
also extract compounds of interest mechanically by sieving the plant parts
that produce those
compounds. Measuring the plant part, i.e. trichome gland head, to be sieved
via optical or
electron microscopy can aid the selection of the optimal sieve pore size,
ranging from 30 to 130
microns, to capture the plant part of interest. The chemical and mechanical
extraction methods
231
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
of the present invention can be used to produce products that combine chemical
extractions with
plant parts containing compounds of interest. The extracts of the present
invention may also be
combined with pure compounds of interest to the extractions, e.g. cannabinoids
or topcnes to
further enhance or modify the resulting formulation's fragrance, flavor or
pharmacology. In
some embodiments the extractions are supplemented with terpenes or
cannabinoids to adjust for
any loss of those compounds during extraction processes. In some embodiments,
the cannabis
extracts of the present invention mimic the chemistry of the cannabis flower
material. In some
embodiments, the cannabis extracts of the present invention will about the
same carmabinoid and
terpene profile of the dried flowers of the specialty cannabis of the present
invention.
Extracts of the present invention can be used for vaporization, production of
e-juice or
tincture for e-cigarettes, or for the production of other consumable products
such as edibles or
topical spreads.
Example 29. Use of Specialty Cannabis in Edibles.
Cannabis edibles such as candy, brownies, and other foods are a popular method
of
consuming cannabis for medicinal and recreational purposes. In some
embodiments, the
specialty cannabis of the present invention is used to make cannabis edibles.
Most cannabis
edible recipes begin with the extraction of cannabinoids and terpenes which
are then used as an
ingredient in various edible recipes. In one embodiment, the cannabis extract
used to make
edibles out of the specialty cannabis of the present invention is cannabis
butter. Cannabis butter
is made by melting butter (not margarine) in a container with cannabis and
letting it simmer for
about half an hour, or until the butter turns green. The butter is then
chilled and used in normal
recipes. Other extraction methods for edibles include extraction into cooking
oil, milk, cream,
flour (grinding cannabis and blending with flour for baking). Lipid rich
extraction
mediums/edibles are believed to facilitate absorption of cannabinoids into the
blood stream. THC
absorbed by the body is converted by the liver into 11-hydroxy-THC. This
modification
increases the ability of the THC molecule to bind to the CB1 receptor and also
facilitates
crossing of the brain blood barrier thereby increasing the potency and
duration of its effects. For
additional information on various edibles that can be produced with the
specialty cannabis of the
present invention, please see (Sarah Conrique "The Vegan Stoner Cookbook: 100
easy Vegan
Recipes to Much" ISBN 1607744643; "Official High Times Cannabis Cookbook" ASIN
232
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
BOOHB7YI8U; Bliss Cameron "Marijuana Cooking: Good Medicine Made Easy" ISBN
1931160325; Tim Pileher "The Cannabis Cookbook: Over 35 Tasty Recipes for
Meals,
Munchics, and More" ISBN 0762430907)
Example 30. Dosing Regimens of Multiplexed Cannabis Medicines
Volunteers
Regardless of the condition being treated, two separate groups of volunteers
are
evaluated: one composed of novice cannabis users and one composed of
experienced cannabis
users. It is helpful to know the past cannabis use history of volunteers since
tolerance can occur
in experienced users, who will therefore experience the therapeutic effects of
the multiplexed
cannabis formulation differently than those with no tolerance. However the
rate and duration of
tolerance varies with the different effects; a particular individual may have
developed tolerance
to one cannabis agent but not to another. This may actually serve to increase
the therapeutic
margin depending on the condition. For instance, tolerance to cognitive and
psychomotor
impairment, the psychological high, tachycardia, and orthostatic hypertension,
tends to develop
rather quickly and chronic users may not experience these detrimental side
effects, while still
benefitting from the analgesic or other therapeutic effects of cannabis.
Conversely, the novice
user who has no tolerance, can be slowly subjected to dose escalation (e.g.
over 30 days or more)
to build tolerance to these effects before given therapeutic doses. Many times
the dysphoria
experienced by naive users is enough to cause discontinuation of the
treatment, and slow dose
escalation which helps induce tolerance to the detrimental side effects may
alleviate this.
The biodistribution and PK of the cannabis active agents administered either
orally or
through inhalation differ substantially. An acute condition may respond better
to an inhaled
formulation while a chronic condition may respond better to the prolonged
plasma
concentrations resulting from oral administration. The higher levels of 11-0H-
THC (and/or CBs)
formed from first-pass metabolism after oral formulation administration, which
is more potent
and has better blood brain barrier penetration than the parent compound, has
implications for
neurological conditions. The dosing studies described herein evaluate the
effects of various doses
of the multiplexed cannabis formulations when administered either orally or
through inhalation.
Formulations
233
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
The amounts and types of bases, cannabinoid and terpene fortifiers are
designed to have a
synergistic effect on the conditions being treated. The multiplexed signaling
resulting from the
synergy of the components may be more effective than any single component
alone and arc
tailored to achieve the desired effects. For instance, analgesia has been
shown to be mediated by
the CB1, CB2, TRPV- 1, and a2-AR receptors, which suggests a component mixture
of THC
(which acts on CB1 and CB2), TRPV-i (which acts on CBD), CBG (which acts on a2-
AR) and 3-
myrcene (which acts on a2-AR) will be therapeutic. Similarly if the cause of
the pain is
inflammation, which is mediated by TNF-a and POE-I, then the synergistic
effects of a
multiplexed medicine comprising CBD-rich extract, which counteracts TNF-a and
a-pinene,
which counteracts POE-i, proves a more effective therapeutic than extracts not
containing both
of these compounds. The following Table 67 shows a few examples of the various
clinical
indications that are treated with cannabis formulations, the cannabinoids and
terpenoids that are
effective therapeutics for each clinical indication, and the pathways each
cannabinoid influences.
Table 67- Non-exhaustive list of clinical indications that can be treated with
cannabis.
Canbod carpen
12-
:tht42n pier r,ync, Lw:
PhanncIogkaI Action (130 CBC ------l lucy ent L--
----.----
eIvn CI;kl
indtiof.
P.Jeufo!rotecffe V --
Down regult
PakInscn S uft) 23( - * Cah+ -- + -
A:zhe:m.i S¨- Down reg.Iae R( --
MS at-ox,d,fl
St.:ke
Vssorelanant V V
GIauore 1l PPAR3 --
Apptlte Stimilnt V . -
-- Ae* -- - -- -
Al-stl.
- -----------------------------------* .-- --4--------
-------+-
Ant-protif8r1iva V - V V V V
rM
upICa-4) --
- UPROS - - - -
(+)C82
(-)TRPMS
lrtetur.alAntl-prokInelk V V - --
234
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Cann TerPent,abinoid ... :
:.:.:.:.::.
:....:=::=::::::::::::::::::: 1:::::.:E::::::E::::::::
....:.:.f:.::=::=::=:,=:=::::::::::.*:.::::::::::::::
,::,::::::::::::::::::::::
:::::::::.::.:::::===: ::::::::::::::::::::::::::.:.*
:::+:,,i,:?+:-.:,,::::::::::
1-)ca, -:=:::=::::=:::::::::::.:.:::::::::::::::.:iii.f.i:iii::::
iiiiii:.:::::::::::::::::: ::::::::.:::::::::3 g.,::::::::::::::,*:
====================== =
Diatrhea
...... = = = :::::::.,,....::::::: Down regulate.......õ....õ%_:.
:::::.:õ.................õ, . .
s: =
::::::::::::::::::::::
FAAH ....-
=
,,,,..---,igiiii.M.fli.g affp: .:=:=::::::::::::::
:::::::::::=:::::::::::
:.1
,..,
: := ........ ==:: :::.:.,:,::::::
::::::::::::::::: iiiiimi.:::: ii.:::::::+:::::::::::::::
om :2,... 1
ImmunosuPPressive ..................................................
============ = = = = ... = = = ''' .0 ' - - '
::::::::::::,..E**E...,...,::::::,.-.....,..,..,..,. .i................
:....::064 ...ii-i*i'A?..Øi.E.i N'wl = . i :::.:;;.........-
..,............. :::.:::::::,....... i. .............õ,õ,,õ
..i.....i...:,..i...i.rii.-..ali,,,,,.. Ceih
= '.' ......'-'-
':::::::::::::::::i:i:iii:i i.,i i.,i, :,..:,:,..,:i..i..i..,..:..,
::' :'...:':5::;.::::===11.= ''..: r'i.'i'l'i'i.'1...i...f.i.i. .,
Aqi,ines
....""...-i.i.i.i.--,i-:::::..f.:::.:.,.:.:..; :.,.................
MS
i 1,-
,.......,--õ,-,::::::
-F,.7..............,..:.::
PA ...i.....:11.....itc.515.1.,:..:::õ..õ
ii.1.===:11.===:1.1.(111[1:11.1.11.111:11=11:111.: 111:111 ....=11:11111
i iii:iii5.5.:::,..:,:,..::::..,...,...,..=..,....,.::::::::::.:::::.....
..................: ::::,,iii....i.gr.i. Li,,,,i,-,:,,i.::: :
.i.i...:::.::...i i i.,:. i..iv ..::..@
= .................=
......::::::::::::::::::::::i:?..: iq iii.i..5.EiiiiiiiiE:,..
1 ::::::.:.,..., V
if i'i iV.::::::: L.,,,,,
r*:*::,:,:::,:....._
:*::::::+:::?-ja V ..i....::',.i...?..:...iii:
,,x,,,,,-,..::::::,,,_-----,.t77.--
V ::,,:*:,.....:
PG El li,:fss..G,.... -, -,......,..,,,,...,..
.........i.i..i:::::::i....1...i..i..ii:ii..4 -- *" r e8uk$t. .,. -
::.'::::.':: i''':':::?.1'..: ::.::::
Anti-inflamm.Ecly_ Dow.; N :=0
..:_:.:.:õ......................................
......,,i
Pa: n
D6*"441k.:-&'a ApoiniliiiiiigiJiiigiiii,::E++:::]
1++:::+,....... i...........,...." :,.5.55,,,,,,.:
,=,..,,,,.= ::;:.5.::.5.:.5.::.:::::::.E ri..,..õ,:,:::::õ..:.;.
-.- : uptake
:===:*:::::*:*:**:**::::::::::::::::::::::::::::::::::: iii iii:iiiiiiiiS,
1:::::::::::5: I.:::::::::::-.i.i Vs....f.f.f.s.s...i.i.i.:
...:......:...:....i....;,.,..,..,=.:=:,...........;k5:1,:::µ !Dowr"egu'l
i:i::ilEiii'iiili'i...i.E;i=i'i..i.E:i*:::;:;;:E..ii....;:;:i.....;:i....i.i..
:i....iil i...,i.i....i.:i.....i.....i...ii....i:::::
.::.+:-::+:.-....i.... f.:.,:.::=::-:H...:::: !......:....:::':+::'a
MS
= ',...11'.:1'i i'i
...;..:::.:E:i'....................... ------------
Arthritis
-i:iiiIpivARK
throws
1.....?..:.::::::::.::::.:.: 1:....,:.:::.::.:..::,:;:;:;:;::
i....,...:=::,,,,,,
11...1.=:,::,H.::
iii:iiiiiii:=.:,:::: ::::::::::::::::.:: - ,
i= ::::::::::::::::::::::::EiTi
::::,.....:Iiiiii:,..1:::::::::::::::::.:1:11::::::::::::!!!!1:11
.1:::.!....E.:.I.:.I.:.I.:11.::
:::::.::::::::: i:.: .:....,:::::,..:
'l=lr'rlr'si:i: t:Si i.i ,:e.:
V k
Sedati
:_.. ::=::=:====::::.:::.::::.::.,.:::::::::::::::õ;..i.E.:õ=:=:õ
:::::::::::::::::: ::::::::::::::::::: ...:::::::::::::::::::::::
t::::::::::::::::::::::::::::
======.=:=::::=::=::=::=:=:=:==::::::::.::: ::
'.......:?.?:::::::::: 1::::::::::::::,..,..f.i.:::: V
Sieep disorders
:.:::::::..:..::.:,: V ,::::,::::::
.,...,...,:.,,,,,...,..=..,.....?...:...:...:..::.::::::::_i_i_
.....:::::::...i..iiiii iii :...i..i =. ...:,...,,:::::,
Anti-epllePtit +::::::::::; :+::::::::':-:::?.:::'::::+1:' V.
:5::........Ã+.44.g.i.1.-..,,
Down
Ca2't Ct:iA
..i....i..--,giii: ()03, ...E.1:: igE5 G;-
' iiigNig.
.....,....................::ii:ii:i...::?:::::::::.::,..ii.ii
i ii.iii.i..Mu
4'1`-s-----;- 0c.wn ,e0th
.ate ':',:::=':=i.i.i.: 1:::::::::::::i:::::Sii
:::.::,:::::::::::.:::::=,,
..........*::::';'::::::::::::.::.:::.::=,:=:=::.i i'i i l -
......:.......:.,,,::::::::::::::, = : i::';'';':=':::::::::i _ '
i:::::::::::::::::::: ...:::::::::::::::::::::
!........???..::::::::::::::
EpleP.,..,1
........--............,* . ...............õ,,
f=:;:::+g:::.:::::: ii....:, iii, iii i...X.:...i..,E
r.....:,...5......:.......................:
DOWn.f4;ituini(eADOiii.Eii,....::-.-..:::::::: :+1,,,,,,i,,,,,.....=
uPtake
............:................:::::::::55.5.....................................
..
]iii.:i.i..ii..=;.=., !..i.......:.............::::::::::::
1.....::::::::_:::::::::::
= , .....:*::*::
:::.:.::. :...:.:::.:::::::: i .::::::::.:,:i:E..i..i.:.::::::
Anti-emetic
ti*.'.:.:.::::::::..k4 V
........:................:,.......,...........................õ ....
::::::::::;:ii i.
-.1'11.1i .......= : i'=:,:i'i i'i i'i'i:::: r.,..........,,,,.....
1.......,,,:i f...........-::,+,;',--- ,i,--...i.......:-
.i...........:J
a ::.........
ii..:-.??.:.:.= 1::::::::::::::::::::::::::.::.:: õ,
i::::::::::::::::::::::::::::::
ci[
1::::::...v.::::: .......,:=::::::......... õ:õ.::::::::::::õ...!
Anxioi r
.............:::: :. . . ... . . .....,.....:. =
::.:::.:E::.::.:::::: i::::::::::::::::::::
1::=:::=:::::::::=11.,11:i:1:1::E ii.::::.:::1.1.:...1..1.:......õ...,....:
1.......:=.:,:,.::::.::::: i::::.::::::::::::::::::::::
i:=:::::=:=::=:::: . : . .:
vtic
ii...:::::::*.:.,.t'. =,..'" :+:::i.::+1...::::::
i=.=5:!,:::::::.4: ,...::::::::::::::: i:::::::::::=:::,::::=:::::::
,;:isHT,,, ii::.:::::::=iiA;m4ii,,,,,,k. = i...=:=::::::::õ...i.õ.
::::::::::::::=::=::==== 1...::::::::.....:;:ti..:.,:,:.
...::::::::::::::::::::::::.::::::::::::::::,
+::::+a----.........-............ +:::: ¨
:::::::::.:ii:ii::.,...:.:::::::.:E::: : :...ii,::=.=:=.=õ:õ.:=.:
ii.::::::....i..:::.=.a.... 1::::::::::.::::::::::::
........j.;i:y:.::::::::::
Pa Mc Disorder
Social Anxiety DI s rder
C.er:eralized An xietY
::::.-:=:::::::::::::::.....i ri.:+::::E.:::Ai iiii.--:+iiimiii.
::::::::,:::.::::::::::,õ,::::= ::::::::.i.:i1.04
.:..iii.:::::::.:.:::+ii.,. .,.:iii::::==============::::::
t.....:.:.:.:-:':::::::
i)iscrder
., ..i..1..?..::.' ................
PTSD
_______________________________________________________ itL=,............
if.:57:::.::. i',...:...i.: = .......:i'i,.::.:E::.:::::E.,:.:i..!
'*:*.:=::=::::===:?. iiiiii:::...1 i.iiiiiiiiiii i
iiiEiiii..i..:,::,..:, :,:::::::::
:i .iiiiii-m. ]:.E.iieiiiii.
---
Pi i iii .:.:.:::::::::E.:::: iiiEii.....?" '..
..... 5:: ,,,,, :::
:..... 5:: . .
An tideerenallt
:'= ...=..
= , =.-{T,.. . j
.....:.:::,:,,, -,.::,:ii..i:i i:i i. ii:i.,iii:i i:iiiiiii..i.: I
i....:?.?..::::::::::::::::...!
]Depression
Anti-psychotic , i yrR di
S.:.:.:1?.!..i 1,i,i,E..i........,..............
...:...E..i...i..........:..i.: iii:iii:
:: µ+, - - -P''
- ..5::::::::: 4....-....-,,,,,,,, ...... -7........................:.:.:
::.
:::iiiiiiiiiiiiii iiiiii.:*:',,::::E:=,,,,,,i 77.................::
":':':':':':::::' :::::::=::.:i'i'i':': l::::::::::::::::::i::::::
..
V ::: ___
V
-i=I'i'f.::::::::: l::::=::::::: Si:::::::::: ::::::::::::::,========::
Anti-spasmodic
,-,:mii
,,,,,::: 1.:.:.:.i..i.,.....i.... ...=...,..:...,.:::::::+ii,i-iii
MS iii iii:iiiiiiiiiiii iii:iiiiiiii ii:E:::::::::::::::,
..............''''''''''' ki..:::::::i:i=i*ii
:5,:E5,5,:::::::::::::,.....
,,,,,,,...............f.
1.....:....'f',..: i.i i' :i............................:
r,.....,....:.........,...,:
.................................................i.i.i.:.i.:..: i
-.........,...'-'..' :.................,::::::?:::i :::::::::.,,,,....õ
Spinal cord Injury
::::::::+:44::::::::::+:1+:::::::::: -711: iliiii ,!::11=111=11.1=Ii rili
i:::+c=il:ii===::11 ...1:===:::1:::::ii..
1:=.11::::::====(::::::+1:7:.i...:::E:: 1... ......1:.:===:........1... :E:
....I..... I.::===:: .......1....1:1 :::+11:::.....i.1:1:::::+1.:
.:1=1:::11:::1111.1::111:11
::,,,::::::: ,,,,
-:':''':=i'ii..:=ia--..:::::::+Zi:::::, :: l l::i::::::::::::i ii
..:::::::::iat7::.:Si::. ....:::,.........:......,....ssi
Cerebral palsy
',.....-i=ii+i-i.':': !::::::::::::::::::S5i
Ana Ige
k::::::::::::::::: V i iiiEiiiiiiiiiiii .:i.:I.:i:::::::::::::::::::.
. ,,...r
.,(is
,:=: :.:,.:':':-:'::: :.:.: :.: :.: :::::::::::: :::::::: %
sic
: :': :'....:':::::: .:.:.::::::: ::: ::: ':',:::::: :::I:::: p =
5.::W::::.
i i=:::::+iiiiii:IiiiP3:33r4i*:::::::::, = - ..........,....,
.:.E.::::::::::+:-iiiii :::::5::::::::::::::: '
,...c.i.,,i++::::+ii.,:..4
..---.5i.:::: ifiTRPV1 -...--.........::::::::.........,,,,.õA
:5......,..i*i..-...= ''''''...iiiiii-:;::::.
iiiiii::::iiiiiiiiii:::::+i,...5::+5,.....-..:
].:.1.ii.k:::iii.:+i :.+:.+:-T.::.--:::::
"OS
....:...:".::::::::::::i.i=:.+:=:,.i........i...iii.,ii.,-;.::,
,:+iiiiiii,5:5,.ii.
i ....ii-EiiiMt41111.P64::::::.5.:::: ifõ...-....--
+++,+tk+Miiiq 1TRP4-
r-bSt-cperatIve pain
::=iii'..:.,..,:i...õ:õ..õ..............::::::::::::.':::::
iiiiM6+iiii+4us
.A.5.,.5.5..1 !:....!....................:
...:,:.
iii:4;*60q
==:..:.:.:.::..=:.::.:.:.:.::::::::::::::::.:1:.::.: .:
:::,.:.:.:.:.:.:.:.::.:,.::., õ,õõõ,..õ:õ..,.., õ............... ...,
%lig; aint
.:,:..,...:.:., :,:,:::.:,..::
i....i. ::::::
i iiiEiiiiiiiiiiØ*'.44*.:',.....:',:::. . .
. ..-
Ne,ropathic pair, :i.mgigiggisaidad.
----
235
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
cannobineid Terpene
atica
Bronchodialator V
:
Asthma============================================== ***
**********************************************
* :
!disorders
........................ = 4-
....... . . .
************
Muscleirelaxant
........
:
tviS
The fortifiers of the present invention are chosen to reinforce the treatment
for the given
clinical condition and to posses an improved therapeutic margin, through
synergy of the various
pathways involved in the disease or disorder. Table 67 is a brief, and by no
means complete,
summary of pharmacological effects of various representative cannabinoids and
terpenoids along
with the relevant therapeutic applications. In cases where a mechanism has
been proposed this
has been included in the table.
Another important aspect of this invention is in the combinatorial and
synergistic
pharmacological effects of the cannabinoids and terpene active ingredients
present in cannabis.
For example, recreational cannabis in the U.S. has been selected (through.
breeding) to contain a
high content of tetrahydrocannabinol (THC.), ignoring or reducing other
cannabirioid and
terpenoid compounds regarded as inactive compounds. Although cannabidiol was
regarded as an
inactive compound in the past, there is now experimental evidence that it has
potentially
beneficial pharmacological activity different from that of THC. Effects of
other terpene
compounds as analgesics or anti-microbial substances is also emerging (Russo,
Ethan, Br .1
Pharmacol: 163(7) 1344-1364 (2011)). The therapeutic effects of cannabis
cannot be
satisfactorily explained just in terms of one or the other "active"
constituent, but are instead a
consequence of the combination of active compounds.
Given the varied above-referenced individual and combinatorial effects of THC
and CBD
cannabinoids on various diseases, Table 68 outlines preferred ratios of
THC:CBD concentrations
for treatment of various diseases (see U.S. Patent Application 11/628,814, and
UK patent
application GB2377633)
Table 68- Preferred TF1C:CBD ratios for the treatment of various diseases.
itirtiti.iiiNffDISEASE
236
CA 02911168 2015-10-30
WO 2015/065544 PCT/US2014/046694
Cancer pain;
High THC >95:5 Migraine;
Appetite stimulation.
Multiple sclerosis;
Spinal cord injury;
Even ratio 50:50
Peripheral neuropathy;
Neuroge.nic pain.
Rheumatoid arthritis;
Broad ratio <15:75
Inflammatory bowel disease.
Psychotic disorders
(schizophrenia);
Epilepsy;
Movement disorders;
High CBD <5:95 Stroke;
Head injury;
Disease modification in
rheumatoid arthritis and other
inflammatory conditions;
Appetite suppression
Volunteer Sub-Groups and Controls
Large volunteer groups (75-100 volunteers) are studied to evaluate the
subjective effects
of the cannabis formulations. For all studies, volunteer groups are chosen
from several locations
and are chosen from various dispensaries and/or solicited, if drug-naive
volunteers are difficult to
find. These volunteers are subdivided into experienced and novice cannabis
users, and then if
the clinical indication warrants it, further subdivided into those receiving
either the oral and
inhaled formulations. Due to the extremely variable bioavailability, dosage
regimens are tailored
to the indication and the volunteer. All studies are done with the appropriate
medical and/or
psychological supervision and evaluation. There are several placebo groups,
with the volunteers
receiving either complete placebos, a placebo containing no cannabinoids and
only terpenes, and
placebos containing no terpenes and only cannabinoids. This will serve to
establish not only
efficacy of the cannabinoids and/or terpenes, but also the synergy. The
complete placebo is
generated from fats and waxes resulting from cannabinoid extraction and is
spiked with terpenes
fortifiers for exact and reproducible levels of terpenes to make the placebo
without cannabinoids,
or it is spiked with cannabinoid fortifiers to make exact and reproducible
levels of cannabinoids
without the terpenes. Cannabis treatments for these studies will include
inhaled, oral buccal, or
ingested cannabis. In some embodiments, the inhaled cannabis formulations are
the specialty
237
DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVETS
COMPREND PLUS D'UN TOME.
CECI EST LE TOME 1 DE 2
NOTE. Pour les tomes additionels. veillez contacter le Bureau Canadien des
Brevets.
JUMBO APPLICATIONS / PATENTS
THIS SECTION OF THE APPLICATION / PATENT CONTAINS MORE
THAN ONE VOLUME.
THIS IS VOLUME 1 OF 2
NOTE: For additional volumes please contact the Canadian Patent Office.
..
